<SEC-DOCUMENT>0001053691-17-000015.txt : 20170515
<SEC-HEADER>0001053691-17-000015.hdr.sgml : 20170515
<ACCEPTANCE-DATETIME>20170515165625
ACCESSION NUMBER:		0001053691-17-000015
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170515
DATE AS OF CHANGE:		20170515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		17845304

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dffn2017033110-q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCA81F6B68E7556FBA0C0A7EEFA5D9D41"></a></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C.&#160;&#160;20549</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Mark one)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:25px;"></td><td style="width:37px;"></td><td style="width:620px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:25px;"></td><td style="width:37px;"></td><td style="width:620px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the transition period from ___________ to ______________.</font></div><div style="line-height:120%;text-align:center;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">000-24477</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">30-0645032</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State of other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020 Avon Court, #4<br>Charlottesville, VA 22902<br></font><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices, including zip code)</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(434) 220-0718</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number including area code)</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160; No&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160; No&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:74%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth&#160;company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of shares of common stock outstanding at May, 5 2017 was 10,345,637 shares.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s945D3638AE795075A666B13C112C2BA7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MARCH&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:80%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8EAAE699924F583BB5421BE0F79EBA4D"><font style="font-family:inherit;font-size:10pt;">PART I &#8211; FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8EAAE699924F583BB5421BE0F79EBA4D">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC7A037416E0E508EAF8404500A3353F4"><font style="font-family:inherit;font-size:10pt;">ITEM 1.&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC7A037416E0E508EAF8404500A3353F4">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s29534F2BB8CF5D0BBCF59947B2416678"><font style="font-family:inherit;font-size:10pt;">ITEM 2.&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s29534F2BB8CF5D0BBCF59947B2416678">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E7BBEA4FB055E4590B22E31F9DDC2C0"><font style="font-family:inherit;font-size:10pt;">ITEM 3.&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E7BBEA4FB055E4590B22E31F9DDC2C0">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CC72A0EE3DC549687D3A75B537798B5"><font style="font-family:inherit;font-size:10pt;">ITEM 4.&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES&#160;</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CC72A0EE3DC549687D3A75B537798B5">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s69BCA6FFA4475337A79607A675594E5E"><font style="font-family:inherit;font-size:10pt;">PART II &#8211; OTHER INFORMATION</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s69BCA6FFA4475337A79607A675594E5E">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s89D9A2093D5B524FBD26C4EAD393F29C"><font style="font-family:inherit;font-size:10pt;">ITEM 1.&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s89D9A2093D5B524FBD26C4EAD393F29C">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF2A1C88EDA659C5A21660944E88E157"><font style="font-family:inherit;font-size:10pt;">ITEM 1A.&#160;&#160;RISK FACTORS</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF2A1C88EDA659C5A21660944E88E157">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3345B5BD1F0D516BA341B17EF1B38291"><font style="font-family:inherit;font-size:10pt;">ITEM 2.&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3345B5BD1F0D516BA341B17EF1B38291">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1932DF922F43577986A81E8540FA7EA9"><font style="font-family:inherit;font-size:10pt;">ITEM 3.&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1932DF922F43577986A81E8540FA7EA9">27</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB3DA15BA775A50D3B1258A2D28686688"><font style="font-family:inherit;font-size:10pt;">ITEM 4.&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB3DA15BA775A50D3B1258A2D28686688">27</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s57E9056EAB87557AB7A562F1104DCB16"><font style="font-family:inherit;font-size:10pt;">ITEM 5.&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s57E9056EAB87557AB7A562F1104DCB16">29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s90970BC27E03530FACF92974BD76D0E7"><font style="font-family:inherit;font-size:10pt;">ITEM 6.&#160;&#160;&#160;&#160;&#160;EXHIBITS</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s90970BC27E03530FACF92974BD76D0E7">29</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unless the context otherwise requires, in this report, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to Diffusion Pharmaceuticals Inc. and its subsidiaries and references to &#8220;common stock&#8221; refer to the common stock, par value $0.001 per share, of the Company.  On August 17, 2016, the Company effected a 1-for-10 reverse split of its common stock. Unless noted otherwise, any share or per share amounts in this report, the accompanying unaudited condensed consolidated financial statements and related notes give retroactive effect to this reverse stock split.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">This report contains the following trademarks, trade names and service marks of ours: Diffusion.  All other trade names, trademarks and service marks appearing in this quarterly report on Form 10-Q are the property of their respective owners.  We have assumed that the reader understands that all such terms are source-indicating.  Accordingly, such terms appear without the trade name, trademark or service mark notice for convenience only and should not be construed as being used in a descriptive or generic sense.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="s8EAAE699924F583BB5421BE0F79EBA4D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sC7A037416E0E508EAF8404500A3353F4"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:597px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL STATEMENTS</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF36D4AF104F156FEB6EB7A77735DB96B"></a></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diffusion Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,212,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,552,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,280,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses, deposits and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,631,946</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,603,696</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,755</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,639,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,639,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,929,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,929,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,343,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,484,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of convertible debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,880,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,880,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,016,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">874,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,599,412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,438,422</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,279,363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,279,363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,462,082</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,299,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and Contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock, $0.001 par value:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A -  13,750,000 shares authorized, 12,376,329 issued and outstanding at March 31, 2017; No shares authorized, issued or outstanding at December 31, 2016 (liquidation value of $25,000,000 at March 31, 2017)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; Equity (Deficit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,000,000 shares authorized; 10,345,637 shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,700,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,363,575</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,829,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,189,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,118,539</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,184,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,343,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,484,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;See accompanying notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s4E0BBEA895685776ACBD1503F20A6644"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diffusion Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Operations</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,007,571</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352,807</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,553,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,862,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,603</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,567,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,223,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liabilities (Note 10)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant related expenses (Note 7)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,225,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other financing expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,870,226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,638,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,223,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A cumulative preferred dividends</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,845</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,697,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,223,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per share information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share of common stock, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,337,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,996,381</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s7663DFFEAA845172B254E1E9CF9518F6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diffusion Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:27%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="18" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders' Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders'</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,345,637</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,346</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">69,363,575</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(60,189,237</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,184,684</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cumulative effect of change in accounting principle </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Sale of Series A convertible preferred stock and common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,376,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Series A cumulative preferred dividend</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(58,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(58,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Beneficial conversion feature for accrued interest of convertible debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">366,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">366,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(28,638,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(28,638,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,376,329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,345,637</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">69,700,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(88,829,149</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(19,118,539</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(a) In 2017, the Company adopted provisions of ASU 2016-09</font><font style="font-family:inherit;font-size:8pt;font-style:italic;">, Improvements to Employee Share Based Payment Accounting</font><font style="font-family:inherit;font-size:8pt;">, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of this standard. </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sB3966718E80D56CBB50EA7E38BC50121"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diffusion Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,638,778</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,223,165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,853</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued for advisory services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant related expense, change in fair value, and other financing expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,015,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses, deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99,737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,123,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,415,901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,630,189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows (used in) provided by investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash received in reverse merger transaction</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,500,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,498,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows provided by financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from the sale of Series A convertible preferred stock, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,269,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,081,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,659,173</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,868,419</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,552,852</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997,192</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,212,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,865,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of deferred offering costs upon completion of private placement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering costs in accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A cumulative preferred dividends</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of subscription receivable upon sale of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,280,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of convertible notes and related accrued interest into common stock</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration in connection with RestorGenex Corporation merger transaction</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s6FA451C87D6155A1A2AA8397281FA2C7"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD71E9DBDBB5B532EAC4888166074A9CE"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Organization and Description of Business</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diffusion Pharmaceuticals Inc. (&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), a Delaware Corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company&#8217;s lead product candidate, trans sodium crocetinate (&#8220;TSC&#8221;), uses a novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby enhancing tumor cells&#8217; response to conventional treatment without additional side effects. TSC has received orphan drug designations for the treatment of glioblastoma multiforme (&#8220;GBM&#8221;) and metastatic brain cancer. The Company expects to enter a Phase III study in newly diagnosed GBM patients in the next twelve months.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the Company completed a reverse merger (the Merger") with RestorGenex Corporation (&#8220;RestorGenex&#8221;) whereby the Company was considered the acquirer for accounting purposes.  The operational activity of RestorGenex is included in the Company&#8217;s consolidated financial statements from the date of acquisition. Accordingly, all comparative period information presented in these unaudited condensed consolidated financial statements from January 1, 2016 through January 7, 2016 exclude any activity related to RestorGenex.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6D5852A2594A5FA0BC410B4B60EA3A6E"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liquidity</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its membership units (prior to the Merger), convertible notes and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. In March 2017, the Company completed a </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;private placement of its securities by offering units consisting of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of the Company's Series A convertible preferred stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (&#8220;Series A Preferred Stock&#8221;) and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of common stock for each share of Series A Preferred Stock purchased in the offering. The Company sold </font><font style="font-family:inherit;font-size:10pt;">12,376,329</font><font style="font-family:inherit;font-size:10pt;">&#32;units and received approximately </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate net cash proceeds from the private placement, after deducting commissions of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and offering expenses of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of net proceeds on April 3, 2017. In addition, the Company granted to its placement agent in the offering warrants to purchase an aggregate </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,179,558</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock as compensation for its services. </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be. The regulatory approval and market acceptance of the Company&#8217;s proposed future products (if any), length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The Company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">believes its cash and cash equivalents at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, together with the subscription receivables related to the Series A private placement received in April 2017, are sufficient to fund operations and meet its research and development goals through March 2018.&#160;</font></div><div><a name="s3F07462DE8895073A7756B97F21292EF"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Summary of Significant Accounting Policies</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Summary of Significant Accounting Policies included in our Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 31, 2017, as amended to this date, have not materially changed, except as set forth below.</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim&#160;condensed consolidated&#160;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#8220;SEC&#8221;). In the opinion of management, the accompanying&#160;unaudited interim condensed consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, its results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The unaudited interim&#160;condensed consolidated&#160;financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying&#160;unaudited interim condensed consolidated&#160;financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;filed with the SEC on Form 10-K on March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period.  Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may materially vary from these estimates.  Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined necessary.  </font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Company&#8217;s outstanding convertible notes was approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Offering Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company&#8217;s private placement financing and are recognized in other assets on the consolidated balance sheet.  At December 31, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in deferred offering costs. These costs were expensed upon completing the private placement of Series A Preferred Stock and common stock warrants in March 2017.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company acquired RES-529 and RES-440, respectively, an </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;indefinite-lived In-Process Research and Development Asset (&#8220;IPR&amp;D&#8221;) and recognized </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in goodwill. In the third quarter of 2016, the IPR&amp;D asset associated with RES-440 was abandoned and written down to </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">. RES-529 and goodwill are assessed for impairment on October 1 of the Company&#8217;s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment indicators or impairments to RES-529 or goodwill during the three months ended March&#160;31, 2017.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:63%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">766,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">428,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,376,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,016,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304,132</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,796,360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,665</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,471,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,715,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts in the table reflect the common stock equivalents of the noted instruments.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2016 and interim periods within those years. The Company adopted this standard in 2017 by electing to account for forfeitures in the period that they occur. Under ASU 2016-09, accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;cumulative-effect adjustment on January 1, 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&#160;15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="sA310AD13365F5D19A7FFF898A5A58A34"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Acquisition</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse Merger with RestorGenex</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the Company completed a reverse merger transaction with RestorGenex. The Company entered into the Merger transaction in an effort to provide improved access to the capital markets in order to obtain the resources necessary to accelerate development of TSC in multiple clinical programs and continue to build an oncology-focused company.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchase price was calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of RestorGenex shares outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,546,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of RestorGenex stock options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,321,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of RestorGenex warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CVRs &#8211; RES-440 product candidate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;The reverse merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&amp;D was the cost approach.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,500,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,929,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(377,432</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,644,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualitative factors supporting the recognition of goodwill due to the reverse merger transaction include the Company&#8217;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the reverse merger transaction to the Company&#8217;s later state product portfolio. The goodwill is not deductible for income tax purposes. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro Forma Financial Information (Unaudited)</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pro forma financial information reflects the condensed consolidated results of operations of the Company as if the acquisition of RestorGenex had taken place on January 1, 2016. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:0%;"></td><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2016</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,655,944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-recurring pro forma transaction costs directly attributable to the Merger were </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;March&#160;31, 2016 and have been deducted from the net loss presented above. The costs deducted from the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;March&#160;31, 2016 period includes a success fee of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and approximately </font><font style="font-family:inherit;font-size:10pt;">46,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock with a fair market value of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;paid to a financial adviser upon the closing of the Merger on January 8, 2016. Additionally, RestorGenex  incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in severance costs as a result of resignations of executive officers immediately prior to the Merger and approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in share based compensation expense as a result of the acceleration of vesting of stock options at the time of the Merger. These costs are excluded from the pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;March&#160;31, 2016. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;such costs were recorded in the three months ended March 31, 2017.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s4E0F0F477F855E218FB05F1F30D38E47"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other Accrued Expenses and Liabilities</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses and liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Series A dividends</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,845</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll and payroll related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,163</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,855</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical studies expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,016,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">874,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3A99A01E2A6E57F493F17B7554AD6C7F"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Convertible Debt</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the details of the convertible debt outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and December 31, 2016:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issue</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/27/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/27/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,880,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/15/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total principal amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,880,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The current and noncurrent portions of accrued interest related to the Company&#8217;s Convertible Notes and 2016 Convertible Notes are included within other accrued expenses and liabilities and other liabilities, respectively, within the unaudited condensed consolidated balance sheets. As of March 31, 2017, the Company had accrued interest of approximately </font><font style="font-family:inherit;font-size:10pt;">$90,000</font><font style="font-family:inherit;font-size:10pt;">.  During the three months ended March 31, 2017, the Company recorded noncash interest expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$28,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with a beneficial conversion feature associated with accrued interest that may be converted into shares of common stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF2925B2E9F82511A8BA04416209C32EA"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">7.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Convertible Preferred Stock and Common Stock Warrants</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contemplation of completing a private placement, the Company amended and restated its articles of incorporation and authorized </font><font style="font-family:inherit;font-size:10pt;">13,750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Preferred Stock. The Company has classified its Series A Preferred Stock outside of stockholders&#8217; equity (deficit) because the shares contain deemed liquidation rights that are contingent redemption features not solely within the control of the Company. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series&#160;A Convertible Preferred Stock Transaction </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company completed a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;private placement of its securities by offering units consisting of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of the Company&#8217;s Series A Preferred Stock and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share common stock for each share of Series A Preferred Stock purchased in the offering.  Each share of Series A Preferred Stock entitles the holder to an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;cumulative dividend payable in shares of our common stock on a semi-annual basis.  The holders may, at their option, convert each share of Series A Preferred Stock into </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of the Company&#8217;s common stock based on the initial conversion price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.02</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, subject to adjustment. Each warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of common stock at an initial exercise price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment and expires on the fifth anniversary of their original issuance date. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon completing the private placement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">12,376,329</font><font style="font-family:inherit;font-size:10pt;">&#32;units and received approximately </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate net cash proceeds from the private placement, after deducting commissions of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and offering expenses of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of net proceeds on April 3, 2017. In addition, as compensation for its services, the Company granted to its placement agent in the offering warrants to purchase an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,179,558</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.22</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, which expire on the fifth anniversary of their original issuance date. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASC 815-40&#8221;).  The conditions within ASC 815-40 are not subject to a probability assessment. As the Company is obligated to issue a variable number of shares to settle the cumulative Series A preferred dividends, the Company cannot assert there will be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants are classified as liabilities. The Company will continue to classify such warrants as liabilities until they are exercised, expire, or are no longer require to be classified as liabilities. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are no proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the Series A offering and the fair value of the warrants granted to its placement agent was </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the aggregate and was recorded as warrant related expenses in the statement of operations for the three months ended March 31, 2017. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company shall pay a cumulative preferential dividend on each share of the Series A Preferred Stock outstanding at a rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum, payable only in shares of common stock, semi-annually in arrears on April 1 and October 1 of each year commencing on October 1, 2017.  This cumulative preferential dividend is not subject to declaration. The Company accrued approximately </font><font style="font-family:inherit;font-size:10pt;">$59,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in dividends for the three months ended March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) or as required by law, the holders of the Series A Preferred Stock and common stock vote together on an as-converted basis.  In accordance with NASDAQ listing rules, in any matter voted on by the holders of our common stock, each share of Series A Preferred Stock entitles the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance.  Accordingly, shares of Series A Preferred Stock issued in the initial closing of the private placement on March 14, 2017 are entitled to </font><font style="font-family:inherit;font-size:10pt;">0.84874</font><font style="font-family:inherit;font-size:10pt;">&#32;votes per share and shares of Series A Preferred Stock issued in the final closing of the private placement on March 31, 2017 are entitled to </font><font style="font-family:inherit;font-size:10pt;">0.50627</font><font style="font-family:inherit;font-size:10pt;">&#32;votes per share.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidation Preference</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Preferred Stock is senior to the common stock.  In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A Preferred Stock shall be entitled to receive their original investment amount.  If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution shall be distributed ratably among the holders of the Series A Preferred Stock in proportion to the full amounts to which they would otherwise be entitled.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Preferred Stock is convertible, at the holder&#8217;s option, into common stock.  At the Company&#8217;s option, the Series A convertible preferred stock can be converted into common stock upon (a) the </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;">-day moving average of the closing price of the Company&#8217;s common stock exceeding </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, (b) a financing of at least </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;or (c) upon the majority vote of the voting power of the then outstanding shares of Series A convertible preferred stock.  The conversion price of the Series A Preferred Stock is subject to adjustment as described in the Certificate of Designation.  </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon any conversion, any unpaid dividends shall be payable to the holders of Series A preferred stock.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Make-Whole Provision</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until March 2020 and subject to certain exceptions, if the Company issues at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of its common stock or securities convertible into or exercisable for common stock at a per share price less than </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.02</font><font style="font-family:inherit;font-size:10pt;">&#32;(such lower price, the &#8220;Make-Whole Price&#8221;) while any shares of Series A Preferred Stock remain outstanding, the Company will be required to issue to these holders of Series A Preferred Stock a number of shares of common stock equal to the additional number of shares of common stock that such shares of Series A Preferred Stock would be convertible into if the conversion price of such shares was equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">105%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Make-Whole Price (the &#8220;Make-Whole Adjustment&#8221;). The Make-Whole Adjustment was evaluated and was not required to be bifurcated from the Series A Preferred Stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2017, the Company had the following warrants outstanding to acquire shares of its common stock:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:68%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of exercise price per share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants issued prior to Merger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$20.00 - $750.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants issued in Series A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,555,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.22</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,016,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants were exercised or expired. The common stock warrants issued prior to the Merger expire periodically through 2019. The common stock warrants issued in connection with the March 2017 Series A private placement expire in March 2022.  During the three months ended March 31, 2017, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in warrant related expenses associated with the private placement, which consisted primarily of the change in fair value of the common stock warrants from issuance and the excess fair value of the common stock warrants over the gross cash proceeds of the Series A offering. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s05DE218BBD9F564B822754666CDCEB87"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">8.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Stock-Based Compensation</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2015 Equity Plan</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Diffusion Pharmaceuticals Inc. 2015 Equity Plan, as amended (the "2015 Equity Plan"), provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the board of directors. Accordingly, </font><font style="font-family:inherit;font-size:10pt;">413,825</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were added to the reserve as of January 1, 2017, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">356,148</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock available for future issuance under the 2015 Equity Plan. </font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,194</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to all stock option grants to employees and non-employees for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercise price</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contractual life</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,207,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.84</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,548,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-employee Stock Options</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. During the three months ended March 31, 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">9,394</font><font style="font-family:inherit;font-size:10pt;">&#32;stock options to non-employees. Key assumptions used to estimate the fair value of the non-employee stock options granted during the three months ended March 31, 2017 included a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">2.4%</font><font style="font-family:inherit;font-size:10pt;">, an expected volatility of </font><font style="font-family:inherit;font-size:10pt;">136.4%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;expected dividend yield and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an expected term equal to the remaining contractual option term. The total fair value of non-employee stock options vested during the three months ended March 31, 2017 and 2016 was approximately </font><font style="font-family:inherit;font-size:10pt;">$53,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. At March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">27,561</font><font style="font-family:inherit;font-size:10pt;">&#32;unvested options subject to remeasurement and approximately </font><font style="font-family:inherit;font-size:10pt;">$65,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized compensation expense that will be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.0 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Employee Stock Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value of stock option awards granted to employees was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.08</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended March 31, 2017. The total fair value of options vested during the three months ended March 31, 2017 and 2016 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. No options were exercised during any of the periods presented.  At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized compensation expense that will be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">5.8 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:90%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Awards</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">7,665</font><font style="font-family:inherit;font-size:10pt;">&#32;unvested shares of restricted stock. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">1,533</font><font style="font-family:inherit;font-size:10pt;">&#32;shares that vested and the Company recognized stock-based compensation expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized compensation expense that will be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s93FA60E50A7458C7AB48CD597BD38957"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">9.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commitments and Contingencies</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Office Space Rental</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases office and laboratory facilities in Charlottesville, Virginia under a month-to-month cancelable operating lease. Rent expense related to the operating lease was </font><font style="font-family:inherit;font-size:10pt;">$17,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. On March 31, 2017, the Company entered into a lease for its office and laboratory facilities at a new location in Charlottesville, Virginia. Lease payments commence on May 1, 2017 and expire on April 30, 2022. The company will recognize rent expense on a straight-line basis over the lease period and will accrue for rent expense incurred but not yet paid. Future minimum rental payments under the Company's new noncancelable operating lease at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rental Commitments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,354</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,464</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company&#8217;s former Chief Executive Officer under the caption </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH </font><font style="font-family:inherit;font-size:10pt;">(Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on April 14, 2015, the Court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. No arbitration hearing has yet been scheduled. The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#8217;s financial position.</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s71CAF5F2F0EB5BA4A90F48E257385C10"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:622px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">10.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;The asset&#8217;s or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,212,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,552,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock Warrant Liability</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued in connection with the Series A convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,225,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common stock warrants issued in connection with the Series A convertible preferred stock are classified as liabilities on the accompanying balance sheet at March 31, 2017. The liability is marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the liability to be reclassified to stockholders&#8217; equity (deficit). The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrants granted during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:90%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="s29534F2BB8CF5D0BBCF59947B2416678"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read the following discussion of our financial condition and results of operations together with the unaudited interim condensed consolidated financial statements and the notes thereto included elsewhere in this report and other financial information included in this report. The following discussion may contain predictions, estimates and other forward looking statements that involve a number of risks and uncertainties, including those discussed under &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part I &#8212; Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Special Note Regarding Forward Looking Statements</font><font style="font-family:inherit;font-size:10pt;">&#8221; in this report and under &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part I &#8212; Item 1A. Risk Factors</font><font style="font-family:inherit;font-size:10pt;">&#8221; in our annual report on Form 10-K for the fiscal year ended December 31, 2016. These risks could cause our actual results to differ materially from any future performance suggested below.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s711E8DFA11EA5C8BA758DFC0247584EF"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. We are developing our lead product candidate, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">transcrocetinate sodium</font><font style="font-family:inherit;font-size:10pt;">, also known as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">trans sodium crocetinate</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;TSC&#8221;), for use in the many cancer types in which tumor oxygen deprivation (&#8220;hypoxia&#8221;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer&#8217;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead development programs target TSC against cancers known to be inherently treatment-resistant, including brain cancers and pancreatic cancer.  A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM). This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care, including a 37% improvement in overall survival over the control group at two years.  A particularly strong efficacy signal was seen in the inoperable patients, where survival of TSC-treated patients at two years was increased by 380% over the controls. At an End-Of-Phase 2 Meeting, the U.S. Food and Drug Administration provided Diffusion with extensive guidance on the design for a Phase 3 trial of TSC in newly diagnosed, inoperable GBM patients. We believe focusing on the inoperable patient group in Phase 3 should reduce the needed number of patients from over 400 to around 230, which is expected to provide real cost savings, while the strength of the Phase 2 efficacy signal should make the showing of significant clinical gain in Phase 3 more likely.  Assuming FDA sign-off on our final protocol design, focusing on the inoperable patients, the study is planned to initiate by the end of 2017. Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in our preclinical and clinical studies.  Diffusion believes its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve standard-of-care treatments of other life-threatening cancers.  Additional planned studies include a Phase 2 trial in pancreatic cancer and a study in brain metastases, with a study initiation subject to receipt of additional funding or collaborative partnering. We also believe that TSC has potential application in other indications involving hypoxia, such as neurodegenerative diseases and emergency medicine. For example, our stroke program is now in advanced discussions with doctors from UCLA and the University of Virginia, with whom we have established a joint team dedicated to developing a program to test TSC in the treatment of stroke, with an in-ambulance trial of TSC in stroke under consideration. </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="sF02D5FEF596951A2A929135596C869A8"></a></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Current Product Candidate Pipeline</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table, as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, summarizes the targeted clinical indications for Diffusion&#8217;s lead molecule, TSC:</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="diffusion.jpg" alt="diffusion.jpg" style="height:316px;width:684px;"></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the TSC programs depicted in the table above, we are exploring alternatives regarding how best to capitalize upon the legacy RestorGenex product candidate, RES-529, a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and was in preclinical development in oncology, specifically GBM.  RES-529 has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and can cross the blood brain barrier.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC1138AD9D18A5272A3EB53747107586B"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Summary</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we completed a $25.0 million private placement of our securities by offering units consisting of one share of our Series A convertible preferred stock, par value $0.001 per share ("Series A Preferred Stock") and a warrant to purchase one share of our common stock for each share of Series A Preferred Stock purchased in the offering. We sold 12,376,329 units and received approximately $22.1 million in aggregate net cash proceeds from the private placement, after deducting commissions of approximately $2.4 million and offering expenses of approximately $0.5 million. The final closing of the private placement occurred on March 31, 2017, and we received $8.3 million of net proceeds on April 3, 2017. In addition, we granted our placement agent in the offering warrants to purchase an aggregate of 1,179,558 shares of our common stock as compensation for its services.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents balances of </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;">. We have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable operations. We incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$28.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Our accumulated deficit as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$88.8 million</font><font style="font-family:inherit;font-size:10pt;">, and we expect to continue to incur substantial losses in future periods. We anticipate that our operating expenses will increase substantially as we continue to advance our lead, clinical-stage product candidate, TSC. We anticipate that our expenses will substantially increase as we:</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">complete regulatory and manufacturing activities and commence our planned Phase II and III clinical trials for TSC;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">continue the research, development and scale-up manufacturing capabilities to optimize products and dose forms for which we may obtain regulatory approval;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">conduct other preclinical and clinical studies to support the filing of a New Drug Application (&#8220;NDA&#8221;) with the FDA;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">maintain, expand and protect our global intellectual property portfolio;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">hire additional clinical, manufacturing, and scientific personnel; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of TSC for use in the treatment of GBM, pancreatic cancer and brain metastases. We believe that our cash and cash equivalents as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, together with the subscription receivables related to the Series A private placement received in April 2017, will enable us to fund our operating expenses and capital expenditure requirements through March 2018. However, we will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of our planned research and development activities with respect to TSC and our other product candidates.</font></div><div style="line-height:174%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As disclosed in our definitive proxy statement (the &#8220;Proxy Statement&#8221;) filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on May 1, 2017, subject to the approval of our stockholders, we intend to offer up to $20 million shares of our Series B convertible preferred stock, $0.001 par value per share (&#8220;Series B Preferred Stock&#8221;), each share of Series B Preferred Stock being initially convertible into one share of our common stock, subject to adjustment, and for each share of Series B Preferred Stock purchased in the offering, a 5-year warrant to purchase one share of common stock.  The proposed terms of this offering are described in more detail in the Proxy Statement.</font></div><div style="line-height:174%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE FOREGOING STATEMENT IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY SHARES OF OUR PREFERRED STOCK, SHARES OF OUR COMMON STOCK OR ANY OTHER SECURITIES.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sD6DF5E26A3345ACB9D40B9B377F3C729"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not yet generated any revenue from product sales. We do not expect to generate revenue from product sales for the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expense</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are charged to expense as incurred. These costs include, but are not limited to, impairment of our in-process research and development, or IPR&amp;D, assets, employee-related expenses, including salaries, benefits, stock-based compensation and travel expense reimbursement, as well as expenses related to third-party contract research arrangements. Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As we advance our product candidates, we expect the amount of research and development costs will continue to increase for the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expense</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist principally of salaries and related costs for executive and other personnel, including stock-based compensation, expenses associated with investment bank and other financial advisory services, and travel </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses. Other general and administrative expenses include costs associated with the Merger, professional fees that were incurred in connection with preparing to operate and operating as a public company, facility-related costs, communication expenses and professional fees for legal, patent prosecution and maintenance, and consulting and accounting services.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense, Net</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net consists principally of the interest expense recorded in connection with our convertible debt instruments offset by the interest earned from our cash and cash equivalents.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Fair Value of Warrant Liabilities, Warrant Related Expenses, and Other Financing Expenses </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with our private placement in March 2017, we recorded warrant expense associated with the change in fair value of the common stock warrants from issuance, the excess fair value of the common stock warrants over the gross cash proceeds from the Series A preferred stock offering, and placement agent commissions and other offering costs.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDE24D5CDC49F57E686A08F4F2DF9B694"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for Three Months Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Compared to Three Months Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31 2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,007,571</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352,807</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,345,236</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,553,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,862,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,309,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,603</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,250</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,567,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,223,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,655,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,225,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,225,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other financing expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,870,226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,870,226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,638,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,223,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,415,613</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A cumulative preferred dividends</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,845</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,845</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,697,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,223,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,474,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in research and development expenses during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in research and development expense was attributable to a $0.9 million decrease in expense related to our pancreatic cancer program and a $0.3 million decrease in animal toxicology expenses. In addition, we had approximately </font><font style="font-family:inherit;font-size:10pt;">$43,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of research and development stock-based compensation expense during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $0.2 million during the same period in 2016. We expect that our research and development expenses will increase significantly in future periods compared to prior year periods due to our anticipated efforts to advance our technologies and product candidates.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses were </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in general and administrative expense was primarily due to a $2.4 million decrease in costs attributable to the reverse merger transaction in January 2016. We had $0.3 million of general and administrative stock-based compensation expense during the three months ended March 31, 2017 compared to $0.2 million during the comparable period in 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in interest expense for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 is primarily attributable to the issuance of our convertible promissory note with a notional value of $1.9 million in September 2016. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the private placement of our Series A preferred stock and common stock warrants, we determined the warrants to be classified as liabilities and subject to remeasurement at each reporting period. As a result of the liability classification, we recognized </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in excess fair value of the common stock warrants over the gross proceeds from our private placement. We also recognized </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in placement agent commission and other offering costs. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we recorded a </font><font style="font-family:inherit;font-size:10pt;">$12.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;expense for the change in fair value of our common stock warrant liabilities which was primarily attributable to the increase in the market price for our common stock</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company shall pay a cumulative preferential dividend on each share of the Series A Preferred Stock at a rate of 8.0% per annum, payable in shares of common stock, semi-annually in arrears on April 1 and October 1 of each year commencing on October 1, 2017.  The Company accrued approximately $59,000 in dividends for the three months ended March 31, 2017 related to the dividends.&#160;</font></div><div><a name="s9A5F18AFFF7B5B80BE9D02FEF91E15BA"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Working Capital</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have funded our operations primarily through the sale and issuance of preferred stock, common stock and convertible promissory notes. In March 2017, we sold 12,376,329 units in the Series A Private placement and received approximately $22.1 million in aggregate net cash proceeds, after deducting commissions of approximately $2.4 million and offering expenses of approximately $0.5 million payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds on April 3, 2017.  As of March 31, 2017, we had </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and cash equivalents, working capital deficit of </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$88.8 million</font><font style="font-family:inherit;font-size:10pt;">. We expect to continue to incur net losses for the foreseeable future. We intend to use our existing cash and cash equivalents to fund our working capital and research and development of our product candidates.   </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our cash flows for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,415,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,630,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,498,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,081,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,659,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,868,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily attributable to our net loss of </font><font style="font-family:inherit;font-size:10pt;">$28.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and our net change in operating assets and liabilities of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">. This amount was offset by </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in non-cash, warrant related and other financing expenses and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in stock-based compensation expense. The net change in our operating assets and liabilities is primarily attributable to the decrease in our accounts payable and accrued expenses due to the payments of employee bonuses and payments to our vendors for professional services and costs associated with our clinical and preclinical activities.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities of </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily attributable to our net loss of </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that was offset by </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of non-cash charges and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the net change </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in our operating assets and liabilities. Non-cash charges primarily consisted of stock-based compensation and common stock issued for advisory services.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017, we had approximately </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in fixed asset purchases. During the three months ended March 31, 2016, net cash provided by investing activities was </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and was attributable to the cash acquired in connection with the reverse merger transaction with RestorGenex. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$14.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;which was attributable to the </font><font style="font-family:inherit;font-size:10pt;">$14.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in proceeds received upon the initial closing of our Series A private placement on March 14, 2017 (but does not include additional amounts received upon the final closing of the private placement on March 31, 2017), offset by </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in payments for related offering costs. There were no cash related financing activities during the three months ended March 31, 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capital Requirements</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to incur substantial expenses and generate significant operating losses as we continue to pursue our business strategy of developing our lead product candidate, TSC, for use in the treatment of GBM, pancreatic cancer and brain metastases.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have primarily used debt and equity financings to fund our ongoing business operations and short-term liquidity needs. We expect to continue this practice for the foreseeable future. We believe our cash and cash equivalents as of March&#160;31, 2017, together with the subscription receivables related to the Series A private placement received in April 2017 will be sufficient to fund our planned operations through March 2018.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not have credit facilities under which we could borrow funds or any other sources of committed capital. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify or delay the development of our product candidates and our operations, or we may need to obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to raise any additional capital in the near-term and/or we cannot significantly reduce our expenses and are forced to terminate our operations, investors may experience a complete loss of their investment.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that we raise additional capital through the sale of our common stock, the interests of our current stockholders may be diluted. If we issue additional preferred stock or convertible debt securities, it could affect the rights of our common stockholders or reduce the value of our common stock or any outstanding classes of preferred stock. In particular, specific rights granted to future holders of preferred stock or convertible debt securities may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As disclosed in the Proxy Statement, subject to the approval of our stockholders, we intend to offer up to $20 million shares of our Series B Preferred Stock, each share of Series B Preferred Stock being initially convertible into one share of our common stock, subject to adjustment, and for each share of Series B Preferred Stock purchased in the offering, a 5-year warrant to purchase one share of common stock.  The proposed terms of this offering are described in more detail in the Proxy Statement.</font></div><div style="line-height:174%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE FOREGOING STATEMENT IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY SHARES OF OUR PREFERRED STOCK, SHARES OF OUR COMMON STOCK OR ANY OTHER SECURITIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s12A3BF515A4C5BAD8525878939AC61FC"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sE9265D791B3455FC8F25AF2F8A88A1E1"></a></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Critical Accounting Policies included in our Form 10-K for the year ended December 31, 2016, filed with the SEC pursuant to Section 13 or 15(d) under the Securities Act on March 31, 2017, as amended to this date, have not changed, except as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Estimated fair value of Common Stock Warrants</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font><font style="font-family:inherit;font-size:12pt;">&#32;w</font><font style="font-family:inherit;font-size:10pt;">arrants issued in conjunction with our Series A convertible preferred stock are accounted for as freestanding financial instruments. These warrants are classified as liabilities on our  condensed consolidated balance sheet and are recorded at their estimated fair value. At the end of each reporting period, changes in the estimated fair value during the period are recorded in our condensed consolidated statement of operations. We will continue to adjust these liabilities for changes in fair value until the earlier of their exercise, termination, or other form of settlement. The estimated fair value of common stock warrants is determined by using the Black-Scholes option-pricing model.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s4C9B0C042016578BB2B64FEF35521DAC"></a></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Special Note Regarding Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This report includes forward-looking statements. We may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements appear in a number of places throughout this Quarterly Report and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, the degree of clinical utility of our products, particularly in specific patient populations, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Actual results could differ materially from our forward-looking statements due to a number of factors, including risks related to:</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain additional financing;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success and timing of our preclinical studies and clinical trials;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the difficulties in obtaining and maintaining regulatory approval of our products and product candidates, and the labeling under any approval we may obtain;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our plans and ability to develop and commercialize our product candidates;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the accuracy of our estimates of the size and characteristics of the potential markets for our product candidates and our ability to serve those markets;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory developments in the United States and foreign countries;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance of any of our product candidates;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to operate our business without infringing the intellectual property rights of others;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">future legislation regarding the healthcare system;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of competing products that are or may become available; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:61px;"></td><td style="width:37px;"></td><td style="width:585px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9679;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the performance of third parties, including contract research organizations, collaborators and manufacturers.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should also read carefully the factors described in the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K filed with the SEC on March 31, 2017, as amended, and elsewhere in our public filings to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any forward-looking statements that we make in this Quarterly Report speak only as of the date of such statement, and, except as required by applicable law, we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report or to reflect the occurrence of unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s3E7BBEA4FB055E4590B22E31F9DDC2C0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Item 3 is not applicable to us as a smaller reporting company and has been omitted.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s2CC72A0EE3DC549687D3A75B537798B5"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible internal controls. Our management evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosure.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in Internal Control Over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting </font><font style="font-family:inherit;font-size:10pt;">(as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><a name="s69BCA6FFA4475337A79607A675594E5E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II &#8211; OTHER INFORMATION</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s89D9A2093D5B524FBD26C4EAD393F29C"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL PROCEEDINGS</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For this item, please refer to Note 9, Commitments and Contingencies to the Notes to the Unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sBF2A1C88EDA659C5A21660944E88E157"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#1f497d;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;">Except as set forth below, there have been no material changes in our assessment of risk factors affecting our business since those presented in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 as filed with the SEC on March 31, 2017</font><font style="font-family:inherit;font-size:11pt;">. </font><font style="font-family:inherit;font-size:10pt;">The information set forth in this report should be read in conjunction with the risk factor set forth below and the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If we cannot continue to satisfy the NASDAQ Capital Market continued listing standards and other NASDAQ rules, our common stock could be delisted, which would harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to maintain our listing on the NASDAQ Capital Market, we are required to comply with NASDAQ rules which include rules regarding minimum stockholders&#8217; equity, minimum share price and certain corporate governance requirements. We may not be able to continue to satisfy the listing standards of the NASDAQ Capital Market and other applicable NASDAQ rules. For example, the accounting treatment of the preferred stock and warrants issued in connection with our March 2017 private placement requires, as a technical accounting matter, that the warrants be recorded as a liability, which has resulted in a reduction of our stockholders&#8217; equity, as of March 31, 2017, below the applicable required level under NASDAQ&#8217;s continued listing standards. &#160;While we are currently exploring alternatives to regain compliance with this listing standard, if we are unable to satisfy the NASDAQ criteria for maintaining listing, our common stock could be subject to delisting. If our common stock is delisted, trading, if any, of our common stock would thereafter be conducted in the over-the-counter market. As a consequence of any such delisting, our share price could be negatively affected and our stockholders would likely find it more difficult to dispose of, or to obtain accurate quotations as to the prices of, our common stock. &#160;In addition, it may be difficult to raise additional capital, if needed, as a company whose stock is not listed on NASDAQ&#160; or another exchange.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3345B5BD1F0D516BA341B17EF1B38291"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unregistered Sales of Equity Securities</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company completed a $25.0 million private placement of its securities by offering units consisting of one share of the Company's Series A Preferred Stock and a warrant to purchase one share of common stock for each share of Series A Preferred Stock purchased in the offering. The Company sold 12,376,329 units and received approximately $22.1 million in aggregate net cash proceeds from the private placement, after deducting placement agent commissions and other offering costs. The final closing of the private placement occurred on March 31, 2017, and the Company received $8.3 million of net proceeds on April 3, 2017. In addition, the Company granted an aggregate of 1,179,558 shares of common stock as compensation to its placement agent in the offering for its services. The securities were issued to accredited investors in reliance upon an exemption pursuant to Section 4(2) of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="s1932DF922F43577986A81E8540FA7EA9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEFAULTS UPON SENIOR SECURITIES</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sB3DA15BA775A50D3B1258A2D28686688"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MINE SAFETY DISCLOSURES</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s57E9056EAB87557AB7A562F1104DCB16"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s90970BC27E03530FACF92974BD76D0E7"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:85px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBITS</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See attached Exhibit Index.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="sDECFE3CCE57A5C1E8A9256301A53BFA2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 15, 2017</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:25%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David G. Kalergis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David G. Kalergis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ben L. Shealy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ben L. Shealy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Finance, Treasurer and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><a name="sC486D6EDAA1051EBA1F9D5783DF2BEC6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:57%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Method of Filing</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of Incorporation of Diffusion Pharmaceuticals Inc., as amended</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, as amended</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock of Diffusion Pharmaceuticals Inc.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2017</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Warrant issued to Investors in the 2017 Series A Private Placement by Diffusion Pharmaceuticals Inc.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2017</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Registration Rights Agreement entered into by and among the Company and Investors in the 2017 Series A Private Placement</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of 2017 Series A Private Placement Subscription Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Placement Agency Agreement, dated January 27, 2017, by and between Diffusion Pharmaceuticals Inc. and Maxim Merchant Capital, a division of Maxim Group LLC, with respect to the Series A Private Placement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment to the Placement Agency Agreement, dated March 14, 2017, by and between Diffusion Pharmaceuticals Inc. and Maxim Merchant Capital, a division of Maxim Group LLC, with respect to the Series A Private Placement</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, as amended</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease Agreement, dated March 31, 2017, by and between Diffusion Pharmaceuticals Inc. and One Carlton LLC</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of principal financial officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furnished herewith</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of principal financial officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furnished herewith</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following materials from Diffusion&#8217;s quarterly report on Form 10-Q for the quarter ended March 31, 2017, formatted in XBRL (Extensible Business Reporting Language): (i) the Unaudited Condensed Consolidated Balance Sheets, (ii) the Unaudited Condensed Consolidated Statements of Operations, (iii) the Unaudited Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Deficit), (iv) the Unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Condensed Consolidated Financial Statements</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>dffn20170331ex42registrati.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s63F67D19B34A664EDC09F44B27D0C669"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:18px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGISTRATION RIGHTS AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:18px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DATED [&#9679;], 2017</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:18px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">SECTION 1.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">GENERAL.&#160;&#160;&#160;&#160;1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Definitions.&#160;&#160;&#160;&#160;1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">SECTION 2.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">REGISTRATION; RESTRICTIONS ON TRANSFER.&#160;&#160;&#160;&#160;3</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Registration.&#160;&#160;&#160;&#160;3</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Registration Procedures.&#160;&#160;&#160;&#160;4</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Expenses of Registration&#160;&#160;&#160;&#160;6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Delay of Registration; Agreement to Furnish Information; Suspension of Sales.&#160;&#160;&#160;&#160;6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Indemnification&#160;&#160;&#160;&#160;7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Assignment of Registration Rights&#160;&#160;&#160;&#160;9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Market Stand-Off Agreement&#160;&#160;&#160;&#160;9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Termination of Registration Provisions&#160;&#160;&#160;&#160;9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">SECTION 3.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MISCELLANEOUS.&#160;&#160;&#160;&#160;9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Governing Law&#160;&#160;&#160;&#160;9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Successors and Assigns&#160;&#160;&#160;&#160;10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Entire Agreement&#160;&#160;&#160;&#160;10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Severability&#160;&#160;&#160;&#160;10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amendment and Waiver&#160;&#160;&#160;&#160;10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Delays or Omissions&#160;&#160;&#160;&#160;10</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notices&#160;&#160;&#160;&#160;11</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Titles and Subtitles&#160;&#160;&#160;&#160;11</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.9.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Counterparts&#160;&#160;&#160;&#160;11</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.10.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pronouns&#160;&#160;&#160;&#160;11</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF8079DBEA06704D580C0F44B281F6701"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:240%;padding-bottom:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGISTRATION RIGHTS AGREEMENT</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This REGISTRATION RIGHTS AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) is made as of the last date set forth on the signature page hereof by and between Diffusion Pharmaceuticals Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and the undersigned investor in the Offering (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Investor</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div><div style="line-height:240%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">W I T N E S S E T H:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Company is conducting an Offering of up to $15,000,000 of its Series A Convertible Preferred Stock, which amount may be increased to $25,000,000 at the discretion of the Placement Agent and the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Investor has purchased or intends to purchase shares of Preferred Stock in accordance with the terms of that certain subscription agreement related to the Offering by and between the Company and the Investor (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Subscription Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;);</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, as additional, supplemental consideration for Investor&#8217;s purchase of Securities, the Company has agreed to provide the Investor with certain registration rights with respect to Investor&#8217;s Registrable Shares (as defined herein) on the terms set forth herein; and</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, capitalized terms used and not otherwise defined herein have the respective meanings given to them in the Subscription Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW, THEREFORE, in consideration of the premises and the mutual representations and covenants hereinafter set forth, the parties hereto do hereby agree as follows:</font></div><div style="line-height:138%;padding-left:0px;padding-bottom:13px;text-align:justify;text-indent:0px;"><font style="padding-bottom:13px;text-align:justify;font-family:inherit;font-size:11pt;font-weight:bold;padding-right:96px;">Section 1.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GENERAL.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Definitions.</font><font style="font-family:inherit;font-size:11pt;">&#32;As used in this Agreement the following terms shall have the following respective meanings:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means the Common Stock of the Company.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Effectiveness Deadline</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means, with respect to the Registration Statement, the ninetieth (90</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) calendar day following the Final Closing (or, in the event the Commission reviews and has written comments to the Registration Statement, the one hundred twentieth (120</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) calendar day following the Final Closing); </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">, that if the Company is notified by the Commission that the Registration Statement will not be reviewed or is no longer subject to further review and comments, the Effectiveness Deadline as to such Registration Statement shall be the fifth (5</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, further</font><font style="font-family:inherit;font-size:11pt;">, that if the Effectiveness Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline shall be extended to the next Trading Day on which the Commission is open for business</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the Securities Exchange Act of 1934, as amended.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Filing Deadline</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means, with respect to the Registration Statement required to be filed pursuant to </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 2(a)</font><font style="font-family:inherit;font-size:11pt;">, May 17, 2017.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Form S-3</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Holder</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means any person owning of record Securities issued in the Offering that has executed and delivered to the Company a registration rights agreement with the Company in the form hereof prior to April 26, 2017.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Preferred Stock&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the Series A Convertible Preferred Stock, par value $0.001 per share, issued in the Offering.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Prospectus</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Shares covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post&#8209;effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Registrable Shares&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means the shares of Common Stock of any Holder that are (a) issued and outstanding, or issuable, pursuant to any conversion of the Preferred Stock, (b) issued and outstanding, or issuable, pursuant to any exercise of the Warrants and (c) issued and outstanding pursuant to the cumulative preferred dividend on each share of the Preferred Stock; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">, that any such shares of Common Stock shall cease to be Registrable Shares on the date which such shares of Common Stock may be sold or otherwise transferred, without volume or manner-of-sale restrictions, pursuant SEC Rule 144.  The Registrable Shares described in clause (b) are sometimes referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Registrable Warrant Shares</font><font style="font-family:inherit;font-size:11pt;">&#8221; and the Registrable Shares described in clauses (a) and (c) are sometimes referred to herein, collectively, as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Registrable Preferred Shares</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Registration Expenses&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means all expenses incurred by the Company in complying with Section 2.1 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding any transfer taxes, and Selling Expenses applicable to the sale).</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;SEC&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">or </font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Commission&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means the Securities and Exchange</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Commission.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;SEC Rule 144&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means Rule 144 promulgated by the SEC under the Securities Act.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Securities Act&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means the Securities Act of 1933, as amended.</font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(n)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Selling Expenses&#8221; </font><font style="font-family:inherit;font-size:11pt;">means all underwriting discounts and selling commissions applicable to the sale.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(o)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Trading Day</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means a day on which the principal Trading Market is open for trading.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(p)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Trading Market</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means the NASDAQ Capital Market; provided, that if the Common Stock ceases to be listed thereon, &#8220;Trading Market&#8221; shall mean (i) any other securities market or exchange on which the Common Stock is principally listed or quoted for trading on the date in question, including the NYSE MKT, the Nasdaq Global Market or the Nasdaq Global Select Market (or any successors to any of the foregoing) or (ii) if the Common Stock is not then listed or quoted for trading on any such securities market or exchange and if prices for the Common Stock are then reported in the &#8220;Pink Sheets,&#8221; OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices).</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(q)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Warrants&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the 5-year warrants received by each Holder to purchase one share of Common Stock for each share of Preferred Stock purchased by such Holder in the Offering.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECTION 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGISTRATION; RESTRICTIONS ON TRANSFER.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Registration.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">On or prior to the Filing Deadline, the Company shall prepare and file with the SEC a registration statement (including any related prospectus, amendments and supplements to such registration statement, and including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement, the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Registration Statement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to register, in accordance with the Securities Act, a number of shares of Common Stock equal to the number of Registrable Shares (a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Registration</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  The Registration Statement shall be on Form S-3 (except if the Company is then ineligible to register for resale the Registrable Shares on Form S-3, in which case such registration shall be on such other form available to register for resale the Registrable Shares as a secondary offering) subject to the provisions of Section 2.1(c).  Notwithstanding the registration obligations set forth in this Section 2.1, in the event the SEC informs the Company that all of the Registrable Shares cannot, as a result of the application of Rule 415 promulgated under the Securities Act, as such Rule may be amended from time to time, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Registration Statement as required by the SEC and/or (ii) withdraw the Registration Statement and file an alternative registration statement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Alternative Registration Statement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), in either case, covering the maximum number of Registrable Shares permitted to be registered by the SEC on Form S-3 or such other form available to register for resale the Registrable Shares as a secondary offering; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">, that prior to filing such amendment or Alternative Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable Shares in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09. Notwithstanding any other provision of this Agreement, if any SEC Guidance sets forth a limitation of the number of Registrable Shares permitted to be registered on the Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SEC for the registration of all or a greater number of Registrable Shares), unless otherwise directed in writing by a Holder as to its Registrable Shares, the number of Registrable Shares to be registered on such Registration Statement will be allocated to the Holders of such Registrable Shares in the following order of priority: first, on a pro rata basis based on the number of Registrable Warrant Shares held by all such Holders; and second, on a pro rata basis based on the number of Registrable Preferred Shares held by all such Holders.  Any Registrable Shares excluded or withdrawn from such Registration Statement shall be withdrawn from the Registration and the Company shall have no obligation to register such securities with the SEC.  For the avoidance of doubt, the Holders are not entitled to participate in any registration of the Company&#8217;s capital stock other than a registration resulting from this Section 2.1.  In the event the Company amends the Registration Statement or files an Alternative Registration Statement, as the case may be, under clauses (i) or (ii) above, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Shares that were not registered for resale on the Registration Statement, as amended, or the Alternative Registration Statement, as amended (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Remainder Registration Statements</font><font style="font-family:inherit;font-size:11pt;">&#8221;)</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective by the Commission as soon as practicable and, with respect to the Registration Statement or the Alternative Registration Statement, as applicable, no later than the Effectiveness Deadline (including filing with the SEC a request for acceleration of effectiveness in accordance with Rule 461 promulgated under the Securities Act), and shall use its commercially reasonable efforts to and keep such Registration Statement effective for as long as such shares of Common Stock are Registrable Shares (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Effectiveness Period</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  The Company, in its sole discretion, may deregister all shares that are no longer Registrable Shares.  The Company shall telephonically request effectiveness of the Registration Statement as of 4:00 P.M. New York City time on a Trading Day.  The Company shall promptly notify the Holders via facsimile or electronic mail file of the effectiveness of the Registration Statement within three (3) Trading Days that the Company telephonically confirms effectiveness with the SEC.  The Company shall, by 5:30 P.M. New York City time on the second Trading Day after the Effective Date, file a final Prospectus with the SEC, as required by Rule 424(b) promulgated under the Securities Act. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event that Form S-3 is not available for the registration of the resale of Registrable Shares hereunder, the Company shall use commercially reasonable efforts to (i) register the resale of the Registrable Shares on another appropriate form and (ii) undertake to register the Registrable Shares on Form S-3 after such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Shares has been declared effective by the SEC.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each Holder agrees to furnish to the Company the information set forth in the Acknowledge, Notice and Questionnaire at the end of this Agreement.  The Company will notify each Holder of any information the Company requires from that Holder other than the information contained herein, if any, which shall be completed and delivered to the Company promptly upon request and, in any event, within two (2) Trading Days after such notification.  Each Holder further agrees that it shall not be entitled to be named as a selling security holder in the Registration Statement or use the Prospectus for offers and resales </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">of Registrable Shares at any time, unless such Holder has returned to the Company a completed and signed this Agreement (including the Acknowledgement, Notice and Questionnaire at the end of this Agreement) and a response to any requests for further information as described in the previous sentence.  The Company has no obligation to include any such Holder as a selling security holder in the Registration Statement or any pre-effective or post-effective amendment or supplement thereto or to include (to the extent not theretofore included) in the Registration Statement the Registrable Shares identified in such request for further information.  Each Holder acknowledges and agrees that the information provided by such Holder herein or in any request for further information as described in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 2(d)</font><font style="font-family:inherit;font-size:11pt;">&#32;will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If the Company intends to distribute the Registrable Shares by means of an underwriting, it shall have sole discretion to select such underwriters.  In such event, the right of any Holder to include its Registrable Shares in such Registration shall be conditioned upon such Holder&#8217;s participation in such underwriting and the inclusion of such Holder&#8217;s Registrable Shares in the underwriting to the extent provided herein.  Any Registrable Shares excluded or withdrawn from such underwriting shall be withdrawn from the Registration.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Registration Procedures.  </font><font style="font-family:inherit;font-size:11pt;">In connection with the Company&#8217;s registration obligations hereunder, the Company shall use its commercially reasonable efforts to:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of the Company, to conduct a reasonable investigation within the meaning of the Securities Act.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(i)  Prepare and file with the SEC such amendments (including post&#8209;effective amendments) and supplements, to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Shares for its Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424 promulgated under the Securities Act; (iii) respond as promptly as reasonably practicable to any comments received from the SEC with respect to the Registration Statement or any amendment thereto and, as promptly as reasonably possible, provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the Holders as &#8220;Selling Stockholders&#8221; but not any comments that would result in the disclosure to the Holders of material and non-public information concerning the Company; and (iv) comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Shares covered by the Registration Statement until such time as all of such Registrable Shares shall have been disposed of (subject to the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such Registration Statement as so amended or in such Prospectus as so supplemented; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">, that each Holder shall be responsible for the delivery of the Prospectus to the Persons to whom such Holder sells any Registrable Shares (including in accordance with Rule 172 promulgated under the Securities Act), and each Holder agrees to dispose of Registrable Shares in compliance with the &#8220;Plan of Distribution&#8221; described in the Registration Statement and otherwise in compliance with </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">applicable federal and state securities laws.  In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 2.2(b)) by reason of the Company filing Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements with the SEC as promptly as reasonably possible.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notify, as promptly as reasonably practicable, each Holder of Registrable Shares covered by such Registration Statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.  The Company will use commercially reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Shares for sale in any jurisdiction, as soon as practicable.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If requested by a Holder, furnish to such Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto and all exhibits to the extent requested by such person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the SEC; provided, that the Company shall have no obligation to provide any document pursuant to this clause that is available on the SEC&#8217;s EDGAR system.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Prior to any resale of Registrable Shares by a Holder, register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Shares for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Shares covered by each Registration Statement; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">&#32;that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates or book-entry statements representing Registrable Shares to be delivered to a transferee pursuant to the Registration Statement.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Cooperate with any registered broker through which a Holder proposes to resell its Registrable Shares in effecting a filing with Financial Industry Regulatory Authority (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">FINRA</font><font style="font-family:inherit;font-size:11pt;">&#8221;) pursuant </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to FINRA Rule 2710 as requested by any such Holder; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:11pt;">, that the Holder shall pay the filing fee required. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Expenses of Registration.  </font><font style="font-family:inherit;font-size:11pt;">Except as specifically provided herein, all Registration Expenses incurred in connection with any Registration, qualification or compliance pursuant to Section 2.1 herein shall be borne by the Company.  All Selling Expenses incurred in connection with any Registration hereunder, shall be borne by the Holders. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delay of Registration; Agreement to Furnish Information; Suspension of Sales.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such Registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">It shall be a condition precedent to the obligations of the Company to take any action pursuant to Section 2.1 that the selling Holders shall furnish to the Company such information regarding themselves and the Registrable Shares held by them as shall be required to effect the Registration of their Registrable Shares, including but not limited to the information required pursuant to Section 2.1(d).  Each Holder acknowledges and agrees that the information provided to the Company will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the Holder&#8217;s obligations under Section 2.7 below or that are necessary to give further effect thereto, including but not limited to powers of attorney and the Acknowledgement, Notice and Questionnaire at the end of this Agreement.  The Company may impose stop-transfer instructions with respect to the shares of Common Stock subject to the foregoing restriction until the end of said one hundred eighty (180) calendar day period set forth in Section 2.7.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Each Holder agrees that any transferee who has become such other than pursuant to the Registration Statement of any shares of Registrable Shares shall be bound by this Section 2.4 and Section 2.7.  The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section 2.4 and Section 2.7 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Company may require each selling Holder to furnish to the Company a certified statement as to (i) the number of shares of Common Stock beneficially owned by such Holder and any affiliate thereof, (ii) any FINRA affiliations, (iii) any natural persons who have the power to vote or dispose of the Common Stock and (iv) any other information as may be requested by the Commission, FINRA or any state securities commission. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Upon notification by the Company pursuant to Section 2.2(c), the Holders shall suspend all transactions under the Registration Statement until such time as the Company has amended or supplemented such Registration Statement in accordance with its obligations under Section 2.2(c).</font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Indemnification.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;In the event any Registrable Shares are included in a Registration Statement under Section 2.1:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Violation</font><font style="font-family:inherit;font-size:11pt;">&#8221;) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such Registration Statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such Registration Statement; and the Company will reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided however</font><font style="font-family:inherit;font-size:11pt;">, that the indemnity agreement contained in this Section 2.5(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such Registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To the extent permitted by law, each Holder will, if Registrable Shares held by such Holder are included in the securities as to which such Registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such Registration Statement or any of such other Holder&#8217;s partners, directors or officers or any person who controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such Registration Statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act (collectively, a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Holder Violation</font><font style="font-family:inherit;font-size:11pt;">&#8221;), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">upon and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such Registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided however</font><font style="font-family:inherit;font-size:11pt;">, that the indemnity agreement contained in this Section 2.5(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided further, that in no event shall any indemnity under this Section 2.5 exceed the net proceeds from the offering received by such Holder.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Promptly after receipt by an indemnified party under this Section 2.5 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.5, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however,</font><font style="font-family:inherit;font-size:11pt;">&#32;that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding.  The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.5, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.5.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If the indemnification provided for in this Section 2.5 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations.  The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, that</font><font style="font-family:inherit;font-size:11pt;">&#32;(i) in no event shall any contribution by a Holder hereunder exceed the net proceeds from the offering received by such Holder and (ii) no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder&#8217;s liability pursuant to this Section </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.5(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.5(b), exceed the proceeds from the offering received by such Holder, except in the case of willful misconduct or fraud by such Holder.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and Holders under this Section 2.5 shall survive completion of any offering of Registrable Shares in a Registration Statement and the termination of this Agreement.  No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Assignment of Registration Rights.  </font><font style="font-family:inherit;font-size:11pt;">The rights to cause the Company to register</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Registrable Shares pursuant to Section 2.1 may be assigned by a Holder to a transferee or assignee of Registrable Shares (for so long as such shares remain Registrable Shares) that (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member, or stockholder of a Holder that is a corporation, partnership or limited liability company or (b) is a Holder&#8217;s family member or trust for the benefit of an individual Holder; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however, </font><font style="font-family:inherit;font-size:11pt;">(i) the transferor shall, prior to consummating such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the Securities with respect to which such registration rights are being assigned, (ii) such transferee shall agree to be subject to all restrictions and obligations set forth in this Agreement and (iii) such transferee shall agree not to sell such Registrable Shares under the Registration Statement until such time as the Company has concluded that the transferee is eligible to sell such Registrable Shares under the Registration Statement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Market Stand-Off Agreement.  </font><font style="font-family:inherit;font-size:11pt;">If requested by an underwriter, each Holder hereby agrees that such Holder shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock of the Company held by such Holder for a period specified by the representative of the underwriters of Common Stock of the Company not to exceed one hundred twenty (120) calendar days following the effective date of a Registration Statement of the Company filed under the Securities Act.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Termination of Registration Provisions.  </font><font style="font-family:inherit;font-size:11pt;">With respect to any Holder, all provisions in Section 2 of this Agreement (other than Section 2.5 and 2.7) shall expire and terminate upon the earlier of (i) sixty-six (66) months after the issue date of the Preferred Stock or (ii) when all Registrable Shares of such Holders are eligible to be sold without restriction under SEC Rule 144 or another similar exemption under the Securities Act of the Securities Act. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECTION 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MISCELLANEOUS.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Any action, arbitration, claim, hearing, litigation or suit (whether civil, criminal, administrative, judicial or investigative, whether formal or informal, whether public or private) commenced, brought, conducted or heard by or before any federal, state, local or foreign government or any court of competent jurisdiction, administrative or regulatory body, agency, bureau, or commission in any domestic or foreign jurisdiction, any appropriate division of any of the foregoing or any arbitrator, or other legal action  (each, a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Proceeding</font><font style="font-family:inherit;font-size:11pt;">&#8221;) relating to this Agreement shall be governed by and construed and </font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.  Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the actions contemplated by this Agreement (whether brought against a party hereto or its affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the Southern District of New York.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the Southern District of New York for the adjudication of any Proceeding related to this Agreement or the actions contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any Proceeding that it is not personally subject to the jurisdiction of any such court, that Proceeding is improper or is an inconvenient venue for such Proceeding.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Successors and Assigns.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable Shares from time to time; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided, however, </font><font style="font-family:inherit;font-size:11pt;">that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Shares specifying the full name and address of the transferee, the Company may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price.  Before the Company records a stock transfer on its corporate record books or issues shares of its capital stock to any person following such transfer or issuance and such person is not a party to this Agreement, such person shall be required to first execute and deliver to the Company a counterpart signature page to this Agreement pursuant to which such person agrees to be bound by all of the terms and conditions of this Agreement (as it may have been amended), and the failure of any such person to do so shall preclude the Company from recording such a transfer or issuance on its corporate record books.  The addition of any such person as a party to this Agreement shall not be deemed an amendment to this Agreement pursuant to Section 3.5 of this Agreement and shall not require the consent of any of the other parties to this Agreement.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Entire Agreement.  </font><font style="font-family:inherit;font-size:11pt;">This Agreement, the Subscription Agreement and the other documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein.  Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Severability.  </font><font style="font-family:inherit;font-size:11pt;">If any provision of this Agreement, or the application of such provision to any person or circumstance, shall be held invalid by a court of competent jurisdiction, the remainder of this Agreement, or the application of such provision to persons or circumstances other than those to which it is held invalid by such court, shall not be affected thereby.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Amendment and Waiver</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise expressly provided, this Agreement may be amended or modified only upon the written consent of the Company and the Holders of at least a majority of the Registrable Shares.</font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise expressly provided, the obligations of the Company and the rights of the Holders under this Agreement may be waived only with the written consent of the Holders of at least a majority of the Registrable Shares.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">For the purposes of determining the number of Holders entitled to exercise any rights hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delays or Omissions.  </font><font style="font-family:inherit;font-size:11pt;">It</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring.  It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party&#8217;s part of any breach, default or noncompliance under the Agreement or any waiver on such party&#8217;s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing.  All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Notices. </font><font style="font-family:inherit;font-size:11pt;">&#32;Any notice or other communication given hereunder shall be deemed sufficient if in writing and sent by registered or certified mail, return receipt requested, delivered by hand against written receipt therefor, or sent in portable document format (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">pdf</font><font style="font-family:inherit;font-size:11pt;">&#8221;) via electronic mail, addressed as follows:</font></div><div style="line-height:240%;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">if to the Company, to it at:</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Diffusion Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2020 Avon Court, Suite 4</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Charlottesville, Virginia 22902</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn: David Kalergis, Chief Executive Officer</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: dkalergis@diffusionpharma.com</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">With a copy to (which shall not constitute notice):</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dechert LLP</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1095 Avenue of the Americas</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">New York, New York 10036</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn:  David Rosenthal, Esq.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: david.rosenthal@dechert.com</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">if to the Investor, to the Investor&#8217;s address indicated on the signature page of this such Investor&#8217;s Subscription Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notices shall be deemed to have been given or delivered (i) on the third (3rd) business day following the date of postmark in the case of delivery by registered or certified mail, (ii) on the date of delivery in the case of delivery by hand or (iii) on the date of delivery if delivered by electronic mail; provided that if such e-mail is received after 4:00 p.m. Eastern Time on a business day or at any time on a non-business day, such notice shall be deemed delivered on the following business day.</font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Titles and Subtitles.  </font><font style="font-family:inherit;font-size:11pt;">The titles of the sections and subsections of this Agreement</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">are for convenience of reference only and are not to be considered in construing this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Counterparts.  </font><font style="font-family:inherit;font-size:11pt;">This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts together shall constitute one and the same instrument.  Delivery of executed signature pages hereof by facsimile transmission or pdf shall constitute effective and binding execution and delivery of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Pronouns.  </font><font style="font-family:inherit;font-size:11pt;">All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[THIS SPACE INTENTIONALLY LEFT BLANK]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:100%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="sDB77064597C95DA8B558F44B28513293"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The undersigned hereby acknowledges and is advised of the following Interpretation A.65 of the July 1997 SEC Manual of Publicly Available Telephone Interpretations regarding short selling:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8220;An Issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet effective.  One of the selling stockholders wanted to do a short sale of common stock &#8220;against the box&#8221; and cover the short sale with registered shares after the effective date.  The issuer was advised that the short sale could not be made before the registration statement become effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made.  There would, therefore, be a violation of Section 5 if the shares were effectively sold prior to the effective date.&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By returning an executed copy of this Agreement, the undersigned will be deemed to be aware of the foregoing interpretation and to have confirmed that, to the best of the undersigned&#8217;s knowledge and belief, the foregoing statements (including without limitation the answers to this Acknowledgment, Notice and Questionnaire) are true, correct and complete.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PLEASE FAX OR E-MAIL A COPY OF THE COMPLETED AND EXECUTED ACKNOWLEDGEMENT, NOTICE AND QUESTIONNAIRE, AS WELL AS THE SIGNATURE PAGE THAT FOLLOWS, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Kevin Silk</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dechert LLP</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2929 Arch Street</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Philadelphia, Pennsylvania 19104</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Fax: 215-655-2506</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Email: kevin.silk@dechert.com</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">*******************************************</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Agreement to be executed and delivered either in person or by its duly authorized agent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:528px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signature&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signature (if shares are held jointly)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:528px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name Typed or Printed&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name Typed or Printed</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:528px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title (if Investor is an Entity)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title (if Investor is an Entity)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AGREED AND ACCEPTED:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DIFFUSION PHARMACEUTICALS INC.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:____________________________________ &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: _________________, 2017</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>lease1317carltonaveste400fu.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s572177B35E4DCEFAD6CBFD184CCFD2F3"></a></div><div><div style="line-height:120%;padding-top:5px;text-align:right;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#4b4b4b;">Tenant: Diffusion Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:right;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#5b5b5b;">Su</font><font style="font-family:inherit;font-size:14pt;color:#2b2b2b;">i</font><font style="font-family:inherit;font-size:14pt;color:#4b4b4b;">te: </font><font style="font-family:inherit;font-size:14pt;color:#5b5b5b;">1317 </font><font style="font-family:inherit;font-size:14pt;color:#4b4b4b;">Carlton Ave., Suite 400</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#4b4b4b;text-decoration:underline;">DEED OF LEASE</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">THIS DEED OF; LEASE (this &#8220;Lease&#8221;) is </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">entered </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">into as of the 31</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;day of </font><font style="font-family:Arial;font-size:12pt;color:#5b5b5b;">March 2017, between</font><font style="font-family:Arial;font-size:12pt;color:#5b5b5b;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">ONE CARLTON, LLC, Aa </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Virginia Limited liability </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">company ("Landlord"), </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and DIFFUSION PHARMACEUTICALS INC., a Delaware corporation (&#8220;Tenant&#8221;).   </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">In consideration of the mutual covenants stated below, and intending to be legally bound, the parties covenant and agree as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;color:#4b4b4b;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">PREMISES</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">. Landlord leases to Tenant, and </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">leases from Landlord, for the Tenant and upon the terms and subject to the conditions of this Lease, the entire second floor of the Building </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(as </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">shown on </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;attached hereto) but exclusive of the mezzanine space, known-as Su</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">i</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">te </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">400 </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">which </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the part</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">i</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">es </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">stipulate </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and agree cons</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">i</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">st of approxima</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">t</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ely 8,221 rentable square feet of space </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(the "</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Premises'')</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">in the Building. The &#8220;Building&#8221; is the building known as </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">1317 Carlton </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Avenue, Charlottesville, Virginia 22902</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">. </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">The </font><font style="font-family:inherit;font-size:12pt;color:#777777;">'</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">'Pro</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;text-decoration:underline;">j</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">ect'</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#777777;">' </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">is the land on </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">which </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Building </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">is </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">located, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">-together with </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the Building and all other improvements thereon. The Premises are delivered </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">"As </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ls".</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">TERM</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">The term of this Lease </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(the "</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;text-decoration:underline;">T</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">erm</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">") shall </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">commence </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">on </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">April </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">15,2017 </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(the "</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Commencement&#173;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Date</font><font style="font-family:inherit;font-size:12pt;color:#939393;">'</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">'</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">)</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">.  </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">The </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">terms and provisions of this Lease are binding on the parties upon Tenant's and Landlord's execution of this Lease </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">notwithstanding </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">a </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">later </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Commencement Date for the Term. </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">The Commencement </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Date and Rent Commencement Date </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(as </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">hereinafter defined) shall be confirmed by Landlord and Tenant by the execution of a</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;Confirmation </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">of Lease Term </font><font style="font-family:inherit;font-size:12pt;color:#777777;">(</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the &#8220;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">COLT</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">") in the form attached </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">hereto </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">as </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">.</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;font-style:italic;">1f </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Tenan</font><font style="font-family:inherit;font-size:12pt;color:#777777;">t </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">fails </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;font-style:italic;">to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">execute or</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;object to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the COLT within </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">ten (I </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">0) business days of its delivery, Landlord's determination of such dates </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">be deemed accepted.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">The Term shall end on </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">April 30, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">2022, unless </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">extended </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or sooner terminate pursuant to the term of this Lease.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Provided Tenant is Diffusion Pharmaceuticals, Inc., or any </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Affiliate </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(as </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">defined in Section 9(b)</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;below</font><font style="font-family:inherit;font-size:12pt;color:#777777;">) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Surviving </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Entity (as defined in Section 9(d) below), Tenant is neither in default at the time of </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">exercise </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">nor has </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ever been in default beyond notice and cure (irrespective of the fact </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">that </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">later </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">cured such default</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;after the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">applicable cure period expired) of any monetary obligations under the Lease more </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">than twice </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">during the Term, Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">is </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">fully occupying </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Premises and the Lease is in full force and effect, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">shall have </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">right to</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;extend </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Term (the "</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">First</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Extension</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">") </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">for sixty </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(60) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">months beyond the end of </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Term as extended by</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;this </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">option </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(i.e.</font><font style="font-family:inherit;font-size:12pt;color:#777777;">, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">from </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">May I</font><font style="font-family:inherit;font-size:12pt;color:#777777;">, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">2022 to April 30, 2027) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">"</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">First</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Extension Term</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">"). Tenant shal</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">l </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">furnish </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">written notice to Landlord of intent to extend </font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">t</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">he Term </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">("Tenant</font><font style="font-family:inherit;font-size:12pt;color:#777777;text-decoration:underline;">'</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">s First</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Extension Notice")</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">no later than May 1, 2021</font><font style="font-family:inherit;font-size:12pt;color:#777777;">,</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;failing </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">which </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the First Extension Option shall be deemed </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">waived; </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">time being of the essence. The terms and </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">conditions </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">of the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Lease </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">during the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">First </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Extension Term shall remain unchanged except that the annual Fixed Rent for each </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">twelve (12)-month </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">period of the First Extension </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Term </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">shall be </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">amount as set forth in Section 3 </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">(a) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">below.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Provided </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Tenant is </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Diffusion Pharmaceuticals </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Inc.</font><font style="font-family:inherit;font-size:12pt;color:#777777;">, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or any Affiliate or Surviving Entity, Tenant is </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">neither </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">in default at the  time of exercise nor  has </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ever been in default beyond notice and  cure</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;(irrespective </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">of the fact that </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">late</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">r </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">cured </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">such default after the applicab</font><font style="font-family:inherit;font-size:12pt;color:#2b2b2b;">l</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">e cure period expired) of any monetary obligations under </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Lease more </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">than </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">twice during the </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Term, Tenant is fully occupying the Premises and the Lease is </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">in full force </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">effect, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Tenant shall have </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the right </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">extend </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Term (the </font><font style="font-family:inherit;font-size:12pt;color:#777777;">''</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Second Extension</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">") for </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">sixty (60) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">months beyond the end of the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Term </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">as </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">extended </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">by this second option </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;font-style:italic;">(i.e., </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">from </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">May </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">1, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">2027 </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to April 30</font><font style="font-family:inherit;font-size:12pt;color:#777777;">,</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;2032) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">"</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Second</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Extension Term</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">''). Tenant shall furnish </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">written </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">notice </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord of intent </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">to extend </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the Term</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;("</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;text-decoration:underline;">Tenant's Second Extension</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Notice</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">") no later than May l, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">2026</font><font style="font-family:inherit;font-size:12pt;color:#777777;">, </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">failing which </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the Second Extension Option shall be deemed waived; time being of the </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">essence. </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">The terms and conditions of </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the Lease </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">during the Second Extension</font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">&#32;Term shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">remain unchanged except that the annual </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Fixed </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Rent for each </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">twelve </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">(12)-month period of </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">the Second</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;Extension Term </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">be the amount as set </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">forth </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">in Section 3(a) below. </font><font style="font-family:inherit;font-size:12pt;color:#5b5b5b;">Notwithstanding </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">anything to the contrary </font><font style="font-family:inherit;font-size:12pt;">herein, Tenant shall have no right to extend the Term other than or beyond the two (2), sixty (60)-month extension terms described in this and the preceding paragraph.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon Tenant&#8217;s timely and proper exercise of the First Extension Option (and, if timely and properly exercised, the Second Extension Option) pursuant to the terms above and satisfaction of the above conditions, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall include the First Extension Term (and the Second Extension Term), and Landlord and Tenant shall execute prior to the expiration of the then-expiring Term an appropriate amendment to this Lease, in form and content reasonably satisfactory to both Landlord and Tenant, memorializing the extension of the Term for the ensuing First or Second Extension Term. Notwithstanding the foregoing, failure of either of the parties to timely execute the said amendment shall not affect the validity of an Extension Term provided Tenant has met the requirements of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2(c)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">2(d)</font><font style="font-family:inherit;font-size:12pt;">&#32;above.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">FIXED RENT; SECURITY DEPOSIT; GUARANTY</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Tenant covenants and agrees to pay to Landlord, commencing on May 1, 2017 (the &#8220;Rent Commencement Date&#8221;) and continuing during the Term, without notice, demand, set-off, deduction or counterclaim, fixed rent (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fixed Rent</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the amounts set forth below, payable in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 3(b)</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TIME PERIOD</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">RENT PER R.S.F.</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">MONTHLY</font></div><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INSTALLMENTS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ANNUAL FIXED RENT</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5/1/17 &#8211; 4/30/18</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$13.50</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$9,248.63</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$110,983.50</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5/1/18 &#8211; 4/30/19</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$13.75</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$9,419.90</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$113,038.75</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5/1/19 &#8211; 4/30/20</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$14.00</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$9,591.17</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$115,094.00</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5/1/20 &#8211; 4/30/21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$14.25</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$9,762.44</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$117,149.25</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5/1/21 &#8211; 4/30/22</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$14.50</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$9,933.71</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$119,204.50</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1st x ext) 5/1/22 &#8211; 4/30/23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$14.75</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$10,104.98</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$121,259.75</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1st x ext) 5/1/23 &#8211; 4/30/24</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$15.00</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$10,276.25</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$123,315.00</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1st x ext) 5/1/24 &#8211; 4/30/25</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$15.25</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$10,447.52</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$125,370.25</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1st x ext) 5/1/25 &#8211; 4/30/26</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$15.50</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$10,618.79</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$127,425.50</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1st x ext) 5/1/26 &#8211; 4/30/27</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$15.75</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:28px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$10,790.06</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$129,480.75</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:58px;text-indent:-31px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2nd x ext) 5/1/27 &#8211; 4/30/32</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Market, but not lower than</font></div><div style="padding-left:8px;text-indent:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$16.00 sf for 1st year with annual increases of $.25 sf</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">--</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">--</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Monthly installments of Fixed Rent shall be payable in advance on or before the first day of each month of the Term by wire transfer or ACH of immediately available funds to the account at Bank of America account of Henry Liscio Company Escrow Account no.435019970194, ABA wire routing number 026009593 (ACH ABA routing number 05100017), or as otherwise directed in writing by Landlord to Tenant.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Together with Tenant&#8217;s execution of this Lease, Tenant shall pay to Landlord the installment of Fixed Rent due for May,2017, and the Security Deposit (as defined below) by two separate checks. If any installment of Fixed Rent is not paid by the fifth of the month, or any other amount due from Tenant is not paid to Landlord when due, Tenant shall also pay as Additional Rent (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:12pt;">) a late fee of ten percent (10%) of the total payment then due. Tenant shall be required to pay a security deposit of $9,248.63 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Security Deposit</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as security for the prompt and complete performance by Tenant of every provision of this Lease. No interest shall be paid to Tenant on the Security Deposit. If Tenant fails to perform any of its obligations hereunder, Landlord may use, apply or retain the whole or any part of the Security Deposit for the payment of: (i) any rent or other sums of money that Tenant may not have paid </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">when due; (ii) any sum expended by Landlord in accordance with the provisions of this Lease; and/or (iii) any sum that Landlord may expend or be required to expend by reason of Tenant&#8217;s default. The use of the Security Deposit by Landlord shall not prevent Landlord from exercising any other remedy provided by this Lease or by law and shall not operate as either liquidated damages or as a limitation </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">on any recovery to which Landlord may otherwise be </font><font style="font-family:inherit;font-size:12pt;color:#414141;">en</font><font style="font-family:inherit;font-size:12pt;color:#666666;">ti</font><font style="font-family:inherit;font-size:12pt;color:#414141;">tled.</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;If any portion of the Security Deposit is used, applied or retained </font><font style="font-family:inherit;font-size:12pt;color:#414141;">b</font><font style="font-family:inherit;font-size:12pt;color:#666666;">y </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord, Tenant agrees, within ten </font><font style="font-family:inherit;font-size:12pt;color:#666666;">(10) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">days after the written demand therefor </font><font style="font-family:inherit;font-size:12pt;color:#414141;">is </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">made by Landlord, to deposit </font><font style="font-family:inherit;font-size:12pt;color:#414141;">cash </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Landlord in </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">an amount sufficient to restore the Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">its </font><font style="font-family:inherit;font-size:12pt;color:#414141;">original amount. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">In </font><font style="font-family:inherit;font-size:12pt;color:#414141;">addition </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to the foregoing, if Tenant defaults </font><font style="font-family:inherit;font-size:12pt;color:#666666;">(irres</font><font style="font-family:inherit;font-size:12pt;color:#414141;">pective </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the fact that Tenant cured </font><font style="font-family:inherit;font-size:12pt;color:#414141;">such default</font><font style="font-family:inherit;font-size:12pt;color:#666666;">) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">more than </font><font style="font-family:inherit;font-size:12pt;color:#414141;">once </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">in its performance of a monetary </font><font style="font-family:inherit;font-size:12pt;color:#414141;">obligation </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and such monetary defaults aggregate in excess of $15,000.00 under this Lease, Landlord may require Tenant to increase </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the greater of twice </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the: </font><font style="font-family:inherit;font-size:12pt;color:#666666;">(i) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Fixed Rent </font><font style="font-family:inherit;font-size:12pt;color:#414141;">paid </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">monthly; or (ii) the initial </font><font style="font-family:inherit;font-size:12pt;color:#414141;">amount </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">If Tenant shall fully </font><font style="font-family:inherit;font-size:12pt;color:#414141;">comply </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">with all of the provisions of this </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Lease, the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">or </font><font style="font-family:inherit;font-size:12pt;color:#414141;">a</font><font style="font-family:inherit;font-size:12pt;color:#666666;">ny </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">balance </font><font style="font-family:inherit;font-size:12pt;color:#666666;">thereof shal</font><font style="font-family:inherit;font-size:12pt;color:#414141;">l be returned to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant within a reasonable time after</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">later of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">end </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Term </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or Tenant's delivery </font><font style="font-family:inherit;font-size:12pt;color:#414141;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Premises to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Landlord a</font><font style="font-family:inherit;font-size:12pt;color:#666666;">s </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">required hereunder</font><font style="font-family:inherit;font-size:12pt;color:#232323;">. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Upon the return </font><font style="font-family:inherit;font-size:12pt;color:#414141;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the original </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">hereunder, or the remaining balance </font><font style="font-family:inherit;font-size:12pt;color:#414141;">thereof, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#414141;">shall be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">completely </font><font style="font-family:inherit;font-size:12pt;color:#666666;">relieved </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of liability with respect to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">In the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">event </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of a transfer of the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Building, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord shall have the right </font><font style="font-family:inherit;font-size:12pt;color:#414141;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">transfer </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit and Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall thereupon be </font><font style="font-family:inherit;font-size:12pt;color:#414141;">released </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by Tenant from all liability for the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">return </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">such </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Security Deposit. Upon the assumption of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">such </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Security </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Deposit </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by the transferee, </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">agrees to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">look </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">solely to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the new </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">landlord </font><font style="font-family:inherit;font-size:12pt;color:#414141;">for </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the return of such Security Deposit.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#666666;">4</font><font style="font-family:inherit;font-size:12pt;color:#939393;">,&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">ADDITIONAL</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#414141;text-decoration:underline;">RENT</font><font style="font-family:inherit;font-size:12pt;color:#414141;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Commencing on the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Commencement Date: </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and in each calendar year thereafter during the Term, </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Tenan</font><font style="font-family:inherit;font-size:12pt;color:#666666;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">covenants and </font><font style="font-family:inherit;font-size:12pt;color:#414141;">agrees </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">pay </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">in advance on a monthly basis to Landlord Tenant's Share of Operating Expenses, without </font><font style="font-family:inherit;font-size:12pt;color:#414141;">deduction, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">counterclaim or set off. "</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Tenant's Share</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">" </font><font style="font-family:inherit;font-size:12pt;color:#414141;">equals the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">number of rentable square </font><font style="font-family:inherit;font-size:12pt;color:#414141;">feet </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the Premises </font><font style="font-family:inherit;font-size:12pt;color:#414141;">divided </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">number of rentable square feet office </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Building </font><font style="font-family:inherit;font-size:12pt;color:#666666;">(which </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the parties confirm contains approximately </font><font style="font-family:inherit;font-size:12pt;color:#414141;">78,454 rentable </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">square feet). Tenant's Share on </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">date of this Lease is stipulated to be 10.48%.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#666666;">"</font><font style="font-family:inherit;font-size:12pt;color:#666666;text-decoration:underline;">O</font><font style="font-family:inherit;font-size:12pt;color:#414141;text-decoration:underline;">perating</font><font style="font-family:inherit;font-size:12pt;color:#414141;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">" are: </font><font style="font-family:inherit;font-size:12pt;color:#666666;">(i) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:12pt;color:#414141;">reasonable operating </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">costs and expenses related to the maintenance, operation and repair of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Project incurred </font><font style="font-family:inherit;font-size:12pt;color:#414141;">by Landlord, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">including </font><font style="font-family:inherit;font-size:12pt;color:#414141;">but not limited to a </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">management fee </font><font style="font-family:inherit;font-size:12pt;color:#414141;">not </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">exceed </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">five percent </font><font style="font-family:inherit;font-size:12pt;color:#666666;font-style:italic;">(5%) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of gross rents </font><font style="font-family:inherit;font-size:12pt;color:#414141;">and </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">revenues </font><font style="font-family:inherit;font-size:12pt;color:#414141;">from </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Project; </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">utilities; and </font><font style="font-family:inherit;font-size:12pt;color:#414141;">capital </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">expenditures and </font><font style="font-family:inherit;font-size:12pt;color:#414141;">capital </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">repairs and replacements, which capital items shall </font><font style="font-family:inherit;font-size:12pt;color:#414141;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">included as operating expenses solely </font><font style="font-family:inherit;font-size:12pt;color:#414141;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the extent of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">amortized costs of same </font><font style="font-family:inherit;font-size:12pt;color:#414141;">over </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the useful life of the improvement in accordance with generally accepted accounting </font><font style="font-family:inherit;font-size:12pt;color:#414141;">principles; </font><font style="font-family:inherit;font-size:12pt;color:#666666;">(ii) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:12pt;color:#666666;">insurance </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">premiums </font><font style="font-family:inherit;font-size:12pt;color:#414141;">payable by Landlord for </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">insurance with respect to </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the Project; </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and (iii) </font><font style="font-family:inherit;font-size:12pt;color:#414141;">taxes </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">payable on the Project. Each </font><font style="font-family:inherit;font-size:12pt;color:#414141;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Operating Expenses </font><font style="font-family:inherit;font-size:12pt;color:#414141;">shall for all </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">purposes be treated </font><font style="font-family:inherit;font-size:12pt;color:#414141;">and considered </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">as Additional Rent. Tenant shall </font><font style="font-family:inherit;font-size:12pt;color:#414141;">pay, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">in monthly installments </font><font style="font-family:inherit;font-size:12pt;color:#414141;">in advance</font><font style="font-family:inherit;font-size:12pt;color:#666666;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">on </font><font style="font-family:inherit;font-size:12pt;color:#414141;">account </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Share of Operating Expenses, the estimated amount of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the Operating </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Expenses for such year as </font><font style="font-family:inherit;font-size:12pt;color:#414141;">determined </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by Land</font><font style="font-family:inherit;font-size:12pt;color:#232323;">l</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ord in </font><font style="font-family:inherit;font-size:12pt;color:#414141;">its reasonable </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">discretion. </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Prior </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to the end </font><font style="font-family:inherit;font-size:12pt;color:#414141;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the calendar year in which the </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Lease </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">commences and thereafter for each successive </font><font style="font-family:inherit;font-size:12pt;color:#414141;">calendar </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">year during the Term (each, a </font><font style="font-family:inherit;font-size:12pt;color:#666666;">''</font><font style="font-family:inherit;font-size:12pt;color:#666666;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:12pt;color:#666666;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Yea</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">r'), or part thereof: or as soon as administratively available thereafter</font><font style="font-family:inherit;font-size:12pt;color:#808080;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord shall send</font><font style="font-family:inherit;font-size:12pt;color:#666666;">&#32;to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant a statement of projected Operating Expenses </font><font style="font-family:inherit;font-size:12pt;color:#414141;">and </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:12pt;color:#414141;">indicate </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">what </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Share of Operating</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Expenses shall be. As soon as administratively available, Landlord shall send to Tenant a </font><font style="font-family:inherit;font-size:12pt;color:#414141;">statement </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of actual Operating Expenses for the prior </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Lease </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Year showing </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">actual </font><font style="font-family:inherit;font-size:12pt;color:#414141;">amount </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">due </font><font style="font-family:inherit;font-size:12pt;color:#414141;">from </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant. </font><font style="font-family:inherit;font-size:12pt;color:#414141;">In </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the event </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">amount prepaid by Tenant exceeds the amount </font><font style="font-family:inherit;font-size:12pt;color:#414141;">that </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">was actually due then Landlord shall </font><font style="font-family:inherit;font-size:12pt;color:#414141;">issue </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">a </font><font style="font-family:inherit;font-size:12pt;color:#414141;">credit </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to Tenant in an amount equal to the overcharge, which </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">credit </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Tenant may </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">apply to future payments on </font><font style="font-family:inherit;font-size:12pt;color:#414141;">account of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Operating Expenses </font><font style="font-family:inherit;font-size:12pt;color:#414141;">until Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">has been fully credited with the overcharge. If the credit due </font><font style="font-family:inherit;font-size:12pt;color:#414141;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant is more than the aggregate total </font><font style="font-family:inherit;font-size:12pt;color:#414141;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">future </font><font style="font-family:inherit;font-size:12pt;color:#414141;">renta</font><font style="font-family:inherit;font-size:12pt;color:#666666;">l </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">payments, Landlord shall </font><font style="font-family:inherit;font-size:12pt;color:#414141;">pay </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to Tenant </font><font style="font-family:inherit;font-size:12pt;color:#414141;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">difference </font><font style="font-family:inherit;font-size:12pt;color:#414141;">between </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the credit and such aggregate total. In the event Landlord has undercharged Tenant, then </font><font style="font-family:inherit;font-size:12pt;color:#414141;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall send Tenant an invoice with the additional amount due, which amount shall be paid in </font><font style="font-family:inherit;font-size:12pt;color:#414141;">full </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by Tenant within twenty (20) days of </font><font style="font-family:inherit;font-size:12pt;color:#414141;">receipt. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant's obligations under this </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;shall survive the expiration or sooner </font><font style="font-family:inherit;font-size:12pt;color:#414141;">termination </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of this Lease.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">ln calculating the Operating Expenses, if for thirty </font><font style="font-family:inherit;font-size:11pt;color:#666666;">(30) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">or more days during </font><font style="font-family:inherit;font-size:11pt;color:#414141;">the </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">preceding Lease Year less than ninety-five percent (95%) of </font><font style="font-family:inherit;font-size:11pt;color:#414141;">the rentable </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">area </font><font style="font-family:inherit;font-size:11pt;color:#414141;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the Building was occupied by tenants, </font><font style="font-family:inherit;font-size:11pt;color:#414141;">then </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the Operating Expenses </font><font style="font-family:inherit;font-size:11pt;color:#414141;">attributable </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to the </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Project </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shall be </font><font style="font-family:inherit;font-size:11pt;color:#414141;">deemed </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">for such Lease Year to be amounts equal to the Operating Expenses </font><font style="font-family:inherit;font-size:11pt;color:#414141;">that </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">would </font><font style="font-family:inherit;font-size:11pt;color:#414141;">normally be </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">expected </font><font style="font-family:inherit;font-size:11pt;color:#414141;">to </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">be incurred bad such occupancy of the </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Building </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">beep at least ninety-five percent </font><font style="font-family:inherit;font-size:11pt;color:#666666;">(95%) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">throughout such year, as reasonably determined </font><font style="font-family:inherit;font-size:11pt;color:#414141;">by </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Landlord </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;font-style:italic;">(i.e., </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">taking into account that certain expenses depend on occupancy </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;font-style:italic;">(e.g., </font><font style="font-family:inherit;font-size:11pt;color:#414141;">janitorial</font><font style="font-family:inherit;font-size:11pt;color:#666666;">) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">and certain expenses do not </font><font style="font-family:inherit;font-size:11pt;color:#666666;font-style:italic;">(e.g., </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">landscaping))</font><font style="font-family:inherit;font-size:11pt;color:#808080;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Furthermore, if Landlord shall </font><font style="font-family:inherit;font-size:11pt;color:#414141;">not </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">furnish any item or items of Operating Expenses to any portions </font><font style="font-family:inherit;font-size:11pt;color:#414141;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Building because </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">such portions are not occupied or because such item is not </font><font style="font-family:inherit;font-size:11pt;color:#414141;">required by </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the tenant of such portion </font><font style="font-family:inherit;font-size:11pt;color:#414141;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the Building, for the purposes </font><font style="font-family:inherit;font-size:11pt;color:#414141;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">computing Operating Expenses, an equitable adjustment shall be made so </font><font style="font-family:inherit;font-size:11pt;color:#414141;">that </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the item of Operating Expense </font><font style="font-family:Arial;font-size:11pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">question </font><font style="font-family:inherit;font-size:11pt;color:#666666;">shall </font><font style="font-family:inherit;font-size:11pt;color:#414141;">be </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shared only </font><font style="font-family:inherit;font-size:11pt;color:#414141;">b</font><font style="font-family:inherit;font-size:11pt;color:#666666;">y </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">tenants actually </font><font style="font-family:inherit;font-size:11pt;color:#414141;">receiving </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the benefits thereof</font><font style="font-family:inherit;font-size:11pt;color:#808080;">.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="sAA80EDF8BCCF02B4B66DFD184E0086FD"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#525252;">All costs and </font><font style="font-family:inherit;font-size:12pt;color:#424242;">expenses </font><font style="font-family:inherit;font-size:12pt;color:#525252;">other </font><font style="font-family:inherit;font-size:12pt;color:#424242;">than </font><font style="font-family:inherit;font-size:12pt;color:#525252;">Fixed Rene </font><font style="font-family:inherit;font-size:12pt;color:#424242;">that Tenant </font><font style="font-family:inherit;font-size:12pt;color:#525252;">assumes </font><font style="font-family:inherit;font-size:12pt;color:#424242;">or </font><font style="font-family:inherit;font-size:12pt;color:#525252;">agrees to pay and </font><font style="font-family:inherit;font-size:12pt;color:#424242;">any</font><font style="font-family:inherit;font-size:12pt;color:#525252;">&#32;other sum payable by Tenant pursuant to this Lease, including, without limitation, pursuant to this </font><font style="font-family:inherit;font-size:12pt;color:#525252;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:12pt;color:#525252;">, shall be deemed "</font><font style="font-family:inherit;font-size:12pt;color:#525252;text-decoration:underline;">Additional</font><font style="font-family:inherit;font-size:12pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#424242;text-decoration:underline;">Rent</font><font style="font-family:inherit;font-size:12pt;color:#424242;">", </font><font style="font-family:inherit;font-size:12pt;color:#525252;">and all remedies applicable to </font><font style="font-family:inherit;font-size:12pt;color:#424242;">the nonpayment of </font><font style="font-family:inherit;font-size:12pt;color:#525252;">Fixed Rent shall be applicable thereto. Fixed Rent and Additional Rent </font><font style="font-family:inherit;font-size:12pt;color:#424242;">are herein referred to collectively </font><font style="font-family:inherit;font-size:12pt;color:#525252;">as "</font><font style="font-family:inherit;font-size:12pt;color:#525252;text-decoration:underline;">Rent</font><font style="font-family:inherit;font-size:12pt;color:#525252;">". Land</font><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">lo</font><font style="font-family:inherit;font-size:12pt;color:#525252;">rd may apply payments </font><font style="font-family:inherit;font-size:12pt;color:#424242;">received</font><font style="font-family:inherit;font-size:12pt;color:#525252;">&#32;from Tenant </font><font style="font-family:inherit;font-size:12pt;color:#424242;">to any obligations </font><font style="font-family:inherit;font-size:12pt;color:#525252;">of Tenant then </font><font style="font-family:inherit;font-size:12pt;color:#424242;">accrued</font><font style="font-family:inherit;font-size:12pt;color:#676767;">, </font><font style="font-family:inherit;font-size:12pt;color:#525252;">without regard to such obligations </font><font style="font-family:inherit;font-size:12pt;color:#424242;">as </font><font style="font-family:inherit;font-size:12pt;color:#525252;">may </font><font style="font-family:inherit;font-size:12pt;color:#424242;">be designated b</font><font style="font-family:inherit;font-size:12pt;color:#676767;">y</font><font style="font-family:inherit;font-size:12pt;color:#525252;">&#32;Tenant. Additional Rent shall be </font><font style="font-family:inherit;font-size:12pt;color:#424242;">paid by Tenant </font><font style="font-family:inherit;font-size:12pt;color:#525252;">in the same manner as </font><font style="font-family:inherit;font-size:12pt;color:#424242;">Fixed Rent, </font><font style="font-family:inherit;font-size:12pt;color:#525252;">without </font><font style="font-family:inherit;font-size:12pt;color:#424242;">any </font><font style="font-family:inherit;font-size:12pt;color:#525252;">prior </font><font style="font-family:inherit;font-size:12pt;color:#424242;">notice or</font><font style="font-family:inherit;font-size:12pt;color:#525252;">&#32;demand </font><font style="font-family:inherit;font-size:12pt;color:#424242;">therefor </font><font style="font-family:inherit;font-size:12pt;color:#525252;">and without </font><font style="font-family:inherit;font-size:12pt;color:#424242;">deduction, set-off </font><font style="font-family:inherit;font-size:12pt;color:#525252;">or counterclaim and without relief from any valuation or appraisement </font><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:12pt;color:#525252;">aws</font><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#525252;">Notwithstanding the foregoing definition of Operating Expenses, for purposes of this lease, &#8220;Operating Expenses&#8221; shall not include the following:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:24px;">(i)</font><font style="font-family:inherit;font-size:12pt;color:#525252;">the cost </font><font style="font-family:inherit;font-size:12pt;color:#424242;">of </font><font style="font-family:inherit;font-size:12pt;color:#525252;">any special work or service performed for </font><font style="font-family:inherit;font-size:12pt;color:#424242;">any </font><font style="font-family:inherit;font-size:12pt;color:#525252;">tenant (including Tenant) at such tenant's cost;</font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:24px;">(ii)</font><font style="font-family:inherit;font-size:12pt;color:#525252;">any real estate brokerage commissions or other costs incurred m procuring tenants or any fee lieu of such commission;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#676767;">(iii) </font><font style="font-family:inherit;font-size:12pt;color:#525252;">the cost of correcting </font><font style="font-family:inherit;font-size:12pt;color:#424242;">defects </font><font style="font-family:inherit;font-size:12pt;color:#525252;">in construction of the Project or the </font><font style="font-family:inherit;font-size:12pt;color:#424242;">Building;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#676767;">(iv) compensation paid to officers and executives of Landlord;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#676767;">(v) the cost of any items</font><font style="font-family:inherit;font-size:12pt;color:#525252;">&#32;for which Landlord is reimbursed by insurance, condemnation or otherwise;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(vi) the cost of any additions, changes, replacements and other items which are solely made in order to prepare for a new tenant&#8217;s occupancy;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(vii) interest on debt or amortization payments on any mortgage or deed to secure debt and rental under any ground lease or other underlying lease;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(viii) capital expenditures to the common areas of the Project, unless such capita</font><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:12pt;color:#525252;">&#32;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">expenditures are </font><font style="font-family:inherit;font-size:12pt;color:#424242;">aimed at </font><font style="font-family:inherit;font-size:12pt;color:#525252;">reducing Operating Expenses, maintenance </font><font style="font-family:inherit;font-size:12pt;color:#424242;">of </font><font style="font-family:inherit;font-size:12pt;color:#525252;">existing equipment, improving safety, or compliance </font><font style="font-family:inherit;font-size:12pt;color:#676767;">with </font><font style="font-family:inherit;font-size:12pt;color:#525252;">governmental rules and </font><font style="font-family:inherit;font-size:12pt;color:#424242;">regulations </font><font style="font-family:inherit;font-size:12pt;color:#676767;">(such </font><font style="font-family:inherit;font-size:12pt;color:#525252;">as the installation </font><font style="font-family:inherit;font-size:12pt;color:#424242;">of low </font><font style="font-family:inherit;font-size:12pt;color:#525252;">energy lights in the parking area on the Project);</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(ix) capital expenditures made as part of the acquisition or redevelopment of the Project; </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(x) any expenses for repairs or maintenance which are covered by warranties and service contracts, to the extent such maintenance and repairs are made at no cost to Landlord;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(xi) legal expenses arising solely out of the construction of the improvements on the Project the entering into or enforcement of the provisions of any lease of space within the Building, including without limitation this Lease;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(xii) any advertising expe3nses incurred in connection with the marketing of any rentable space; and</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525252;">(xiii) rental payments for base building equipment such as HVAC equipment and elevators.</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;font-style:italic;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;color:#525252;">UTILITIES.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;Landlord shall use commercially reasonable efforts to sub meter utilities to the Premises, in </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">which case Tenant shall make arrangements with the applicable service provider to provide such serv</font><font style="font-family:inherit;font-size:12pt;color:#282828;">i</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ces to the Premises in </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">name, and Tenant shall pay directly to such service providers the cost of all service connection fees and utilities consumed at the Premises throughout the Term. If any utility service is not </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">separately </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">metered, Landlord shall pay such bills and Tenant shall pay </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord within fifteen (15) days after actual receipt of the amount due from Landlord an amount based </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">on the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">actual usage by Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(as </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">determined by submeter read by Landlord) and </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">actual rate charged to Landlord by </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">utility provider without additional fee from Landlord. </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">If </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">fails </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to pay in a timely manner any sum required under this. Article </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">5.</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;Landlord shall have the right, but not me obligation, to pay any such sum</font><font style="font-family:inherit;font-size:12pt;color:#282828;">. </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Any sum so paid </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">by </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord shall be deemed </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">be owing by Tenant to </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and due and pc1yable as Additional Rent within ten </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(l</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;0) days after demand therefor. </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Notwithstanding </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">anything </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">herein </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to the contrary, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">any supplemental </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">heating and/or cooling systems and equipment serving the Premises shall be separately metered to the Premises at Tenant's cost, and Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">be solely responsible for all electricity registered by such meters</font><font style="font-family:inherit;font-size:12pt;color:#282828;">. </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord shall not be liable for any interruption or delay in </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">electric </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or any other utility service for any reason unless caused by the gross negligence or </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">willful </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">misconduct of Landlord.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Use of the-Premises-, or any part thereof, in a manner exceeding the design </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">conditions (including </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">occupancy and connected electrical load) for the heating, ventilation and air conditioning </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">("HV</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;font-style:italic;text-decoration:underline;">AC")</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">units serving the Premises, or rearrangement of partitioning which interferes with normal operation of the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;font-style:italic;">HV</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">AC system </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">serving </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the Premises, may require </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">changes </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">in the HVAC system serving the Premises. Landlord has no obligation to keep cool any of Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">information </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">technology equipment that is placed </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">together </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">in one room</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">on </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">a rack, or in any simi</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ar manner ("</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">IT Equipmen</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">t"), and Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">waives </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">any claim agains</font><font style="font-family:inherit;font-size:12pt;color:#282828;">t </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord in connection </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">with</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;Tenant's IT Equipmen</font><font style="font-family:inherit;font-size:12pt;color:#282828;">t</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">. </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">If Tenant exceeds </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">design conditions for the heating or cooling unts in the </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Premises </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or introduces into the Premise&#8217;s equipment that overloads the system. and/or in any oilier </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">way </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">causes the system not</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">&#32;adequately </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to perform their proper functions, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">supplementary systems </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">may at Landlord</font><font style="font-family:inherit;font-size:12pt;color:#757575;">' </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">s option be provided by Landlord at </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">expense. Tenant shall </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">not </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">change or adjust any closed or sealed thermostat o</font><font style="font-family:inherit;font-size:12pt;color:#282828;">r </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">other </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">element of the HV AC system without Landlord's express prior written consent. Landlord may install and </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">operate </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">meters </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">any</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;other reasonable system for monitoring or estimating any services or utilities used by Tenant in excess of those</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">&#32;required </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to be provided by Landlord </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(including </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">a </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">system </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">for Landlord's engineer reasonab</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">y </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to estimate any such</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">&#32;excess </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">usage). If such </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">system </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">indicates such </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">excess </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">services or </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">utilities, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Tenant shall pay Landlord</font><font style="font-family:inherit;font-size:12pt;color:#757575;">1</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">s reasonable</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">&#32;charges </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">for </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">installing </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and operating such </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">system </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and any supplementary air conditioning, ventilation., beat, electrical,</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">&#32;or </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">other </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">systems or </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">equipment {or adjustments or modifications </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">to the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">existing Building </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">systems </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and equ</font><font style="font-family:inherit;font-size:12pt;color:#282828;">i</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">pment), and Landlord's reasonable charges for such </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">amount </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">of excess services or </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">utilities </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">used by Tenant</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;font-style:italic;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">SIGNS: USE OF PREMISES AND COMMON AREAS</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">.  </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">At Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">cost, Land</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ord shal</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l provide</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">with </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Building-standard identification signage on all Building directories and at the entrance to the Premises. No other signs shall be placed, erected </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">or </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">maintained by Tenant at any place upon the Premises, Building or Project. Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">use </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">of the Premises shall be limited to general office and laboratory, including, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">without </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">limitation, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">medical</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">&#32;testing, use </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(the </font><font style="font-family:inherit;font-size:12pt;color:#757575;">&#8220;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">Permitted</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;text-decoration:underline;">Use</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">"). The </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Permitted Use shall be subject to all applicable Laws </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(as </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">defined in </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;text-decoration:underline;">Article 21</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">to all </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">reasonable requirements of the insurers of the Building. Without Landlord's prior written consent, Tenant shall not install in or for the Premises any equipment that requires more </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">electric </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">current </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">than </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">is standard in </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Building. Tenant shall have the right, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">non-exclusive </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and in common </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">with others, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to use: (i) the exterior paved driveways and wa</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">kways of the Building for </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">vehicular </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and pedestrian access to the Building; </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(ii) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the internal </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">common </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">area, if any; and </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(</font><font style="font-family:inherit;font-size:12pt;color:#282828;">i</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">i</font><font style="font-family:inherit;font-size:12pt;color:#282828;">i</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">) </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the designated parking areas of the Project for the parking of automobiles </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">of </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">and its employees </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">and business visitors and vendors; provided Landlord shall have the right in its sole discretion and from time to time, to construct</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">maintain, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">operate, repair</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">close</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">limit, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">take out </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">of </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">service</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">alter, change, and modify all or any part of the commo</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">n </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">areas of the </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Project, including </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">without limitation, </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">restricting </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">or limiting Tenant's utilization </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">of </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the parking areas in the event the same become overburdened and in such </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">case to equitably allocate on proportiona</font><font style="font-family:inherit;font-size:12pt;color:#282828;">t</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">e basis or assign parking spaces among Tenant and the other tenants of the Building. Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">be </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">solely </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">responsible for installation of </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">its </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">data/te1ecommurucation systems </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">and wiring </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">at the </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">Premises, which </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">shall be done </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">in </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">compliance </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">with </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">all applicable Laws. Subject </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord</font><font style="font-family:inherit;font-size:12pt;color:#757575;">' </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">s </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">reasonable </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">approval, Tenant may </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">use </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">vendor </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">of its choice for such installation</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">mark the spaces outside the front door of the Building as reserved for </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">visitors. In </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">no event </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">will Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">reduce </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">ratio of parking spaces </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">to </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">rentable square feet </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">of the </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">Project below the ratio that exists as </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">of </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">the date of this Lease. Tenant </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">be given four </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">(</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">4) </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">reserved </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">parking spaces in the </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">parking </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">lot </font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;">closest </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">to the entrance to the Premises.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s0523A3B022F0930339EBFD184E8FB800"></a></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;font-style:italic;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">ENVIRONMENT</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;text-decoration:underline;">AL</font><font style="font-family:inherit;font-size:12pt;color:#5d5d5d;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;text-decoration:underline;">MATTERS</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">. Tenant shall not use</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">generate, manufacture, refine, transport, treat</font><font style="font-family:inherit;font-size:12pt;color:#757575;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">store, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">handle, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">dispose, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">bring </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or otherwise cause to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">brought or permit any </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">its agents, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">employees, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">subtenants, contractors or invitees to bring, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">in, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">on or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">about </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">any part of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Project, any hazardous. waste, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">hazardous </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">substances</font><font style="font-family:inherit;font-size:12pt;color:#828282;">, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">toxic </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">substances, oil, asbestos or other hazardous material, pollutant or contaminant as defined by 42 U.S.C. Sections 960 </font><font style="font-family:inherit;font-size:12pt;color:#282828;">1 </font><font style="font-family:inherit;font-size:12pt;color:#646464;font-style:italic;">et </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">seq., </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">same may from time to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">time </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">be amended, and the regulations promulgated pursuant thereto (CERCLA), or now or hereafter regulated by any Law. </font><font style="font-family:inherit;font-size:12pt;color:#646464;">N</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">otwithstanding </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the foregoing</font><font style="font-family:inherit;font-size:12pt;color:#282828;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant shall be permitted to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">bring </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">onto the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Hazardous </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Materials </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(as defined below) used in connection with its business provided Tenant shall at all times comp</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">y \with all </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">La</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ws </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(including</font><font style="font-family:inherit;font-size:12pt;color:#828282;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">without limitation laws gove1ning the use of laboratory space) pertaining </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the storage handling, use and application of such Hazardous Materials. This </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Article</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">7</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">survive </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the expiration or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">sooner </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">termination of this Lease. In no event shall Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">required to consent to </font><font style="font-family:inherit;font-size:12pt;color:#646464;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">installation or use of any </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Hazar</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">dous </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Material storage tanks at </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Project. </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">at </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">its sole cost </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and expense</font><font style="font-family:inherit;font-size:12pt;color:#727272;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall remediate in a manner satisfactory to the applicable governmental agencies </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">any </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Hazardous Materials released on or from the Project by Tenant, its agents, employees, contractors, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">assignees, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">subtenants or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">invitees. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant shall complete and certify disclosure statements as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">requested </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">from time </font><font style="font-family:inherit;font-size:12pt;color:#646464;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">time relating </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">transportation, storage, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">use</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">generation, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">manufacture </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">o</font><font style="font-family:inherit;font-size:12pt;color:#282828;">r </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">release </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Hazardous </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Materials at the Premises. As defined in any applicable Laws, Tenant </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">is </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">be deemed to be the </font><font style="font-family:inherit;font-size:12pt;color:#646464;">"op</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">erator&#8221; of Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">''facility&#8221; and the </font><font style="font-family:inherit;font-size:12pt;color:#646464;">"</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">owner" </font><font style="font-family:inherit;font-size:12pt;color:#646464;font-weight:bold;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">a1J </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Hazardous </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Materials brought on the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by Tenant, its </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">agents, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">employees, contractors, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">assignees</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, su</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">btenants</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or invitees, and the wastes, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">byproducts</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or residues </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">generated, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">resulting, or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">produced therefrom</font><font style="font-family:inherit;font-size:12pt;color:#828282;">. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">''</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Hazardous Materials</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">" means </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">any </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">flammable </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">items, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">explosives, radioactive materials, hazardous or toxic</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;substances, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">material or waste or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">related </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">materials, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">including any </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">substances defined as or included in </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">definition of "hazardous </font><font style="font-family:inherit;font-size:12pt;color:#646464;">substance", "</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">hazardous </font><font style="font-family:inherit;font-size:12pt;color:#646464;">wastes/' </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">"hazardous material", or "toxic substances" now or subsequently regulated under any applicable federal, state or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">local La</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ws </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">regulations</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">including without limitation petroleum&#173; based products, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">paints, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">solvents, lead, cyanide</font><font style="font-family:inherit;font-size:12pt;color:#828282;">, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">DDT, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">printing inks, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">acids, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">pesticides, ammonia compounds and other chemical </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">products, asbestos, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">PCBs and similar compounds. and including any diffe</font><font style="font-family:inherit;font-size:12pt;color:#282828;">r</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ent </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">products </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and materials that are subsequently found to have adverse effects </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">on </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the environment or the health and safety of persons. </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">In the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">event that Hazardous Materia1s are discovered that (i) are located in the Premises and pre-date Tenant's occupancy of the Premises; or, </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(ii) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">are located </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">in </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and were introduced </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">by </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Land</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ord., its </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">agents</font><font style="font-family:inherit;font-size:12pt;color:#727272;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">employees, or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">contracto</font><font style="font-family:inherit;font-size:12pt;color:#646464;">rs, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">such Hazardous Materials shall be remediated by Landlord in a manner satisfactory to the applicable governmental agencies </font><font style="font-family:inherit;font-size:12pt;color:#646464;">at Lan</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">dl</font><font style="font-family:inherit;font-size:12pt;color:#646464;">o</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">rd</font><font style="font-family:inherit;font-size:12pt;color:#727272;">1</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">s sole </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">cost </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and expense. Landlord </font><font style="font-family:inherit;font-size:12pt;color:#282828;">r</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">epresents and warrants to Tenant </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">that </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">it </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ha</font><font style="font-family:inherit;font-size:12pt;color:#646464;">s re</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">cei</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ved </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">no notice and has no knowledge of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">any </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">violations of any federal state or local </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">laws</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ordinances, orders, regulations and requirements affecting the Premises, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the Building</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or the Project.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;font-style:italic;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">TENANT'S ALTERATIONS</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">. </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Tenan</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall not cut, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">drill </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">into </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">secure any fixture, apparatus or equipment or make alterations, improvements or physical additions </font><font style="font-family:inherit;font-size:12pt;color:#727272;">(</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">collectively, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">"</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;text-decoration:underline;">Alterations</font><font style="font-family:inherit;font-size:12pt;color:#646464;">") </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of any kind to any</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;part </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the Premises without first obtaining </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">written consent of Landlord, such consent not to be unreasonably</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;w</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ithheld, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Alterations shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be in </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">compliance with all Laws. With </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">respect to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">all Alterations made after the date hereof, other than those expressly </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">made by Landlord pursuant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to this </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Lease, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant acknowledges and agrees </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">that</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(i) Tenant is no</font><font style="font-family:inherit;font-size:12pt;color:#727272;">t, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">under any circumstance, acting as the agent of Landlord; </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ii</font><font style="font-family:inherit;font-size:12pt;color:#646464;">) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Lru1d!ord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">did </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">not cause or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">request</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;s</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">uch </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Alterations to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">made; </font><font style="font-family:inherit;font-size:12pt;color:#646464;font-style:italic;">(iii) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord has not ratified such work; </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(iv) </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">did </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">not </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">authorize such Alterations within the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">meaning </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of Section </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">43 </font><font style="font-family:inherit;font-size:12pt;color:#646464;">3 </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Code of Virginia </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or any </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">amendment </font><font style="font-family:inherit;font-size:12pt;color:#646464;">thereof </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">All Alterations (whether temporary or permanent in character) made in or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">upon </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">either by Landlo</font><font style="font-family:inherit;font-size:12pt;color:#282828;">r</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">d </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or Tenant, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall be Landlo1'd's property </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">upon </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">installation and sha</font><font style="font-family:inherit;font-size:12pt;color:#282828;">l</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">l remain on the Premises without </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">compensation </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to Tenant unless</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;Landlor</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">d </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">provides written </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">notice to Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to remove same at the expiration or sooner termination of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">this </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Lease, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">in</font><font style="font-family:inherit;font-size:12pt;color:#727272;">&#32;w</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">hich event Tenant shall promptly remove such Alterations and restore </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Premises to good </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">order </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and condition. Notwithstanding the foregoing, Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">has consented to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant's initial </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">up-fit </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the Premises </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">pursuant to the </font><font style="font-family:inherit;font-size:12pt;color:#646464;">plans</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;attached hereto as </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Exhibit "D</font><font style="font-family:inherit;font-size:12pt;color:#727272;text-decoration:underline;">"</font><font style="font-family:inherit;font-size:12pt;color:#727272;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">("Tenant's Initial Work"). Further, the following items of Tenant's Initial Work shall at all times remain Tenant's property and may be removed on or before the expiration of the Temby Tenant, at Tenant's sole cost and e:XJ&gt;ense, and so long as Tenant repairs any </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">damage </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">occasioned </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">by the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">removal of such item</font><font style="font-family:inherit;font-size:12pt;color:#727272;">,  </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">s and restore</font><font style="font-family:inherit;font-size:12pt;color:#727272;">s_ </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Premises to at least as good of a condition </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">as </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">existed </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">as </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the date of </font><font style="font-family:inherit;font-size:12pt;color:#646464;">this </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Lease, ordinary </font><font style="font-family:inherit;font-size:12pt;color:#646464;">wear </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and tear excepted: </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">All parts of Tenant's laboratory space</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;font-style:italic;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">ASSIGNMENT Mm   SUBLETTING</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Except as o </font><font style="font-family:inherit;font-size:12pt;color:#646464;">otherwise </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">expressly provided in this </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Article</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;text-decoration:underline;">9,</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">neither Tenant </font><font style="font-family:inherit;font-size:12pt;color:#646464;">nor </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant</font><font style="font-family:inherit;font-size:12pt;color:#727272;">'</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">s </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">legal</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;representatives or successors-in-interest </font><font style="font-family:inherit;font-size:12pt;color:#646464;">by </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">operation of law or otherwise, shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">sell, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">assign, transfer</font><font style="font-family:inherit;font-size:12pt;color:#828282;">, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">hypotheca</font><font style="font-family:inherit;font-size:12pt;color:#646464;">te,</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;mortgage</font><font style="font-family:inherit;font-size:12pt;color:#727272;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">encumber, grant concessions or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">licenses</font><font style="font-family:inherit;font-size:12pt;color:#727272;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">sublet, or otherwise dispose of all or any interest in </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">this </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Lease </font><font style="font-family:inherit;font-size:12pt;color:#646464;">or</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">permit </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">person </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or entity </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">other </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">than Tenant </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">occupy any portion of the Premises, without Landlord's prior written consent, which consent shall not be unreasonably withheld, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">conditioned </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">delayed. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Any </font><font style="font-family:inherit;font-size:12pt;color:#646464;">of</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">foregoing </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">acts (a </font><font style="font-family:inherit;font-size:12pt;color:#646464;">"</font><font style="font-family:inherit;font-size:12pt;color:#646464;text-decoration:underline;">Transfer</font><font style="font-family:inherit;font-size:12pt;color:#646464;">" </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to a "</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Transferee</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">") without such consent shall constitute an Event of Default and shall, at Landlord's option, be void </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">and/or terminate </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">this Lease. Landlord and Tenant acknowledge that </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">is a publicly traded entity and so </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">long </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">as </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant remains a publicly traded entity </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">an </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">assignment shall not include any </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">assignment </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by operation of law, any merger, consolidation, or asset sale involving Tenant, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">any direc</font><font style="font-family:inherit;font-size:12pt;color:#646464;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or indirect transfer </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">o</font><font style="font-family:inherit;font-size:12pt;color:#646464;">f </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">control of Tenant and any transfer of a majority of the</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">&#32;ownership </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">interests in Tenant. Consent </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">by </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Landl</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to any Transfer shall be held to apply only to the </font><font style="font-family:inherit;font-size:12pt;color:#646464;">spe</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">cific Transfer </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">authorized. Such consent shall not be construed as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">a </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">waiver of the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">duty </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of Tenant, or Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">legal </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">representatives or assigns, to obtain from Landlord consent </font><font style="font-family:inherit;font-size:12pt;color:#646464;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">any other or subsequent </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Transfers</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or as modifying or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">limiting </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the rights of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">La</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ndlo</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">rd </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">under the foregoing covenant by Tenant not </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Transfer without Landlord's consent. The acceptance of rental by Landlord from any other person shall not </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be deemed to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">be a waiver by Landlord of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">any provision </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">hereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">If at any </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">time </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">during the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Term </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant desires to consummate a </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Transfer </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">which requires Landlord consent, Tenant shall give notice to Landlord of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">such </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">desire, including the name, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">addre</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ss </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and contact party for the proposed Transferee, the effective </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">date of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the proposed Transfer (including the proposed occupancy date by the proposed </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Transferee</font><font style="font-family:inherit;font-size:12pt;color:#646464;">), </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and in the instance </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">a proposed sublease, the square footage </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">subleased, a floor plan professonally drawn to scale depicting the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">proposed </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">sublease area and a statement of the duration of the proposed sublease </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(which </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall in any and all events expire by its terms prior to the scheduled expiration of this Lease</font><font style="font-family:inherit;font-size:12pt;color:#7c7c7c;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and immediately upon the sooner </font><font style="font-family:inherit;font-size:12pt;color:#646464;">terminatio</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">n </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">hereof). Landlord may, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">a</font><font style="font-family:inherit;font-size:12pt;color:#646464;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">its option, exercisable by notice given </font><font style="font-family:inherit;font-size:12pt;color:#646464;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant within forty</font><font style="font-family:inherit;font-size:12pt;color:#050505;">-</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">five (45) days following Landlord's receipt of Tenant's notice, elect to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">r</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ecapture </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Premises if Tenant is proposing to sublet, or </font><font style="font-family:inherit;font-size:12pt;color:#646464;">termina</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">te </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">this Lease in the event of an assignment.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Regardless of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord</font><font style="font-family:inherit;font-size:12pt;color:#646464;">'s </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">consent, no Transfer shall release Tenant of Tenant's obligation or alter the primary </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">liability </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of Tenant to pay the Rent and to perform all other obligations to be performed by Tenant hereunder, and DIFFUSlON </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">PHARMACEUTICALS  </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">INC. and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">all </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">assignees shall be jointly </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">severally liable for all Tenant obligations under this Lease, In connection with each proposed Transfer requiring </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">approval and regardless of whether consent </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">is </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">given, Tenant shal</font><font style="font-family:inherit;font-size:12pt;color:#262626;">l </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">pay </font><font style="font-family:inherit;font-size:12pt;color:#646464;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord: (i) an administrative fee of $1,000 per request in order to defer Landlord's administrative expenses arising from such request; </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">plus </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(ii) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord's </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">reasonab</font><font style="font-family:inherit;font-size:12pt;color:#646464;">le</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;attorneys' fees. Any sums or other economic consideration received by Tenant as a result of any </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Transfer </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(except payments that are unrelated to Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">leasehold </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">interest in the Premises (such as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">cash </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">consideration for Tenant's</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;sto</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ck</font><font style="font-family:inherit;font-size:12pt;color:#646464;">), </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and rental or other payments </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">received </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">that </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">are </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">attributable </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the amortization of the cost of leasehold improvements made </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">transferred </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">portion </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of the Premises by </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Transferee, and other reasonable</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;expenses </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">incident to the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Transfer, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">including standard </font><font style="font-family:inherit;font-size:12pt;color:#646464;">leasing </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">commissions</font><font style="font-family:inherit;font-size:12pt;color:#646464;">) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">whether </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">denominated </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">rentals under the sublease or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">otherwise</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">that exceed, in the aggregate, the total sums which Tenant is obligated </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">pay Land</font><font style="font-family:inherit;font-size:12pt;color:#262626;">l</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ord under this Lease (prorated to reflect obligations </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">allocable </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to that portion of the Premises subject to such </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Transfer) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall be divided evenly between Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">and </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant, with Landlord's </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">portion </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">being payable to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Additiona</font><font style="font-family:inherit;font-size:12pt;color:#646464;">l </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Rent without affecting </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">reducing any other obligation of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">.hereunder</font><font style="font-family:inherit;font-size:12pt;color:#262626;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Notwithstanding </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">foregoing, Tenant shall have the right without the prior </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">con</font><font style="font-family:inherit;font-size:12pt;color:#646464;">sen</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of Landlord, but after </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">at </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">least fifteen </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(15) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">days' prior written notice to Landlord, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;font-style:italic;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ass</font><font style="font-family:inherit;font-size:12pt;color:#262626;">i</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">gn this Lease or sublet any portion of the Premises to any Affiliate (as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">defined </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">below), or an entity </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(the </font><font style="font-family:inherit;font-size:12pt;color:#646464;text-decoration:underline;">''Sur</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;text-decoration:underline;">viving</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Entity")</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;into which Tenant merges or that acquires substantially all of the assets or stock of1'enant; provided: </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(i) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">such assignee shall, in writing, assume and agree to perform all of the obligations of Tenant under this Lease, and it shall deliver a copy of such assignment and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">assumption agreement </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to Landlord within ten (</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">10</font><font style="font-family:inherit;font-size:12pt;color:#646464;">) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">days thereafter, together with a certificate of insurance evidencing the assignee's compliance with the insurance requirements of Tenant under this </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Lease; (ii) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Surviving Entity shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">have </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">a tangible </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">net </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">worth at </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">least </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">equal to the greater of the net worth of Tenant on the date of this Lease or on the date of such </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Transfer; </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(iii)</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">DIFFUSION </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">PHARMACEUTICALS INC. and any subsequent Tenant/assignor shall not be released or discharged from any liability under this Lease by reason of such Transfer; </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(iv) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the use of the Premises shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">for the Permitted Use; and (v) </font><font style="font-family:inherit;font-size:12pt;color:#646464;">if </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">assignmen</font><font style="font-family:inherit;font-size:12pt;color:#646464;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or subletting is to an Affiliate, such assignee or subtenant shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">remain </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">an Affiliate</font><font style="font-family:inherit;font-size:12pt;color:#646464;">1hro</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ughout the Term </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and if such </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">assignee </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or subtenant shall cease being an Affiliate, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall notify Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">in </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">writing of such change and such transfer shall be deemed an Event of Default if Landlord's consent thereto is not given in writing within ten (l 0) business </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">da</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ys </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">such notification. An "</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">" shall mean: (i) an entity which is </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">50% or more owned </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by those owning 50% or more of</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;Tenan</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">t; </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(ii) a subsidiary of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(ill) a parent entity of Tenant; </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(iv) a subsidiary of the parent entity of Tenant.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;color:#4f4f4f;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;text-decoration:underline;">LANDLORD</font><font style="font-family:inherit;font-size:12pt;color:#646464;">'S </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">RIGHT OF ENTRY. </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">persons autb01ized </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">by Landlord may enter the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">at all reasonable times upon reasonable advance </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">notice </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">with the accompaniment by a Tenant representative or specific written consent of the Tenant to the areas </font><font style="font-family:inherit;font-size:12pt;color:#646464;">where </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and persons authorized by Landlord will be allowed to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ent</font><font style="font-family:inherit;font-size:12pt;color:#646464;">er (</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or any time without </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">notice </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">in the case of an </font><font style="font-family:inherit;font-size:12pt;color:#646464;">emerge</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">ncy</font><font style="font-family:inherit;font-size:12pt;color:#646464;">). </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord shall not </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">liable for inconvenience to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or disturbance of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">by </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">reason of any such entity; provided</font><font style="font-family:inherit;font-size:12pt;color:#797979;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">however, in the case of repairs or work, such </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">be </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">done, so far </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">practicable, so as to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">not unreasonably interfere with Tenant's use of the Premises. Notwithstanding the foregoing, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">acknowledge that, as </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">a re</font><font style="font-family:inherit;font-size:12pt;color:#646464;">sult </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">nature of Tenant's business operations in the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant is </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">required by </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">applicable laws and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">regulations </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to restrict access to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Premises and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">comply with other extraordinary security procedures. Accordingly, Landlord expressly acknowledges </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">that </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">as a material condition of the Lease, it shall comply with Tenant's security provisions when </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">accessing </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Premises for any reason, however</font><font style="font-family:inherit;font-size:12pt;color:#797979;">, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">in the</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">event</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;of an emergency, Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">may use </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">any means necessary to access the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Premises. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord agrees that if it accesses the Premises </font><font style="font-family:inherit;font-size:12pt;">in t</font><font style="font-family:inherit;font-size:12pt;color:#c6c6c6;">he </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">event of an emergency, Landlord shall immediately or as soon as reasonably practical, notify Tenant of </font><font style="font-family:inherit;font-size:12pt;color:#646464;">such </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">access. Tenant </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">deals </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">with sensitive non-public information in the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">conduc</font><font style="font-family:inherit;font-size:12pt;color:#646464;">t </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the Permitted </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Use and Landlord shall, and shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">require </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">its contractors&#8217; agents, and employees to, keep confidential any items observed, seen, l1eard, or </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">learned </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">while inside </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Premises.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;color:#646464;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">REPAJRS AND MAINTENANCE</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">(a) Tenant</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">at its sole cost </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">an</font><font style="font-family:inherit;font-size:12pt;color:#646464;">d </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">exp.en.se and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">throughout </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:12pt;color:#646464;">Term, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall keep and maintain the interior of the Premises and mechanical, </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">plumbing </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and electrical systems </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">exclusivel</font><font style="font-family:inherit;font-size:12pt;color:#646464;">y </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">serving the Premises </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(incl</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">uding</font><font style="font-family:inherit;font-size:12pt;color:#797979;">; </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">without limitation, HVAC systems and equipment serving </font><font style="font-family:inherit;font-size:12pt;color:#646464;">th</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">e </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Premises) in good order and condition, free of rubbish, and shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">promptly </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">make all non-structural </font><font style="font-family:inherit;font-size:12pt;color:#646464;">re</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">pairs </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">necessary to keep and maintain such </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">good </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">order and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">condition. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">When used</font><font style="font-family:inherit;font-size:12pt;color:#9a9a9a;">.</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">in this</font><font style="font-family:inherit;font-size:12pt;color:#9a9a9a;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Article</font><font style="font-family:inherit;font-size:12pt;color:#9a9a9a;">-</font><font style="font-family:inherit;font-size:12pt;">II</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">, the term &#8220;repairs" </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">include replacements and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">renewals </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">when necessary. All repairs made by Tenant </font><font style="font-family:inherit;font-size:12pt;color:#646464;">stall </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">utilize </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">materials </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">equipment </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">that area </font><font style="font-family:inherit;font-size:12pt;color:#646464;">l</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">east </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">equal in quality and usefulness to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">those </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">originally used in constructing the Building and the Premises. Landlord shall not be liable to Tenant for any damage caused to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">and its property </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">due </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to the Building or any part or appurtenance thereof being improperly constructed or being or becoming out of repair, or arising from the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">leaking </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">of gas</font><font style="font-family:inherit;font-size:12pt;color:#797979;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">water, sewer or steam</font><font style="font-family:inherit;font-size:12pt;color:#b1b1b1;">&#183;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">pipe</font><font style="font-family:inherit;font-size:12pt;color:#c6c6c6;">&#183;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">s, or from problems with e</font><font style="font-family:inherit;font-size:12pt;color:#242424;">l</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">ectrical service, so long </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">as </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">diligently </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">remedies such defect to the extent under Landlord's control.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant shall, at its expense, enter into contracts </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">at. Landlord&#8217;s option</font><font style="font-family:inherit;font-size:12pt;color:#797979;">, accept</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;the assignment and </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">responsibili</font><font style="font-family:inherit;font-size:12pt;color:#646464;">ty </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">for existing contracts) for: (i) preventive maintenance and service for regularly scheduled maintenance of all HVAC systems and equipment serving the Premises; and </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(ii) </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">termite and pest prevention and extermination </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">services to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the Premises. </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">The </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">contractors and the terms and conditions of the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">contracts</font><font style="font-family:inherit;font-size:12pt;color:#646464;">, </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">including the scope of services and the maintenance </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">service schedule, shall </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">subject to the prior written approval </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord, which </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">approva</font><font style="font-family:inherit;font-size:12pt;color:#646464;">l </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">shall not be unreasonably withheld. The contracts </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">must </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">be in effect and a fully executed copy thereof must </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">be provided </font><font style="font-family:inherit;font-size:12pt;color:#646464;">to </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord within thirty (30) days after the Commencement </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Date</font><font style="font-family:inherit;font-size:12pt;color:#242424;">. </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant shall provide or </font><font style="font-family:inherit;font-size:12pt;color:#646464;">cause </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">the contractors to provide </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">with copies of all work </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">orders and </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">other </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">main</font><font style="font-family:inherit;font-size:12pt;color:#646464;">tenance </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">or</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">&#32;service </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">records for all work performed w</font><font style="font-family:inherit;font-size:12pt;color:#242424;">i</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">thin the </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Pr</font><font style="font-family:inherit;font-size:12pt;color:#646464;">emises </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">promptly </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">following </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">each maintenance </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">service activity.</font><font style="font-family:inherit;font-size:12pt;color:#646464;">&#32;If </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Tenant shall fai</font><font style="font-family:inherit;font-size:12pt;color:#242424;">l </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">perform </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">any of its obligations hereunder, Landlord may cure such default on behalf of </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Tenant</font><font style="font-family:inherit;font-size:12pt;color:#646464;">,</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;and Tenant shall reimburse </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">Landlord upon </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">demand for any sums paid </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">costs incurred </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">b</font><font style="font-family:inherit;font-size:12pt;color:#646464;">y </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord in cure such default, including attorneys' fees and other </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">legal </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">expenses, together </font><font style="font-family:inherit;font-size:12pt;color:#646464;">with </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">interest at </font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">the Default</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;Rate </font><font style="font-family:inherit;font-size:12pt;color:#646464;">(as </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">defined </font><font style="font-family:inherit;font-size:12pt;color:#646464;">in</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;text-decoration:underline;">Section 19(b)</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">&#32;below).</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">Landlord shall make all</font><font style="font-family:inherit;font-size:12pt;color:#3f3f3f;">necessary </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">repairs to thefooti(c) Landlord shall make all necessary repairs to the footings and foundations and the steel columns and girders forming a part of the Premises, and to the Building outside of the Premises and repairs made necessary by a negligent or willful act or omission of Tenant or any employee, agent, contractor, or invitee of Tenant shall be made at sole cost and expense of Tenant, except to the extent of insurance proceeds received by Landlord. Landlord represents and warrants to the best of Landlord&#8217;s knowledge that, as of the date of this Lease, for buildings, of like age and class, all structural parts of the Premises, including but not limited to the foundation, roof, exterior walls, plumbing and electrical systems meet and comply with all federal, state, and local laws, ordinances and regulations, all handicapped accessibility standards, including but not limited to the Americans with Disabilities Act (&#8220;ADA&#8221;) accessibility requirements, and are in good, sanitary order, condition, and repair.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shall deliver the Premises with the</font><font style="font-family:inherit;font-size:11pt;color:#b6b6b6;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">HVAC systems </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">equipment serving the</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">&#32;Premises </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">in good working order. If me cost of any one (l) repair </font><font style="font-family:inherit;font-size:11pt;color:#646464;">to </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the HVAC systems and equipment serving the</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">&#32;Premises </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">incurred by Tenant during </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">first twelve </font><font style="font-family:inherit;font-size:11pt;color:#646464;">(12) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">months after the Commencement </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Date </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">exceeds Five</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">&#32;Hundred and</font><font style="font-family:inherit;font-size:11pt;color:#646464;">Nol</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">l00 </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Dollars ($500.00), then </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Land1ord </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shall reimburse Tenant for such costs </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">incurred </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">in excess of Five Hundred and Noll00 Dollars ($500.00) within thirty </font><font style="font-family:inherit;font-size:11pt;color:#646464;">(30) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">days after receipt of an </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">invoice </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">therefor </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">together </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">with reasonable </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">supporting documentation. If </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the costs of any series of repairs or </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">replacemen</font><font style="font-family:inherit;font-size:11pt;color:#646464;">ts </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">HV</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">AC </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">systems </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">exceeds $1,500 in any twelve (12) month period </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">during </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Term</font><font style="font-family:inherit;font-size:11pt;color:#646464;">, </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Landlord shall </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">reimburse </font><font style="font-family:inherit;font-size:11pt;color:#646464;">Te</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">nant </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">for such costs incurred in excess of $1,500 within thirty (30) days after receipt </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">of an </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">invoice </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">therefor </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">together with reasonable supporting </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">documentation. </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Notwithstanding </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">foregoing, </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Land</font><font style="font-family:inherit;font-size:11pt;color:#646464;">lord's </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">obligation to reimburse Tenant </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">is </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">expressly conditioned on; (i) Tenant </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">maintaining </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">a preventative maintenance contract </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">on </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the HVAC units; </font><font style="font-family:inherit;font-size:11pt;color:#646464;">(ii) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the cause </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">for </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the repairs or replacements </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">not being </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the negligence </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">willful </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">misconduct of Tenant </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">or </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">its </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">agents, employees or contractors; and </font><font style="font-family:inherit;font-size:11pt;color:#646464;">(iii) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Landlord </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">being </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">given the opportunity to inspect the applicable and equipment and proposals prior to </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">either </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">party incurring costs.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:11pt;color:#646464;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;text-decoration:underline;">INSURANCE: SUBROGATION RIGHT&#8217;S</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">. Tenant shall obtain and keep in force at </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">all </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">times during the Term, at its own expense, commercial general liability insurance </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">including </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">contractual liability and personal injury</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">1iability </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">all </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">similar coverage, with combined single limits of $2,000,0Qp.oo </font><font style="font-family:inherit;font-size:11pt;color:#808080;">.</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">on account of bodily injury to or death of one or more persons as the result of any one </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">accident </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">or </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">disaster </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">and on account </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">damage to property</font><font style="font-family:inherit;font-size:11pt;color:#808080;">, </font><font style="font-family:inherit;font-size:11pt;color:#646464;">toge</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">ther </font><font style="font-family:inherit;font-size:11pt;color:#646464;">with </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">an umbrella policy of$4,000,000.00, or in such other amounts as </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">may </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">from </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">time </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">to time </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">require. Tenant shall also require </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">its </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">movers to procure </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">deliver to </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">a certificate of insurance covering. </font><font style="font-family:inherit;font-size:11pt;color:#808080;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Landlord as an additional insured. Tenant shall, at </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">its </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">sole cost and expense, maintain in full force and effect </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">on </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">al} Tenant's trade fixtures, equipment and personal </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">property </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">in the Premises, a policy of </font><font style="font-family:inherit;font-size:11pt;color:#646464;">''speci</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">al form</font><font style="font-family:inherit;font-size:11pt;color:#646464;">&#8221; property</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">&#32;insurance covering the full </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">replacement </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">value of such property. All liability insurance required </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">hereunder </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shall IlQ1 be subject to cancellation without </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">a</font><font style="font-family:inherit;font-size:11pt;color:#646464;">t </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">least </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">thirty (30) days' prior notice to all insureds, and shall name </font><font style="font-family:inherit;font-size:11pt;color:#646464;">Tenant </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">as insured, </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Landlord and Landlord's property manager as additional insureds, and, if </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">requested </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">by Landlord, shall also name as an additional insured any </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">mortgagee </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">or holder of any mortgage that may be or </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">become </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">a lien </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">upon </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">any part of the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Premises. </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Prior to the commencement of the Term, </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Tenant </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shall provide Landlord with certificates </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">that </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">evidence that the coverages required have </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">been </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">obtained for the policy </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">periods. </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Tenant shall also furnish.to Landlord or Landlord's designated agent throughout the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Term </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">replacement certificates at least thirty (30) </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">days </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">prior to the expiration dates </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">then</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">-</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">current policy or policies</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">. </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">All the insurance required under this </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Lease </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">shall be issued by insurance companies authorized to </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">do </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">business in the Commonwealth of Virginia with a financial </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">rating </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">of at least an A</font><font style="font-family:inherit;font-size:11pt;color:#1a1a1a;">-</font><font style="font-family:inherit;font-size:11pt;color:#646464;">X </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">as rated in </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">most recent edition of Best's Insurance Reports and in </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">business for </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">past </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">five (5) years. The limit of any </font><font style="font-family:inherit;font-size:11pt;color:#646464;">such </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">insurance shall not </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">limit </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the liability of Tenant hereunder. If Tenant fails </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">maintain such insurance, Landlord may but is not </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">required </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to, procure and maintain the same, at Tenant's expense to be</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">&#32;reimbursed by </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Tenant as Additional Rent within </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">ten </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(I 0) days of written demand. Any deductible under such insurance policy in excess of Twenty-Five Thousand Dollars ($25,000) must be approved </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">by Landlord </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">in writing prior to </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">issuance </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">of such policy. Tenant </font><font style="font-family:inherit;font-size:11pt;color:#646464;">s</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">hall </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">not self-insure-without Landlord's prior written consent Landlord and Tenant shall each procure an appropriate clause in or endorsement to any property </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">insurance </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">covering the Project or any </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">portion </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">thereof and personal property, fu.1Ures and equipment located therein, wherein the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">insurer </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">waives subrogation or consents </font><font style="font-family:inherit;font-size:11pt;color:#646464;">to </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">a </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">waiver of right </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">of recovery. </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Both Landlord </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Tenant agree </font><font style="font-family:inherit;font-size:11pt;color:#646464;">t</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">o </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">immediately give each insurance company which has issued to it policies of fire and </font><font style="font-family:inherit;font-size:11pt;color:#646464;">exte</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">nded </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">coverage </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">insurance </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">written </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">notice of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">the</font><font style="font-family:inherit;font-size:11pt;color:#646464;">&#32;terms </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">of such mutu.al waivers and to cause such insurance </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">policies </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to be properly endorsed, if </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">necessary</font><font style="font-family:inherit;font-size:11pt;color:#808080;">, </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to prevent the invalidation thereof by reason of such waivers and shall furnish to the other party written evidence of such foregoing endorsements or that such endorsement is not required. Landlord and Tenant hereby waive and agree not to make any claim against, or seek to recover from, the other for any loss or damage to its property or the property of others resulting from tire or other hazards to the e&gt;..1:ent covered </font><font style="font-family:inherit;font-size:11pt;color:#646464;">(</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">or would have been covered if the party </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">had</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">&#32;obtained and maintained </font><font style="font-family:inherit;font-size:11pt;color:#646464;">the </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">insurance it was required </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">to carry under </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">this Lease or </font><font style="font-family:inherit;font-size:11pt;color:#646464;">if </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Tenant did not elect to </font><font style="font-family:inherit;font-size:11pt;color:#646464;">self-</font><font style="font-family:inherit;font-size:10pt;color:#525252;">insure for any such matter or </font><font style="font-family:inherit;font-size:10pt;color:#414141;">risk) </font><font style="font-family:inherit;font-size:10pt;color:#525252;">by the property insurance that was required co </font><font style="font-family:inherit;font-size:10pt;color:#414141;">be </font><font style="font-family:inherit;font-size:10pt;color:#525252;">carried by that party under the terms of this </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Lease. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">The foregoing waivers shall </font><font style="font-family:inherit;font-size:10pt;color:#414141;">not </font><font style="font-family:inherit;font-size:10pt;color:#525252;">apply to </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Joss or damage </font><font style="font-family:inherit;font-size:10pt;color:#525252;">in </font><font style="font-family:inherit;font-size:10pt;color:#414141;">excess </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of actual or required policy limits (whichever is greater) </font><font style="font-family:inherit;font-size:10pt;color:#414141;">or to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the first $25,000.00 of any deductible, co-insurance or self-ins</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">ur</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ed </font><font style="font-family:inherit;font-size:10pt;color:#414141;">retentions </font><font style="font-family:inherit;font-size:10pt;color:#525252;">applicable </font><font style="font-family:inherit;font-size:10pt;color:#414141;">under </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any policy </font><font style="font-family:inherit;font-size:10pt;color:#414141;">maintained </font><font style="font-family:inherit;font-size:10pt;color:#525252;">by </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Landlord. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Landlord. will maintain a policy of </font><font style="font-family:inherit;font-size:10pt;color:#414141;">&#8220;special </font><font style="font-family:inherit;font-size:10pt;color:#525252;">form:</font><font style="font-family:inherit;font-size:10pt;color:#757575;">'</font><font style="font-family:inherit;font-size:10pt;color:#525252;">' property insurance covering the full replacement value of Landlord's interest in the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Project </font><font style="font-family:inherit;font-size:10pt;color:#525252;">with </font><font style="font-family:inherit;font-size:10pt;color:#414141;">a deductible </font><font style="font-family:inherit;font-size:10pt;color:#525252;">in an amount not </font><font style="font-family:inherit;font-size:10pt;color:#414141;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">exceed $25,000</font><font style="font-family:inherit;font-size:10pt;color:#757575;">. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Landlord will maintain </font><font style="font-family:inherit;font-size:10pt;color:#414141;">a </font><font style="font-family:inherit;font-size:10pt;color:#525252;">commercial general </font><font style="font-family:inherit;font-size:10pt;color:#414141;">liability </font><font style="font-family:inherit;font-size:10pt;color:#525252;">insurance policy for </font><font style="font-family:inherit;font-size:10pt;color:#414141;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Project in a </font><font style="font-family:inherit;font-size:10pt;color:#414141;">reasonable </font><font style="font-family:inherit;font-size:10pt;color:#525252;">amount.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">INDEMNIFICATION</font><font style="font-family:inherit;font-size:10pt;color:#525252;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant shall defend, indemnify and bold </font><font style="font-family:inherit;font-size:10pt;color:#414141;">harmless Landlord, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Landlord's property manager and each of Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#414141;">directors, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">officers, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">members, partners</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">trustees, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">employees and agents (collectively, the "</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Landlord Indemnitees</font><font style="font-family:inherit;font-size:10pt;color:#525252;">") from and against any </font><font style="font-family:inherit;font-size:10pt;color:#414141;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">all third-party claims, actions</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">damages</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">liabilities and expenses (including </font><font style="font-family:inherit;font-size:10pt;color:#414141;">all </font><font style="font-family:inherit;font-size:10pt;color:#525252;">reasonable costs and expenses (including reasonable attorneys</font><font style="font-family:inherit;font-size:10pt;color:#757575;">' </font><font style="font-family:inherit;font-size:10pt;color:#525252;">fees)) arising from: (i) </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#525252;">breach of this Lease; (ii) any negligence </font><font style="font-family:inherit;font-size:10pt;color:#414141;">or </font><font style="font-family:inherit;font-size:10pt;color:#525252;">willful </font><font style="font-family:inherit;font-size:10pt;color:#414141;">act of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Indemnitees </font><font style="font-family:inherit;font-size:10pt;color:#525252;">(as  </font><font style="font-family:inherit;font-size:10pt;color:#414141;">defined </font><font style="font-family:inherit;font-size:10pt;color:#525252;">in Section 13(b) below), or any of </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#757575;">'</font><font style="font-family:inherit;font-size:10pt;color:#525252;">s invitees, subtenants, or contractors; provided, however</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#757575;">'</font><font style="font-family:inherit;font-size:10pt;color:#525252;">s </font><font style="font-family:inherit;font-size:10pt;color:#414141;">indemnity </font><font style="font-family:inherit;font-size:10pt;color:#525252;">obligations shall not </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525252;">extend to loss of business</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">loss of profits, or other consequential damages that may be suffered by Landlord and (iii) any </font><font style="font-family:inherit;font-size:10pt;color:#414141;">acts or </font><font style="font-family:inherit;font-size:10pt;color:#525252;">omissions occurring </font><font style="font-family:inherit;font-size:10pt;color:#414141;">at</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">condition, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">use </font><font style="font-family:inherit;font-size:10pt;color:#414141;">or operation of, the Premises, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">except </font><font style="font-family:inherit;font-size:10pt;color:#414141;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the extent arising from Landlord's negligence or willful misconduct. If Tenant fai</font><font style="font-family:inherit;font-size:10pt;color:#757575;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">s to promptly defend a Landlord Indemnitee following written demand by the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Indemnitee, the Landlord </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Indemnitee </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall </font><font style="font-family:inherit;font-size:10pt;color:#414141;">defend </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the same at Tenant's expense, by retaining or employing counsel reasonably satisfactory to such Landlord Indemnitee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">Landlord shall defend, indemnify </font><font style="font-family:inherit;font-size:10pt;color:#414141;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">ho</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">d </font><font style="font-family:inherit;font-size:10pt;color:#414141;">harmless </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant and each of </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Tenant's directors,</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;officers, members, partners, trus</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">t</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ees,employees </font><font style="font-family:inherit;font-size:10pt;color:#414141;">and agents </font><font style="font-family:inherit;font-size:10pt;color:#525252;">(collectively, t</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">he </font><font style="font-family:inherit;font-size:10pt;color:#525252;">'</font><font style="font-family:inherit;font-size:10pt;color:#757575;">'</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#414141;text-decoration:underline;">Indemnitees")</font><font style="font-family:inherit;font-size:10pt;color:#414141;">&#32;from </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and against any and all third</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">-</font><font style="font-family:inherit;font-size:10pt;color:#525252;">party claims, actions, damages, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">liabilities </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and </font><font style="font-family:inherit;font-size:10pt;color:#414141;">expenses </font><font style="font-family:inherit;font-size:10pt;color:#525252;">(including all reasonable costs </font><font style="font-family:inherit;font-size:10pt;color:#414141;">and</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;expenses (including reasonable attorneys' fees)) arising from: (i) Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#414141;">breach </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of </font><font style="font-family:inherit;font-size:10pt;color:#414141;">this </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Lease; and (ii) any negligence or w</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">i</font><font style="font-family:inherit;font-size:10pt;color:#525252;">llful </font><font style="font-family:inherit;font-size:10pt;color:#414141;">misconduct </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of Landlord or any Landlord indemnitees; provided, however Landlord's</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525252;">indemnity obligations shall not extend to </font><font style="font-family:inherit;font-size:10pt;color:#414141;">loss </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of business, loss of profits, or other consequential </font><font style="font-family:inherit;font-size:10pt;color:#414141;">damages that </font><font style="font-family:inherit;font-size:10pt;color:#525252;">may be suffered by </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Tenant. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">If Landlord fails to </font><font style="font-family:inherit;font-size:10pt;color:#414141;">promptly defend </font><font style="font-family:inherit;font-size:10pt;color:#525252;">a Tenant Indemnitee following written </font><font style="font-family:inherit;font-size:10pt;color:#414141;">demand </font><font style="font-family:inherit;font-size:10pt;color:#525252;">by the Tenant indemnitee, the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Tenant Indemnitee </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall </font><font style="font-family:inherit;font-size:10pt;color:#414141;">defend the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">same at Landlord's expense</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">by retaining or </font><font style="font-family:inherit;font-size:10pt;color:#414141;">employing </font><font style="font-family:inherit;font-size:10pt;color:#525252;">counsel reasonably satisfactory to such Tenant </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Indemnitee.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#414141;">The provisions </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of this Article 13 shall survive the expiration or earlier termination of this Lease</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">FIRE</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#414141;text-decoration:underline;">DAMAGE</font><font style="font-family:inherit;font-size:10pt;color:#414141;">. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">If there occurs any casualty to the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Premises </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and: {i) the casualty damage </font><font style="font-family:inherit;font-size:10pt;color:#525252;font-style:italic;">is </font><font style="font-family:inherit;font-size:10pt;color:#414141;">of a</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525252;">nature or extent that, in Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#414141;">reasonable </font><font style="font-family:inherit;font-size:10pt;color:#525252;">judgment, the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">repair </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and restoration work would require more than two </font><font style="font-family:inherit;font-size:10pt;color:#414141;">hundred </font><font style="font-family:inherit;font-size:10pt;color:#525252;">ten (210) consecutive days </font><font style="font-family:inherit;font-size:10pt;color:#414141;">to complete </font><font style="font-family:inherit;font-size:10pt;color:#525252;">after the casualty (assuming normal work crews not engaged in overtime); or (ii) more than </font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">th</font><font style="font-family:inherit;font-size:10pt;color:#525252;">irty (30%) percent of the total area of the Building </font><font style="font-family:inherit;font-size:10pt;color:#414141;">is </font><font style="font-family:inherit;font-size:10pt;color:#525252;">extensively </font><font style="font-family:inherit;font-size:10pt;color:#414141;">damaged; </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or (iii) the casualty occurs in the </font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ast Lease Year of the Term and Tenant </font><font style="font-family:inherit;font-size:10pt;color:#414141;">bas </font><font style="font-family:inherit;font-size:10pt;color:#525252;">not exercised a renewal right; or (iv) insurance proceeds are unavailable or insufficient, either party shall have the right to </font><font style="font-family:inherit;font-size:10pt;color:#414141;">terminate </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this Lease and all the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">unaccrued </font><font style="font-family:inherit;font-size:10pt;color:#525252;">obligations of the  </font><font style="font-family:inherit;font-size:10pt;color:#414141;">parties </font><font style="font-family:inherit;font-size:10pt;color:#525252;">hereto, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">by </font><font style="font-family:inherit;font-size:10pt;color:#525252;">sending written notice of such </font><font style="font-family:inherit;font-size:10pt;color:#414141;">termination </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to the other within thirty</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525252;">(30</font><font style="font-family:inherit;font-size:10pt;color:#757575;">) </font><font style="font-family:inherit;font-size:10pt;color:#525252;">days of the date of </font><font style="font-family:inherit;font-size:10pt;color:#414141;">casualty. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Such notice is to </font><font style="font-family:inherit;font-size:10pt;color:#414141;">specify </font><font style="font-family:inherit;font-size:10pt;color:#525252;">a </font><font style="font-family:inherit;font-size:10pt;color:#414141;">termination </font><font style="font-family:inherit;font-size:10pt;color:#525252;">date no </font><font style="font-family:inherit;font-size:10pt;color:#414141;">less</font><font style="font-family:inherit;font-size:10pt;color:#525252;">1han fifteen (15) </font><font style="font-family:inherit;font-size:10pt;color:#414141;">days </font><font style="font-family:inherit;font-size:10pt;color:#525252;">after its</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525252;">transmission. Notwithstanding the foregoing, if the casualty was </font><font style="font-family:inherit;font-size:10pt;color:#414141;">caused </font><font style="font-family:inherit;font-size:10pt;color:#525252;">by the act or omission of Tenant or any of Tenant's agents, employees, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">invitees, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">assignees</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">subtenants</font><font style="font-family:inherit;font-size:10pt;color:#757575;">, </font><font style="font-family:inherit;font-size:10pt;color:#414141;">licensees </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or contractors, Tenant shall have no right to terminate th.is Lease due to the casualty. In </font><font style="font-family:inherit;font-size:10pt;color:#414141;">the event of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">damage or </font><font style="font-family:inherit;font-size:10pt;color:#414141;">destruction </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to </font><font style="font-family:inherit;font-size:10pt;color:#414141;">the Premises </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or any </font><font style="font-family:inherit;font-size:10pt;color:#414141;">part </font><font style="font-family:inherit;font-size:10pt;color:#525252;">thereof and neither </font><font style="font-family:inherit;font-size:10pt;color:#525252;font-style:italic;">party </font><font style="font-family:inherit;font-size:10pt;color:#414141;">has </font><font style="font-family:inherit;font-size:10pt;color:#525252;">terminated this </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Lease, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant's obligation </font><font style="font-family:inherit;font-size:10pt;color:#414141;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">pay Fixed Rent and Additional Rent shall be equitably adjusted or abated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;color:#757575;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">SUBORDINATION AND NON-DISTURBANCE: RIGHTS OF MORTGAGEE</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. Provided the holder of a mortgage or Deed of Trust (as hereinafter </font><font style="font-family:inherit;font-size:10pt;color:#414141;">defined) </font><font style="font-family:inherit;font-size:10pt;color:#525252;">agrees to recognize ibis Lease</font><font style="font-family:inherit;font-size:10pt;color:#414141;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the event of a foreclosure or deed in l</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">ieu </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of </font><font style="font-family:inherit;font-size:10pt;color:#414141;">foreclosure, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this Lease shall </font><font style="font-family:inherit;font-size:10pt;color:#414141;">be </font><font style="font-family:inherit;font-size:10pt;color:#525252;">subordinate at </font><font style="font-family:inherit;font-size:10pt;color:#414141;">all </font><font style="font-family:inherit;font-size:10pt;color:#525252;">times to the </font><font style="font-family:inherit;font-size:10pt;color:#414141;">lien of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any mortgages </font><font style="font-family:inherit;font-size:10pt;color:#414141;">now </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or </font><font style="font-family:inherit;font-size:10pt;color:#414141;">hereafter </font><font style="font-family:inherit;font-size:10pt;color:#525252;">placed upon the Premises, Building and/or </font><font style="font-family:inherit;font-size:10pt;color:#414141;">Project </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and land of which they are a </font><font style="font-family:inherit;font-size:10pt;color:#414141;">part </font><font style="font-family:inherit;font-size:10pt;color:#525252;">withou</font><font style="font-family:inherit;font-size:10pt;color:#2a2a2a;">t </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the necessity of any further instrument or </font><font style="font-family:inherit;font-size:10pt;color:#414141;">act </font><font style="font-family:inherit;font-size:10pt;color:#525252;">on the part of Tenant to effectuate </font><font style="font-family:inherit;font-size:10pt;color:#414141;">such </font><font style="font-family:inherit;font-size:10pt;color:#525252;">subordination. Tenant further agrees to execute and </font><font style="font-family:inherit;font-size:10pt;color:#414141;">deliver </font><font style="font-family:inherit;font-size:10pt;color:#525252;">within ten (10) days of demand such further instrument evidencing such subordination, non-disturbance and </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">attornment as sha</font><font style="font-family:inherit;font-size:10pt;color:#313131;">ll </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">be reasonably required by any mortgagee. </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">If </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Landlo</font><font style="font-family:inherit;font-size:10pt;color:#313131;">r</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">d shall be or is alleged to be in defaul</font><font style="font-family:inherit;font-size:10pt;color:#313131;">t </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">of any of its obligations owing to Tenant under this Lease, Tenant shall give to the holder (the "</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">Mortgagee</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">'') of any mortgage or deed of </font><font style="font-family:Arial;font-size:8.5pt;color:#4d4d4d;">trust </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">now or </font><font style="font-family:inherit;font-size:10pt;color:#313131;">h</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">ere after placed upon the Premises, Building and/or </font><font style="font-family:inherit;font-size:10pt;color:#313131;">P</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">roject (provided Tenant has received written notice of the name and address of such Mortgagee), notice by overnight mail of </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">any </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">such default that Tenant shall have served upon Landlord</font><font style="font-family:inherit;font-size:10pt;color:#313131;">. </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant shall not be entitled to terminate this Lease because of any default by Landlord without having given such notice to the Mortgagee. If Landlord shall </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">fail </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">to cure such default, prior </font><font style="font-family:inherit;font-size:7.5pt;color:#4d4d4d;">t0 </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant terminating the Lease, the Mortgagee shall have forty-five (45) </font><font style="font-family:inherit;font-size:10pt;color:#313131;">a</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">dditional days within which to cute such default. </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">In </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">addition</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the Mortgagee (or a trustee on behalf of the Mortgagee), may, at its option</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">execute and record among the land records of the jurisdiction where the Premises are located a subordination s</font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">atement or statements w</font><font style="font-family:inherit;font-size:10pt;color:#313131;">i</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">th respect </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">this Lease whereby this Lease </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">will </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">be made superior to the lien of the deed of trust or the mortgage held by the Mortgagee and encumbe1ing the: Project (the "</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">Deed of Trus</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">t''). Tenant acknow</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">edges the </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">right </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">of the Mortgagee to file such a subo</font><font style="font-family:inherit;font-size:10pt;color:#313131;">r</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">dination statement</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">and agrees that from and after the recordation of such a subordination statement, this Lease shall be superior in lien and in </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">dignity </font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">o the lien of the Deed of Trust, and shall not be affected by any foreclosure  of the De</font><font style="font-family:inherit;font-size:10pt;color:#313131;">e</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">d of Trust.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:9pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">CONDEMNATION.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">If </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">a taking rende</font><font style="font-family:inherit;font-size:10pt;color:#313131;">r</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">s the Building reasonably unsuitable for the Permitted Use, this Lease s</font><font style="font-family:inherit;font-size:10pt;color:#313131;">h</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">all, at e</font><font style="font-family:inherit;font-size:10pt;color:#313131;">i</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">ther party's option, terminate as of the date ti</font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">le to condemned real estate vests </font><font style="font-family:Arial;font-size:10.5pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the condemner, the Rent herein reserved shall </font><font style="font-family:inherit;font-size:10pt;color:#313131;">b</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">e apportioned and paid </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">full by Tenant to Landlord to such date, a</font><font style="font-family:inherit;font-size:10pt;color:#313131;">ll </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Rent prepaid for pe</font><font style="font-family:inherit;font-size:10pt;color:#313131;">r</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">iod beyond that date shall </font><font style="font-family:Arial;font-size:9.5pt;color:#4d4d4d;">forthwith </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">be repaid by Landlord </font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">o Tenant, and neither party sha</font><font style="font-family:inherit;font-size:10pt;color:#313131;">ll </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">th</font><font style="font-family:inherit;font-size:10pt;color:#313131;">e</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">reafter have any liability for any unaccrued obligations here</font><font style="font-family:inherit;font-size:10pt;color:#313131;">un</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">der. If this Lease is not terminated after a condemnation, the Fixed </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Rent and the Additional Rent shall be equitab</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">y reduced in proportion to the area of the Premises that has been taken for the balance of the Term. Tenant shall have the </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">right </font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">o make a claim against </font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">he condemner for moving expenses and business dislocation damages to the extent that such claim does not reduce the sums otherwise payab</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">e by the condemner to Land</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">ord.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;color:#4d4d4d;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">ESTESTOP&#163;'.E.L CERTIFICATE.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;Each party agrees at any time and from time to time</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">within ten </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">(1</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">0) days after the other party's written request, to execute and deliver </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">of </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the other party a written instrument: in</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">recordable form certifying all information reasonably requested.</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;text-decoration:underline;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:9pt;color:#4d4d4d;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;text-decoration:underline;">DEFAULT</font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">An </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">"Ev</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">ent</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;of Default</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">" </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">shall be deemed to exist and Tenant shall be </font><font style="font-family:Arial;font-size:10.5pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">default hereunder </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">if: </font><font style="font-family:Arial;font-size:12pt;color:#4d4d4d;">CO </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant fails to pay any Rent when due and such failure continues for more than three (3) business days after Landlord bas given Tenant writte</font><font style="font-family:inherit;font-size:10pt;color:#313131;">n </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">notice of such failure; provided, however, </font><font style="font-family:Arial;font-size:10.5pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">no event shall Landlor</font><font style="font-family:inherit;font-size:10pt;color:#313131;">d </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">have any obligation </font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">o give Tenant more than two (2) such notices in any twelve </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">(12)-month </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">period, after which there shall be an Event of </font><font style="font-family:inherit;font-size:10pt;color:#313131;">D</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">efault </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">if </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant fails to pay </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">any </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">'Rent when due, regardless of Tenant's receipt of notice of such non-&#173; payment; </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">(ii) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant ceases to use the Premises for its Permitted Use or removes substantially all of </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">its </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">furniture, equipment and personal property from the Premises (other than in the case of a permitted subletting or assignment</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">)</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">t or permits the same to be unoccupied; </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">(iii) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant fails to bond over </font><font style="font-family:Arial;font-size:9pt;color:#4d4d4d;">-a </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">construction or mechanics lien within ten </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">(10) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">days of demand; (iv) any assignment or subletting (regardless of whe</font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">her the same m</font><font style="font-family:inherit;font-size:10pt;color:#313131;">i</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">ght be void under this Lease) </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">violation</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;of the terms of this Lease; (v) the occurrence of any default beyond any applicable </font><font style="font-family:inherit;font-size:10pt;color:#313131;">notice</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;and/or cure period under any guaranty executed in connection with this Lease; </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">(</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">vi)Tenant fails to delive</font><font style="font-family:inherit;font-size:10pt;color:#313131;">r </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">any Landlord&#173; requested estoppel certificate or subordination agreement within ten (10) business days afte</font><font style="font-family:inherit;font-size:10pt;color:#313131;">r </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">receipt of notice that such document was not received w</font><font style="font-family:inherit;font-size:10pt;color:#313131;">i</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">thin the time period required under this Lease; or (vii) Tenant fails to observe or perform any of Tenant's other non-monetary agreements or obligations herein contained </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">within </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">ten </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">(l0) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">days after written notice specifying the defau</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">t</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">,  </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">or the expiration of such add</font><font style="font-family:inherit;font-size:10pt;color:#313131;">i</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">tional time period as is reasonab</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">y necessary to cure such default (not to exceed ninety (90) days</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">)</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">, provided Tenant immediately commences and thereafter proceeds with all due diligence and in good faith to cure such default</font><font style="font-family:inherit;font-size:10pt;color:#838383;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">h</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">If an Event of Defau</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">t shall occur</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the following provisions shall apply and Landlord shall have, in addition to all other rights and remedies available at law or in equity, including the right to terminate this Lease</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">. </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the rights and remedies set forth herein</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">which may be exercised upon or at </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">any </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">rime following the occurrence of an Event of Default. </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">1. </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">Acceleration of Rent</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">. Landlord sha</font><font style="font-family:inherit;font-size:10pt;color:#313131;">ll </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">have the right to accelerate all Rent and all expenses due hereunder and o</font><font style="font-family:inherit;font-size:10pt;color:#313131;">t</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">herwise payable in insta</font><font style="font-family:inherit;font-size:10pt;color:#313131;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">lments over the remainder of t</font><font style="font-family:inherit;font-size:10pt;color:#313131;">h</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">e Term. The amount of accelerated rent to the termination </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">da te</font><font style="font-family:inherit;font-size:9pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">without further notice or demand for payment</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">shall be due and payable by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant </font><font style="font-family:Arial;font-size:10.5pt;color:#4f4f4f;">within </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">five </font><font style="font-family:inherit;font-size:10pt;color:#676767;">(</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">5) days after Landlord has so notified Tenant. If Tenant has paid to Landlord all accelerated rent for the balance of the Term and if Landlord shall subseq</font><font style="font-family:inherit;font-size:10pt;color:#676767;">u</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ently lease the Premises or a portion thereof for the balanc</font><font style="font-family:inherit;font-size:10pt;color:#676767;">e </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the</font><font style="font-family:inherit;font-size:10pt;color:#676767;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Term or portion thereof: Landlord shall pay Tenant 50% of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such rent actually collected</font><font style="font-family:inherit;font-size:10pt;color:#676767;">. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Additiona</font><font style="font-family:inherit;font-size:10pt;color:#676767;">l </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Rent that has not been included</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">whol</font><font style="font-family:inherit;font-size:10pt;color:#676767;">e </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or in part, </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">accelerated rent, shall be due and payable by Tenant during the remainder of the Term, in the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">amount</font><font style="font-family:inherit;font-size:10pt;color:#676767;">s and</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;at the times otherwise provided for in this Lease. 2. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Termination of</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:10pt;color:#676767;text-decoration:underline;">;</font><font style="font-family:inherit;font-size:10pt;color:#676767;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Termination of Possession. </font><font style="font-family:inherit;font-size:10pt;color:#676767;">L</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">andlord </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">have the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">right </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to terminate this Lease and recover all damages </font><font style="font-family:inherit;font-size:10pt;color:#676767;">c</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">aused </font><font style="font-family:Arial;font-size:9pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#676767;">' </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s breach</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">including consequential damages for lost future rent, and/or repossess the Premises</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">with or without terminating, and </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">relet </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the Premise</font><font style="font-family:inherit;font-size:10pt;color:#676767;">s </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">at such amount as Landlord deems </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">reasonable, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and/or seize and bold any personal property of </font><font style="font-family:inherit;font-size:10pt;color:#676767;">T</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">enant located in the Premises and assert against the same a lien for monies due Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and/or lock the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Premises </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and deny Tenant access </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">thereto </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">without obtaining any court authorization, and/or obtain an order for unlawful detainer from any court of competent jurisdiction without prejudice to Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">'</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s rights to otherwise collect Rent or breach of contract damages from </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Tenant, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">an</font><font style="font-family:inherit;font-size:10pt;color:#676767;">d/</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or pursue any </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">other </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">remedy available </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">law or equity. 3. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Landlord's Damages</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. The damages tha</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord shall be entitled to recover from Tenant shall be the sum of: </font><font style="font-family:Arial;font-size:9pt;color:#4f4f4f;">(i)  </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">all Fixed Ren</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and Additional Rent accrued and unpaid as of the termination date</font><font style="font-family:inherit;font-size:10pt;color:#676767;">; </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">(ii) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">all costs and expenses incurred by Landlord </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">recovering </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">possession of the Premises, including legal fees, and removal and storage of Tenant's property; (iii) the cost</font><font style="font-family:inherit;font-size:10pt;color:#676767;">s  </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and expenses o</font><font style="font-family:inherit;font-size:10pt;color:#676767;">f </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">restoring </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the Premises to the condition in which the same were </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">have been surrendered by Tenant as of the expiration of the Term</font><font style="font-family:inherit;font-size:10pt;color:#676767;">;  (</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">i</font><font style="font-family:inherit;font-size:10pt;color:#676767;">v</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">) the costs of reletting commissions; (v) </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">all </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Fixed Rent </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Additional </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">otherwise payable </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenan</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">over the remainder of the Term as reduced to present value and </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">all </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">consequential damages relating to Tenant's breach of this Lease; (vi) all legal</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">&#32;fees </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and court costs incurred by Landlord </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">connection </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the Event of </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Default; </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;font-style:italic;">plus </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">(vii</font><font style="font-family:inherit;font-size:10pt;color:#676767;">) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the unamortized portion (as </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">reasonably </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">determined by Landlord) of brokerage commissions </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">consulting fees incurred by Landlord, and tenant concessions including free rent given by Landlord, </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">connection </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">th.is Lease. Less deducting from the total determined under subsections (i) through (vii) above</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Rent that Landlord rece</font><font style="font-family:inherit;font-size:10pt;color:#676767;">i</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ves from other tenant(s) by reason of the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">leasing </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the Premises during </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">period falling </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">within </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the otherwise remainder of </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Term. 4. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Landlord's Right to Cure</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. Without </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">limiting </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the generality of </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">foregoing, if </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">fail </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to perform any of its obligations </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">hereunder</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord may, </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">addition </font><font style="font-family:inherit;font-size:10pt;color:#676767;">t</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">o any other </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">rights it </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">may </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">have </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">law </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">equity</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">cure such default on behalf of Tenant, and Tenan</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall reimburse Landlord upon demand for any sums paid or cost</font><font style="font-family:inherit;font-size:10pt;color:#676767;">s </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">incurred by Landlord in curing such default, including attorne</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s' fees and other legal expenses, </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">together </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">with inte</font><font style="font-family:inherit;font-size:10pt;color:#676767;">r</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">est a</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">twe</font><font style="font-family:inherit;font-size:10pt;color:#676767;">l</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ve percent (12%) </font><font style="font-family:inherit;font-size:10pt;color:#676767;">(</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the "</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Default Rate</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">"</font><font style="font-family:inherit;font-size:10pt;color:#676767;">) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">from1he </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">dates </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">'</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s incurring of costs or expenses. 5. Int</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">eres</font><font style="font-family:inherit;font-size:10pt;color:#676767;text-decoration:underline;">t</font><font style="font-family:inherit;font-size:10pt;color:#676767;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">on Damage Amounts</font><font style="font-family:inherit;font-size:10pt;color:#676767;">. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Any sums pa</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">able by </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">hereunder that are not paid after the same shall be due shall </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">bear </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">interest at the Default </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Rate. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">6. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">No Waiver by Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">No delay or forbearance by </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">in exercising. any </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">right </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or remedy hereunder, or </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">undertaking or performing </font><font style="font-family:inherit;font-size:9.5pt;color:#3b3b3b;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">act or matter that is not expressly required to be undertaken </font><font style="font-family:Arial;font-size:9pt;color:#4f4f4f;">b </font><font style="font-family:Arial;font-size:9pt;color:#676767;">y </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord shall be construed</font><font style="font-family:inherit;font-size:4pt;color:#4f4f4f;">1    </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">respectively, to be a wai</font><font style="font-family:inherit;font-size:10pt;color:#676767;">v</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">er of Landlord's rights or to represent any agreement by Landlord to undertake or perform such act or matter thereafter. Waiver by </font><font style="font-family:inherit;font-size:10pt;color:#1f1f1f;">L</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">andlord of </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">breach by Tenant of any covenant or condition herein contained (which waiver shall be effective onl</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">if </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">so expressed </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">writing by Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or failure </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord to exercise any right or </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">remedy </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">respect </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of any such breach shall not constitute a waiver or relinquishment for the future of Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">'</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s right to have any such covenant or condition </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">duly </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">performed or observed </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or of Landlord's rights arising because o</font><font style="font-family:inherit;font-size:10pt;color:#676767;">f </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">subsequent breach of </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such. covenant or condition nor bar any right or remedy of Landlord </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">respect of such breach o</font><font style="font-family:inherit;font-size:10pt;color:#676767;">r </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">any subsequent </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">breach. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">All tights and remedi</font><font style="font-family:inherit;font-size:10pt;color:#676767;">e</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s of </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">are cumulative, and the exercise of any one shall </font><font style="font-family:inherit;font-size:10pt;color:#676767;">n</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ot be an election excluding Landlord at any other time from exercise of a different or inconsistent remedy.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#676767;">I</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">f Landlord is compelled to engage the services of attorneys </font><font style="font-family:inherit;font-size:10pt;color:#676767;">(</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">either outside counsel or in&#173; house counsel) to enforce the provisions of </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Lease, to the extent that Landlord incurs any cost or expense in connection with such enforcemen</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">including without limitation instituting, prosecuting or defending its rights in an</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;action, proceeding or dispute </font><font style="font-family:Arial;font-size:9pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">reason </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of any default </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">by Tenant, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the sum or </font><font style="font-family:inherit;font-size:10pt;color:#676767;">s</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ums so paid or billed to Landlord</font><font style="font-family:inherit;font-size:10pt;color:#676767;">,</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;t</font><font style="font-family:inherit;font-size:10pt;color:#676767;">o</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">gether </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">with </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">interes</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">costs and disbursements, shall be due from </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">immediately upon receipt of an invoice therefor following the occurrence of such expenses. </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">If, in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the context of a bankruptcy ca</font><font style="font-family:inherit;font-size:10pt;color:#676767;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">se Landlord is compelled a</font><font style="font-family:inherit;font-size:10pt;color:#676767;">t</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;any time to incur any expense, including attorneys</font><font style="font-family:inherit;font-size:10pt;color:#676767;">' </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">fees, </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">enforcing or attempting </font><font style="font-family:inherit;font-size:10pt;color:#676767;">t</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">o enforce the terms of this Lease or to enforce or attempt to enforce any actions required under the Bankruptcy Code to be taken by the trustee or by Tenant</font><font style="font-family:inherit;font-size:10pt;color:#676767;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">as </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">debtor-in</font><font style="font-family:inherit;font-size:10pt;color:#1f1f1f;">-</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">possession then the sum so, paid </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">by Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">be </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">awarded to Landlord b</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">&#32;Bankruptcy </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Court and shall be immediately due and payable by the trustee or b</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant's bankruptcy estate to Land</font><font style="font-family:inherit;font-size:10pt;color:#676767;">l</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">ord in accordance with </font><font style="font-family:inherit;font-size:10pt;color:#676767;">t</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">he terms of the order of the Bankruptc</font><font style="font-family:inherit;font-size:10pt;color:#676767;">y </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Court.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">If Landlord fails to </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">pay </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">when due any sum due Tenant hereunder, which failure continues for a</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">period </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">fifteen </font><font style="font-family:inherit;font-size:10pt;color:#646464;">(</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">15) days after </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">receip</font><font style="font-family:inherit;font-size:10pt;color:#646464;">t </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of written notice of such failure from Tenant </font><font style="font-family:inherit;font-size:10pt;color:#646464;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord, or </font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">if </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord fail </font><font style="font-family:inherit;font-size:10.5pt;color:#646464;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">keep, perform or observe any of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">other covenants to be kept, observed or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">performed by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">hereunder, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">which failure continues for a period of </font><font style="font-family:Arial;font-size:9pt;color:#4f4f4f;">thirty </font><font style="font-family:inherit;font-size:9.5pt;color:#646464;">(30) </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">days </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">after written notice of such failure from Tenant to </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlo</font><font style="font-family:inherit;font-size:10pt;color:#646464;">rd </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">(unless </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such failure is</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of such a </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">nature </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">that </font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">it </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">will </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">require more </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">than </font><font style="font-family:Arial;font-size:8.5pt;color:#4f4f4f;">thirty </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">(30) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">days to cure, </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">which case such cure period shall be extended for so long as </font><font style="font-family:inherit;font-size:10pt;color:#646464;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall promptly </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">commence </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and diligently prosecute the cure of such failure, and </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">while </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">doing so shall continue to perform </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">monetary obligations hereunder, but in no event to exceed one hundred twenty </font><font style="font-family:inherit;font-size:10pt;color:#646464;">(</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">120</font><font style="font-family:inherit;font-size:10pt;color:#646464;">) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">days), then, </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">either of such events, an ''Event of Default by Landlord" shall exist hereunder.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">If an Event of Default by Landlord exists</font><font style="font-family:inherit;font-size:10pt;color:#797979;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">then Tenant may </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">exercise any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and all remedies available </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">at </font><font style="font-family:Arial;font-size:8.5pt;color:#4f4f4f;">law </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or </font><font style="font-family:Arial;font-size:11pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">equity, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">including</font><font style="font-family:inherit;font-size:10pt;color:#797979;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">without </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">limitation, </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">one or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">more </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the following remedies, </font><font style="font-family:inherit;font-size:10pt;color:#646464;">while such</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;default</font><font style="font-family:inherit;font-size:10pt;color:#646464;">&#32;is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">continuing </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">remains uncured:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">commence an </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">action </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">for specific performance against Landlord; and/or</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">to commence</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;an action for damages suffered or incurred </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant as a result </font><font style="font-family:inherit;font-size:10pt;color:#646464;">of</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;Landlord's default; and/or</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">itself perform, or cause to be performed, the covenant, performance or condition required to be kept, observed or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">p</font><font style="font-family:inherit;font-size:10pt;color:#646464;">erformed</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">by Landlord </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">which </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">is </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">default and </font><font style="font-family:inherit;font-size:10pt;color:#646464;">to thereafter</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;pursue a court action against Landlord for amounts expended </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">on </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">account.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;color:#4f4f4f;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">SURRENDER.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;No later than upon </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">expiration or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">earlier </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">termination of the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Term </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or Tenant</font><font style="font-family:inherit;font-size:10pt;color:#797979;">'</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s right to </font><font style="font-family:inherit;font-size:10pt;color:#646464;">possess</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">ion</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;of the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Premises, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant shall vacate and surrender the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Premises to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord in good order and condition and </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">conformity with the applicable provisions of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Lease, including without </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">limitation </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Article</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;11. Tenant shall have no right to hold over beyond </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">expiration </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Term, and if Tenant does not vacate </font><font style="font-family:Arial;font-size:8.5pt;color:#4f4f4f;">as </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">required </font><font style="font-family:inherit;font-size:10pt;color:#646464;">such </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">failure shall be </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">deemed </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">an Event of Default and Tenant's occupancy shall </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">not </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be construed </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:10pt;color:#646464;">effect </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or constitute anything other than a </font><font style="font-family:inherit;font-size:10pt;color:#646464;">tenancy </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">at sufferance. </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">During </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">any period of occupancy beyond the expiration or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">earlier </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">termination of the Term the amount </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of Rent </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">owed by </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Tenant. a</font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlord shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be one hundred </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">fifty </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">percent </font><font style="font-family:inherit;font-size:10pt;color:#646464;">(150%) </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Rent that would otherwise be due under this Lease, </font><font style="font-family:inherit;font-size:10pt;color:#646464;">wi</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">thout </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">prorating for </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">partial month of holdover. The acceptance of </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#646464;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord or the failure or delay of Landlord </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">notifying or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">evicting Tenant following the expiration or earlier </font><font style="font-family:inherit;font-size:10pt;color:#646464;">termination </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Term </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall not create </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#646464;">tenancy </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">rights </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant and any such payments by Tenant may be </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">applied </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">against its costs and expenses, including reasonable attorneys' fees, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">incurred </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:9.5pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">as a result of such holdover</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">. The provisions </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">section shall not constitute a waiver by Landlord </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">right </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">re-entry as set forth </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">this Lease; nor </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">receipt </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Rent or any </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">other </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">act </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">apparent </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">affirmance </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the tenancy operate as a waiver of Landlord's right to terminate </font><font style="font-family:inherit;font-size:9.5pt;color:#646464;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Lease for </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">a breach </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of any of the terms, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">covenants, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or obligations herein on Tenant's part to be performed. </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">In </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">addition, if Tenant fails to vacate and surrender the Premises as herein </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">required, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant shall indemnify, defend and hold harmless </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">from all costs, losses, expenses or liabilities incurred as a result </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such failure, including without limitation</font><font style="font-family:inherit;font-size:10pt;color:#797979;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">claims made by any succeeding tenant and real estate brokers' </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">claims </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and reasonable attorneys' fees. At the end of the Term or sooner </font><font style="font-family:inherit;font-size:10pt;color:#646464;">termination </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">right to </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">possession </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Premises, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant shall, at Landlord's option, remove all furniture, movable trade</font><font style="font-family:inherit;font-size:10pt;color:#646464;">&#32;fixtures </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and equipment </font><font style="font-family:inherit;font-size:10pt;color:#646464;">(including </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">telephon</font><font style="font-family:inherit;font-size:10pt;color:#646464;">e </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">security and </font><font style="font-family:inherit;font-size:10pt;color:#646464;">communication </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">equipment system wiring and cabling) </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">a </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">good and workmanlike manner so as not to damage </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Premises or Building and in </font><font style="font-family:inherit;font-size:10pt;color:#646464;">such </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">manner so as not </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">disturb </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">other </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">tenants </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">Building. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant's obligation to pay Rent and to perform all other Lease obligations for </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the period </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">up to and including the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">expiration </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or earlier termination of </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Lease</font><font style="font-family:inherit;font-size:10pt;color:#797979;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and the provisions of this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Article</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;text-decoration:underline;">19</font><font style="font-family:inherit;font-size:9.5pt;color:#797979;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:9.5pt;color:#797979;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">sha11survive </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">expiration or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">earlier </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">termination of this Lease.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">RULES AND </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">REGULATIONS.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;At </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">times during the Term, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Tenant, </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">employees, agents,</font><font style="font-family:inherit;font-size:10pt;color:#646464;">&#32;subtenan</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">ts, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">invitees and licensees shall </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">compl</font><font style="font-family:inherit;font-size:10pt;color:#646464;">y </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">rules </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and regulations specified on </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Exhibit</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:11.5pt;color:#4f4f4f;font-style:italic;text-decoration:underline;">G</font><font style="font-family:Arial;font-size:11.5pt;color:#4f4f4f;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">attached hereto and such other written rules and regulations established </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">for the Project from time </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">time (provided, no later </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">adopted </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">rules shall interfere </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#797979;">' </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s use of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Premises for the Permitted Use). In.the event of an</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">&#32;inconsi</font><font style="font-family:inherit;font-size:10pt;color:#646464;">stency </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">between the rules and </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">regulations </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and this Lease, the provisions of this Lease shall </font><font style="font-family:inherit;font-size:10pt;color:#646464;">contro</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">l.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;color:#4f4f4f;padding-right:48px;">21.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">GOVERNMENTAL REGULATIONS.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;Tenant shall. in the use and </font><font style="font-family:inherit;font-size:10pt;color:#646464;">occupancy </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the Premises and the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">conduct of Tenant's business or profession therein, at all times </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">comply </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">all applicable laws, ordinances, orders</font><font style="font-family:inherit;font-size:10pt;color:#727272;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">notices, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">rules </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and regulations </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the federal, state and municipal governments </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">collectively</font><font style="font-family:inherit;font-size:10pt;color:#727272;">, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;text-decoration:underline;">Laws</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"). </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord shall be responsible for compliance </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Title III </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the Americans with Disabilities Act of 1990, 42 U.S.C. </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">&#167;</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">12181 </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;font-style:italic;">et </font><font style="font-family:inherit;font-size:11.5pt;color:#5b5b5b;font-style:italic;">seq. </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and </font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">its </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">regulations </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(collectively, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;text-decoration:underline;">ADA</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"): (a) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">as to the design and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">construc</font><font style="font-family:inherit;font-size:10pt;color:#363636;">tion </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of exterior and interior </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">common </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">areas </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(e.g. </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">sidewalks, parking areas and common area bathrooms); and </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">(b) </font><font style="font-family:Arial;font-size:9pt;color:#5b5b5b;">with </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">respect </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">to </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">design and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">construction </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of the Premises </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">as </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of the date of this Lease. </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Except as </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">set </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">forth </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">above in the preceding sentence, Tenant shall be responsible for compliance with the ADA </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">all other respects concerning the use </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">occupancy of the Premises, which. Compliance shall </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">include, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">without limitation: </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(i) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">provision for full and equal enjoyment of the goods, services, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">facilit</font><font style="font-family:inherit;font-size:10pt;color:#363636;">ies</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">privileges, advantages or accommodations of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Premises as contemplated by and to the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">extent </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">required by the ADA; </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(ii) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">compliance relating to requirements under the ADA or amendments </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">thereto </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">arising </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">after </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the date of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">this Lease; </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(</font><font style="font-family:inherit;font-size:10pt;color:#363636;">ii</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">i) compliance </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">re1ating </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">design, layout, renovation redecorating, refurbishment,</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;alteration, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or improvement </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Premises </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">made or requested by Tenant.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10.5pt;padding-right:48px;">22.</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;text-decoration:underline;">NOTIC</font><font style="font-family:inherit;font-size:10pt;color:#363636;text-decoration:underline;">ES</font><font style="font-family:inherit;font-size:10pt;color:#363636;">. </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Wherever in this Lease </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">it </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be required </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">permitted that notice or demand </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">be </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">given </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;served </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">either party </font><font style="font-family:inherit;font-size:10pt;color:#363636;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">this Lease </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or on the other party, such </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">notice</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;or demand </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be duly given or served </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">if in </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">writing </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and either: (i) personally served; </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">(ii) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">delivered by pre-paid </font><font style="font-family:inherit;font-size:10pt;color:#363636;">nationall</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">y </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">recognized overnight courier service</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;</font><font style="font-family:Arial;font-size:9pt;color:#5b5b5b;font-style:italic;">(e.g., </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Federal </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Express) with evidence of receipt required for delivery; </font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">(ill) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">forwarded </font><font style="font-family:Arial;font-size:9pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">registered </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">certified </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">mail, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">return receipt </font><font style="font-family:inherit;font-size:10pt;color:#363636;">r</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">equested, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">postage prepaid</font><font style="font-family:inherit;font-size:10pt;color:#727272;">; </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(iv) sen</font><font style="font-family:inherit;font-size:10pt;color:#363636;">t by </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">facsimile </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">a </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">copy </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">mailed by first class </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;United </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">States </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">mail;</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;or </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">(v) </font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">if </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">an e-mail </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">address </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">is </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">provided, e-mailed </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">evidence of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">receipt </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and delivery </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">a </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">copy of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">notice </font><font style="font-family:Arial;font-size:9pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">first </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">class mail in all such cases </font><font style="font-family:inherit;font-size:10pt;color:#363636;">addressed to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">parties </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">at the addresses </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">set </font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">forth </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">below_ </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Each </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">such </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">notice shall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;deemed to </font><font style="font-family:inherit;font-size:10pt;color:#363636;">h</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">ave </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">been given to or served upon the party to </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">which </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">addressed on the date the same is delivered or delivery is refused. Each </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">party </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall have the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">right </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">to </font><font style="font-family:inherit;font-size:10pt;color:#363636;">chang</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">e its </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">address for </font><font style="font-family:inherit;font-size:10pt;color:#363636;">no</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">tices</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;(provided such new address </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">is </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">in </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">continental </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">United </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">States) by </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">a writing </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">sent to the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">other </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">party </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">acco</font><font style="font-family:inherit;font-size:10pt;color:#363636;">rdanc</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">e </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">with </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">this</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">Article</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;text-decoration:underline;">22,</font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">each </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">party</font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall, </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">if </font><font style="font-family:inherit;font-size:10pt;color:#363636;">reque</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">sted, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">within ten </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">(10) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">days </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">confirm </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">to the other its notice address. </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Notices </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">from Landlord may be given by </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">either an </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">agent or </font><font style="font-family:inherit;font-size:10pt;color:#363636;">attorney</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">acting on </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">beha</font><font style="font-family:inherit;font-size:10pt;color:#363636;">lf </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of Landlord.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3931623931624%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">DIFFUSION PHARMACEUTICALS INC</font><font style="font-family:inherit;font-size:10pt;color:#9e9e9e;">,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;color:#5b5b5b;">Attn: </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">David Kalergis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">1317 </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Carlton </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Avenue</font><font style="font-family:inherit;font-size:10pt;color:#727272;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">S&#181;ite400</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Charlottesville, VA </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">22902</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">Pax </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">No: </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">(434) </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">220</font><font style="font-family:inherit;font-size:9pt;color:#363636;">-</font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">0722</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">E-mail:   dkalergis@diffusionpharma.com</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ONE </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">CARL</font><font style="font-family:inherit;font-size:10pt;color:#363636;">TO </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">N, LLC</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Attn: </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Frayse</font><font style="font-family:inherit;font-size:10pt;color:#363636;">r </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">White</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">1100 Harris </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Street</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Char</font><font style="font-family:inherit;font-size:10pt;color:#363636;">lottesville</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:9pt;color:#4b4b4b;">VA 22903</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">E-mail: </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">frayser.white@!!lilaiLcom</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With a copy to:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">Henry </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Lisico</font></div><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Henry Lisico </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Company </font></div><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">12704 </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Crimson Ct.</font><font style="font-family:inherit;font-size:10pt;color:#727272;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Suite 101</font></div><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Richmond, VA.23233-7657</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">E-mail: h</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">enrviisjco@verizon.net</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:9.5pt;padding-right:48px;">23.</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">BROKERS</font><font style="font-family:inherit;font-size:10pt;color:#727272;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:10pt;color:#727272;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Tenant each represents </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">warrants to </font><font style="font-family:inherit;font-size:9pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">other that such </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">party </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">has had </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">no</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;dealings, negotiations or consultations </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">respect </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the Premises </font><font style="font-family:Arial;font-size:9.5pt;color:#4b4b4b;font-style:italic;">or </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">this transaction wi.th </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">any broker</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;or finder</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;other </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">than </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Cushman </font><font style="font-family:Arial;font-size:10.5pt;color:#4b4b4b;">&amp; </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Wakefield/Thalhimer. </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Each </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">party </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">indemnify and hold the other harmless from </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">and</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;against </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">all </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">liability, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">cost </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and expense</font><font style="font-family:inherit;font-size:10pt;color:#727272;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">including attorneys' fees and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">court </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;font-style:italic;">costs</font><font style="font-family:inherit;font-size:10.5pt;color:#363636;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">arising out of </font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">any </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">misrepresentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">breach of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">warranty </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">under this </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Article.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">24.</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">LANDLORD</font><font style="font-family:inherit;font-size:10pt;color:#727272;text-decoration:underline;">'</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">S LIABILITY.</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;Landlor</font><font style="font-family:inherit;font-size:10pt;color:#727272;">d&#8217;s </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">obligations hereunder </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">binding </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">upon </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">Landlord </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">only</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">for </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the period of time that Landlord </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">is in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ownership of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Building, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">upon </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">t</font><font style="font-family:inherit;font-size:10pt;color:#363636;">ermination </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of that </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ownership</font><font style="font-family:inherit;font-size:10pt;color:#727272;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#525252;">except as </font><font style="font-family:inherit;font-size:10pt;color:#424242;">to any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">obligations </font><font style="font-family:inherit;font-size:10pt;color:#424242;">that are then due </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and owing, shall </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ook </font><font style="font-family:inherit;font-size:10pt;color:#424242;">solely to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Landlord's successor-in-interest in </font><font style="font-family:inherit;font-size:10pt;color:#424242;">ownership </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Building </font><font style="font-family:inherit;font-size:10pt;color:#525252;">for the satisfaction of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">each </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and every obl</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">i</font><font style="font-family:inherit;font-size:10pt;color:#525252;">gation of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#525252;">hereunder. Upon </font><font style="font-family:inherit;font-size:10pt;color:#424242;">request </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and without </font><font style="font-family:inherit;font-size:10.5pt;color:#525252;">charge, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall </font><font style="font-family:inherit;font-size:10pt;color:#424242;">attorn to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any successor to Landlord's interest </font><font style="font-family:Arial;font-size:10.5pt;color:#525252;">in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this Lease </font><font style="font-family:inherit;font-size:10.5pt;color:#424242;">and, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">at the option of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any Mort gees</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t</font><font style="font-family:inherit;font-size:10pt;color:#525252;">o such Mortgagees. Landlord shall have no personal liability under any </font><font style="font-family:inherit;font-size:10pt;color:#424242;">of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">term</font><font style="font-family:inherit;font-size:10pt;color:#525252;">s, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">conditions </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or covenants </font><font style="font-family:inherit;font-size:10pt;color:#424242;">of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Lease and Tenant shall look </font><font style="font-family:inherit;font-size:10pt;color:#525252;">solely to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">equity of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Landlord in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the Building and/or the proceeds the</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">r</font><font style="font-family:inherit;font-size:10pt;color:#525252;">efrom for the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">satisfaction </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">claim, remedy </font><font style="font-family:inherit;font-size:10pt;color:#424242;">or cause </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of action of any kind whatsoever </font><font style="font-family:inherit;font-size:10pt;color:#424242;">arising </font><font style="font-family:inherit;font-size:10pt;color:#525252;">from </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">relationship between </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">part</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">i</font><font style="font-family:inherit;font-size:10pt;color:#525252;">es or </font><font style="font-family:inherit;font-size:10pt;color:#424242;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">rights </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">obligations </font><font style="font-family:inherit;font-size:10pt;color:#424242;">they </font><font style="font-family:inherit;font-size:10pt;color:#525252;">may </font><font style="font-family:inherit;font-size:10pt;color:#424242;">have </font><font style="font-family:inherit;font-size:10pt;color:#525252;">rela</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ing </font><font style="font-family:inherit;font-size:10pt;color:#424242;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">Proj</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ect, this Lease, or anything related to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">either, including </font><font style="font-family:inherit;font-size:10pt;color:#525252;">without limitation as a result of the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">breach </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of any section of this Lease </font><font style="font-family:inherit;font-size:10pt;color:#424242;">by Landlord. In addition, no </font><font style="font-family:inherit;font-size:10pt;color:#525252;">recourse shall be had </font><font style="font-family:inherit;font-size:10pt;color:#424242;">for an </font><font style="font-family:inherit;font-size:10pt;color:#525252;">ob</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">li</font><font style="font-family:inherit;font-size:10pt;color:#525252;">gation of Landlord </font><font style="font-family:inherit;font-size:10pt;color:#424242;">hereunder</font><font style="font-family:inherit;font-size:10pt;color:#696969;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">o</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">r </font><font style="font-family:inherit;font-size:10pt;color:#525252;">for </font><font style="font-family:inherit;font-size:10pt;color:#424242;">any claim based </font><font style="font-family:inherit;font-size:10pt;color:#525252;">thereon or otherwise in respect  thereof or the  relationship between </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">parties, against any past, present or future </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Indemnitee (other than </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Landlord), </font><font style="font-family:inherit;font-size:10pt;color:#525252;">whe</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">th</font><font style="font-family:inherit;font-size:10pt;color:#525252;">er </font><font style="font-family:inherit;font-size:10pt;color:#424242;">by </font><font style="font-family:inherit;font-size:10pt;color:#525252;">virtue of any statute or rule of law, or by the enforcement of any assessment or </font><font style="font-family:inherit;font-size:10pt;color:#424242;">penalty </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or otherwise, all such other </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">li</font><font style="font-family:inherit;font-size:10pt;color:#525252;">ability being </font><font style="font-family:inherit;font-size:10pt;color:#424242;">expressly </font><font style="font-family:inherit;font-size:10pt;color:#525252;">waived and released </font><font style="font-family:inherit;font-size:10pt;color:#424242;">by </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant with respect to the Landlord </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Indemnitees </font><font style="font-family:inherit;font-size:10pt;color:#696969;">(oth</font><font style="font-family:inherit;font-size:10pt;color:#424242;">er </font><font style="font-family:inherit;font-size:10pt;color:#525252;">than Landlord)</font><font style="font-family:inherit;font-size:10pt;color:#808080;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;color:#525252;padding-right:48px;">25.</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">MISCELLANEOUS</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#424242;text-decoration:underline;">PROVISIONS</font><font style="font-family:inherit;font-size:10pt;color:#424242;">.</font><font style="font-family:inherit;font-size:10pt;color:#151515;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">(a) </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Successors</font><font style="font-family:inherit;font-size:10pt;color:#696969;">. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">The respective rights and obligations provided </font><font style="font-family:inherit;font-size:10pt;color:#424242;">in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Lease </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall </font><font style="font-family:inherit;font-size:10pt;color:#424242;">bind </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and inure to the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">benefit of the parties hereto, their </font><font style="font-family:inherit;font-size:10pt;color:#525252;">successors </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and assigns; provided</font><font style="font-family:inherit;font-size:10pt;color:#696969;">; </font><font style="font-family:inherit;font-size:10pt;color:#525252;">however, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">no </font><font style="font-family:inherit;font-size:9pt;color:#424242;">rights </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall inure to the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">benefit </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">successo</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">rs </font><font style="font-family:inherit;font-size:10pt;color:#424242;">or assigns </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of Tenant unless Landlord's written consent for the transfer to such successor and/or assignee has first </font><font style="font-family:inherit;font-size:10pt;color:#424242;">been </font><font style="font-family:inherit;font-size:10pt;color:#525252;">obtained </font><font style="font-family:inherit;font-size:10pt;color:#424242;">as </font><font style="font-family:inherit;font-size:10pt;color:#525252;">provided </font><font style="font-family:inherit;font-size:10pt;color:#424242;">in</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Art</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;text-decoration:underline;">i</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">cle</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:9pt;color:#525252;font-style:italic;text-decoration:underline;">9</font><font style="font-family:Arial;font-size:9pt;color:#525252;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">hereof. (b)</font><font style="font-family:inherit;font-size:10pt;color:#424242;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#424242;text-decoration:underline;">Governing</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">La</font><font style="font-family:inherit;font-size:10pt;color:#525252;">w</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">This Lease shall be construed, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">governed </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and enforced </font><font style="font-family:Arial;font-size:10pt;color:#525252;">in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">accordance with the laws of the Commonwealth of Virginia, without </font><font style="font-family:inherit;font-size:10pt;color:#424242;">regard </font><font style="font-family:inherit;font-size:9.5pt;color:#525252;">to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">principles relating </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">conflicts of l a</font><font style="font-family:inherit;font-size:10pt;color:#696969;">w</font><font style="font-family:inherit;font-size:10pt;color:#424242;">. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">(c) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. </font><font style="font-family:inherit;font-size:10pt;color:#424242;">The </font><font style="font-family:inherit;font-size:10pt;color:#525252;">exhibits attached to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">this</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;Lease are expressly incorporated </font><font style="font-family:inherit;font-size:10pt;color:#424242;">into this </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Lease. This </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Lease </font><font style="font-family:inherit;font-size:10pt;color:#525252;">supersedes any </font><font style="font-family:inherit;font-size:10pt;color:#424242;">prior </font><font style="font-family:inherit;font-size:10pt;color:#525252;">discussions, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">proposals,</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;negotiations and discussions between the parties, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this Lease contains all the agreements, conditions, understandings, representations and warranties </font><font style="font-family:inherit;font-size:10pt;color:#424242;">made betw</font><font style="font-family:inherit;font-size:10pt;color:#696969;">een </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the parties hereto with </font><font style="font-family:inherit;font-size:10pt;color:#424242;">respect </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">subject matter hereof, and may not </font><font style="font-family:inherit;font-size:10pt;color:#424242;">be </font><font style="font-family:inherit;font-size:10pt;color:#525252;">modified orally or </font><font style="font-family:Arial;font-size:10pt;color:#525252;">in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any manner other than by an agreement </font><font style="font-family:Arial;font-size:10pt;color:#424242;">in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">writing signed by both parties </font><font style="font-family:inherit;font-size:10pt;color:#424242;">hereto </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or their respective successors </font><font style="font-family:Arial;font-size:10pt;color:#525252;">in </font><font style="font-family:inherit;font-size:10pt;color:#424242;">interest. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Without </font><font style="font-family:Arial;font-size:10pt;color:#424242;">in </font><font style="font-family:inherit;font-size:10pt;color:#424242;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">way </font><font style="font-family:inherit;font-size:10pt;color:#424242;">limiting the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">generality of the foregoing, this Lease </font><font style="font-family:inherit;font-size:10pt;color:#424242;">can </font><font style="font-family:inherit;font-size:10pt;color:#525252;">only </font><font style="font-family:inherit;font-size:10pt;color:#424242;">be </font><font style="font-family:inherit;font-size:10pt;color:#525252;">extended pursuant </font><font style="font-family:inherit;font-size:10pt;color:#424242;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">terms hereof, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">with the due </font><font style="font-family:inherit;font-size:10pt;color:#424242;">exercise </font><font style="font-family:inherit;font-size:9.5pt;color:#525252;font-style:italic;">of. </font><font style="font-family:inherit;font-size:10pt;color:#424242;">a</font><font style="font-family:inherit;font-size:10pt;color:#acacac;">n</font><font style="font-family:inherit;font-size:10pt;color:#424242;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">option</font><font style="font-family:Arial;font-size:9pt;color:#696969;">(if  </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any) </font><font style="font-family:inherit;font-size:10pt;color:#424242;">contained </font><font style="font-family:inherit;font-size:10pt;color:#525252;">herein or pursuan</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to a written agreement signed by </font><font style="font-family:inherit;font-size:10pt;color:#424242;">both </font><font style="font-family:inherit;font-size:10pt;color:#525252;">La</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">n</font><font style="font-family:inherit;font-size:10pt;color:#525252;">dlord </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant specifically extending the </font><font style="font-family:inherit;font-size:10pt;color:#696969;">term. No</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;negotiations, correspondence </font><font style="font-family:inherit;font-size:9pt;color:#525252;">by </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or offers </font><font style="font-family:Arial;font-size:9pt;color:#525252;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">extend the term shal</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">l </font><font style="font-family:inherit;font-size:10pt;color:#525252;">be deemed an extension of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;termination </font><font style="font-family:inherit;font-size:10pt;color:#424242;">date </font><font style="font-family:inherit;font-size:10pt;color:#525252;">for any </font><font style="font-family:inherit;font-size:10pt;color:#424242;">period </font><font style="font-family:inherit;font-size:10pt;color:#525252;">whatsoever. (d) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Time of the Essence</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. </font><font style="font-family:inherit;font-size:10pt;color:#424242;font-weight:bold;">TXME IS OF THE ESSENCE </font><font style="font-family:inherit;font-size:10pt;color:#525252;">IN </font><font style="font-family:inherit;font-size:10pt;color:#424242;font-weight:bold;">ALL PROVISIONS </font><font style="font-family:inherit;font-size:10pt;color:#525252;font-weight:bold;">OF </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;font-weight:bold;">THI</font><font style="font-family:inherit;font-size:10pt;color:#525252;font-weight:bold;">S </font><font style="font-family:inherit;font-size:10pt;color:#424242;font-weight:bold;">LEASE, </font><font style="font-family:inherit;font-size:10pt;color:#525252;font-weight:bold;">INCLUDING </font><font style="font-family:inherit;font-size:10pt;color:#424242;font-weight:bold;">ALL </font><font style="font-family:inherit;font-size:10pt;color:#525252;font-weight:bold;">N</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;font-weight:bold;">OTIC</font><font style="font-family:inherit;font-size:10pt;color:#525252;font-weight:bold;">E </font><font style="font-family:inherit;font-size:10pt;color:#424242;font-weight:bold;">PROVISIONS. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">(e) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Accord and Satisfaction</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. No </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#525252;">payment by </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or receipt </font><font style="font-family:inherit;font-size:10pt;color:#424242;">by Landlord </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of a </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">esser-amount </font><font style="font-family:inherit;font-size:10pt;color:#424242;">than any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">payment of Fixed </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#525252;font-style:italic;">or </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Additional</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">Rent herein stipulated shall </font><font style="font-family:inherit;font-size:10pt;color:#424242;">be deemed </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to be other than on ac</font><font style="font-family:inherit;font-size:10pt;color:#acacac;">-</font><font style="font-family:inherit;font-size:10pt;color:#525252;">count of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the earliest </font><font style="font-family:inherit;font-size:10pt;color:#696969;">stip</font><font style="font-family:inherit;font-size:10pt;color:#424242;">ulated </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Fixed </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or Additional Rent due and </font><font style="font-family:inherit;font-size:10pt;color:#424242;">payable </font><font style="font-family:inherit;font-size:10pt;color:#525252;">hereunder, nor shall any endorsement or </font><font style="font-family:inherit;font-size:10pt;color:#696969;">s</font><font style="font-family:inherit;font-size:10pt;color:#424242;">tatement or </font><font style="font-family:inherit;font-size:9pt;color:#424242;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">check or </font><font style="font-family:inherit;font-size:9pt;color:#525252;">any </font><font style="font-family:inherit;font-size:10pt;color:#525252;">letter accompanying any check or payment as </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#525252;">be deemed an </font><font style="font-family:inherit;font-size:10pt;color:#424242;">accord </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and satisfaction. Landlord may </font><font style="font-family:inherit;font-size:10pt;color:#424242;">accept </font><font style="font-family:inherit;font-size:10pt;color:#525252;">such check or payment without prejudice </font><font style="font-family:inherit;font-size:10pt;color:#424242;">to Landlord</font><font style="font-family:inherit;font-size:10pt;color:#696969;">&#8217;s right</font><font style="font-family:inherit;font-size:9pt;color:#525252;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;">to recover the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">balance </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of such </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or </font><font style="font-family:inherit;font-size:10pt;color:#424242;">pursue any other </font><font style="font-family:inherit;font-size:10pt;color:#525252;">right or remedy provided for </font><font style="font-family:Arial;font-size:9.5pt;color:#424242;">in </font><font style="font-family:inherit;font-size:10pt;color:#424242;">this Lease</font><font style="font-family:inherit;font-size:10pt;color:#696969;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">at </font><font style="font-family:inherit;font-size:10pt;color:#424242;">law </font><font style="font-family:inherit;font-size:10pt;color:#525252;">o</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">r </font><font style="font-family:Arial;font-size:10pt;color:#525252;">in </font><font style="font-family:inherit;font-size:10pt;color:#525252;">equity. </font><font style="font-family:inherit;font-size:9pt;color:#525252;">(f) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Guaranty.</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;Intentionally deleted. </font><font style="font-family:inherit;font-size:9pt;color:#525252;">(g) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. Whenever </font><font style="font-family:inherit;font-size:10pt;color:#696969;">a</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;party hereto </font><font style="font-family:Arial;font-size:9.5pt;color:#525252;">is </font><font style="font-family:inherit;font-size:10pt;color:#696969;">require</font><font style="font-family:inherit;font-size:10pt;color:#424242;">d by </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">provisions </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">this </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Lease to </font><font style="font-family:inherit;font-size:10pt;color:#424242;">perform </font><font style="font-family:inherit;font-size:10pt;color:#525252;">an obligation and such party is prevented beyond its reasonable control from doing so </font><font style="font-family:inherit;font-size:10pt;color:#424242;">by </font><font style="font-family:inherit;font-size:10pt;color:#525252;">reason of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">a Force </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Majeure Event (as defined below), such </font><font style="font-family:inherit;font-size:10pt;color:#424242;">party </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall be temporarily </font><font style="font-family:inherit;font-size:10pt;color:#424242;">relieved </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of its obligation </font><font style="font-family:inherit;font-size:10pt;color:#424242;">to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">perform the obligation provided such </font><font style="font-family:inherit;font-size:10pt;color:#424242;">party </font><font style="font-family:inherit;font-size:10pt;color:#525252;">promptly notifies </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the other </font><font style="font-family:inherit;font-size:10pt;color:#525252;">party of the specific </font><font style="font-family:inherit;font-size:10pt;color:#424242;">delay </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and exercises due </font><font style="font-family:inherit;font-size:10pt;color:#424242;">diligence </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to remove or overcome </font><font style="font-family:inherit;font-size:9pt;color:#525252;">it. </font><font style="font-family:inherit;font-size:10.5pt;color:#525252;">In </font><font style="font-family:inherit;font-size:10pt;color:#525252;">no event, however, shall Tenant be</font><font style="font-family:inherit;font-size:10pt;color:#424242;">&#32;excu</font><font style="font-family:inherit;font-size:10pt;color:#696969;">s</font><font style="font-family:inherit;font-size:10pt;color:#424242;">ed </font><font style="font-family:inherit;font-size:10pt;color:#525252;">from paying </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Rent because </font><font style="font-family:inherit;font-size:10pt;color:#525252;">of a Force Majeure Event</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">. </font><font style="font-family:inherit;font-size:10pt;color:#424242;">A </font><font style="font-family:inherit;font-size:10pt;color:#525252;">"</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#424242;text-decoration:underline;">Event</font><font style="font-family:inherit;font-size:10pt;color:#424242;">" </font><font style="font-family:inherit;font-size:10pt;color:#525252;">shall </font><font style="font-family:inherit;font-size:10pt;color:#424242;">mean </font><font style="font-family:inherit;font-size:10pt;color:#525252;">any and all delays beyond a </font><font style="font-family:inherit;font-size:10pt;color:#424242;">party&#8217;s </font><font style="font-family:inherit;font-size:10pt;color:#525252;">reasonable control, including without limitatio</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">n</font><font style="font-family:inherit;font-size:10pt;color:#696969;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">delays caused </font><font style="font-family:Arial;font-size:9.5pt;color:#525252;">by </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the other </font><font style="font-family:inherit;font-size:10pt;color:#424242;">party</font><font style="font-family:inherit;font-size:10pt;color:#696969;">,</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;governmental </font><font style="font-family:inherit;font-size:10pt;color:#424242;">restrictions, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">governmental regulations and controls, order of civil, </font><font style="font-family:inherit;font-size:9pt;color:#424242;">military </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or naval authority, governmental preemption, strikes, labor </font><font style="font-family:inherit;font-size:10pt;color:#424242;">disputes, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">lock-outs, acts of God, fire, earthquake, floods, e:xplosions, extreme </font><font style="font-family:inherit;font-size:10pt;color:#696969;">weathe</font><font style="font-family:inherit;font-size:10pt;color:#424242;">r </font><font style="font-family:inherit;font-size:10pt;color:#525252;">conditions, enemy </font><font style="font-family:inherit;font-size:10pt;color:#424242;">action, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">and </font><font style="font-family:inherit;font-size:10pt;color:#424242;">civil </font><font style="font-family:inherit;font-size:10pt;color:#525252;">commotion, riot or insurrection, but expressly </font><font style="font-family:inherit;font-size:10pt;color:#424242;">excluding</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;insufficiency of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">funds</font><font style="font-family:inherit;font-size:10pt;color:#696969;">, </font><font style="font-family:inherit;font-size:9.5pt;color:#525252;">inability </font><font style="font-family:inherit;font-size:10pt;color:#525252;">to obtain </font><font style="font-family:inherit;font-size:11pt;color:#525252;">financing. </font><font style="font-family:inherit;font-size:10pt;color:#525252;">casualty and condemnation. </font><font style="font-family:inherit;font-size:9pt;color:#525252;">(h) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Financial Statements</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. Tenant shall furnish to Landlord, </font><font style="font-family:inherit;font-size:10pt;color:#424242;">the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Mortgagee, prospective </font><font style="font-family:inherit;font-size:10pt;color:#424242;">mortgagee </font><font style="font-family:inherit;font-size:10pt;color:#525252;">or purchaser reasonably requested financial information; provided, so long as </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#525252;">is publicly traded, Tenant's financial statements which are publicly available on the SEC website shall be </font><font style="font-family:inherit;font-size:9pt;color:#525252;">all </font><font style="font-family:inherit;font-size:10pt;color:#424242;">that </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant is </font><font style="font-family:inherit;font-size:10pt;color:#424242;">required to </font><font style="font-family:inherit;font-size:10pt;color:#525252;">provide. </font><font style="font-family:inherit;font-size:9pt;color:#525252;">(i) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Authority</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. Each of Tenant and Landlord represents and warrants </font><font style="font-family:inherit;font-size:10pt;color:#424242;">to the </font><font style="font-family:inherit;font-size:10pt;color:#525252;">other that: (i) i</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t </font><font style="font-family:inherit;font-size:10pt;color:#525252;">is duly organized, va</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">idly </font><font style="font-family:inherit;font-size:10pt;color:#424242;">existing </font><font style="font-family:inherit;font-size:10pt;color:#525252;">in </font><font style="font-family:inherit;font-size:9pt;color:#525252;">its </font><font style="font-family:inherit;font-size:10pt;color:#525252;">state of incorporation/organization </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">legally authorized to do business in the Commonwealth </font><font style="font-family:inherit;font-size:10pt;color:#424242;">of </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Virginia; and </font><font style="font-family:inherit;font-size:9pt;color:#525252;">(ii) </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the persons executing </font><font style="font-family:inherit;font-size:10pt;color:#424242;">this Lease are duly </font><font style="font-family:inherit;font-size:10pt;color:#525252;">authorized to execute </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and deli</font><font style="font-family:inherit;font-size:10pt;color:#696969;">ver </font><font style="font-family:inherit;font-size:10pt;color:#525252;">this </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Lease </font><font style="font-family:inherit;font-size:10pt;color:#525252;">on behalf of such party. </font><font style="font-family:Arial;font-size:9.5pt;color:#525252;">(j) </font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Attorneys' Fees</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">&#32;</font><font style="font-family:inherit;font-size:10.5pt;color:#525252;">In </font><font style="font-family:inherit;font-size:10pt;color:#525252;">connection with any litigation arising out of </font><font style="font-family:inherit;font-size:9.5pt;color:#525252;">this </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Lease, </font><font style="font-family:inherit;font-size:10pt;color:#696969;">the </font><font style="font-family:inherit;font-size:10pt;color:#424242;">prevailing </font><font style="font-family:inherit;font-size:10pt;color:#525252;">pa1iy, Tenant or Landlo</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#525252;">rd shall be entitled </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">t</font><font style="font-family:inherit;font-size:10pt;color:#525252;">o </font><font style="font-family:inherit;font-size:10pt;color:#424242;">recover </font><font style="font-family:inherit;font-size:10pt;color:#525252;">all costs incurred, including reasonabl1;1 attorneys' fees. </font><font style="font-family:inherit;font-size:10pt;color:#696969;">(</font><font style="font-family:inherit;font-size:10pt;color:#424242;">k)</font><font style="font-family:inherit;font-size:10pt;color:#525252;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Waiver: of</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:9pt;color:#525252;text-decoration:underline;">Jury</font><font style="font-family:Arial;font-size:9pt;color:#525252;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#525252;text-decoration:underline;">Trial</font><font style="font-family:inherit;font-size:10pt;color:#525252;">. </font><font style="font-family:inherit;font-size:10pt;color:#696969;">To </font><font style="font-family:inherit;font-size:10pt;color:#525252;">the extent permitted </font><font style="font-family:inherit;font-size:10pt;color:#424242;">b</font><font style="font-family:inherit;font-size:10pt;color:#696969;">y </font><font style="font-family:inherit;font-size:10pt;color:#525252;">applicab</font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">e </font><font style="font-family:inherit;font-size:10pt;color:#2d2d2d;">l</font><font style="font-family:inherit;font-size:10pt;color:#525252;">aw, Landlord </font><font style="font-family:inherit;font-size:10pt;color:#424242;">and </font><font style="font-family:inherit;font-size:10pt;color:#525252;">Tenant hereby waive trial by </font><font style="font-family:inherit;font-size:9pt;color:#525252;">jury </font><font style="font-family:inherit;font-size:10pt;color:#525252;">in any action, proceeding or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">counterclaim brought by either against the other on any matter arising out of or in any way connected </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">this Lease, the </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">relationship </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of Landlord </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant, or Tenant's use or occupancy of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">the Building, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">any claim or </font><font style="font-family:inherit;font-size:9pt;color:#3d3d3d;">injury </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or damage, or any emergency or other statutory remedy </font><font style="font-family:inherit;font-size:10pt;color:#626262;">w</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">ith respect </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">thereto. (1) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Press Releases</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. </font><font style="font-family:inherit;font-size:10pt;color:#626262;">Landlord </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">have the </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">right, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">without further </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">notice </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#626262;">, </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">include general information relating to </font><font style="font-family:inherit;font-size:10pt;color:#626262;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Lease including without</font><font style="font-family:inherit;font-size:5pt;color:#7e7e7e;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">limitation </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">Tenant's name</font><font style="font-family:inherit;font-size:9pt;color:#7e7e7e;">, </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Building </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:9pt;color:#626262;">the </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">square </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">footage of the Premises, in press releases </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">relating </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to Landlord's and </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">affiliates' </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">leasing </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">activity. Information relating to rates </font><font style="font-family:inherit;font-size:10pt;color:#626262;">will </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">not </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">be </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">released without Tenant's prior written consent, such consent not </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">b</font><font style="font-family:inherit;font-size:10pt;color:#626262;">e </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">unreasonably </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">withheld, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">conditioned or delayed. </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">(m) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Calculation of </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">T</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;text-decoration:underline;">im</font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">e. </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">Io </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">computing any period of time prescribed or allowed by any </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">provision </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:9pt;color:#626262;">this </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Lease, the day </font><font style="font-family:inherit;font-size:10pt;color:#626262;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the act, </font><font style="font-family:inherit;font-size:10pt;color:#626262;">event </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or default from which the designated period of </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">time </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">begins </font><font style="font-family:inherit;font-size:10pt;color:#626262;">to </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">run shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">not be included. </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">The </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">last </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">day of </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">period so computed shall be included, unless </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">it is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">a Saturday, Sunday or a </font><font style="font-family:inherit;font-size:10pt;color:#626262;">lega</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">l </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">holiday, in which event </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">period runs until the end </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:9pt;color:#3d3d3d;">the </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">next </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">day which </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">not a Saturday</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Sunday; or </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">legal holiday. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Unless otherwise provided herein, </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">all </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">notices </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and other periods expire as of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;font-style:italic;">5</font><font style="font-family:inherit;font-size:10pt;color:#626262;">:00 </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">p.ro.. </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(local </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">time </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Charlottesville, Virginia) on the last day of </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">notice </font><font style="font-family:inherit;font-size:10pt;color:#626262;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">other period. </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">n) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Landlord's Consent</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. Under no </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">circumstances </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall Landlord be liable to Tenant for </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">failure or refusal to grant </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">consent when consent is </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">required </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">hereunder. Tenant shall </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">not </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">claim any money damages by </font><font style="font-family:inherit;font-size:10pt;color:#626262;">way </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of setoff, counterclaim or </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">defense, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">based on any claim that Landlord unreasonably withbe1d its consent, in </font><font style="font-family:inherit;font-size:10pt;color:#626262;">which</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;case Tenant</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">' </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s sole and exclusive </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">remedy </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">be </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">an </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">action </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">for </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">specific performance, injunction or declaratory judgment. </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:inherit;font-size:10pt;color:#626262;">) </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:10pt;color:#626262;text-decoration:underline;">'s</font><font style="font-family:inherit;font-size:10pt;color:#626262;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Fees</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">.  </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Whenever Tenant requests Landlord to take any action not required of it </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">hereunder</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;or give any consent required or </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">permitted </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">under this Lease, Tenant shall reimburse Landlord for </font><font style="font-family:inherit;font-size:10pt;color:#626262;">Landlo</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">rd</font><font style="font-family:inherit;font-size:10pt;color:#626262;">'s </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">reasonable, out of-pocket costs incurred by Landlord </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">reviewing </font><font style="font-family:inherit;font-size:10pt;color:#626262;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">proposed action or consent. including reasonable attorneys', engineers' or architects' fees; </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">within </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">thirty </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(30) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">days after Landlord's delivery to Tenant of a statement </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such costs. Tenant shall make such reimbursement without regard to </font><font style="font-family:inherit;font-size:10pt;color:#626262;">wh</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">ether </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord consents to any such proposed action. Tenant shall not owe any fees </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord for review and approval of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Initial Work. </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">(p) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. Tenant acknowledges and agrees that the terms of this </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Lease </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">(and any preliminary drafts hereof) are confidential </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">constitute </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">proprietary </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">information </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of Landlord, and may not be disclosed </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">b</font><font style="font-family:inherit;font-size:10pt;color:#626262;">y </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant to anyone</font><font style="font-family:inherit;font-size:10pt;color:#626262;">&#32;except </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">employees</font><font style="font-family:inherit;font-size:10pt;color:#626262;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">brokers, accountants, </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">attorneys</font><font style="font-family:inherit;font-size:10pt;color:#626262;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">permitted </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">assignees and subtenants, who have </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">each </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">been informed </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">confidentiality </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">clause </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">this </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">Lease, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">any  manner </font><font style="font-family:inherit;font-size:10pt;color:#626262;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">means, directly </font><font style="font-family:inherit;font-size:9pt;color:#626262;">or  </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">indirectly, without Landlord</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">'</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">s prior written consent except </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">as </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">to the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">extent required by court order. </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">The </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">consent by Landlord to </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">disclosures </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">not be deemed to be a </font><font style="font-family:inherit;font-size:10pt;color:#626262;">waiver </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">on </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">part of Landlord of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">prohibition </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">against </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">future </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">disclosure</font><font style="font-family:inherit;font-size:10pt;color:#626262;">. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Disclosure of thee </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">ter.ms </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of 'this Lease could adversely affect the ability of </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Landlord to</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;negotiate other </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">leases </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and may impair Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">relat</font><font style="font-family:inherit;font-size:10pt;color:#626262;">ionship </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">with other </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">tenants. </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">It </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">understood </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">agreed that damages alone would be an inadequate </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">remedy </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">for the breach of this provision by Tenant, and </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall also</font><font style="font-family:inherit;font-size:10pt;color:#626262;">&#32;have </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the right to seek specific </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">performance </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of this </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">provis</font><font style="font-family:inherit;font-size:10pt;color:#626262;">ion </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and injunctive </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">relief </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to prevent </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">breach or continued</font><font style="font-family:inherit;font-size:10pt;color:#626262;">&#32;breach.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">26.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">CONSENT TO 1URISD1CTION</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. Landlord and Tenant hereby consent to </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">exclusive </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">jurisdiction </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">state </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">courts located </font><font style="font-family:Arial;font-size:10.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the jurisdiction in</font><font style="font-family:inherit;font-size:10pt;color:#626262;">&#32;which </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the Project is located. For purposes of Section 55</font><font style="font-family:inherit;font-size:10pt;color:#232323;">-</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">2 of the </font><font style="font-family:inherit;font-size:10pt;color:#626262;">C</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">ode of </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">Virginia </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(1950), </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">as amended from time to time, this Lease </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">is and shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be deemed </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be a </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">deed </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of lease.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">27.</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">OFAC/PATRIOT ACT COMPLIANCE</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">. Tenant </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">represents</font><font style="font-family:inherit;font-size:10pt;color:#626262;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">warrants and covenants that neither Tenant nor any of </font><font style="font-family:Arial;font-size:9pt;color:#626262;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">partners, officers, or directors: </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(i) </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">listed on </font><font style="font-family:inherit;font-size:10pt;color:#626262;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Specially </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Designated </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Nationals and Blocked Persons List maintained by </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Office of Foreign Asset Control, Department of </font><font style="font-family:inherit;font-size:10pt;color:#626262;">the </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">Treasury </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">("OF</font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;text-decoration:underline;">AC")</font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">pursuant to</font><font style="font-family:inherit;font-size:10pt;color:#626262;">&#32;Executive </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Order No. 13224, 66 Fed. Reg. 49079 (Sept </font><font style="font-family:inherit;font-size:10pt;color:#626262;">25, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">2001) </font><font style="font-family:inherit;font-size:10pt;color:#626262;">t' </font><font style="font-family:inherit;font-size:10pt;color:#626262;text-decoration:underline;">O</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;text-decoration:underline;">rder</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">"</font><font style="font-family:inherit;font-size:10pt;color:#626262;">) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and all applicable </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">provision</font><font style="font-family:inherit;font-size:10pt;color:#626262;">s </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of Title III of </font><font style="font-family:inherit;font-size:10pt;color:#626262;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">USA </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Patriot Act (Public </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Law </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">No. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">107</font><font style="font-family:inherit;font-size:10pt;color:#232323;">-</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">56 </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(O</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">ctober</font><font style="font-family:inherit;font-size:10pt;color:#626262;">26, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">2001)); </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">(ii) </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">listed on </font><font style="font-family:inherit;font-size:9.5pt;color:#3d3d3d;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Denied :Persons </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">List and</font><font style="font-family:inherit;font-size:9.5pt;color:#626262;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#626262;">Ent</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">ity </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">List </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">maintained </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the United States Department of Commerce; </font><font style="font-family:Arial;font-size:9.5pt;color:#626262;">(iii) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">is listed on the List of Terrorists </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">and List </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of  Disbarred Part</font><font style="font-family:inherit;font-size:10pt;color:#232323;">i</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">es maintained </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the United States </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Department </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of State; (iv) </font><font style="font-family:inherit;font-size:10pt;color:#626262;">is </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">listed on </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">list</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or qualification of</font><font style="font-family:inherit;font-size:10pt;color:#626262;">&#32;"Des</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">ignat</font><font style="font-family:inherit;font-size:10pt;color:#626262;">ed </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Nationa1s" </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">as </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">defined </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">Cuban </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Assets Control Regulations </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">31 </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">C,F.R.. </font><font style="font-family:inherit;font-size:10.5pt;color:#3d3d3d;">Part </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">515; </font><font style="font-family:inherit;font-size:10pt;color:#626262;">(v) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">is listed on </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">other publicly available </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">List </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">terrorists, terrorist</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">organizations or narcotics traffickers maintained by the United States Department of State, the </font><font style="font-family:inherit;font-size:10pt;color:#626262;">United </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">States D</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">epartment </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of Commerce or </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">other governmental authority or pursuant to the Order, </font><font style="font-family:inherit;font-size:10pt;color:#626262;">th</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">e </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">rules and regulations of OFAC (including without limitation the Trading with </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10.5pt;color:#626262;">Economy </font><font style="font-family:inherit;font-size:9pt;color:#626262;">Act, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;font-style:italic;">50 </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">U.S.C. App. </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">1-44; </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">International </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Emergency </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Economic Powers Act, 50 U.S.C. </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">&#167;&#167;  </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">1701</font><font style="font-family:inherit;font-size:10pt;color:#232323;">-</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">06; </font><font style="font-family:inherit;font-size:10pt;color:#626262;">the</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;unrepealed provision of the Iraq Sanctions Act, </font><font style="font-family:inherit;font-size:9pt;color:#3d3d3d;">Pub .L. </font><font style="font-family:inherit;font-size:9pt;color:#626262;">, </font><font style="font-family:inherit;font-size:10pt;color:#626262;">No. </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">101-513</font><font style="font-family:inherit;font-size:10pt;color:#626262;">; </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the United </font><font style="font-family:inherit;font-size:10pt;color:#626262;">Nations </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Participation Act, </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">22</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">U.S.C. </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;font-style:italic;">&#167; </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">2349 </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">as-9; </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">The </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Cuban Democracy </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">Act, 22 </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">V.S.C</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">. </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">&#167;&#167; </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">6001-10; The Cuban Liberty and Democratic</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Solidarity </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">Act, 18</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">U.S.C. </font><font style="font-family:inherit;font-size:9pt;color:#4f4f4f;">&#167;&#167; </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">2332d and </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">233; </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">The </font><font style="font-family:inherit;font-size:10pt;color:#626262;">Foreign </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Narcotic Kingpin Designation Act, </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Pub. </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">L. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">No</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">. </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">106- </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">120 and 107-108</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">all as </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">may be </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">amended from time </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">time); or any other applicable requirements contained in any enabling legislation or other Executive Orders in </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">respect </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the Order (the Order and such other rules, regulations</font><font style="font-family:inherit;font-size:10pt;color:#7e7e7e;">; </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">legislation </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">orders are collectively </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">called </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;text-decoration:underline;">Orders</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"); (vi) </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">is </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">engaged </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">activities </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">prohibited </font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the Orders; or</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10pt;color:#7b7b7b;">(</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">vii) </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">has </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">been convicted, pleaded </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;font-style:italic;">nolo contendere, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">indicted</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">arraigned or custodially detained on charges involving money laundering or predicate crimes </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">money </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">laundering, </font><font style="font-family:Arial;font-size:9pt;color:#4d4d4d;">drug </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">trafficking, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">terrorist</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">-r</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">elate</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">d </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">activities </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">other money laundering predicate crimes </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">connection </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the Bank Secrecy </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Act (31 </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">U.S.C. </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;font-style:italic;">&#167;&#167; </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">5311 </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;font-style:italic;">et </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">seq.). Tenant shall defend, indemnify</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">and hold harmless Landlord from and against any and all claims</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">damages, losses, risks</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">,</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;liabilities, and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">expenses (inc</font><font style="font-family:inherit;font-size:10pt;color:#282828;">l</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">uding attorneys' fees and costs) arising from or related to any breach of the foregoing representation, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">warranty </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">and covenant. The breach of this representation, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">warranty </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">covenant </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">by </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant shall be</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;an </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">immediate Event of Default under this Lease without cure.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">28.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">QUIET ENJOYMENT.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;Provided Tenant has performed all of the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">te</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">rms </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">and conditions of this Lease10 be performed by Tenant, </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">including </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the payment of Rent, Tenant shall peaceably and quietly hold and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">enjoy </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the Prem1ses </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">for </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Term, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">wi</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">thout </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">hindrance from </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Land</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">lord </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">or anyone claiming by through or under Landlord, under and subject </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the terms and conditions of this Lease and of any deeds of </font><font style="font-family:Arial;font-size:8.5pt;color:#4d4d4d;">trust </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">now or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">hereafte</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">r </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">affecting all or any</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;portion </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">of the Premises.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:9.5pt;padding-right:48px;">29.</font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;text-decoration:underline;">RIGHT</font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;text-decoration:underline;">OFFIRST OFFER</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">If </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">at any time or times during the Term</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">or any </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">renewal </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">term: </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(i) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">any area </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">becom</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">es</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;available </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">for </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">lease on </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Floo</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">r </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">1 in the Building, and </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">(1i) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">no </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">event </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">of default by </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">shall have occurred </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">with.in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the preceding </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">thirty </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(30) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">months and no event of default by </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">shall have occurred and be continuing hereunder, all applicable cure periods having expired,, and </font><font style="font-family:Arial;font-size:9pt;color:#5b5b5b;">(iii) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">such space </font><font style="font-family:Arial;font-size:9pt;color:#4d4d4d;">is </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">not </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">s</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">ubject to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">an expansion opt</font><font style="font-family:inherit;font-size:10pt;color:#282828;">i</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">on or renewal option or agreement for expansion or relocation </font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">in </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">favor of another tenant existing as the date of this Lease, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">a </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">lease term is extended for a </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">then </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">existing tenant, Landlord shall not enter into a lease of </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">any </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">such </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">space except upon compliance </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">wi</font><font style="font-family:inherit;font-size:10.5pt;color:#3b3b3b;">th </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the following procedures.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Each such time </font><font style="font-family:Arial;font-size:9.5pt;color:#4d4d4d;">any </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">such space becomes available for direct </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">lease (whether </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">or not Tenant has previously declined </font><font style="font-family:Arial;font-size:9pt;color:#4d4d4d;">to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">lease such space)</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Landlord shall give </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">written </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">notice to Tenant </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">such fact at least sixty </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(60)</font><font style="font-family:inherit;font-size:9.5pt;color:#3b3b3b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">da</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">ys </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">before marketing the space, such notice to set out the amount and location of the space, the date that the present tenant</font><font style="font-family:Arial;font-size:5.5pt;color:#4d4d4d;">1</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">s lease expires, -and the proposed Rent for the space. Tenant shall have a period of ten (10) days from the receipt of such </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">not</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">ice </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">from Landlord, within</font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">which </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">elect </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">include all of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">suc</font><font style="font-family:inherit;font-size:10pt;color:#282828;">h </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">space under this </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Le</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">as</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">e (the &#8220;Right</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;of First Offering"). </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">If </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant does not timely exercise </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">its </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">option under </font><font style="font-family:Arial;font-size:9pt;color:#4d4d4d;">this </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">paragraph, then Landlord shall </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">be </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">free </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">to lease </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the space to a </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">third </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">party </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">upon terms acceptable to Landlord provided the Rent shall not be more than 10% less </font><font style="font-family:inherit;font-size:9.5pt;color:#4d4d4d;">than </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">Rent </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">offered to Tenant without re-offering the space to Tenant.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">c.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10.5pt;color:#3b3b3b;">In </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">the event </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">elects to lease </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">s</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">uch </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">space</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">an amendment of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">this </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Lease shal1 be</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;executed </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">by Landlord and Tenant no later than </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">fift</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">een (15) </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">days after Landlord shall have </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">su</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">bmitted </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">to Tenant copies of a </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">draft </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">of such amendment for </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">execu</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">tio</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">n </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">purposes. </font><font style="font-family:inherit;font-size:8.5pt;color:#5b5b5b;font-style:italic;">1f </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">exercises </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">its option </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">to </font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">lease </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">such </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">additional</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;s</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">p</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">ace: </font><font style="font-family:Arial;font-size:9pt;color:#5b5b5b;">(i) the</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">&#32;lease term for such space and Rent shall commence upon Landlord's ability to deliver such space to Tenant ready </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">for </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">alteration and finish-out, and (ii) all such </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">space shall be </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">tendered by Landlord and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">accepted </font><font style="font-family:Arial;font-size:9pt;color:#4d4d4d;">by </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Tenant in an </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">"as</font><font style="font-family:inherit;font-size:10pt;color:#3b3b3b;">-is</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">'' </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">condition</font><font style="font-family:inherit;font-size:10pt;color:#7b7b7b;">.</font></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6ACCFF5FD2112F6D9021FD18549B48D7"></a></div><div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">[S</font><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">I</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">GNATURES </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;font-weight:bold;">ON  FOLLOWING- </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">PAGE]</font></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:26px;text-indent:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1N WITNESS WHEREOF, the parties hereto have executed </font><font style="font-family:inherit;font-size:9.5pt;">this </font><font style="font-family:inherit;font-size:10pt;">Lease, under Seal, the </font><font style="font-family:inherit;font-size:8.5pt;">day </font><font style="font-family:inherit;font-size:10pt;">and year </font><font style="font-family:Arial;font-size:9.5pt;">first </font><font style="font-family:inherit;font-size:10pt;">above </font><font style="font-family:inherit;font-size:9.5pt;">written.</font></div><div style="line-height:100%;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;">ONB CARLTON, LLC, </font><font style="font-family:inherit;font-size:10.5pt;">a </font><font style="font-family:inherit;font-size:10pt;">Virginia limited liability company</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="lease1317signature.jpg" alt="lease1317signature.jpg" style="height:40px;width:220px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">DIFFUSION PHARMACEUTICALS INC., </font><font style="font-family:Arial;font-size:8.5pt;">a</font><font style="font-family:Arial;font-size:9pt;">&#160;Delaware</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">By:.</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;">_ __</font></div><div style="padding-top:2px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Name: David Kalergis</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: Chief Executive Officer</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Date:.</font><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">_</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:100%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:115%;padding-top:6px;text-align:left;padding-left:8px;text-indent:93px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">IN WITNESS WHEREOF, the </font><font style="font-family:inherit;font-size:9.5pt;color:#808282;">parties </font><font style="font-family:inherit;font-size:10pt;color:#808282;">hereto have executed this </font><font style="font-family:inherit;font-size:9.5pt;color:#808282;">Lease, </font><font style="font-family:inherit;font-size:10pt;color:#808282;">under Seal, the day and year </font><font style="font-family:inherit;font-size:10.5pt;color:#808282;">first above, written.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:20pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;">ONB CARLTON, LLC, </font><font style="font-family:inherit;font-size:10.5pt;">a </font><font style="font-family:inherit;font-size:10pt;">Virginia limited liability company</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  _ _ _ _ _ _ _ _ _ _ _ _ _</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">DIFFUSION PHARMACEUTICALS INC., </font><font style="font-family:Arial;font-size:8.5pt;">a</font><font style="font-family:Arial;font-size:9pt;">&#160;Delaware</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="lease1317sig2.jpg" alt="lease1317sig2.jpg" style="height:62px;width:244px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:13px;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#a5a3a8;font-style:italic;">By: f )</font><font style="font-family:inherit;font-size:9.5pt;color:#808282;">Name: </font><font style="font-family:inherit;font-size:10pt;color:#808282;">David Kalergis</font></div><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">Title: Chief Executive Officer </font></div><div style="padding-top:2px;font-size:12.5pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">Date:   </font><font style="font-family:Arial;font-size:11pt;color:#484848;font-weight:bold;text-decoration:underline;">03</font><font style="font-family:Arial;font-size:11pt;color:#484848;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;color:#484848;text-decoration:underline;">/</font><font style="font-family:Arial;font-size:11pt;color:#484848;text-decoration:underline;">&#160;</font><font style="font-family:Arial;font-size:11pt;color:#484848;font-weight:bold;text-decoration:underline;">81</font><font style="font-family:Arial;font-size:11pt;color:#484848;font-weight:bold;text-decoration:underline;">&#160;</font><font style="font-family:Arial;font-size:11pt;color:#484848;text-decoration:underline;">/&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;color:#484848;font-weight:bold;text-decoration:underline;">c,&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12.5pt;color:#484848;font-style:italic;font-weight:bold;text-decoration:underline;">ti</font><font style="font-family:inherit;font-size:12.5pt;color:#484848;font-style:italic;font-weight:bold;">&#160;</font></div><div style="text-align:center;padding-left:84px;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;color:#484848;">I</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div></div></div><div><a name="s1998EB69AB04259F5516FD1855472AC7"></a></div><div style="line-height:113%;padding-top:5px;text-align:center;padding-left:206px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;text-decoration:underline;">EXHIBITA</font></div><div style="line-height:107%;text-align:center;padding-left:206px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">LOCATION </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">PLAN </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(NOT TO SCALE)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:206px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">[Attached]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s70647EE5116EAB11BD69FD185578E3CA"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="lease1317exa.jpg" alt="lease1317exa.jpg" style="font-size:8.5pt;height:910px;width:662px;"></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE1F84C5877E6D7B34620FD185670F6FF"></a></div><div></div><div><br></div><div style="line-height:118%;padding-top:5px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#808282;text-decoration:underline;">EXHIBIT B</font></div><div style="line-height:112%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">CONFIR.t\1ATION OF </font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">LE</font><font style="font-family:inherit;font-size:10pt;color:#808282;">ASE TERM</font></div><div style="line-height:112%;padding-top:10px;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">THIS MEMORANDUM </font><font style="font-family:Arial;font-size:9.5pt;color:#808282;">is </font><font style="font-family:inherit;font-size:10pt;color:#808282;">made as of the </font><font style="font-family:inherit;font-size:13.5pt;color:#505050;font-weight:bold;text-decoration:underline;">2,1</font><font style="font-family:inherit;font-size:13.5pt;color:#505050;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">!a y</font><font style="font-family:inherit;font-size:10pt;color:#808282;">&#32;of </font><font style="font-family:inherit;font-size:13.5pt;color:#505050;font-weight:bold;">March&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#808282;">20I7, between ONE CARLTON, LLC, a Virginia limited liability company ("</font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:10pt;color:#808282;">"), and DIFFUS</font><font style="font-family:inherit;font-size:10pt;color:#505050;">I</font><font style="font-family:inherit;font-size:10pt;color:#808282;">ONPHARMA.CEUTICALS </font><font style="font-family:inherit;font-size:9pt;color:#808282;">INC., </font><font style="font-family:inherit;font-size:10pt;color:#808282;">a Delaware corporation ("</font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:10pt;color:#808282;">''), who entered into a Deed of Lease (the "</font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:10pt;color:#808282;">") dated as of  </font><font style="font-family:inherit;font-size:10pt;color:#505050;text-decoration:underline;">&#32;"'&#160;&#160;&#160;&#160;"&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-style:italic;font-weight:bold;text-decoration:underline;">1,</font><font style="font-family:Arial;font-size:11pt;color:#505050;text-decoration:underline;">\</font><font style="font-family:Arial;font-size:11pt;color:#505050;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;color:#808282;">, </font><font style="font-family:inherit;font-size:10pt;color:#808282;">201 covering premises located at 1317 Carlton Avenue, Suite 400, Charlottesville, Virginia 22902. All capitalized terms, if not defined herein, shall be defined as they are defined </font><font style="font-family:inherit;font-size:9pt;color:#808282;">in </font><font style="font-family:inherit;font-size:10pt;color:#808282;">the Lease</font><font style="font-family:inherit;font-size:10pt;color:#8c97b5;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:100%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:8.5pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;color:#808282;">The parties to this Memorandum hrre agree that the date of</font><font style="font-family:inherit;font-size:10pt;color:#505050;">&#32;</font><font style="font-family:inherit;font-size:18.5pt;color:#505050;font-style:italic;font-weight:bold;text-decoration:underline;">April 15</font><font style="font-family:inherit;font-size:13pt;color:#505050;font-style:italic;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:13pt;color:#505050;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:13pt;color:#808282;">, </font><font style="font-family:inherit;font-size:10pt;color:#808282;">2017 is the Commencement Date of the Term, </font><font style="font-family:inherit;font-size:10.5pt;color:#808282;">and </font><font style="font-family:inherit;font-size:10pt;color:#808282;">the date</font><font style="font-family:inherit;font-size:12pt;color:#505050;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#505050;text-decoration:underline;">Apfl</font><font style="font-family:inherit;font-size:16pt;color:#505050;font-weight:bold;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:13pt;color:#3d3d3d;text-decoration:underline;">I</font><font style="font-family:inherit;font-size:13pt;color:#505050;">&#32;</font><font style="font-family:inherit;font-size:10.5pt;color:#505050;text-decoration:underline;">3</font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">&#32;</font><font style="font-family:inherit;font-size:10.5pt;color:#505050;text-decoration:underline;">0</font><font style="font-family:inherit;font-size:10.5pt;color:#808282;">&#32;</font><font style="font-family:inherit;font-size:10.5pt;color:#808282;text-decoration:underline;">,</font><font style="font-family:inherit;font-size:10.5pt;color:#808282;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">2 0</font><font style="font-family:inherit;font-size:10pt;color:#505050;text-decoration:underline;">2-2.</font><font style="font-family:inherit;font-size:10pt;color:#808282;text-decoration:underline;">is</font><font style="font-family:inherit;font-size:10pt;color:#808282;">&#32;the expiration date of the Lease.</font></div><div style="line-height:120%;padding-left:0px;padding-top:12px;text-align:left;text-indent:0px;"><font style="padding-top:12px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;color:#808282;">Tenant hereby confirms the following:</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">That it has accepted possession of the Premises pursuant to the terms of the Lease;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:110%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">That the improvements, if any, required to be furnished according to the Lease by Landlord have been Substantially Completed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:115%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#808282;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:115%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">That Landlord has fulfilled all of its duties of an inducement nature or as otherwise set forth </font><font style="font-family:Arial;font-size:10pt;color:#808282;">in </font><font style="font-family:inherit;font-size:10pt;color:#808282;">the Lease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:115%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#808282;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:115%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">That there are no offsets or credits against rentals, and the $9,248</font><font style="font-family:inherit;font-size:10pt;color:#505050;">.</font><font style="font-family:inherit;font-size:10pt;color:#808282;">63Sccurity Deposit has been paid </font><font style="font-family:inherit;font-size:11pt;color:#808282;">as </font><font style="font-family:inherit;font-size:10pt;color:#808282;">provided </font><font style="font-family:Arial;font-size:10pt;color:#808282;">in </font><font style="font-family:inherit;font-size:10pt;color:#808282;">the Lease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:115%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#808282;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:115%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">That there is no default by Landlord or Tenant under the Lease and the Lease is in full force and effect.</font></div></td></tr></table><div style="line-height:115%;padding-top:6px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:115%;padding-left:0px;padding-top:6px;text-align:left;text-indent:0px;"><font style="padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;color:#808282;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;color:#808282;">Landlord hereby confirms to Tenant that its Lease number is _____ . This information must accompany each Rent check or wire payment.</font></div><div style="line-height:115%;padding-left:0px;padding-top:6px;text-align:left;text-indent:0px;"><font style="padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;color:#808282;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;color:#808282;">This memorandum, each and all of the provisions here of shall inure to the benefit, or bind, as the case may require, the parties hereto, and their respective successors and assigns, subject to the restirctions upon assinment and subletting contained in the Lease.</font></div><div style="line-height:115%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:115%;padding-top:6px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#808282;">IN WITNESS \\'HEREOF, the parties hereto have executed this Memorandum, under Seal, the day and year first above written.</font></div><div style="line-height:115%;padding-top:6px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.58974358974359%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;">ONB CARLTON, LLC, </font><font style="font-family:inherit;font-size:10.5pt;">a </font><font style="font-family:inherit;font-size:10pt;">Virginia limited liability company</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  _ _ _ _ _ _ _ _ _ _ _ _ _</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">DIFFUSION PHARMACEUTICALS INC., </font><font style="font-family:Arial;font-size:8.5pt;">a</font><font style="font-family:Arial;font-size:9pt;">&#160;Delaware</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="lease1317sig2.jpg" alt="lease1317sig2.jpg" style="height:62px;width:244px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="lease1317sig3.jpg" alt="lease1317sig3.jpg" style="height:120px;width:276px;"></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sC09863C4D490292DE877FD1858124D5A"></a></div><div></div><div><br></div><div style="line-height:100%;padding-top:6px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">EXHIBIT B</font></div><div style="line-height:122%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">CONFIRMATION </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Of </font><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">LEASE </font><font style="font-family:Arial;font-size:11.5pt;text-decoration:underline;">TERM</font></div><div style="line-height:106%;padding-top:9px;text-align:left;text-indent:48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:9.5pt;">THIS MEMORANDUM </font><font style="font-family:Arial;font-size:9pt;">is </font><font style="font-family:inherit;font-size:9.5pt;">made as of the&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">day </font><font style="font-family:inherit;font-size:9.5pt;">of</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9.5pt;">&#160;&#160;&#160;&#160;2017, between ONE CARLTON, LLC, </font><font style="font-family:Arial;font-size:8.5pt;font-weight:bold;">a </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Virginia </font><font style="font-family:inherit;font-size:9.5pt;">limited </font><font style="font-family:inherit;font-size:9pt;">liability company ("</font><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">Landlord)</font><font style="font-family:inherit;font-size:9pt;">&#32;</font><font style="font-family:inherit;font-size:4.5pt;">1 , </font><font style="font-family:inherit;font-size:9pt;">and DIFFUSION PHARMACEUTICALS INC"II a Delaware </font><font style="font-family:inherit;font-size:8pt;">corporation  &#183;).who entered into a Deed of Lease(the" dated as </font><font style="font-family:inherit;font-size:9pt;">of </font><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">_,..., </font><font style="font-family:inherit;font-size:8pt;">2012. </font><font style="font-family:inherit;font-size:9.5pt;">covering premises located at 131? Carlton Avenue, Suite 400, Charlottesville, Virginia 22902. All </font><font style="font-family:inherit;font-size:10pt;">capitalized </font><font style="font-family:inherit;font-size:9.5pt;">terms, </font><font style="font-family:inherit;font-size:10.5pt;">if </font><font style="font-family:inherit;font-size:10pt;">not defined herein, shall be defined as </font><font style="font-family:inherit;font-size:9.5pt;">they </font><font style="font-family:inherit;font-size:10pt;">are </font><font style="font-family:inherit;font-size:8pt;">defined </font><font style="font-family:Arial;font-size:9.5pt;">in </font><font style="font-family:inherit;font-size:8pt;">the </font><font style="font-family:inherit;font-size:9.5pt;">Lease.</font></div><div style="line-height:100%;text-align:left;font-size:4.5pt;"><font style="font-family:inherit;font-size:4.5pt;">)</font></div><div style="line-height:108%;padding-top:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;The parties to this Memorandum hereby agree that the date of</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">2017 is the Commencement Date of the Term, and the date </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">20_is the expiration date of the Lease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;Tenant hereby confirms the following:</font></div><div style="line-height:120%;padding-left:48px;padding-top:10px;text-align:left;"><font style="padding-top:10px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;">That it has accepted possession of the Premises pursuant to the terms of the Lease;</font></div><div style="line-height:107%;padding-left:48px;padding-top:10px;text-align:left;"><font style="padding-top:10px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;">That the improvements. if any, required to be: furnished a according to the Lease </font><font style="font-family:Arial;font-size:11pt;">by</font></div><div style="line-height:102%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Landlord have been Substantially Completed;</font></div><div style="line-height:102%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">c.</font><font style="font-family:inherit;font-size:11pt;">That Lanlord has fulfilled all of its duties of an inducement nature or as otherwise set forth in the Lease;</font></div><div style="line-height:102%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">d.</font><font style="font-family:inherit;font-size:11pt;">That there are no offsets or credits against rentals, and the S9,248.63 Secwity Deposit has been paid as provided the Lease;</font></div><div style="line-height:102%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">e.</font><font style="font-family:inherit;font-size:11pt;">That there is no default by the Landlord or Tenant under the Lease and the Lease is in full force and effect.</font></div><div style="line-height:102%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:102%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:11pt;">Landlord hereby confirms to Tenant that its Lease number is _____ . This information must accompany each Rent check or wire payment.</font></div><div style="line-height:102%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:11pt;">This Memorandum, each and all of the provisions hereof: shall inure to the benefit, or bind, as the caes may require, the parties herto, and their respective successors and assigns, subject to the restrictions upon assignment and subletting contained in the Lease.</font></div><div style="line-height:102%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:102%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEROF, the parties hereto have executed this Memorandum, under Seal, the day and year first above wrtieen.</font></div><div style="line-height:102%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.77220956719817%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;">ONB CARLTON, LLC, </font><font style="font-family:inherit;font-size:10.5pt;">a </font><font style="font-family:inherit;font-size:10pt;">Virginia limited liability company</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="lease1317sig4.jpg" alt="lease1317sig4.jpg" style="height:35px;width:244px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WITNESS:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">DIFFUSION PHARMACEUTICALS INC., </font><font style="font-family:Arial;font-size:8.5pt;">a</font><font style="font-family:Arial;font-size:9pt;">&#160;Delaware</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: _ _ _ _ _ _ _ _ _ _ _ _ _</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  _ _ _ _ _ _ _ _ _ _ _ _ _</font></div></td></tr></table></div></div><div style="line-height:102%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s281BFA4CC7D1451329A8FD18592E2994"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:292px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;text-decoration:underline;">EXHIBITC</font></div><div style="line-height:115%;padding-top:1px;text-align:center;padding-left:292px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">BUILDING </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">RULES AND REGULATIONS </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">LAST</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;text-decoration:underline;">REVISIO</font><font style="font-family:inherit;font-size:10pt;color:#676767;text-decoration:underline;">N:</font><font style="font-family:inherit;font-size:10pt;color:#676767;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;text-decoration:underline;">DECEMBER 17.</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;text-decoration:underline;">2003</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:115%;text-align:left;padding-left:102px;text-indent:46px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord reserves </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the right </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">rescind </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">o</font><font style="font-family:inherit;font-size:10pt;color:#676767;">f </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">these rules and </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">make </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such other and further rules and regulations as in </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">judgment </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord shall from time </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">time be needed for the safety, protection, care and cleanliness of the Project, the operations </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">thereof, the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">preservation </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">good order therein and the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">protection </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and comfort of its tenants, their agents, employees and invitees, which rules </font><font style="font-family:inherit;font-size:10pt;color:#676767;">when </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">made and </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">notice </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">thereof given to Tenant </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be binding upon Tenant </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">a </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">like manner </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">as if originally prescribed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:148px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:116%;font-size:10pt;padding-left:104px;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">l.</font></div></td><td style="vertical-align:top;"><div style="line-height:116%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Sidewalks, entrances, passages, elevators, vestibules, stairways, corridors, halls, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">lobby </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">and -any other part of the Building shall </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">not </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be obstructed or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">encumbered </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">by any </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">tenant </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or used for any purpose other than ingress or egress to </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">from each </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">tenant's </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">premises. Landlord </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">have the right to control and operate the common portions of the Building and exterior facilities furnished for common use of the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">tenants </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">{such as the eating, smoking, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">and </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">parking areas) </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such a manner as Landlord </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">deems </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">appropriate.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:148px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:113%;font-size:11pt;padding-left:101px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:113%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#676767;">No </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">awnings or o her projections shall be </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">attached </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">to </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">outside walls of the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">B1.1ilding </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">without the prior written consent of Landlord. All </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">drapes, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or window blinds, must be of a quality, type and design color and attached </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">a manner approved </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">by </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Landlord.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:146px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:115%;font-size:11pt;padding-left:101px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:115%;text-align:left;font-size:11pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">No showcases </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">other articles shall be put </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">front of or affixed </font><font style="font-family:inherit;font-size:10pt;color:#676767;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">any part of the exterior </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Building,</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;or placed in </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">hallways or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">vestibules without prior written consent of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlord</font><font style="font-family:inherit;font-size:10pt;color:#9e9e9e;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:146px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:114%;font-size:11pt;padding-left:101px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:114%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Rest rooms and other </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">plumbing </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">fixtures shall </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">not be </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">used for </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">purposes other than those for </font><font style="font-family:inherit;font-size:10pt;color:#676767;">w</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">hich </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">they were constructed and no debris, robbi.sh, rags or other substances shall be thrown therein. Only standard toilet tissue may </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">be flushed </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">commodes. All </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">damage </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">resulting from </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">misuse of these fixtures shall be the responsibility of the tenant who, or whose emp</font><font style="font-family:inherit;font-size:10pt;color:#282828;">l</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">oyees, agents, visitors, clients, or licensees shall have caused same.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:145px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:115%;font-size:11pt;padding-left:100px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:115%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">No </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">tenant, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">without the prior </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">consent </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Landlord, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall mark, paint, </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">drill </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">into, bore, cut or string wires or in any way deface </font><font style="font-family:Arial;font-size:8.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">part of the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Premises </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or the Building </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">which they form a </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">part </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">except for </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">reasonable hanging of decorative or instructional materials on </font><font style="font-family:inherit;font-size:10pt;color:#282828;">th</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">e </font><font style="font-family:Arial;font-size:9pt;color:#4f4f4f;">walls </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of the Premises.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:145px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:116%;font-size:11pt;padding-left:100px;"><font style="font-family:inherit;font-size:11pt;">6.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:116%;text-align:left;font-size:11pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Tenants shall not construct or </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">maintain, </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">use </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">operate </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">many </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">part </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the Project </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">any electrical </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">device, wiring or other </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">apparatus </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">connection </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">a loud speaker system or other sound/communication system</font><font style="font-family:inherit;font-size:10pt;color:#676767;">&#32;whi</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">ch </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">may </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">be </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">heard outside the </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">Premises. </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">Any such communication system to be installed within the</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">&#32;Premises </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">shall require prior written </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">approval </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of Landlord.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:107%;font-size:11.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:107%;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">No mopeds, skateboards, scooters, roller blades </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">other vehicles and </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">no </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">animals, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">birds </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or other pets of any kind </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">brought </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">into, used </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">kept </font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">o</font><font style="font-family:inherit;font-size:10pt;color:#282828;">r </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">about the Building other </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">than </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">a service animal performing </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">a</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;specified task. </font><font style="font-family:inherit;font-size:10pt;color:#676767;">Notwithstanding</font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the foregoing, Diffusion Pharmaceuticals&#8217; Inc </font><font style="font-family:inherit;font-size:11pt;color:#676767;">(and </font><font style="font-family:inherit;font-size:10pt;color:#676767;">its </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">permitted successors and ass</font><font style="font-family:inherit;font-size:10pt;color:#282828;">i</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">gns) shall be permitted to use animals for medical testing </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">purposes </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">the ordinary course of </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">its</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">&#32;business, </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">provided </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such animals are handled </font><font style="font-family:inherit;font-size:10.5pt;color:#4f4f4f;">in </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">such a manner as to </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">(i) </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">keep them confined in vivariums, </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">(ii) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">prevent any sound or smell originating from the animals from intruding into the </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">common </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">areas of the Building, </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">(iii) </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">ensure any dead animals are properly disposed of by a professional disposal company and not as part of </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">th</font><font style="font-family:inherit;font-size:11pt;color:#676767;">e </font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">Building </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">trash collection, and (v) otherwise comply </font><font style="font-family:inherit;font-size:9.5pt;color:#676767;">with </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">generally accepted practices </font><font style="font-family:Arial;font-size:11pt;color:#4f4f4f;">in</font><font style="font-family:Arial;font-size:11pt;color:#3f3f3f;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3f3f3f;">handling </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">animals as part </font><font style="font-family:inherit;font-size:11.5pt;color:#676767;">of </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">medical testing.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:106%;font-size:10pt;padding-left:98px;"><font style="font-family:Arial;font-size:9pt;color:#676767;font-weight:bold;">S.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:106%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;color:#676767;">No </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">tenant shall cause or permit </font><font style="font-family:Arial;font-size:9.5pt;color:#4f4f4f;">any </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">unusual or objectionable odors </font><font style="font-family:inherit;font-size:10pt;color:#676767;">to </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">be produced upon or permeate from its premises.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:108%;padding-left:56px;text-align:left;text-indent:42px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:45px;">9.</font><font style="font-family:inherit;font-size:10pt;color:#676767;">No </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">space in the Building shall be used for </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">sale at auction of merchand</font><font style="font-family:inherit;font-size:10pt;color:#282828;">i</font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">se, goods </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">property of any</font></div><div style="line-height:108%;text-align:left;padding-left:144px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">kind</font><font style="font-family:Arial;font-size:10pt;color:#898989;">.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:97px;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">No tenant, or </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">employ</font><font style="font-family:inherit;font-size:10pt;color:#676767;">ee</font><font style="font-family:inherit;font-size:10pt;color:#c1c1c1;">, </font><font style="font-family:inherit;font-size:10pt;color:#676767;">s </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">of tenant, shall make any unseemly or disturbing </font><font style="font-family:inherit;font-size:10pt;color:#3f3f3f;">noises </font><font style="font-family:inherit;font-size:10pt;color:#4f4f4f;">or disturb or interfere </font><font style="font-family:inherit;font-size:9.5pt;color:#4f4f4f;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the occupants of this or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">neighboring </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">buildings or residences </font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">b</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">y voice, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">musical instrument, radio, </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:144px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">talking machines, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">whistling, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">singing</font><font style="font-family:inherit;font-size:10pt;color:#1a1a1a;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or in any way. </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">All </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">passage through the Building</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">' </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">s hallways</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">e</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">l</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">evators, and </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">main </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">lobby </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">shall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be conducted </font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">a quiet, business</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">-</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">like </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">manner.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">No tenant shall throw </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">anything out </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">doors, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">windows, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or down </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">corridors </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">stairs </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Building.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:115%;font-size:12.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:115%;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Except in connection </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">with </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Permitted Use and </font><font style="font-family:Arial;font-size:9.5pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">compl</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">i</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ance </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">with </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">an applicable Laws, </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall not p)ace</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">install </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or operate on the Premises o</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">r </font><font style="font-family:Arial;font-size:9.5pt;color:#4b4b4b;">in any </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">part of </font><font style="font-family:Arial;font-size:8.5pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Project</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">any engine</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">stove </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or machinery or</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;conduct </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">mechanical operations or cook thereon o</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">r </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">therein </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">(</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">except for coffee machine, microwave oven, and/or vending machine)</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or place or use in or about the Premises </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">any </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">explosives</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">gasoline</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">kerosene oil,</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;acids, caustics </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or any other </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">flammable., </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">explosive or hazardous materia</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">l, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">without prior written consent of</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;Landlord. </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord consents to the use </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(i) </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Hazardous </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Materials </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">in accordance with Section </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">7 </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of the </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Lease; </font><font style="font-family:inherit;font-size:9.5pt;color:#5b5b5b;">(ii) </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">kitchen in </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Premises</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and (iii) lab equipment </font><font style="font-family:Arial;font-size:12.5pt;color:#4b4b4b;">m </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ordinary course of </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">busine</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">ss.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:118%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;font-weight:bold;">l </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:118%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Tenants </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">are no</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">t </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">to install any additional locks </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or bolts </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">of any kind upon any door or window of the Building </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">without </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">prior written consent of Landlord. Each tenan</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">t </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">must</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">upon the termination of tenancy</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">return to </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord all keys for the Premises, either furnished </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or otherwise procured </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">such </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">tenant, and all </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">security </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">access cards to the </font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">B</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">uilding. Land</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">l</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ord hereby consents to </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">installing </font><font style="font-family:Arial;font-size:8.5pt;color:#5b5b5b;font-weight:bold;">a </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ke</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">y </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">card s</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">e</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">curity </font><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">system </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">as </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;font-style:italic;">part </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">of Tenant's Initial Work.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:110%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:110%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">All doors </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">hallways and corridors shall be </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">kept closed </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">during busin</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">e</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ss hours </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">except </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">as they </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">may </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be used for ingress or egress.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:108%;font-size:10.5pt;padding-left:96px;"><font style="font-family:Arial;font-size:9.5pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:108%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">not </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">use the name of the Building</font><font style="font-family:inherit;font-size:6pt;color:#6b6b6b;">1 </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Project, Landlord or Land</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">l</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ord's Agent </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">any </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">way </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">connection </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">with </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">its </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">business except as the address </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">thereof. </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord shall also have </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">right to prohibit an</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">y</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;advertising </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">by tenant, which, in. its </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">sole </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">opinion, tends </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to impair </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the reputation of the Building or its desirab</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">i</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">lity </font><font style="font-family:Arial;font-size:9.5pt;color:#4b4b4b;">as a </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">building </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">for offices</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">and upon written notice. from Landlord, tenan</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">t </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall refrain from</font><font style="font-family:Arial;font-size:9.5pt;color:#4b4b4b;">&#32;or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">discontinue such </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">advertising.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:113%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:113%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">All </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">deliveries by vendors, couriers, clients, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">employees </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or visitors to the B</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">u</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ilding which involve the use </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">a hand </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">cart, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">hand truck, or other heavy equipment or device must be made </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">via </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the freight elevator, </font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">if </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">such freight </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">elevator </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">exists in the Building. Tenan</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">t </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall be responsib</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">l</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">e to Landlord for </font><font style="font-family:Arial;font-size:9pt;color:#4b4b4b;">any </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">loss or damage</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;resu1ting </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">from </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">any </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">delive</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">ri</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">es made </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">for tenant to the Building. </font><font style="font-family:inherit;font-size:10pt;">Tenant s</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">hall </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">procure and deliver a certificate </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">insurance from </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">tenant's </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">movers </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">which </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">certificate </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">shall name Landlord as an </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">additional insured.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:110%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">1</font><font style="font-family:inherit;font-size:10pt;color:#858585;">7</font><font style="font-family:inherit;font-size:10pt;color:#afafaf;">,</font></div></td><td style="vertical-align:top;"><div style="line-height:110%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord reserves the right to exclude from </font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">t</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">he Building at all times any person who is not known or does not properly </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">identify </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">himself to Landlord</font><font style="font-family:inherit;font-size:10pt;color:#858585;">' </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">s </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">management or security personnel.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:113%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">18</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">.</font></div></td><td style="vertical-align:top;"><div style="line-height:113%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">No </font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;font-style:italic;">space </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">within the Building, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:9pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the common areas such as the parking </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">lot, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">may be used at </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">any </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">time </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">for </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the purpose of lodging, sleeping, or for any immoral </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">illegal purposes.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:114%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">1 </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:114%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">N</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">o canvassing</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">soliciting or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">peddling is permitted </font><font style="font-family:Arial;font-size:10.5pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">Building </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">or </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">i</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ts common areas </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">tenants, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">their employees, or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">other </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">persons.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:108%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:108%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">N</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">o </font><font style="font-family:inherit;font-size:10.5pt;color:#4b4b4b;">mats, </font><font style="font-family:inherit;font-size:9.5pt;color:#4b4b4b;">trash, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">or </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">other </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">objects shall</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;be </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">placed in the public corridors, hallways, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">stairs, or other common</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;areas </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">the Building</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:112%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:112%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#5b5b5b;">if </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Landlord elects </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">to have in effect a recycling </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">program, Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">mu</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">s</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">t place all </font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">re</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">cyclable </font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">i</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">tems </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">of </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">cans</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">,</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">&#32;bottles, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">plastic </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">and </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">office </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">recyclable </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">paper </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">in </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">appropriate containers provided </font><font style="font-family:Arial;font-size:9pt;color:#4b4b4b;">by </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">in each </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">tenant</font><font style="font-family:inherit;font-size:10pt;color:#858585;">' </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">s</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">&#32;space.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:9.5pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">Landlord does not maintain su</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">ite </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">finishes which </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">are </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">non-standard</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">such </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">as kitchens</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">bathrooms</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">wallpaper; special </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">lights</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">, </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">etc. Ho</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">w</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ever, should </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">the need </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">arise for repair of i</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">t</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">ems no</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">t </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">maintained by Landlo</font><font style="font-family:inherit;font-size:10pt;color:#2f2f2f;">r</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">d, </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">Landlord</font><font style="font-family:Arial;font-size:9.5pt;color:#c1c1c1;">,</font><font style="font-family:Arial;font-size:9.5pt;color:#4b4b4b;">-at </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">its sole option, may arrange for the work </font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">to </font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">be done at tenan</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">t</font><font style="font-family:inherit;font-size:10pt;color:#4b4b4b;">s&#8217;</font><font style="font-family:inherit;font-size:10pt;color:#6b6b6b;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5b;">expense.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:110%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:110%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#606060;">No pictures, signage</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">advertising, decals</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">banners</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, e</font><font style="font-family:inherit;font-size:10pt;color:#606060;">tc. are permitted </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">to </font><font style="font-family:inherit;font-size:10pt;color:#606060;">be placed in or on </font><font style="font-family:inherit;font-size:10pt;color:#727272;">windows </font><font style="font-family:inherit;font-size:10pt;color:#606060;">in </font><font style="font-family:inherit;font-size:10pt;color:#727272;">such </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">a </font><font style="font-family:inherit;font-size:10pt;color:#606060;">manner </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">as </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">they are </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">visible from </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">the </font><font style="font-family:inherit;font-size:10pt;color:#606060;">exterior, without </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">the </font><font style="font-family:inherit;font-size:10pt;color:#606060;">prior </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">written </font><font style="font-family:inherit;font-size:10pt;color:#606060;">consent of </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Landlord</font><font style="font-family:inherit;font-size:10pt;color:#808080;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:113%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">24.</font></div></td><td style="vertical-align:top;padding-left:89.33333333333333px;"><div style="line-height:113%;text-align:left;font-size:10pt;text-indent:-89.33333333333333px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">Tenant shall </font><font style="font-family:inherit;font-size:10pt;color:#727272;">be </font><font style="font-family:inherit;font-size:10pt;color:#606060;">responsible to </font><font style="font-family:inherit;font-size:10pt;color:#727272;">Landlord for </font><font style="font-family:inherit;font-size:10pt;color:#606060;">any acts </font><font style="font-family:inherit;font-size:10pt;color:#727272;">of </font><font style="font-family:inherit;font-size:10pt;color:#606060;">vandalism performed </font><font style="font-family:Arial;font-size:10pt;color:#727272;">in </font><font style="font-family:inherit;font-size:10pt;color:#606060;">the Building </font><font style="font-family:inherit;font-size:9pt;color:#727272;">by its </font><font style="font-family:inherit;font-size:10pt;color:#606060;">Employees, </font><font style="font-family:inherit;font-size:10pt;color:#727272;">agents, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">invitees </font><font style="font-family:inherit;font-size:10pt;color:#727272;">or </font><font style="font-family:inherit;font-size:10pt;color:#606060;">visitors</font><font style="font-family:inherit;font-size:10pt;color:#808080;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:112%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">25.</font></div></td><td style="vertical-align:top;padding-left:89.33333333333333px;"><div style="line-height:112%;text-align:left;font-size:10.5pt;text-indent:-89.33333333333333px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#727272;">emp</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">loyees </font><font style="font-family:inherit;font-size:10pt;color:#606060;">shall not </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">perform </font><font style="font-family:inherit;font-size:10pt;color:#606060;">any </font><font style="font-family:inherit;font-size:10pt;color:#727272;">work </font><font style="font-family:inherit;font-size:10pt;color:#606060;">or do </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">anything </font><font style="font-family:inherit;font-size:10pt;color:#606060;">outside of their regular duties unless</font><font style="font-family:inherit;font-size:10pt;color:#727272;">&#32;under </font><font style="font-family:inherit;font-size:10pt;color:#606060;">special </font><font style="font-family:inherit;font-size:10pt;color:#727272;">instructions </font><font style="font-family:inherit;font-size:10pt;color:#606060;">from Landlord. Requests </font><font style="font-family:inherit;font-size:10pt;color:#727272;">for </font><font style="font-family:inherit;font-size:10pt;color:#606060;">such requirements must be submitted </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">in </font><font style="font-family:inherit;font-size:9pt;color:#606060;">writing </font><font style="font-family:inherit;font-size:10pt;color:#727272;">to Landlord.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:112%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">26.</font></div></td><td style="vertical-align:top;padding-left:90.66666666666667px;"><div style="line-height:112%;text-align:justify;font-size:10pt;text-indent:-90.66666666666667px;"><font style="font-family:inherit;font-size:10pt;color:#727272;">Landlor</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">d will </font><font style="font-family:inherit;font-size:10pt;color:#606060;">not </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">be responsible </font><font style="font-family:Arial;font-size:9.5pt;color:#606060;">foi:</font><font style="font-family:inherit;font-size:10pt;color:#606060;">1ost or stolen persona! property, equipment, money or jewelry from tenant's area or common areas of the P</font><font style="font-family:inherit;font-size:10pt;color:#808080;">r</font><font style="font-family:inherit;font-size:10pt;color:#606060;">oject regardless </font><font style="font-family:inherit;font-size:10pt;color:#727272;">of </font><font style="font-family:inherit;font-size:10pt;color:#606060;">whether </font><font style="font-family:inherit;font-size:10pt;color:#727272;">such </font><font style="font-family:inherit;font-size:10pt;color:#606060;">loss occurs </font><font style="font-family:inherit;font-size:10pt;color:#727272;">when </font><font style="font-family:inherit;font-size:10pt;color:#606060;">area is</font><font style="font-family:Arial;font-size:9.5pt;color:#606060;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#606060;">locked against entry or not.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:104%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">27.</font></div></td><td style="vertical-align:top;padding-left:90.66666666666667px;"><div style="line-height:104%;text-align:left;font-size:11pt;text-indent:-90.66666666666667px;"><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#606060;">will </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">not </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">permit </font><font style="font-family:inherit;font-size:10pt;color:#606060;">entrance to tenant's </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">premis</font><font style="font-family:inherit;font-size:11pt;color:#727272;">es </font><font style="font-family:inherit;font-size:10pt;color:#606060;">by </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">use </font><font style="font-family:inherit;font-size:10pt;color:#606060;">of </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">pass</font><font style="font-family:inherit;font-size:10pt;color:#606060;">key </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">controlled </font><font style="font-family:inherit;font-size:10pt;color:#606060;">by </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">Landlord</font><font style="font-family:inherit;font-size:10.5pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10.5pt;color:#4d4d4d;">to </font><font style="font-family:inherit;font-size:10pt;color:#606060;">any person at any time without written permission of tenant</font><font style="font-family:inherit;font-size:5pt;color:#808080;">1 </font><font style="font-family:inherit;font-size:10pt;color:#606060;">except employees</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">contractors or service </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">personnel </font><font style="font-family:inherit;font-size:10pt;color:#606060;">supervised or employed </font><font style="font-family:inherit;font-size:10pt;color:#727272;">by </font><font style="font-family:inherit;font-size:10pt;color:#606060;">Landlord.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:113%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">28.</font></div></td><td style="vertical-align:top;padding-left:90.66666666666667px;"><div style="line-height:113%;text-align:left;font-size:11pt;text-indent:-90.66666666666667px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">Te11ant </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">and </font><font style="font-family:inherit;font-size:10pt;color:#606060;">its agents, employees and invitees shall observe and </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">comply </font><font style="font-family:inherit;font-size:11pt;color:#606060;">with </font><font style="font-family:inherit;font-size:10pt;color:#606060;">the driving and parking </font><font style="font-family:inherit;font-size:10pt;color:#727272;">signs</font><font style="font-family:inherit;font-size:10pt;color:#606060;">&#32;and markers on the </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Building </font><font style="font-family:inherit;font-size:10pt;color:#606060;">grounds and surrounding areas.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:114%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">29.</font></div></td><td style="vertical-align:top;padding-left:90.66666666666667px;"><div style="line-height:114%;text-align:left;font-size:10pt;text-indent:-90.66666666666667px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">Tenan</font><font style="font-family:inherit;font-size:10pt;color:#808080;">t </font><font style="font-family:inherit;font-size:10pt;color:#606060;">and </font><font style="font-family:inherit;font-size:9.5pt;color:#606060;">its </font><font style="font-family:inherit;font-size:10pt;color:#727272;">employees, invitees, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">agents, etc. shall no</font><font style="font-family:inherit;font-size:10pt;color:#808080;">t en</font><font style="font-family:inherit;font-size:10pt;color:#606060;">te</font><font style="font-family:inherit;font-size:10pt;color:#808080;">r </font><font style="font-family:inherit;font-size:10pt;color:#606060;">other </font><font style="font-family:inherit;font-size:10pt;color:#727272;">s</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">eparat</font><font style="font-family:inherit;font-size:10pt;color:#727272;">e </font><font style="font-family:inherit;font-size:10pt;color:#606060;">tenants' hallways, restroom</font><font style="font-family:inherit;font-size:10pt;color:#808080;">s or </font><font style="font-family:inherit;font-size:10pt;color:#606060;">premises unless they have received prior </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">approval </font><font style="font-family:inherit;font-size:10pt;color:#606060;">from Landlord's </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">managemen</font><font style="font-family:inherit;font-size:10pt;color:#808080;">.</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">t</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:144px;text-indent:-48px;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:9pt;">30.</font></div></td><td style="vertical-align:top;padding-left:90.66666666666667px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-90.66666666666667px;"><font style="font-family:inherit;font-size:9pt;color:#808080;">Tenant</font><font style="font-family:inherit;font-size:9pt;color:#606060;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#606060;">shall not </font><font style="font-family:inherit;font-size:9pt;color:#606060;">use </font><font style="font-family:inherit;font-size:10pt;color:#606060;">or </font><font style="font-family:inherit;font-size:9pt;color:#606060;">permit </font><font style="font-family:inherit;font-size:10pt;color:#606060;">the </font><font style="font-family:inherit;font-size:9pt;color:#4d4d4d;">u</font><font style="font-family:inherit;font-size:9pt;color:#727272;">se </font><font style="font-family:inherit;font-size:10pt;color:#606060;">of any portion of </font><font style="font-family:inherit;font-size:9pt;color:#606060;">the </font><font style="font-family:inherit;font-size:10pt;color:#606060;">Premises for outdoor storage.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:113%;font-size:10.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">31</font><font style="font-family:inherit;font-size:10pt;color:#808080;">.</font></div></td><td style="vertical-align:top;padding-left:90.66666666666667px;"><div style="line-height:113%;text-align:left;font-size:10.5pt;text-indent:-90.66666666666667px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">Tenant shall not overload any floor in the Premises </font><font style="font-family:inherit;font-size:10pt;color:#727272;">or </font><font style="font-family:inherit;font-size:10pt;color:#606060;">the Building</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">including any public </font><font style="font-family:inherit;font-size:10pt;color:#727272;">corridors </font><font style="font-family:inherit;font-size:10pt;color:#606060;">or </font><font style="font-family:inherit;font-size:10pt;color:#727272;">elevat</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">ors </font><font style="font-family:inherit;font-size:10pt;color:#606060;">therein, by </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">bringing </font><font style="font-family:Arial;font-size:9.5pt;color:#606060;">in, </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">placing, </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">storing; </font><font style="font-family:inherit;font-size:10pt;color:#606060;">installing or </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">removing </font><font style="font-family:inherit;font-size:10pt;color:#606060;">any large or </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">heavy </font><font style="font-family:inherit;font-size:10pt;color:#606060;">articles</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">and </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">La11dlord </font><font style="font-family:inherit;font-size:10pt;color:#606060;">may prohibit, or may direct and control the </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">location </font><font style="font-family:inherit;font-size:10pt;color:#606060;">and size </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">of</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:Arial;font-size:10pt;color:#606060;">safes </font><font style="font-family:inherit;font-size:10pt;color:#606060;">and all other </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">heavy </font><font style="font-family:inherit;font-size:10pt;color:#606060;">articles, and may require</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">at </font><font style="font-family:inherit;font-size:10pt;color:#727272;">tenant's sole cost </font><font style="font-family:inherit;font-size:10pt;color:#606060;">and expense</font><font style="font-family:inherit;font-size:10pt;color:#808080;">, </font><font style="font-family:inherit;font-size:10pt;color:#606060;">supplementary </font><font style="font-family:inherit;font-size:10pt;color:#727272;">supports </font><font style="font-family:inherit;font-size:10pt;color:#606060;">of </font><font style="font-family:inherit;font-size:10pt;color:#727272;">such </font><font style="font-family:inherit;font-size:10pt;color:#606060;">materia</font><font style="font-family:inherit;font-size:10pt;color:#808080;">l </font><font style="font-family:inherit;font-size:10pt;color:#606060;">and dimensions </font><font style="font-family:inherit;font-size:10pt;color:#727272;">as </font><font style="font-family:inherit;font-size:10pt;color:#606060;">Landlord may </font><font style="font-family:inherit;font-size:10pt;color:#727272;">deem </font><font style="font-family:inherit;font-size:10pt;color:#606060;">necessary to properly </font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">distribu</font><font style="font-family:inherit;font-size:10.5pt;color:#808080;">t</font><font style="font-family:inherit;font-size:10.5pt;color:#606060;">e </font><font style="font-family:inherit;font-size:10pt;color:#606060;">the </font><font style="font-family:inherit;font-size:10pt;color:#727272;">weight.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:52px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:109%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">32.</font></div></td><td style="vertical-align:top;padding-left:92px;"><div style="line-height:109%;text-align:left;font-size:10pt;text-indent:-92px;"><font style="font-family:inherit;font-size:10pt;color:#606060;">Tenant </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">shall </font><font style="font-family:inherit;font-size:10pt;color:#606060;">not commit or suffer any waste upon the </font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">Premise</font><font style="font-family:inherit;font-size:10pt;color:#727272;">s, </font><font style="font-family:Arial;font-size:9.5pt;color:#606060;">Building </font><font style="font-family:inherit;font-size:10pt;color:#606060;">or Project or a:ny nuisance, or do </font><font style="font-family:inherit;font-size:10pt;color:#727272;">any </font><font style="font-family:inherit;font-size:10pt;color:#606060;">other act </font><font style="font-family:inherit;font-size:10pt;color:#727272;">or </font><font style="font-family:inherit;font-size:10pt;color:#606060;">thing that ma</font><font style="font-family:inherit;font-size:10pt;color:#808080;">y </font><font style="font-family:inherit;font-size:10pt;color:#606060;">disturb </font><font style="font-family:inherit;font-size:10pt;color:#727272;">the </font><font style="font-family:inherit;font-size:10pt;color:#606060;">quiet enjoyment of an</font><font style="font-family:inherit;font-size:10pt;color:#808080;">y </font><font style="font-family:inherit;font-size:10pt;color:#727272;">other </font><font style="font-family:inherit;font-size:10pt;color:#606060;">tenant </font><font style="font-family:inherit;font-size:9.5pt;color:#606060;">in </font><font style="font-family:inherit;font-size:10pt;color:#606060;">the Building or Project</font><font style="font-family:inherit;font-size:10pt;color:#808080;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s51029DA526008B4E4940FD1859D6B8D6"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:248%;padding-top:6px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#505050;text-decoration:underline;">Exhibit D</font></div><div style="line-height:248%;padding-top:6px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#505050;">Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#505050;">Initial </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">Work</font></div><div style="line-height:248%;padding-top:6px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:111%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#505050;">Tenant shal</font><font style="font-family:inherit;font-size:10pt;color:#282828;">l </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">do </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">all </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">construction </font><font style="font-family:inherit;font-size:10pt;color:#505050;">and </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">alterations </font><font style="font-family:inherit;font-size:10.5pt;color:#3d3d3d;">that </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">are </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">part of Tenant's </font><font style="font-family:inherit;font-size:10pt;color:#505050;">Initial </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">Work </font><font style="font-family:inherit;font-size:10pt;color:#505050;">in </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">compliance </font><font style="font-family:inherit;font-size:10pt;color:#505050;">with</font></div><div style="line-height:139%;padding-top:2px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#505050;">all </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">building </font><font style="font-family:inherit;font-size:10pt;color:#505050;">rules and regulations, co</font><font style="font-family:inherit;font-size:10pt;color:#282828;">n</font><font style="font-family:inherit;font-size:10pt;color:#505050;">sistent w</font><font style="font-family:inherit;font-size:10pt;color:#282828;">i</font><font style="font-family:inherit;font-size:10pt;color:#505050;">th existing building systems and </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">in </font><font style="font-family:inherit;font-size:10pt;color:#505050;">a manner aimed at </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">limiting </font><font style="font-family:inherit;font-size:10.5pt;color:#3d3d3d;">disruption </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">to </font><font style="font-family:inherit;font-size:10pt;color:#505050;">existing </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">tenants of the </font><font style="font-family:inherit;font-size:10pt;color:#505050;">Building. </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#505050;">understands </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">the </font><font style="font-family:inherit;font-size:10pt;color:#505050;">attached plans are schematic </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">and </font><font style="font-family:inherit;font-size:10pt;color:#505050;">minor modifications </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">are </font><font style="font-family:inherit;font-size:10pt;color:#505050;">acceptable. Tenant will provide </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Landlord </font><font style="font-family:inherit;font-size:10pt;color:#505050;">with revised </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">plans </font><font style="font-family:inherit;font-size:10pt;color:#505050;">as </font><font style="font-family:inherit;font-size:10.5pt;color:#505050;">they </font><font style="font-family:inherit;font-size:10pt;color:#505050;">become avai</font><font style="font-family:inherit;font-size:10pt;color:#282828;">l</font><font style="font-family:inherit;font-size:10pt;color:#505050;">able.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;color:#505050;">[Approved </font><font style="font-family:inherit;font-size:10.5pt;color:#3d3d3d;">Plans </font><font style="font-family:inherit;font-size:10pt;color:#505050;">to be Attached]</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s5AD85CC9CC02E8139597FD1859EC75C8"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="lease1317img2.jpg" alt="lease1317img2.jpg" style="height:1008px;width:778px;"></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>dffn20170331ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s989637873BF95F6F860F51AB3B2A6AD0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David G. Kalergis, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Diffusion Pharmaceuticals Inc.;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:40px;"></td><td style="width:301px;"></td><td style="width:40px;"></td><td style="width:301px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David G. Kalergis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David G. Kalergis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>dffn20170331ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s76C6F79502EC54AABE238FF4C7EA6B93"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Ben L. Shealy, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Diffusion Pharmaceuticals Inc.;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:40px;"></td><td style="width:301px;"></td><td style="width:40px;"></td><td style="width:301px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 15, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ben L. Shealy&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ben L. Shealy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Finance, Treasurer and Secretary</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>dffn20170331ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF2E15B5F4DCB572BAB805F19A8351C99"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David G. Kalergis, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:60px;"></td><td style="width:24px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:60px;"></td><td style="width:24px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:341px;"></td><td style="width:341px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David G. Kalergis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David G. Kalergis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 15, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>dffn20170331ex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9A24F4DE6150542DA3E32AF727F9A35F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Ben L. Shealy, Senior Vice President, Finance, Treasurer and Secretary of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:60px;"></td><td style="width:24px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:60px;"></td><td style="width:24px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:341px;"></td><td style="width:341px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;/s/ Ben L. Shealy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ben L. Shealy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Finance, Treasurer and Secretary</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 15, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>dffn-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:38BFC535BACF592DBF832A6C6EBC9F82,x:9d4ecfae56c94e9cb67baf8beba874e5-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:dffn="http://www.diffusionpharma.com/20170331" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="dffn-20170331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar1-31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar1-31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar1-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_CommonStockWarrantsSeriesAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:CommonStockWarrantsSeriesAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES440Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES440Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1SD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES529Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES529Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1SD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES440Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES440Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_dffn_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">dffn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES529Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES529Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1SD_dei_LegalEntityAxis_dffn_DiffusionLLCMember_us-gaap_BusinessAcquisitionAxis_dffn_RestorGenexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:RestorGenexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1SD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember_us-gaap_NonrecurringAdjustmentAxis_us-gaap_AcquisitionRelatedCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1SD_us-gaap_TitleOfIndividualAxis_dffn_ExecutiveOfficersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:ExecutiveOfficersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember_us-gaap_NatureOfExpenseAxis_dffn_SuccessFeeAgreementCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">dffn:SuccessFeeAgreementCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNoteSeriesBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNoteSeriesBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNotes2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotes2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:LegacyRestorGenexWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_dffn_ConversionofPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:ConversionofPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar1-31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_dffn_ConversionofPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:ConversionofPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr3_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-03</xbrli:startDate>
			<xbrli:endDate>2017-04-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_SubsidiarySaleOfStockAxis_dffn_ConversionofPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:ConversionofPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:LegacyRestorGenexWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1March14">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:LegacyRestorGenexWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:LegacyRestorGenexWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dffn:NonemployeeOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Jan1_us-gaap_PlanNameAxis_dffn_RestorgenexCorporation2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dffn:NonemployeeOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dffn:NonemployeeOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_PlanNameAxis_dffn_RestorgenexCorporation2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_PlanNameAxis_dffn_RestorgenexCorporation2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_StatementGeographicalAxis_dffn_CharlottesvilleVirginiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">dffn:CharlottesvilleVirginiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_StatementGeographicalAxis_dffn_CharlottesvilleVirginiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">dffn:CharlottesvilleVirginiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dffn_CommonStockWarrantsSeriesAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:CommonStockWarrantsSeriesAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="vote_per_share">
		<xbrli:measure>dffn:vote_per_share</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q1YTD" id="Fact-1B1E996BE07A546CAE4FBE593553ADF1">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q1YTD" id="Fact-CD1F824843F15FF597C74DDD7340B581">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q1YTD" id="Fact-A8F9AB4790835106B33CA710ECC618FD">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q1YTD" id="Fact-2E6142F06C355921AD6C7CFE9C39FC82">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q1YTD" id="Fact-8E21575CE5005B7E8C42FFF6CFB6FAD3">2017-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q1YTD" id="Fact-9498E15D60835A35A0E5E75EBD5ACB5C">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q1YTD" id="Fact-24633D75D9D15D8E8178AC9201D2F609">0001053691</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q2" decimals="INF" id="Fact-9D0F505E18D55BBE8288F684FE4C6005" unitRef="shares">10345637</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q1YTD" id="Fact-34E180F998C55E0C820D68DA25670427">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q1YTD" id="Fact-0C9180786B845DAC91636DBD90E91B03">Diffusion Pharmaceuticals Inc.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2017Q1YTD" id="Fact-1B92E96D2F0854F3BDA903B21BD7E6E8">dffn</dei:TradingSymbol>
	<dffn:AccruedClinicalStudiesExpensesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-EA3577B2F7235101A918A2D8246CD693" unitRef="usd">220978</dffn:AccruedClinicalStudiesExpensesCurrent>
	<dffn:AccruedClinicalStudiesExpensesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-84A32D67795D54DDA928E713ADE9BD4E" unitRef="usd">346861</dffn:AccruedClinicalStudiesExpensesCurrent>
	<dffn:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="2" id="Fact-0CE90C0967FC59019E3A5EF40A479474" unitRef="usdPerShare">0.47</dffn:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
	<dffn:BusinessCombinationPreliminaryPurchasePriceConsideration contextRef="D2016Q1SD_dei_LegalEntityAxis_dffn_DiffusionLLCMember_us-gaap_BusinessAcquisitionAxis_dffn_RestorGenexMember" decimals="-3" id="Fact-D1F939303C8B5A58A255F3FE0B4027EC" unitRef="usd">21261000</dffn:BusinessCombinationPreliminaryPurchasePriceConsideration>
	<dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights contextRef="D2016Q1SD_dei_LegalEntityAxis_dffn_DiffusionLLCMember_us-gaap_BusinessAcquisitionAxis_dffn_RestorGenexMember" decimals="-3" id="Fact-5DA29C01548556F994FDA3C34DB71870" unitRef="usd">10000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights>
	<dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed contextRef="D2016Q1SD_dei_LegalEntityAxis_dffn_DiffusionLLCMember_us-gaap_BusinessAcquisitionAxis_dffn_RestorGenexMember" decimals="-3" id="Fact-249E3E0DDB7B5E3BAC6E51F786EBF1CF" unitRef="usd">1321000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed>
	<dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed contextRef="D2016Q1SD_dei_LegalEntityAxis_dffn_DiffusionLLCMember_us-gaap_BusinessAcquisitionAxis_dffn_RestorGenexMember" decimals="-3" id="Fact-389B480CF2CF59A79FC0F45790043275" unitRef="usd">384000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed>
	<dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding contextRef="D2016Q1SD_dei_LegalEntityAxis_dffn_DiffusionLLCMember_us-gaap_BusinessAcquisitionAxis_dffn_RestorGenexMember" decimals="-3" id="Fact-6CE6D2C6D952552D80350C64791FD98D" unitRef="usd">19546000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding>
	<dffn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-073BFE10CCA15303B1D1307FBD15BAD6" unitRef="usd">377432</dffn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
	<dffn:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember" decimals="INF" id="Fact-FF0709F8895756CDAA2609D90B43AA8B" unitRef="shares">0</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
	<dffn:ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-4B69AEEDE2B99ABC5C04C13346A234C9" unitRef="number">1.05</dffn:ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage>
	<dffn:ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice contextRef="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-80D95E489AFF7D58EEBFC107ABE782F3" unitRef="usdPerShare">8.00</dffn:ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice>
	<dffn:ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-5" id="Fact-8651F1E18B8E4569D3D5C12E07847D89" unitRef="usd">10000000</dffn:ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock>
	<dffn:ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_dffn_ConversionofPreferredStockMember" decimals="-5" id="Fact-C4965E7A15C3BADB5293C12AE03BEC5B" unitRef="usd">10000000</dffn:ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock>
	<dffn:ConvertiblePreferredStockNumberofVotesperShare contextRef="FI2017Q1" decimals="INF" id="Fact-18ACE16CC870E13E6688FE5CC36566C0" unitRef="vote_per_share">0.50627</dffn:ConvertiblePreferredStockNumberofVotesperShare>
	<dffn:ConvertiblePreferredStockNumberofVotesperShare contextRef="I2017Q1March14" decimals="INF" id="Fact-E13931B818FB7ADDBA5DFE5CC35B4D7E" unitRef="vote_per_share">0.84874</dffn:ConvertiblePreferredStockNumberofVotesperShare>
	<dffn:ConvertiblePreferredStockThresholdConsecutiveTradingDays contextRef="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" id="Fact-F017D0865F5C0671EC3BC1100E413DD2">P30D</dffn:ConvertiblePreferredStockThresholdConsecutiveTradingDays>
	<dffn:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations contextRef="FD2016Q1YTD" decimals="0" id="Fact-4FE93AF26DD45CDB99AC4F689B04C360" unitRef="usd">7853</dffn:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations>
	<dffn:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations contextRef="FD2017Q1YTD" decimals="0" id="Fact-B686F568AE2E58F5BC991FB96BE807C0" unitRef="usd">6603</dffn:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations>
	<dffn:FairValueAssumptionsStockPrice contextRef="FD2017Q1YTD" decimals="2" id="Fact-DF3F36669E9244343497F8048544FC1B" unitRef="usdPerShare">2.38</dffn:FairValueAssumptionsStockPrice>
	<dffn:NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts contextRef="FD2016Q1YTD" decimals="0" id="Fact-DFD30F2461A16D28B4EBC0530976FF80" unitRef="usd">0</dffn:NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts>
	<dffn:NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts contextRef="FD2017Q1YTD" decimals="0" id="Fact-E5A1CF00203A2611DCC0C052C086F61A" unitRef="usd">180456</dffn:NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts>
	<dffn:OfferingCostsIncurredButNotYetPaid contextRef="FD2016Q1YTD" decimals="0" id="Fact-39E1500076683001101A8C3FC82EF788" unitRef="usd">0</dffn:OfferingCostsIncurredButNotYetPaid>
	<dffn:OfferingCostsIncurredButNotYetPaid contextRef="FD2017Q1YTD" decimals="0" id="Fact-E4A9ED9980C2732D194C8C3F80B3CD4B" unitRef="usd">178258</dffn:OfferingCostsIncurredButNotYetPaid>
	<dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis contextRef="FD2017Q1YTD_us-gaap_PlanNameAxis_dffn_RestorgenexCorporation2015EquityIncentivePlanMember" decimals="3" id="Fact-3A5AC468244C7DC4BC50D07AFC8EC7BE" unitRef="number">0.040</dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis>
	<dffn:PrepaidExpensesDepositsAndOtherAssets contextRef="FI2016Q4" decimals="0" id="Fact-6A1C3B47EC3D514EA3A3A2E640B41A3D" unitRef="usd">50844</dffn:PrepaidExpensesDepositsAndOtherAssets>
	<dffn:PrepaidExpensesDepositsAndOtherAssets contextRef="FI2017Q1" decimals="0" id="Fact-8AD739BDB9C75099A7F8B1513614B23F" unitRef="usd">138986</dffn:PrepaidExpensesDepositsAndOtherAssets>
	<dffn:ProceedsFromReverseMergerTransaction contextRef="FD2016Q1YTD" decimals="0" id="Fact-4DA14CD02D515055B143488A4DA354BF" unitRef="usd">8500602</dffn:ProceedsFromReverseMergerTransaction>
	<dffn:ProceedsFromReverseMergerTransaction contextRef="FD2017Q1YTD" decimals="0" id="Fact-0B0ED4FB27F95962BE5E4A35819F9541" unitRef="usd">0</dffn:ProceedsFromReverseMergerTransaction>
	<dffn:TemporaryEquityConsiderationReceived contextRef="D2017Q1Mar1-31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-5" id="Fact-63C6747D6075CCB5F6F8C0324678B013" unitRef="usd">25000000</dffn:TemporaryEquityConsiderationReceived>
	<dffn:TemporaryEquityConsiderationReceivedNet contextRef="D2017Q1Mar1-31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-5" id="Fact-29989A689C2DE86E7147CF0ACCF7FD37" unitRef="usd">22100000</dffn:TemporaryEquityConsiderationReceivedNet>
	<dffn:TemporaryEquityConsiderationReceivedNet contextRef="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-5" id="Fact-87C40E7EEDFDD60B180ECEFA8A843FC3" unitRef="usd">22100000</dffn:TemporaryEquityConsiderationReceivedNet>
	<dffn:TemporaryEquityIssuanceCosts contextRef="D2017Q1Mar1-31" decimals="-5" id="Fact-A4C11E20BFEBF910A1C9C0727AE44E84" unitRef="usd">2400000</dffn:TemporaryEquityIssuanceCosts>
	<dffn:TemporaryEquityOfferingCosts contextRef="D2017Q1Mar1-31" decimals="-5" id="Fact-44113C4EF1EB554629C3C03386A6097C" unitRef="usd">500000</dffn:TemporaryEquityOfferingCosts>
	<dffn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q1YTD" decimals="INF" id="Fact-5E060705CFBA5515A5418C1237CBD18D" unitRef="shares">12376329</dffn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<dffn:WarrantExpenseandFairValueAdjustmentofWarrantLiability contextRef="FD2016Q1YTD" decimals="0" id="Fact-4601CF9BFC14021C5C318C3513CE696F" unitRef="usd">0</dffn:WarrantExpenseandFairValueAdjustmentofWarrantLiability>
	<dffn:WarrantExpenseandFairValueAdjustmentofWarrantLiability contextRef="FD2017Q1YTD" decimals="0" id="Fact-280C8DAF074E677D4DAE8BF6244CEE04" unitRef="usd">26015746</dffn:WarrantExpenseandFairValueAdjustmentofWarrantLiability>
	<dffn:WarrantExpenseandFairValueAdjustmentofWarrantLiability contextRef="FD2017Q1YTD" decimals="-5" id="Fact-1B2F0F0DDCE4C7BE1B3EF87ACB0831CF" unitRef="usd">26000000</dffn:WarrantExpenseandFairValueAdjustmentofWarrantLiability>
	<dffn:WarrantRelatedExpense contextRef="D2017Q1Mar1-31" decimals="-5" id="Fact-7AE4C9C7FE6D71287638F94417CA855D" unitRef="usd">10200000</dffn:WarrantRelatedExpense>
	<dffn:WarrantRelatedExpense contextRef="FD2016Q1YTD" decimals="0" id="Fact-223C624B9D5474C575678BF64E3CEFBB" unitRef="usd">0</dffn:WarrantRelatedExpense>
	<dffn:WarrantRelatedExpense contextRef="FD2017Q1YTD" decimals="0" id="Fact-879BAE9AC1F66F3CB235FE72722D9050" unitRef="usd">10225846</dffn:WarrantRelatedExpense>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="0" id="Fact-46FAE85B810D517B8822B3A6EB5BE8DE" unitRef="usd">1684158</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q1" decimals="0" id="Fact-AA686A0A38605616A69E6177189CDE90" unitRef="usd">557629</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-F934F99246EF501C91307C717236F8DE" unitRef="usd">72855</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-8F1431DCE222515EB6BBBD763B3D9CDA" unitRef="usd">185163</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-6B25CB5FEA5F51C98995ADB095149160" unitRef="usd">399740</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-6859673CE1745314BA6F658FF8ECF647" unitRef="usd">135072</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="0" id="Fact-BCD73E73477459A8857168D613D511B6" unitRef="usd">69363575</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q1" decimals="0" id="Fact-A2ED906B5DC858479939917E36D0FB4B" unitRef="usd">69700264</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="FD2017Q1YTD" decimals="0" id="Fact-98EB8728841D0659335AC043C5DEAC8F" unitRef="usd">28017</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-ADFA64C66B5A80198982C043549325EF" unitRef="usd">28017</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q1YTD" decimals="0" id="Fact-2D4D22BA07E356268AE470107636B63A" unitRef="usd">366383</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-E33A2546BCB558B281648B2AF82CC1E9" unitRef="usd">366383</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2017Q1YTD" decimals="0" id="Fact-F66E92E4A05A5C48BEBD68E22EE1EDF0" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-F485ECC6B1133ACAE827C041051D4AF8" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q1SD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="-5" id="Fact-FB7AE9B51039911202F6EB0547E38556" unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD" decimals="0" id="Fact-DCE1FD91D6205EC18F246D1D9DD1ACF5" unitRef="usd">393471</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-A5E4587333535A3B9748A30CAD2AA5F3" unitRef="usd">151194</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-0D7E8B10FD585CB496E2F073F7C9F939" unitRef="usd">242277</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD" decimals="0" id="Fact-7B45C71B70285172A362264230C6B2D6" unitRef="usd">366383</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-36300E960B16E7658C03C161D15E8C75" unitRef="usd">3000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="INF" id="Fact-0FCB77576FFAF6A9CDC7EB078BB7C6B7" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-F5C873349BF85996B66C10B565B23FBD" unitRef="usd">323061</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-C2565CD5FCA952CA8870687CCABB3F33" unitRef="usd">43322</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2016Q1YTD" decimals="0" id="Fact-CB07797291875100B9D1A00F2AEB0FB6" unitRef="usd">3383</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q1YTD" decimals="0" id="Fact-0849B3CDD7235943ACD36D76844AACFC" unitRef="usd">57185</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD" decimals="0" id="Fact-5D35ED99C8905E1B93B6616A3A02B97A" unitRef="shares">2715984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="0" id="Fact-BCF2C68FD77B514AAC610A6E50B04031" unitRef="shares">428134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-097411E25F5CD0238908C08B1163FBAC" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-FBD14018C62F5BC0A4A117E9E3C8CD4A" unitRef="shares">1796360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="0" id="Fact-383E28F992655A709D9C83D8EA4195A5" unitRef="shares">13802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-74492F093D3252B9A9F05A1D24788EF1" unitRef="shares">477688</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD" decimals="0" id="Fact-5089EFDAB8225244966D52E8785B3EAC" unitRef="shares">29471085</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="0" id="Fact-72DF6FC849AE539A8FC044C61BDB15D5" unitRef="shares">766351</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-C87A25FF98248ECCA3A5C08B0EFB03B5" unitRef="shares">12376329</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-DADC2DD1E27050969992FEA134A516C4" unitRef="shares">2304132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="0" id="Fact-B3CE1876B465575596D5EBAFF2D41AFA" unitRef="shares">7665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-DA47E3ACFE6958618AE51E5B5367B7E7" unitRef="shares">14016608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="0" id="Fact-20DBCE56D8575BB091D9D06B55A411A8" unitRef="usd">17484384</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q1" decimals="0" id="Fact-C9D05586E4DB5C5EA6CEEB0B80E3A004" unitRef="usd">36343543</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="0" id="Fact-B9562F4D17BD5F16A229A436147E6CAB" unitRef="usd">1603696</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q1" decimals="0" id="Fact-460B110D3BE45FD282E7DACC1FDA7501" unitRef="usd">20631946</us-gaap:AssetsCurrent>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-8916376E268A5D0FBBBD55968C4CEC3B" unitRef="usd">-4655944</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-CCEAC1CA36635DF1811E378A4DF29EB0" unitRef="usd">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2016Q1YTD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember_us-gaap_NonrecurringAdjustmentAxis_us-gaap_AcquisitionRelatedCostsMember" decimals="-5" id="Fact-0F7A46AB21FE5F3B9F8052D1010C34E5" unitRef="usd">1600000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-1048BD686A2050ED887CEC6420A41E13" unitRef="usd">8500602</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-3975AE83DC2B589C91D982CFB9688246" unitRef="usd">195200</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-E0793A0CC8DE5684BD2CA5666A037FE0" unitRef="usd">3644159</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-2FC9A29C44D9543899CD160B614165C9" unitRef="usd">9600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-A5163CBA51285F709A66C79CFCD1D3AE" unitRef="usd">57531</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-906C15F2430C535A87231CF1B3816443" unitRef="usd">21261000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="0" id="Fact-CE2B3697A2DB53F0B7B51C13BFC44508" unitRef="usd">1997192</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q1" decimals="0" id="Fact-8030752079655F9D8D84B7ADE873720E" unitRef="usd">5865611</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="0" id="Fact-708EBED6A4635582AA4A5CBC9E12C03B" unitRef="usd">1552852</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-A2F9001D9E425CBF95B0E959EBC99113" unitRef="usd">1552852</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-3EBEE63A59308B1D41D7EB461F43425B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-F62630DB0876C75D63E2EB4621AA5D03" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="0" id="Fact-321CEEF2C5D0540CB45272D66BB0A2FC" unitRef="usd">12212025</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-47DF67EADC3F2A39C225F07FF6075429" unitRef="usd">12212025</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-58EBE1C1EF300CDB8D21EB4537343610" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-B4B70753621343E2C3F7EB45AD113C79" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q1YTD" decimals="0" id="Fact-440A9DDAD4D951CBBB2AEEA4854F3846" unitRef="usd">3868419</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q1YTD" decimals="0" id="Fact-049EF773DF785CC48A597BE59597F6BE" unitRef="usd">10659173</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1" decimals="2" id="Fact-4CE4A3D0221A2A2002CAC0CAD2A54034" unitRef="usdPerShare">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_CommonStockWarrantsSeriesAMember" decimals="INF" id="Fact-9D7CBAA8A24F679765ACC0FF51747DD1" unitRef="usdPerShare">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-378FC54800B0AA0AC075C1041B5692D7" unitRef="usdPerShare">750.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-15179A4D8B8B565EA1CAD555D959EDE6" unitRef="usdPerShare">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="FI2017Q1" decimals="INF" id="Fact-1FD3802B8E8C7CB340F4C065F2E960D2" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_CommonStockWarrantsSeriesAMember" decimals="INF" id="Fact-E15CF4018546D9BC6E8CC06DA39C0986" unitRef="shares">1179558</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q1" decimals="INF" id="Fact-1D776E3A3D586A5CEEC0C0F954132301" unitRef="shares">14016608</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_CommonStockWarrantsSeriesAMember" decimals="INF" id="Fact-17D968220438FF4A6A3BC0FD7D325EE2" unitRef="shares">13555887</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_dffn_LegacyRestorGenexWarrantsMember" decimals="INF" id="Fact-DA1B4EA862C544AA9499C0F691FD0545" unitRef="shares">460721</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-090F73C03A056971E7D78BD2BCB6A4E5" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q1" id="Fact-6ED86821B9CC748E6F018BD1E7E27DCF" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-5A11D3E0EBBA5B0CA649122318B88386" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-B548C414AC5A5F2BB23D0CFCBFB9A3E2" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-3ADC25ADD820541C8B562AE283B00BB1" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-6BE0208C0EA25559ADB35EF5E76540B0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-AE7C5AEEE5BE57718440E9C0640DFE9A" unitRef="shares">10345637</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q1" decimals="INF" id="Fact-3B3355F5C03457A3938AD4CA7FA52E5D" unitRef="shares">10345637</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-77F9EF7080C85E789EA3260092F86315" unitRef="shares">10345637</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q1" decimals="INF" id="Fact-52495407CAE25F1D8968219EAF2A07EA" unitRef="shares">10345637</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="0" id="Fact-2C868EA1F8005E56AEF1B8F8CE4E49AD" unitRef="usd">10346</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q1" decimals="0" id="Fact-D33919FA5112584A9B941D2A6E293C20" unitRef="usd">10346</us-gaap:CommonStockValue>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2016Q4" decimals="0" id="Fact-02CF43F5939356B980EC82ECD64396AF" unitRef="usd">1880000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2017Q1" decimals="0" id="Fact-9A8D781B149455E0AD0CCD13F86C5143" unitRef="usd">1880000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-5" id="Fact-ED69B9212BD358EE9FDD7503F30B43C2" unitRef="usd">2600000</us-gaap:ConvertibleDebtFairValueDisclosures>
	<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-5" id="Fact-C4568152A0775FB2BAC8DB1DEC67E2D8" unitRef="usd">3500000</us-gaap:ConvertibleDebtFairValueDisclosures>
	<us-gaap:ConvertibleDebtNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-E46CAFEF409D53C9A2D887193B30ADC5" unitRef="usd">550000</us-gaap:ConvertibleDebtNoncurrent>
	<us-gaap:ConvertibleDebtNoncurrent contextRef="FI2017Q1" decimals="0" id="Fact-CAD637C834F45C37855A2869BE5062E5" unitRef="usd">550000</us-gaap:ConvertibleDebtNoncurrent>
	<us-gaap:ConvertibleLongTermNotesPayable contextRef="FI2017Q1" decimals="-3" id="Fact-195BB0F881880BFF2170C0987A69BD87" unitRef="usd">550000</us-gaap:ConvertibleLongTermNotesPayable>
	<us-gaap:ConvertibleNotesPayable contextRef="FI2017Q1" decimals="-3" id="Fact-35B1276744615BA5968C41020B6F9CF5" unitRef="usd">2430000</us-gaap:ConvertibleNotesPayable>
	<us-gaap:ConvertibleNotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNoteSeriesBMember" decimals="-3" id="Fact-5ED47F93C1F45848B8963B54B8BA7A4F" unitRef="usd">550000</us-gaap:ConvertibleNotesPayable>
	<us-gaap:ConvertibleNotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNotes2016Member" decimals="-3" id="Fact-24AE0014AD135D6CB63C9798F15AEFEE" unitRef="usd">1880000</us-gaap:ConvertibleNotesPayable>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-9FA0F37AC32AE4E32982C098A821FE5D" unitRef="usd">1880000</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-C2D72FB0F4BBFB44F454C063A4226B68" unitRef="shares">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4" decimals="0" id="Fact-E70E9809545D9A95C4F0F4340450F1A0" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_dffn_AccountingStandardsUpdate201609Member" decimals="-3" id="Fact-7079A9E08B229B444381F804B44F29E0" unitRef="usd">-1000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-BCFD8C020A8972234502F4340447F94D" unitRef="usd">1134</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-EC8C334F0E8EE028C19FF434042D1B58" unitRef="usd">-1134</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2016Q1YTD" decimals="0" id="Fact-937235069BF251198B5C42852BE2A01C" unitRef="usd">711495</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q1YTD" decimals="0" id="Fact-DC017C9BCB9D50D2AA7F66651EF7B46B" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="FD2017Q1YTD" decimals="-3" id="Fact-DC0A8F5D167CFD9A2BB1C0A1D839D425" unitRef="usd">-28000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNoteSeriesBMember" decimals="INF" id="Fact-6229FCC4E061570482890F0C349F99D1" unitRef="usdPerShare">2.74</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNotes2016Member" decimals="INF" id="Fact-A7A0CC6D84F0545290DB7E678FEE5F8C" unitRef="usdPerShare">3.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNoteSeriesBMember" decimals="INF" id="Fact-1A9647F9262C596581E2AA4BB852B506" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_dffn_ConvertibleNotes2016Member" decimals="INF" id="Fact-E992F1A99E1C59C1B979B6912A5D8A92" unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredOfferingCosts contextRef="FI2016Q4" decimals="-5" id="Fact-0EE9FBD49EF1D970F912C08293F2746D" unitRef="usd">200000</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-9F0C08A2EC0654CE971AB580E0B0D73C" unitRef="usd">3279363</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q1" decimals="0" id="Fact-F0E3F52D42DC53B3B87551804C2CCA38" unitRef="usd">3279363</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DepreciationNonproduction contextRef="FD2016Q1YTD" decimals="0" id="Fact-9F17E1D6A1FB54BEB2D9ECAE8E6D1446" unitRef="usd">7853</us-gaap:DepreciationNonproduction>
	<us-gaap:DepreciationNonproduction contextRef="FD2017Q1YTD" decimals="0" id="Fact-D2379A96879A5BF3B971205A4DF00B9C" unitRef="usd">6603</us-gaap:DepreciationNonproduction>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-E6E829C2B3A67F352B8FF878C1BFF9AF" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-05B3FE5C51E7EEC236FEF7D8E1F94996" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-91EB7B19F3FF8EC5EE1AF7D8E37D4F06" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-BC1685D8ABF3F2D9C133F9126FF2A098" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-C62F930767941D2B18A3F878C1BCCF40" unitRef="usd">48145520</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-D187FD51AC6A13CADD9CF7D6B7AEA6F5" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-96F5F1C64F0EAD76C047F7D6B9297CA6" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-C0B84F18F68A7848C305F9115588D5CC" unitRef="usd">48145520</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-422477C2E7BC44885290EB319B4EC623" unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
	<us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-2DC14FD737550A20341FC0BE8450577A" unitRef="usd">59000</us-gaap:DividendsPayableCurrentAndNoncurrent>
	<us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="FI2017Q1" decimals="0" id="Fact-FD360821478286DDB38FEB3030894495" unitRef="usd">58845</us-gaap:DividendsPayableCurrentAndNoncurrent>
	<us-gaap:DividendsPreferredStock contextRef="FD2017Q1YTD" decimals="0" id="Fact-B71BFE43607E0A77ABCC8C246AC9F05B" unitRef="usd">58845</us-gaap:DividendsPreferredStock>
	<us-gaap:DividendsPreferredStock contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-0E6892E3F22C7FB2990A8C2442F071C9" unitRef="usd">58845</us-gaap:DividendsPreferredStock>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1YTD" decimals="2" id="Fact-51DA006BCFEA5F84A8A57CD78B306BCF" unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1YTD" decimals="2" id="Fact-AD2AC4D6DD2F50A9B79F070E73015754" unitRef="usdPerShare">-2.78</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q1" decimals="-5" id="Fact-FBC106C4622E5454A073132F5D68725A" unitRef="usd">2900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q1_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="-3" id="Fact-DAF9CD3645EA82294F05C1A1D543D5C4" unitRef="usd">65000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q1YTD" id="Fact-3D8BE12B6252576A915CCD83CDD6C19E">P5Y310D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" id="Fact-AA520D41444ADD182CF2C1A2B23E84BD">P2Y0M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" id="Fact-EA4497944320F37A0533C1629927F1D3">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-BB44A5EAA0A4DC690E14C16235B98ECB" unitRef="usd">15000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q1YTD" decimals="0" id="Fact-68A742314D3D405CE4C9FE3F1C97BD19" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q1YTD" decimals="0" id="Fact-ADD251854450CE70E258FE3E2C7D810F" unitRef="usd">12919674</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-96829CCAE67F5E54B5B6F804D454F940" unitRef="usdPerShare">2.22</us-gaap:FairValueAssumptionsExercisePrice>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q1YTD" id="Fact-108D0F1E95813745801DF803DA351409">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD" decimals="3" id="Fact-A8F7BF7DE7D8210B55F2F7FF90CC6A5B" unitRef="number">1.270</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD" decimals="3" id="Fact-4CF554706CC55A8014B7F80534C7D050" unitRef="number">0.021</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsWeightedAverageExpectedDividend contextRef="FD2017Q1YTD" decimals="INF" id="Fact-60D1CE2B2A18E0D69B6EF8062BDB3384" unitRef="usdPerShare">0</us-gaap:FairValueAssumptionsWeightedAverageExpectedDividend>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dffn_CommonStockWarrantsSeriesAMember" decimals="0" id="Fact-720DEC273D46CA72D39BF7F632B4E4BF" unitRef="usd">35225846</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="FD2017Q1YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-922A801E795E5861ADC8F7F1BF3FD15E" unitRef="usd">12919674</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-AC9E047DD81186A12456F7E27F09FC65" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-E6DE778B2FB49E0FD4DEF7E29E3ED16C" unitRef="usd">48145520</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueOfAssetsAcquired contextRef="FD2016Q1YTD" decimals="0" id="Fact-C521CB59723A561C8D5FE0E53DEF41FA" unitRef="usd">21261000</us-gaap:FairValueOfAssetsAcquired>
	<us-gaap:FairValueOfAssetsAcquired contextRef="FD2017Q1YTD" decimals="0" id="Fact-BC3DAA659E44598AA69CBB029851BA50" unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4" decimals="0" id="Fact-323F1849592A52CAA8D0BBCEECFB1C0C" unitRef="usd">8639000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1" decimals="0" id="Fact-72B4EFE1951255B1B795A505B2DFD493" unitRef="usd">8639000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q1YTD" decimals="0" id="Fact-B47EB3022C5C523FADFF28538971A820" unitRef="usd">3862484</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1YTD" decimals="0" id="Fact-4B9AA246C7A1590F9A8C476837D266FC" unitRef="usd">1553139</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="0" id="Fact-AAF8A825E22251D0B5741A40CD9C84F0" unitRef="usd">6929258</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q1" decimals="0" id="Fact-B386E975AEDA5E9393BE80383DDD9313" unitRef="usd">6929258</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember" decimals="0" id="Fact-3A3F2CF2BC2252A1AE1546DA69ED4F75" unitRef="usd">6929258</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2016Q1SD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES529Member" decimals="-5" id="Fact-1EA477A97B78EA2A86B2C08038CAA255" unitRef="usd">6900000</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2017Q1YTD" decimals="INF" id="Fact-C7DE83CBF8C5005C5510EAFFCA203F96" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2017Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES529Member" decimals="INF" id="Fact-5FAB9FA10C0A7FF9D702EAFEB9AB133B" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q1YTD" decimals="0" id="Fact-210616252E4D5ED9A9B7CC69F2D1B996" unitRef="usd">797827</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q1YTD" decimals="0" id="Fact-81234C40E79A51848A794EA0150C4865" unitRef="usd">-1123303</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q1YTD" decimals="0" id="Fact-22C88095AF2157FCB00FED4D645EC3B1" unitRef="usd">97058</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q1YTD" decimals="0" id="Fact-3B84C5FB37A35B09AA85A78BD54466A0" unitRef="usd">99737</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES440Member" decimals="-5" id="Fact-1BD75852C62316234E10EAFB3357BF56" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="I2016Q1SD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES440Member" decimals="-5" id="Fact-CB726D998315A09DCD70EAF8D34229B2" unitRef="usd">1000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="I2016Q1SD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dffn_RES529Member" decimals="-5" id="Fact-E0EDC1C3E09FD0A6AF11C07F06F27656" unitRef="usd">8600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2016Q1YTD" decimals="0" id="Fact-A478687FA1EA5682B3C0A1B4BF732270" unitRef="usd">21</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q1YTD" decimals="0" id="Fact-248B82DAB00C5F86BF66078251C479FA" unitRef="usd">55719</us-gaap:InterestExpense>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q4" decimals="0" id="Fact-3BD4177A61D95AAF96CA7BF5921E902C" unitRef="usd">29359</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2017Q1" decimals="0" id="Fact-8311F8008099545092155D386B20B505" unitRef="usd">57173</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-458246B67DCFC035F0AAC09E5425863F" unitRef="usd">90000</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2016Q1YTD" decimals="0" id="Fact-B82F8C1EA30757BCA4A3B392109F4526" unitRef="usd">487500</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2017Q1YTD" decimals="0" id="Fact-642504B6E2EE5AB1A710F4BF77E82D0A" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="0" id="Fact-2994D1E030CA5D92ADE80B7C94D6ED2C" unitRef="usd">8299700</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q1" decimals="0" id="Fact-0221B2F03DD55793A0725EE40363EA2A" unitRef="usd">55462082</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="0" id="Fact-B2DE961E0E4B57B490A2CBCAFBB18DD1" unitRef="usd">17484384</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q1" decimals="0" id="Fact-14A9A7D0830E5FD8877BC514C0A5B53A" unitRef="usd">36343543</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-ECAE9C5CF6645CBFB082219C57D0A84D" unitRef="usd">4438422</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-07691640DB6655BFB4D15EFC36043A8C" unitRef="usd">51599412</us-gaap:LiabilitiesCurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q1YTD" decimals="0" id="Fact-BF61E95AF2C55DF2A71098275088FFE3" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1YTD" decimals="0" id="Fact-2211C31C42795C2E872EBAAB8341539C" unitRef="usd">14081446</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q1YTD" decimals="0" id="Fact-34645D8758635435907FE22DA9B9CEA2" unitRef="usd">8498608</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1YTD" decimals="0" id="Fact-D803E8C0B1345893B6C0DF4092B95170" unitRef="usd">-6372</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q1YTD" decimals="0" id="Fact-253B1D7B949A56499DC77EE11CFBCBF0" unitRef="usd">-4630189</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1YTD" decimals="0" id="Fact-B13686849C1354ABA8BF167CACB9B251" unitRef="usd">-3415901</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1YTD" decimals="0" id="Fact-D47A7CCA4EAD5EA1B7E13D911481FB3A" unitRef="usd">-6223165</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD" decimals="0" id="Fact-E445A61B2880535EB0EDD6577D7C6C6D" unitRef="usd">-28638778</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-50438EBA6D2FF67F31128C029FEAB176" unitRef="usd">-28638778</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q1YTD" decimals="0" id="Fact-4C16B71BFD0D9DC78B3FC03FD9095830" unitRef="usd">-6223165</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q1YTD" decimals="0" id="Fact-7BF6BCFE14D6F3BA5B9CC03CFCAC754A" unitRef="usd">-28697623</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1YTD" decimals="0" id="Fact-C3658B3B7A665EFC91D6CB7F3DE93374" unitRef="usd">-6223144</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1YTD" decimals="0" id="Fact-1BDAFD558A4450478736753DC1856B51" unitRef="usd">-2567313</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q1" decimals="0" id="Fact-FEDB944C62D5FEB519E2C12336971B7E" unitRef="usd">575470</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q1" decimals="0" id="Fact-7F8D98D9F54E991D6508C121B2A3CD46" unitRef="usd">118519</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q1" decimals="0" id="Fact-FA5B062A992CD81FBC8BC1214D85C449" unitRef="usd">116464</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q1" decimals="0" id="Fact-569E49BBCC18F8C6FB33C12105C46342" unitRef="usd">114409</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q1" decimals="0" id="Fact-338338993963D66381FFC120900D6617" unitRef="usd">112354</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2017Q1" decimals="0" id="Fact-F5BC1DC8F752F5860578C1225FCC01B0" unitRef="usd">39735</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2017Q1" decimals="0" id="Fact-4A9AFF2E4B6645105AC9C12031ED3A0C" unitRef="usd">73989</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q1YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_StatementGeographicalAxis_dffn_CharlottesvilleVirginiaMember" decimals="-3" id="Fact-4437D48D50A1A13C4FAFEB440B6A9AC2" unitRef="usd">17000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q1YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_StatementGeographicalAxis_dffn_CharlottesvilleVirginiaMember" decimals="-3" id="Fact-CE79D18CF81B5BDD9050FAA3439AC8CA" unitRef="usd">17000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-A38D2B73EE87533A9F25462FAE1564EE" unitRef="usd">874264</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-2F247A45F853574B9151FA9CA75ECA48" unitRef="usd">1016263</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-5BFDB2DD849F58B3B7F802AD785B1C59" unitRef="usd">232675</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q1" decimals="0" id="Fact-CD1A1788A82A5E1292C7A13611C0E250" unitRef="usd">63815</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-99AF56586D2B5AF4BC008255838F7A26" unitRef="usd">31915</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q1" decimals="0" id="Fact-29AEA3DED0E35C14A07E85B00D66FE67" unitRef="usd">33307</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingExpense contextRef="FD2016Q1YTD" decimals="0" id="Fact-5A7A06F2EC7ED4661946FE4592B18108" unitRef="usd">0</us-gaap:OtherNonoperatingExpense>
	<us-gaap:OtherNonoperatingExpense contextRef="FD2017Q1YTD" decimals="0" id="Fact-79E9996FC17B38679C33FE454288F87A" unitRef="usd">2870226</us-gaap:OtherNonoperatingExpense>
	<us-gaap:OtherSundryLiabilitiesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-580DF7D0388859D28FC83DFD8B99B7E4" unitRef="usd">151332</us-gaap:OtherSundryLiabilitiesCurrent>
	<us-gaap:OtherSundryLiabilitiesCurrent contextRef="FI2017Q1" decimals="0" id="Fact-B58ABFE1387957A0B9359197DB41F55B" unitRef="usd">233149</us-gaap:OtherSundryLiabilitiesCurrent>
	<us-gaap:PaymentsForFees contextRef="D2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember_us-gaap_NatureOfExpenseAxis_dffn_SuccessFeeAgreementCostsMember" decimals="-5" id="Fact-CD8C891AFBC95F44861DCC1B4EDCE040" unitRef="usd">1100000</us-gaap:PaymentsForFees>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q1YTD" decimals="0" id="Fact-FB279F781B9DF08599539238A8D0796E" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q1YTD" decimals="0" id="Fact-D184E9B71C04ED5E53D4C045696B8E8B" unitRef="usd">187649</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q1YTD" decimals="0" id="Fact-F0CD442DD60152A682C6941EEFD83EE4" unitRef="usd">1994</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1YTD" decimals="0" id="Fact-4E98B65837A950CE8698C521A617CE91" unitRef="usd">6372</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="D2017Q1Mar1-31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-6BC7E5BE0E53ED7A3487C0BAF5275FB9" unitRef="number">0.08</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="D2017Q2Apr3_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-DA8B82CECA8728EBB2DAEED1E2D9C0E2" unitRef="usd">8300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2016Q1YTD" decimals="0" id="Fact-030A7E99313E37D91DA08C39032A77FA" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2017Q1YTD" decimals="0" id="Fact-59D8BDFAA3493673CF5B8C38B5B8B425" unitRef="usd">14269095</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="0" id="Fact-9501A7889E0F5D5C911D30B41AA29866" unitRef="usd">79755</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q1" decimals="0" id="Fact-5370BEF4364F5680B9F500BE36439248" unitRef="usd">79524</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1YTD" decimals="0" id="Fact-88FF0562C2D85F2CAADB9E4D2A70C682" unitRef="usd">2352807</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1YTD" decimals="0" id="Fact-4C66482694DB5D3FB24CA56CEE258AE3" unitRef="usd">1007571</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="0" id="Fact-C291C0E5F267511FB0591583FFD21676" unitRef="usd">-60189237</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q1" decimals="0" id="Fact-75906ECC67D65FA6B84C96BE4B4F9C06" unitRef="usd">-88829149</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SeveranceCosts1 contextRef="D2016Q1SD_us-gaap_TitleOfIndividualAxis_dffn_ExecutiveOfficersMember" decimals="-5" id="Fact-B0499CF4E2AA51E28EB94C8EB979A19B" unitRef="usd">3000000</us-gaap:SeveranceCosts1>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q1YTD" decimals="0" id="Fact-E18101C5879D53BBA347445381E48FD4" unitRef="usd">393471</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1YTD" decimals="0" id="Fact-111DB591A3025FE0BBCBCC54941CC193" unitRef="usd">366383</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-96DFD17392C242B174FAC161037B7B5C" unitRef="shares">7665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-C4D31959A05DAA42B59CC19672F2FB34" unitRef="usdPerShare">2.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-D1551459AF9362DC5281C1617016B4AE" unitRef="shares">1533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q1YTD" decimals="INF" id="Fact-C288A55AB675C4FC7156C15F670D98BF" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="INF" id="Fact-C8DD7FA225577CBD49EFC19503CE3DA5" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD" decimals="3" id="Fact-FF005CE3C5B656E7B0A63F5ED4DC2291" unitRef="number">1.252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="3" id="Fact-A9D4CD3C2A6E9C2793FCC1930894FEFD" unitRef="number">1.364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD" decimals="3" id="Fact-A5BF7A7567ED5B3891241CC700EAC2D7" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="3" id="Fact-2750ACA79208D0E5F6B6C19413AF9BF8" unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q1Jan1_us-gaap_PlanNameAxis_dffn_RestorgenexCorporation2015EquityIncentivePlanMember" decimals="INF" id="Fact-839B7AD6989730C125D0C15C5D992771" unitRef="shares">413825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q1_us-gaap_PlanNameAxis_dffn_RestorgenexCorporation2015EquityIncentivePlanMember" decimals="INF" id="Fact-8A270ECDB91D57A8B67C847ADA1F3814" unitRef="shares">356148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q1" decimals="INF" id="Fact-8D0E12DFB3B25BC5BC1DEB60C4E0626F" unitRef="shares">1548216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-CFFA2B7B2AB35D87AEDE69DA2D9F2F79" unitRef="usdPerShare">9.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2017Q1YTD" decimals="INF" id="Fact-1B85CE06A26C3EF60E67C15D88138093" unitRef="shares">1461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q1YTD" decimals="INF" id="Fact-9E44F919FC7250FBAC563198D2750F50" unitRef="shares">98184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="INF" id="Fact-6B8E8BA5383FC4FEFF95C18C2BC8E9B3" unitRef="shares">9394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-F7294E7F3F4D5CE998685FB571A0F29B" unitRef="shares">2207409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q1" decimals="INF" id="Fact-AFCE25581E1A5F0293310250ADA1E264" unitRef="shares">2304132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-619AAE1D8D6A57CBB63CACCA5F771F0D" unitRef="usdPerShare">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-7623EAE92C725DD3AC7B2FFD44A37F0B" unitRef="usdPerShare">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD" decimals="2" id="Fact-5B76F1149C56D00FD091C15DF46FE8D6" unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD" decimals="2" id="Fact-A3DD0D6236D852A4AF8C1E427B51A2B0" unitRef="usdPerShare">2.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q1YTD" id="Fact-25E7D04BF32D55E58333643CC1E712ED">P5Y281D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q1YTD" id="Fact-1DE0ED52DEFA53438F77F4ED7942DB5B">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2017Q1_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="INF" id="Fact-FF9FED4B808CE0185C5FC18F5AAF7411" unitRef="shares">27561</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q1YTD" id="Fact-4146260491955718AC6B176998559D3D">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="-5" id="Fact-DA4BE489689F8A5F1F2AC19CD9D175AC" unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-C12725C187311F289633C19DA7796DEF" unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_dffn_NonemployeeOptionsMember" decimals="-3" id="Fact-2DD11D6E69FE67B717E7C19C7529CDA7" unitRef="usd">53000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-BDE81661EF0B1107BB80C19D5E5BE935" unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-34CAD56C44215600A8D78863734A973B" unitRef="shares">10345637</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F866DE3F0FED54CC97C2A57BA1EFC774" unitRef="shares">10345637</us-gaap:SharesOutstanding>
	<us-gaap:StockIssued1 contextRef="FD2016Q1YTD" decimals="0" id="Fact-1794D93E8838078D219B8C4EED69A1E4" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2017Q1YTD" decimals="0" id="Fact-4A34857430F90EFBAF858C4E9E5EFA7E" unitRef="usd">8280935</us-gaap:StockIssued1>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember_us-gaap_NatureOfExpenseAxis_dffn_SuccessFeeAgreementCostsMember" decimals="-3" id="Fact-F4AFE4EBC7C951B0928AAE9FCC37BD12" unitRef="shares">46000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="D2016Q1SD_us-gaap_BusinessAcquisitionAxis_dffn_DiffusionLLCMember_us-gaap_NatureOfExpenseAxis_dffn_SuccessFeeAgreementCostsMember" decimals="-5" id="Fact-9608E5FC57E153D4A9B5718D53837945" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="0" id="Fact-CE41C11194985CA18598945ABDDC4ABC" unitRef="usd">9184684</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-63B22EAB20725DE3B273571279604B5B" unitRef="usd">69363575</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-EF45EDECCDBA52ADBBA7A7095C298E0A" unitRef="usd">10346</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-253DA57362535A8887B54E5D96D47E33" unitRef="usd">-60189237</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1" decimals="0" id="Fact-375E3BB78B2F56AFB879855050F91597" unitRef="usd">-19118539</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-39EAA16AB0AC5B9E8EBA8DCF3A6774B2" unitRef="usd">69700264</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-889F525B922B5B539B79436A5CD72A0E" unitRef="usd">10346</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-55CD7149EB5A5DE7B738DEEDF9B3E6A0" unitRef="usd">-88829149</us-gaap:StockholdersEquity>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4" decimals="0" id="Fact-60E16BEEEE691C97899C8BE4AE93D099" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q1" decimals="0" id="Fact-7EDDAF4F93138C4D8F3A8BE471F99182" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityDividendsAdjustment contextRef="FD2016Q1YTD" decimals="0" id="Fact-4F13F951FC0FBA720ADDC03B615E4630" unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
	<us-gaap:TemporaryEquityDividendsAdjustment contextRef="FD2017Q1YTD" decimals="0" id="Fact-BA3B183313337A737979C03B14BE6C4E" unitRef="usd">58845</us-gaap:TemporaryEquityDividendsAdjustment>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q1" decimals="0" id="Fact-4FF866B67ECCCFBD2AB08BEF7A5804C0" unitRef="usd">25000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-F3FC8C71D5C4DCC878BFEB25CC49D256" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityRedemptionPricePerShare contextRef="FI2017Q1_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_dffn_ConversionofPreferredStockMember" decimals="2" id="Fact-FEBBA913FFD0734BF894C12FAAAEC514" unitRef="usdPerShare">2.02</us-gaap:TemporaryEquityRedemptionPricePerShare>
	<us-gaap:TemporaryEquityRedemptionPricePerShare contextRef="FI2017Q1_us-gaap_SubsidiarySaleOfStockAxis_dffn_ConversionofPreferredStockMember" decimals="2" id="Fact-A188118AC52D8A811C3EC0C989A5C1F6" unitRef="usdPerShare">2.02</us-gaap:TemporaryEquityRedemptionPricePerShare>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-70A1D5E094A2E76B78558BEDB6FD7CB5" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-20D07CA88D7DC716BF97C037C2D3F4F0" unitRef="shares">13750000</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-F0CBB57AA7C7092DD81C8BEE118BE7C4" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q1" decimals="INF" id="Fact-B995B26F6757C3361FEBC037C3742056" unitRef="shares">12376329</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-F2685AE07F97F2FD96998BEE978DC6E9" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q1" decimals="INF" id="Fact-355CAA09F19BCECF8120C037C41BB99B" unitRef="shares">12376329</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable contextRef="FI2016Q4" decimals="0" id="Fact-8D62FDC82F53823A315F8BB677DEA6F7" unitRef="usd">0</us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable>
	<us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable contextRef="FI2017Q1" decimals="0" id="Fact-7F73EC7D42A23D9ADCC88BB61D6A1153" unitRef="usd">8280935</us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable>
	<us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-5" id="Fact-4F1E6B7934A91CA8D112C060583B1F7B" unitRef="usd">8300000</us-gaap:TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q1YTD" decimals="0" id="Fact-D5227634D6EBF6EDA7238C1299B2C671" unitRef="usd">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="FI2016Q4" decimals="INF" id="Fact-5FD509FAC1C8C41A36AFF83A34C6389D" unitRef="usd">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
	<us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="FI2017Q1" decimals="INF" id="Fact-4ED49129ADD3E15D4CE7F83A34CCAB2D" unitRef="usd">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q1YTD" decimals="0" id="Fact-EED6371680DC5CF591811440D79A1D94" unitRef="shares">9996381</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1YTD" decimals="0" id="Fact-FCBEDAEB14865C878B8FC20B6DAE7D45" unitRef="shares">10337726</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock contextRef="FD2017Q1YTD" id="Fact-8EE277DE58F4571BA1DA449CA9FC1469">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The purchase price was calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of RestorGenex shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,546,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated fair value of RestorGenex stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,321,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated fair value of RestorGenex warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;384,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;CVRs &amp;#8211; RES-440 product candidate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,261,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock>
	<dffn:OfferingCostsPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-4EFD023D961D8F0E17F28CD13AB9BA29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Offering Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company&amp;#8217;s private placement financing and are recognized in other assets on the consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</dffn:OfferingCostsPolicyPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-C4785FA6BD12540F9AC544EA0C9FA91C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited interim&amp;#160;condensed consolidated&amp;#160;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information as found in the Accounting Standard Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Updates (&amp;#8220;ASUs&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;), and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). In the opinion of management, the accompanying&amp;#160;unaudited interim condensed consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&amp;#8217;s financial position as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, its results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Operating results for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The unaudited interim&amp;#160;condensed consolidated&amp;#160;financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying&amp;#160;unaudited interim condensed consolidated&amp;#160;financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; filed with the SEC on Form 10-K on March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2017Q1YTD" id="Fact-EF3CA5C18B8455E9B6029BD5F33AC884">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,655,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-B98B1078EA825F84BB13D250E158F5AB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;4.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Acquisition&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Reverse Merger with RestorGenex&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 8, 2016, the Company completed a reverse merger transaction with RestorGenex. The Company entered into the Merger transaction in an effort to provide improved access to the capital markets in order to obtain the resources necessary to accelerate development of TSC in multiple clinical programs and continue to build an oncology-focused company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The purchase price was calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of RestorGenex shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,546,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated fair value of RestorGenex stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,321,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated fair value of RestorGenex warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;384,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;CVRs &amp;#8211; RES-440 product candidate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,261,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The reverse merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&amp;amp;D was the cost approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,500,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;195,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,600,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,929,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(377,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,644,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,261,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Qualitative factors supporting the recognition of goodwill due to the reverse merger transaction include the Company&amp;#8217;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the reverse merger transaction to the Company&amp;#8217;s later state product portfolio. The goodwill is not deductible for income tax purposes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro Forma Financial Information (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following pro forma financial information reflects the condensed consolidated results of operations of the Company as if the acquisition of RestorGenex had taken place on January 1, 2016. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,655,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-recurring pro forma transaction costs directly attributable to the Merger were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; March&amp;#160;31, 2016 and have been deducted from the net loss presented above. The costs deducted from the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; March&amp;#160;31, 2016 period includes a success fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock with a fair market value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; paid to a financial adviser upon the closing of the Merger on January 8, 2016. Additionally, RestorGenex  incurred approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in severance costs as a result of resignations of executive officers immediately prior to the Merger and approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in share based compensation expense as a result of the acceleration of vesting of stock options at the time of the Merger. These costs are excluded from the pro forma financial information for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; March&amp;#160;31, 2016. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; such costs were recorded in the three months ended March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-B1B284A665A25DEEA947A36A731089E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;9.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Office Space Rental&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company leases office and laboratory facilities in Charlottesville, Virginia under a month-to-month cancelable operating lease. Rent expense related to the operating lease was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. On March 31, 2017, the Company entered into a lease for its office and laboratory facilities at a new location in Charlottesville, Virginia. Lease payments commence on May 1, 2017 and expire on April 30, 2022. The company will recognize rent expense on a straight-line basis over the lease period and will accrue for rent expense incurred but not yet paid. Future minimum rental payments under the Company's new noncancelable operating lease at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rental Commitments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;575,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company&amp;#8217;s former Chief Executive Officer under the caption &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Paul Feller v. RestorGenex Corporation, Pro Sports &amp;amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&amp;#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&amp;#8217;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on April 14, 2015, the Court granted the Company&amp;#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. No arbitration hearing has yet been scheduled. The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&amp;#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&amp;#8217;s financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConvertibleDebtTableTextBlock contextRef="FD2017Q1YTD" id="Fact-73DE3BC4572B563AAEA88BCB04E6027E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides the details of the convertible debt outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Note&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Issue&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Conversion&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Principal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016 Convertible Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9/27/2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9/27/2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,880,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series B Note&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/15/2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6/30/2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,430,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion of convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,880,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible notes, net of current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-BFCA26C20E4859E0AA443EB22F4D2C1F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;6.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Convertible Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides the details of the convertible debt outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Note&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Issue&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Conversion&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Principal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016 Convertible Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9/27/2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9/27/2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,880,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series B Note&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/15/2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6/30/2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,430,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion of convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,880,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible notes, net of current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The current and noncurrent portions of accrued interest related to the Company&amp;#8217;s Convertible Notes and 2016 Convertible Notes are included within other accrued expenses and liabilities and other liabilities, respectively, within the unaudited condensed consolidated balance sheets. As of March 31, 2017, the Company had accrued interest of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$90,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  During the three months ended March 31, 2017, the Company recorded noncash interest expense of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$28,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with a beneficial conversion feature associated with accrued interest that may be converted into shares of common stock&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q1YTD" id="Fact-601A41CDCA2F5098ADCE8F4632A12367">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;8.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2015 Equity Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Diffusion Pharmaceuticals Inc. 2015 Equity Plan, as amended (the "2015 Equity Plan"), provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total shares of the Company&amp;#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the board of directors. Accordingly, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;413,825&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were added to the reserve as of January 1, 2017, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;356,148&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock available for future issuance under the 2015 Equity Plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;242,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;323,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;366,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;393,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the activity related to all stock option grants to employees and non-employees for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;exercise price&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;contractual life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,207,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,304,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,548,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Non-employee Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. During the three months ended March 31, 2017, the Company granted &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,394&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stock options to non-employees. Key assumptions used to estimate the fair value of the non-employee stock options granted during the three months ended March 31, 2017 included a risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an expected volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136.4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; expected dividend yield and an expected term equal to the remaining contractual option term. The total fair value of non-employee stock options vested during the three months ended March 31, 2017 and 2016 was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$53,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. At March 31, 2017, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,561&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unvested options subject to remeasurement and approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$65,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense that will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.0 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Employee Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant date fair value of stock option awards granted to employees was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three months ended March 31, 2017. The total fair value of options vested during the three months ended March 31, 2017 and 2016 was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. No options were exercised during any of the periods presented.  At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense that will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three months of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:90%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock Awards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,665&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unvested shares of restricted stock. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,533&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares that vested and the Company recognized stock-based compensation expense of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense that will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-5677ABB96A7C5A81B94E5B26257B1665">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q1YTD" id="Fact-C5820D9612915E7BB3506D69D35E80FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;10.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2&amp;#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The asset&amp;#8217;s or liability&amp;#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,212,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,145,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,552,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued in connection with the Series A convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,225,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,919,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,145,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The common stock warrants issued in connection with the Series A convertible preferred stock are classified as liabilities on the accompanying balance sheet at March 31, 2017. The liability is marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the liability to be reclassified to stockholders&amp;#8217; equity (deficit). The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrants granted during the first three months of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:90%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="FD2017Q1YTD" id="Fact-164520FCF8279F8194BAF7FD8321F89B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrants granted during the first three months of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:90%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q1YTD" id="Fact-DB843D868A3D7AF0BC07F7E0FEF80B4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued in connection with the Series A convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,225,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,919,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,145,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q1YTD" id="Fact-E7FDA06854255CA5BB324E5A60D0B5A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2017Q1YTD" id="Fact-1F5F786931BD5694A9158C9D046A0C77">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, the Company acquired RES-529 and RES-440, respectively, an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; indefinite-lived In-Process Research and Development Asset (&amp;#8220;IPR&amp;amp;D&amp;#8221;) and recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in goodwill. In the third quarter of 2016, the IPR&amp;amp;D asset associated with RES-440 was abandoned and written down to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. RES-529 and goodwill are assessed for impairment on October 1 of the Company&amp;#8217;s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:NatureOfOperations contextRef="FD2017Q1YTD" id="Fact-C002A80F0C195C63A6101458AC586FE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:621px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diffusion Pharmaceuticals Inc. (&amp;#8220;Diffusion&amp;#8221; or the &amp;#8220;Company&amp;#8221;), a Delaware Corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company&amp;#8217;s lead product candidate, trans sodium crocetinate (&amp;#8220;TSC&amp;#8221;), uses a novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby enhancing tumor cells&amp;#8217; response to conventional treatment without additional side effects. TSC has received orphan drug designations for the treatment of glioblastoma multiforme (&amp;#8220;GBM&amp;#8221;) and metastatic brain cancer. The Company expects to enter a Phase III study in newly diagnosed GBM patients in the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 8, 2016, the Company completed a reverse merger (the Merger") with RestorGenex Corporation (&amp;#8220;RestorGenex&amp;#8221;) whereby the Company was considered the acquirer for accounting purposes.  The operational activity of RestorGenex is included in the Company&amp;#8217;s consolidated financial statements from the date of acquisition. Accordingly, all comparative period information presented in these unaudited condensed consolidated financial statements from January 1, 2016 through January 7, 2016 exclude any activity related to RestorGenex.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-125573A5958E5AC9AB9FAE8C09C83523">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March&amp;#160;2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2016 and interim periods within those years. The Company adopted this standard in 2017 by electing to account for forfeitures in the period that they occur. Under ASU 2016-09, accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cumulative-effect adjustment on January 1, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&amp;#160;15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="FD2017Q1YTD" id="Fact-885E84DF21265E2A9BEC79191ECA0681">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses and liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued Series A dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll and payroll related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;135,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;399,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;185,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical studies expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,861&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;233,149&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,016,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;874,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
	<us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-2C29A40FFD445038852D9F3893F25D02">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;5.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Other Accrued Expenses and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses and liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued Series A dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll and payroll related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;135,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;399,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;185,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical studies expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,861&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;233,149&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,016,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;874,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q1YTD" id="Fact-7CBA7D4E5C7E537394414D91A4E4B03A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following potentially dilutive securities outstanding as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;766,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;428,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,376,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,016,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;477,688&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,304,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,796,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock awards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,471,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,715,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q1YTD" id="Fact-CA046EC1DCBD5EF0BBFDE1AA86D68E65">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;242,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;323,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;366,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;393,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2017Q1YTD" id="Fact-3B207E9C8164565288B5CF98A7672F33">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,212,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,145,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,552,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q1YTD" id="Fact-D29E478D82FB5ECEA184E8BE1302DFC3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum rental payments under the Company's new noncancelable operating lease at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rental Commitments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;575,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2017Q1YTD" id="Fact-C18867BA96705C709B21A59BDF17485B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,500,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;195,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,600,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,929,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(377,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,644,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,261,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q1YTD" id="Fact-A5C5923575835184B9F37DC6B66CA324">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the activity related to all stock option grants to employees and non-employees for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;exercise price&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;contractual life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,207,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,304,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,548,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-6E4E36A71F1D5ACEA1D5A9EAFD8CE751">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three months of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:90%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2017Q1YTD" id="Fact-30A7A472AFC3A024D07EC0DCDD401EBE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2017, the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range of exercise price per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants issued prior to Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;460,721&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.00 - $750.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants issued in Series A &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,555,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,016,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q1YTD" id="Fact-87FAC7094E8753BDAE30603736815175">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:621px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Summary of Significant Accounting Policies included in our Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 31, 2017, as amended to this date, have not materially changed, except as set forth below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited interim&amp;#160;condensed consolidated&amp;#160;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information as found in the Accounting Standard Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Updates (&amp;#8220;ASUs&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;), and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). In the opinion of management, the accompanying&amp;#160;unaudited interim condensed consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&amp;#8217;s financial position as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, its results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Operating results for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The unaudited interim&amp;#160;condensed consolidated&amp;#160;financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying&amp;#160;unaudited interim condensed consolidated&amp;#160;financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; filed with the SEC on Form 10-K on March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period.  Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may materially vary from these estimates.  Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined necessary.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair value of the Company&amp;#8217;s outstanding convertible notes was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Offering Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company&amp;#8217;s private placement financing and are recognized in other assets on the consolidated balance sheet.  At December 31, 2016, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in deferred offering costs. These costs were expensed upon completing the private placement of Series A Preferred Stock and common stock warrants in March 2017.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, the Company acquired RES-529 and RES-440, respectively, an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; indefinite-lived In-Process Research and Development Asset (&amp;#8220;IPR&amp;amp;D&amp;#8221;) and recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in goodwill. In the third quarter of 2016, the IPR&amp;amp;D asset associated with RES-440 was abandoned and written down to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. RES-529 and goodwill are assessed for impairment on October 1 of the Company&amp;#8217;s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment indicators or impairments to RES-529 or goodwill during the three months ended March&amp;#160;31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following potentially dilutive securities outstanding as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;766,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;428,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,376,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,016,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;477,688&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,304,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,796,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock awards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,471,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,715,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts in the table reflect the common stock equivalents of the noted instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March&amp;#160;2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2016 and interim periods within those years. The Company adopted this standard in 2017 by electing to account for forfeitures in the period that they occur. Under ASU 2016-09, accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cumulative-effect adjustment on January 1, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&amp;#160;15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-E52C480E33405A32AA7A61990910EC37">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:622px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;7.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Convertible Preferred Stock and Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In contemplation of completing a private placement, the Company amended and restated its articles of incorporation and authorized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Preferred Stock. The Company has classified its Series A Preferred Stock outside of stockholders&amp;#8217; equity (deficit) because the shares contain deemed liquidation rights that are contingent redemption features not solely within the control of the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:13px;text-indent:-14px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Series&amp;#160;A Convertible Preferred Stock Transaction &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:13px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2017, the Company completed a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; private placement of its securities by offering units consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of the Company&amp;#8217;s Series A Preferred Stock and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share common stock for each share of Series A Preferred Stock purchased in the offering.  Each share of Series A Preferred Stock entitles the holder to an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cumulative dividend payable in shares of our common stock on a semi-annual basis.  The holders may, at their option, convert each share of Series A Preferred Stock into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of the Company&amp;#8217;s common stock based on the initial conversion price of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, subject to adjustment. Each warrant entitles the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of common stock at an initial exercise price of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, subject to adjustment and expires on the fifth anniversary of their original issuance date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon completing the private placement, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,376,329&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units and received approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate net cash proceeds from the private placement, after deducting commissions of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and offering expenses of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of net proceeds on April 3, 2017. In addition, as compensation for its services, the Company granted to its placement agent in the offering warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,179,558&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at an initial exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, which expire on the fifth anniversary of their original issuance date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC 815-40, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging, Contracts in an Entity&amp;#8217;s own Equity&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASC 815-40&amp;#8221;).  The conditions within ASC 815-40 are not subject to a probability assessment. As the Company is obligated to issue a variable number of shares to settle the cumulative Series A preferred dividends, the Company cannot assert there will be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants are classified as liabilities. The Company will continue to classify such warrants as liabilities until they are exercised, expire, or are no longer require to be classified as liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are no proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the Series A offering and the fair value of the warrants granted to its placement agent was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the aggregate and was recorded as warrant related expenses in the statement of operations for the three months ended March 31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Dividends&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company shall pay a cumulative preferential dividend on each share of the Series A Preferred Stock outstanding at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum, payable only in shares of common stock, semi-annually in arrears on April 1 and October 1 of each year commencing on October 1, 2017.  This cumulative preferential dividend is not subject to declaration. The Company accrued approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$59,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in dividends for the three months ended March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Voting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &amp;#8220;Certificate of Designation&amp;#8221;) or as required by law, the holders of the Series A Preferred Stock and common stock vote together on an as-converted basis.  In accordance with NASDAQ listing rules, in any matter voted on by the holders of our common stock, each share of Series A Preferred Stock entitles the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance.  Accordingly, shares of Series A Preferred Stock issued in the initial closing of the private placement on March 14, 2017 are entitled to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.84874&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; votes per share and shares of Series A Preferred Stock issued in the final closing of the private placement on March 31, 2017 are entitled to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.50627&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; votes per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Liquidation Preference&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Series A Preferred Stock is senior to the common stock.  In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A Preferred Stock shall be entitled to receive their original investment amount.  If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution shall be distributed ratably among the holders of the Series A Preferred Stock in proportion to the full amounts to which they would otherwise be entitled.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Conversion&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Series A Preferred Stock is convertible, at the holder&amp;#8217;s option, into common stock.  At the Company&amp;#8217;s option, the Series A convertible preferred stock can be converted into common stock upon (a) the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;thirty&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day moving average of the closing price of the Company&amp;#8217;s common stock exceeding &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, (b) a financing of at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or (c) upon the majority vote of the voting power of the then outstanding shares of Series A convertible preferred stock.  The conversion price of the Series A Preferred Stock is subject to adjustment as described in the Certificate of Designation.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon any conversion, any unpaid dividends shall be payable to the holders of Series A preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Make-Whole Provision&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Until March 2020 and subject to certain exceptions, if the Company issues at least &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its common stock or securities convertible into or exercisable for common stock at a per share price less than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (such lower price, the &amp;#8220;Make-Whole Price&amp;#8221;) while any shares of Series A Preferred Stock remain outstanding, the Company will be required to issue to these holders of Series A Preferred Stock a number of shares of common stock equal to the additional number of shares of common stock that such shares of Series A Preferred Stock would be convertible into if the conversion price of such shares was equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;105%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Make-Whole Price (the &amp;#8220;Make-Whole Adjustment&amp;#8221;). The Make-Whole Adjustment was evaluated and was not required to be bifurcated from the Series A Preferred Stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2017, the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range of exercise price per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants issued prior to Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;460,721&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.00 - $750.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants issued in Series A &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,555,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,016,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants were exercised or expired. The common stock warrants issued prior to the Merger expire periodically through 2019. The common stock warrants issued in connection with the March 2017 Series A private placement expire in March 2022.  During the three months ended March 31, 2017, the Company incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$26.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in warrant related expenses associated with the private placement, which consisted primarily of the change in fair value of the common stock warrants from issuance and the excess fair value of the common stock warrants over the gross cash proceeds of the Series A offering. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="FD2017Q1YTD" id="Fact-EC0CFE9E685C5504A8025D9470A385DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:621px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has not generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its membership units (prior to the Merger), convertible notes and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&amp;#8217;s research and development efforts will be successful.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. In March 2017, the Company completed a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; private placement of its securities by offering units consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of the Company's Series A convertible preferred stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (&amp;#8220;Series A Preferred Stock&amp;#8221;) and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of common stock for each share of Series A Preferred Stock purchased in the offering. The Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,376,329&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units and received approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate net cash proceeds from the private placement, after deducting commissions of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and offering expenses of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of net proceeds on April 3, 2017. In addition, the Company granted to its placement agent in the offering warrants to purchase an aggregate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,179,558&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock as compensation for its services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&amp;#8217;s product candidates become approved drugs and how significant their market share will be. The regulatory approval and market acceptance of the Company&amp;#8217;s proposed future products (if any), length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&amp;#8217;s financial condition and future operations. The Company believes its cash and cash equivalents at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, together with the subscription receivables related to the Series A private placement received in April 2017, are sufficient to fund operations and meet its research and development goals through March 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q1YTD" id="Fact-C1501A74523C1BD97A6AC0848DA4F636">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period.  Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may materially vary from these estimates.  Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined necessary.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-BCFD8C020A8972234502F4340447F94D" xlink:label="Fact-BCFD8C020A8972234502F4340447F94D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E70E9809545D9A95C4F0F4340450F1A0" xlink:label="Fact-E70E9809545D9A95C4F0F4340450F1A0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-EC8C334F0E8EE028C19FF434042D1B58" xlink:label="Fact-EC8C334F0E8EE028C19FF434042D1B58_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BCFD8C020A8972234502F4340447F94D_lbl" xlink:to="Footnote-5F8F7D62FAC8C9491E9AF43357D42BC4_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E70E9809545D9A95C4F0F4340450F1A0_lbl" xlink:to="Footnote-5F8F7D62FAC8C9491E9AF43357D42BC4_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-EC8C334F0E8EE028C19FF434042D1B58_lbl" xlink:to="Footnote-5F8F7D62FAC8C9491E9AF43357D42BC4_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-5F8F7D62FAC8C9491E9AF43357D42BC4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of this standard.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>dffn-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diffusionpharma.com/20170331" xmlns:dffn="http://www.diffusionpharma.com/20170331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisition" roleURI="http://www.diffusionpharma.com/role/Acquisition">
        <link:definition>2103100 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDetailsTextual" roleURI="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual">
        <link:definition>2403405 - Disclosure - Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionProFormaFinancialInformationDetails" roleURI="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails">
        <link:definition>2403404 - Disclosure - Acquisition - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionPurchasePriceConsiderationDetails" roleURI="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails">
        <link:definition>2403402 - Disclosure - Acquisition - Purchase Price Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>2403403 - Disclosure - Acquisition - Summary of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTables" roleURI="http://www.diffusionpharma.com/role/AcquisitionTables">
        <link:definition>2303301 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>2402403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails">
        <link:definition>2402404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingencies">
        <link:definition>2111100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual">
        <link:definition>2411402 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails">
        <link:definition>2411403 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2311301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.diffusionpharma.com/role/ConvertibleDebt">
        <link:definition>2107100 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtDetailsTextual" roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual">
        <link:definition>2407403 - Disclosure - Convertible Debt (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtOutstandingConvertibleNotesDetails" roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails">
        <link:definition>2407402 - Disclosure - Convertible Debt - Outstanding Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtTables">
        <link:definition>2307301 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndCommonStockWarrantsDetails" roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails">
        <link:definition>2409402 - Disclosure - Convertible Preferred Stock and Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndCommonStockWarrantsNotes" roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes">
        <link:definition>2109100 - Disclosure - Convertible Preferred Stock and Common Stock Warrants (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails">
        <link:definition>2409403 - Disclosure - Convertible Preferred Stock and Common Stock Warrants Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockAndCommonStockWarrantsTables" roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables">
        <link:definition>2309301 - Disclosure - Convertible Preferred Stock and Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.diffusionpharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.diffusionpharma.com/role/FairValueMeasurements">
        <link:definition>2112100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueOnRecurringBasisDetails" roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails">
        <link:definition>2412402 - Disclosure - Fair Value Measurements - Fair Value On a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails">
        <link:definition>2412403 - Disclosure - Fair Value Measurements - Schedule of Common Stock Warrant Liability Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfFairValueInputsDetails" roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails">
        <link:definition>2412404 - Disclosure - Fair Value Measurements - Schedule of Fair Value Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2312301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.diffusionpharma.com/role/Liquidity">
        <link:definition>2102100 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityNarrativeDetails" roleURI="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails">
        <link:definition>2402401 - Disclosure - Liquidity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedExpensesAndLiabilities" roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities">
        <link:definition>2104100 - Disclosure - Other Accrued Expenses and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails">
        <link:definition>2404402 - Disclosure - Other Accrued Expenses and Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedExpensesAndLiabilitiesTables" roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables">
        <link:definition>2304301 - Disclosure - Other Accrued Expenses and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.diffusionpharma.com/role/StockBasedCompensation">
        <link:definition>2110100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetailsTextual" roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual">
        <link:definition>2410402 - Disclosure - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails">
        <link:definition>2410405 - Disclosure - Stock-based Compensation - Share-based Payment Award, Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2410404 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>2410403 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationTables">
        <link:definition>2310301 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="dffn_AccountingStandardsUpdate201609Member" name="AccountingStandardsUpdate201609Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" name="BusinessCombinationPreliminaryPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" name="BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" name="BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" name="BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" name="BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" name="BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dffn_CharlottesvilleVirginiaMember" name="CharlottesvilleVirginiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_CommonStockWarrantsSeriesAMember" name="CommonStockWarrantsSeriesAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_ConversionofPreferredStockMember" name="ConversionofPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_ConvertibleNoteSeriesBMember" name="ConvertibleNoteSeriesBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_ConvertibleNotes2016Member" name="ConvertibleNotes2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage" name="ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice" name="ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock" name="ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dffn_ConvertiblePreferredStockNumberofVotesperShare" name="ConvertiblePreferredStockNumberofVotesperShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays" name="ConvertiblePreferredStockThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_DiffusionLLCMember" name="DiffusionLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_FairValueAssumptionsStockPrice" name="FairValueAssumptionsStockPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_LegacyRestorGenexWarrantsMember" name="LegacyRestorGenexWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts" name="NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_NonemployeeOptionsMember" name="NonemployeeOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_OfferingCostsIncurredButNotYetPaid" name="OfferingCostsIncurredButNotYetPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_OfferingCostsPolicyPolicyTextBlock" name="OfferingCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" name="PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_PrepaidExpensesDepositsAndOtherAssets" name="PrepaidExpensesDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="dffn_ProceedsFromReverseMergerTransaction" name="ProceedsFromReverseMergerTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_RES440Member" name="RES440Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_RES529Member" name="RES529Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_RestorGenexMember" name="RestorGenexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" name="RestorgenexCorporation2015EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dffn_SuccessFeeAgreementCostsMember" name="SuccessFeeAgreementCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_TemporaryEquityConsiderationReceived" name="TemporaryEquityConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dffn_TemporaryEquityConsiderationReceivedNet" name="TemporaryEquityConsiderationReceivedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dffn_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dffn_TemporaryEquityOfferingCosts" name="TemporaryEquityOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability" name="WarrantExpenseandFairValueAdjustmentofWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dffn_WarrantRelatedExpense" name="WarrantRelatedExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dffn-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/Acquisition" xlink:href="dffn-20170331.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual" xlink:href="dffn-20170331.xsd#AcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails" xlink:href="dffn-20170331.xsd#AcquisitionProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails" xlink:href="dffn-20170331.xsd#AcquisitionPurchasePriceConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="dffn-20170331.xsd#AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionTables" xlink:href="dffn-20170331.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingencies" xlink:href="dffn-20170331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:href="dffn-20170331.xsd#CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebt" xlink:href="dffn-20170331.xsd#ConvertibleDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual" xlink:href="dffn-20170331.xsd#ConvertibleDebtDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:href="dffn-20170331.xsd#ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtTables" xlink:href="dffn-20170331.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/DocumentAndEntityInformation" xlink:href="dffn-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurements" xlink:href="dffn-20170331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsTables" xlink:href="dffn-20170331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/Liquidity" xlink:href="dffn-20170331.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails" xlink:href="dffn-20170331.xsd#LiquidityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dffn-20170331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensation" xlink:href="dffn-20170331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual" xlink:href="dffn-20170331.xsd#StockBasedCompensationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationTables" xlink:href="dffn-20170331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/Acquisition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_7f62fa88-236f-e848-6e59-5e6fa422c22c" xlink:type="locator" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_35aed13c-e8ed-a9a0-a901-5e6fa42288ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_7f62fa88-236f-e848-6e59-5e6fa422c22c" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_35aed13c-e8ed-a9a0-a901-5e6fa42288ef" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_6c7b0d94-ba9e-ddda-d0ee-5e6fa4236464" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_7f62fa88-236f-e848-6e59-5e6fa422c22c" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_6c7b0d94-ba9e-ddda-d0ee-5e6fa4236464" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_b4e98b2c-6ddf-78bb-2c6b-5e6fa42271d8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_7f62fa88-236f-e848-6e59-5e6fa422c22c" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_b4e98b2c-6ddf-78bb-2c6b-5e6fa42271d8" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_bc8611ae-24cd-15bf-69ac-5e6fa422f6e2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_7f62fa88-236f-e848-6e59-5e6fa422c22c" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_bc8611ae-24cd-15bf-69ac-5e6fa422f6e2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e1978724-efbf-19b9-3963-b8987dc665d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e1978724-efbf-19b9-3963-b8987dc665d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_56c651eb-cb40-cb88-2b7a-85ce69b038b1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_56c651eb-cb40-cb88-2b7a-85ce69b038b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_be07dd0f-4dac-2e35-9d0a-97c001db45cf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_be07dd0f-4dac-2e35-9d0a-97c001db45cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_00bc711a-f441-7a2b-f270-5792bfbbf725" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_00bc711a-f441-7a2b-f270-5792bfbbf725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_6c6005b4-0cc7-65e8-d808-5e6fa4220e3d" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_6c6005b4-0cc7-65e8-d808-5e6fa4220e3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6c0e2cf3-b408-a0fe-d82f-5f58e9301a59" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6c0e2cf3-b408-a0fe-d82f-5f58e9301a59" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1261866d-0058-b147-bcc2-b0839e573baf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1261866d-0058-b147-bcc2-b0839e573baf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d7e45dda-b3de-1974-4726-54d18939cd1c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d7e45dda-b3de-1974-4726-54d18939cd1c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b89e7a90-e5d1-031a-5e13-781005c7ec6e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b89e7a90-e5d1-031a-5e13-781005c7ec6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="loc_dffn_PrepaidExpensesDepositsAndOtherAssets_455fd3da-1892-0e9c-e8a2-5e6fa423ace3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_dffn_PrepaidExpensesDepositsAndOtherAssets_455fd3da-1892-0e9c-e8a2-5e6fa423ace3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_f36c8c92-d0d7-0116-5d8f-8e01aaf2fd7a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_f36c8c92-d0d7-0116-5d8f-8e01aaf2fd7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_6743ba80-ee40-7fb3-fa59-4c41257a91a1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_6743ba80-ee40-7fb3-fa59-4c41257a91a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_abb88b5c-ef84-43b7-a075-78b44bb32132" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_abb88b5c-ef84-43b7-a075-78b44bb32132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9ce5f9cd-4945-be32-a3ba-e650057e868b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9ce5f9cd-4945-be32-a3ba-e650057e868b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5edda81e-c711-ca69-2826-8af23da46bd2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5edda81e-c711-ca69-2826-8af23da46bd2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations" xlink:label="loc_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_9fe21cbd-4bf5-a48d-b21f-5e6fa4224f93" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_9fe21cbd-4bf5-a48d-b21f-5e6fa4224f93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_7eaea36c-0f2e-a233-4f5f-e9bbb24cbfcf" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_7eaea36c-0f2e-a233-4f5f-e9bbb24cbfcf" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability" xlink:label="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_E297C861C4331AE78859F82DC56CDA88" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_E297C861C4331AE78859F82DC56CDA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_721e1a2c-7f31-841f-8094-3b154fa61fcf" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_721e1a2c-7f31-841f-8094-3b154fa61fcf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1e4f1a3a-9baa-2a33-2b31-4d8aa4b5bb4b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1e4f1a3a-9baa-2a33-2b31-4d8aa4b5bb4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a92fcd53-a70b-5961-cbbe-44e0298b332c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a92fcd53-a70b-5961-cbbe-44e0298b332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="loc_dffn_ProceedsFromReverseMergerTransaction_f25e6fc0-dda4-28d5-6d6b-5e6fa423b64d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_dffn_ProceedsFromReverseMergerTransaction_f25e6fc0-dda4-28d5-6d6b-5e6fa423b64d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction_0b03b496-8325-72c3-c21b-3accd14e1911" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_DepreciationNonproduction_0b03b496-8325-72c3-c21b-3accd14e1911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantRelatedExpense" xlink:label="loc_dffn_WarrantRelatedExpense_E42A96270DFCFB7C5A85FE4269F31E6D" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_dffn_WarrantRelatedExpense_E42A96270DFCFB7C5A85FE4269F31E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_bd352d70-5a6b-2579-1d97-81ddce33e517" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OtherNonoperatingExpense_bd352d70-5a6b-2579-1d97-81ddce33e517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_5a43addb-8872-1d64-42b9-9748cf6f47ca" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_5a43addb-8872-1d64-42b9-9748cf6f47ca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_07e1cb47-3734-7bfe-e430-6fb1f458259b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_c21ba53d-96fd-2485-c9ab-89ecc5de0549" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayable_07e1cb47-3734-7bfe-e430-6fb1f458259b" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_c21ba53d-96fd-2485-c9ab-89ecc5de0549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_8dba6c2e-ca9d-158c-a959-680ef5f4eae2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayable_07e1cb47-3734-7bfe-e430-6fb1f458259b" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_8dba6c2e-ca9d-158c-a959-680ef5f4eae2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/Liquidity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:to="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_bbb88956-2391-237d-9ac1-fd1ab1783864" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:to="loc_us-gaap_AccruedSalariesCurrent_bbb88956-2391-237d-9ac1-fd1ab1783864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="loc_dffn_AccruedClinicalStudiesExpensesCurrent_222bed29-3324-b1e5-5c91-5e6fa422afc0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:to="loc_dffn_AccruedClinicalStudiesExpensesCurrent_222bed29-3324-b1e5-5c91-5e6fa422afc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_c8eafa7a-93d9-32a8-7452-89f55bebf588" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_c8eafa7a-93d9-32a8-7452-89f55bebf588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_33ebeff6-db7f-0d57-2a30-aed748170482" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_33ebeff6-db7f-0d57-2a30-aed748170482" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>dffn-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/Acquisition" xlink:href="dffn-20170331.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual" xlink:href="dffn-20170331.xsd#AcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails" xlink:href="dffn-20170331.xsd#AcquisitionProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails" xlink:href="dffn-20170331.xsd#AcquisitionPurchasePriceConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="dffn-20170331.xsd#AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionTables" xlink:href="dffn-20170331.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingencies" xlink:href="dffn-20170331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:href="dffn-20170331.xsd#CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebt" xlink:href="dffn-20170331.xsd#ConvertibleDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual" xlink:href="dffn-20170331.xsd#ConvertibleDebtDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:href="dffn-20170331.xsd#ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtTables" xlink:href="dffn-20170331.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/DocumentAndEntityInformation" xlink:href="dffn-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurements" xlink:href="dffn-20170331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsTables" xlink:href="dffn-20170331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/Liquidity" xlink:href="dffn-20170331.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails" xlink:href="dffn-20170331.xsd#LiquidityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dffn-20170331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensation" xlink:href="dffn-20170331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual" xlink:href="dffn-20170331.xsd#StockBasedCompensationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationTables" xlink:href="dffn-20170331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/Acquisition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232" xlink:to="loc_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ExecutiveOfficersMember" xlink:label="loc_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:to="loc_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="loc_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:to="loc_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:to="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:to="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorGenexMember" xlink:label="loc_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:to="loc_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:to="loc_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6EBF36A4E2EA4822DDC5F8101F61F232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92" xlink:to="loc_dffn_DiffusionLLCMember_6EBF36A4E2EA4822DDC5F8101F61F232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:to="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:to="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:to="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_BAA705DB0E21FA1666FBF8101F6A053D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45" xlink:to="loc_dffn_DiffusionLLCMember_BAA705DB0E21FA1666FBF8101F6A053D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorGenexMember" xlink:label="loc_dffn_RestorGenexMember_EC7D19E0A615D735CE09F8101F6B745E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B" xlink:to="loc_dffn_RestorGenexMember_EC7D19E0A615D735CE09F8101F6B745E" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6E17A02994CDAFE01DC3F8101F663EEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1" xlink:to="loc_dffn_DiffusionLLCMember_6E17A02994CDAFE01DC3F8101F663EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:to="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:to="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_AccountingStandardsUpdate201609Member" xlink:label="loc_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:to="loc_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A6837406F8898AB90CBEF8101F77CE5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A6837406F8898AB90CBEF8101F77CE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RES529Member" xlink:label="loc_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:to="loc_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RES440Member" xlink:label="loc_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:to="loc_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B82842EC2F0AA751834EF8101F780479" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_Goodwill_B82842EC2F0AA751834EF8101F780479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:to="loc_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:to="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="loc_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:to="loc_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:to="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:to="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:to="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="loc_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="loc_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E0C05B02E4D46742AB55F8101F96363D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_NetIncomeLoss_E0C05B02E4D46742AB55F8101F96363D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:to="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertibleNotes2016Member" xlink:label="loc_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:to="loc_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="loc_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:to="loc_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:to="loc_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:to="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:to="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_800C993475265C8D00160C423C7D3F13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:to="loc_us-gaap_MinimumMember_800C993475265C8D00160C423C7D3F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_952EA01A2E69945085E00C423C7ED194" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:to="loc_us-gaap_MaximumMember_952EA01A2E69945085E00C423C7ED194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_A8F61D83114E6D2A86C60C423C7EC9E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:to="loc_dffn_CommonStockWarrantsSeriesAMember_A8F61D83114E6D2A86C60C423C7EC9E7" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_LegacyRestorGenexWarrantsMember" xlink:label="loc_dffn_LegacyRestorGenexWarrantsMember_5B5A1E2D4716366262510C423C7E698D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:to="loc_dffn_LegacyRestorGenexWarrantsMember_5B5A1E2D4716366262510C423C7E698D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_62D07BEBEE3BC3CD5C060C423C7E7215" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:to="loc_us-gaap_PrivatePlacementMember_62D07BEBEE3BC3CD5C060C423C7E7215" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConversionofPreferredStockMember" xlink:label="loc_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:to="loc_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:to="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:to="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3F2FE278188EB6DC1F870C423C7FD7EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3F2FE278188EB6DC1F870C423C7FD7EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_DD51C328B81EF7030CDC0C423C7FC8CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_DD51C328B81EF7030CDC0C423C7FC8CC" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceived" xlink:label="loc_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6C2687510FA7C7302DA70C423C80EF3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6C2687510FA7C7302DA70C423C80EF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4A16B6A5AF54B8CD85290C423C8091B9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4A16B6A5AF54B8CD85290C423C8091B9" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceivedNet" xlink:label="loc_dffn_TemporaryEquityConsiderationReceivedNet_6E4F1602099FB60022530C423C805195" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityConsiderationReceivedNet_6E4F1602099FB60022530C423C805195" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityIssuanceCosts" xlink:label="loc_dffn_TemporaryEquityIssuanceCosts_4E2D34B1EE96ED573FC40C423C801883" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityIssuanceCosts_4E2D34B1EE96ED573FC40C423C801883" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityOfferingCosts" xlink:label="loc_dffn_TemporaryEquityOfferingCosts_5B1476B5C9679AC533E80C423C807366" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityOfferingCosts_5B1476B5C9679AC533E80C423C807366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_482F8276AA7C164EEDEB0C423C80571D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_482F8276AA7C164EEDEB0C423C80571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E0C5E7999A7714FF669D0C423C80BBBC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E0C5E7999A7714FF669D0C423C80BBBC" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantRelatedExpense" xlink:label="loc_dffn_WarrantRelatedExpense_EE806F865B0CECBA84FE0C423C81EC06" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_WarrantRelatedExpense_EE806F865B0CECBA84FE0C423C81EC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockNumberofVotesperShare" xlink:label="loc_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays" xlink:label="loc_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="loc_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability" xlink:label="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_4FB8FB8F32868B57AFDA0C423C81F3B4" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_4FB8FB8F32868B57AFDA0C423C81F3B4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:to="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:to="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:to="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:to="loc_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:to="loc_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_LegacyRestorGenexWarrantsMember" xlink:label="loc_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:to="loc_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_120B3051AAE99A26CD8DFE1ED56E185F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:to="loc_dffn_CommonStockWarrantsSeriesAMember_120B3051AAE99A26CD8DFE1ED56E185F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D19D9A445C655CF52C1DF958CC34941E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D19D9A445C655CF52C1DF958CC34941E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2DC92DEC38C02FF07D93F958CC33E9B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2DC92DEC38C02FF07D93F958CC33E9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2352C62E58DCC1EDD3FCF958CC347819" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2352C62E58DCC1EDD3FCF958CC347819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D19D9A445C655CF52C1DF958CC34941E" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:to="loc_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/Liquidity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:to="loc_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:to="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:to="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_DCAEFBA9B62E6D74A2E50C74756E25D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_DCAEFBA9B62E6D74A2E50C74756E25D9" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceived" xlink:label="loc_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceivedNet" xlink:label="loc_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityIssuanceCosts" xlink:label="loc_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityOfferingCosts" xlink:label="loc_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_E9B14A2D05BDD8C208A90C74756F5328" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_E9B14A2D05BDD8C208A90C74756F5328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:to="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:to="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:to="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="loc_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:to="loc_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:to="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_NonemployeeOptionsMember" xlink:label="loc_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="loc_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28163DFF554F1DB9AD32F8101F2A515A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28163DFF554F1DB9AD32F8101F2A515A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_471D7C11C239ECEDE553F8101F2A92E7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="loc_us-gaap_RestrictedStockMember_471D7C11C239ECEDE553F8101F2A92E7" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="loc_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38A2EFC0FF3213D5F516F8101F24885A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38A2EFC0FF3213D5F516F8101F24885A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC537C9C47D3590F85C1F8101F244A7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38A2EFC0FF3213D5F516F8101F24885A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC537C9C47D3590F85C1F8101F244A7E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>dffn-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses and Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:type="arc" />
    <link:label id="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03_terseLabel_en-US" xlink:label="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Series A</link:label>
    <link:label id="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03_label_en-US" xlink:label="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Series A [Member]</link:label>
    <link:label id="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03_documentation_en-US" xlink:label="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Series A [Member]</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:to="lab_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, liability at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued in connection with the Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, liability at fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7_label_en-US" xlink:label="lab_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:to="lab_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:to="lab_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Arrangements with Employees and Nonemployees [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:to="lab_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:to="lab_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:type="arc" />
    <link:label id="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720_terseLabel_en-US" xlink:label="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restorgenex Corporation 2015 Equity Incentive Plan</link:label>
    <link:label id="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720_label_en-US" xlink:label="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restorgenex Corporation 2015 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720_documentation_en-US" xlink:label="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to RestorGenex Corporation 2015 equity incentive plan.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="loc_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:to="lab_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:to="lab_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:type="arc" />
    <link:label id="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167_terseLabel_en-US" xlink:label="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-employee Options</link:label>
    <link:label id="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167_label_en-US" xlink:label="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Options [Member]</link:label>
    <link:label id="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167_documentation_en-US" xlink:label="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-employee Options [Member]</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_NonemployeeOptionsMember" xlink:label="loc_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:to="lab_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:type="arc" />
    <link:label id="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618_terseLabel_en-US" xlink:label="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total shares eligible for plan reserve on an annual basis</link:label>
    <link:label id="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618_label_en-US" xlink:label="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</link:label>
    <link:label id="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618_documentation_en-US" xlink:label="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="loc_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:to="lab_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of options vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of unvested options (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost not yet recognized, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested shares of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vested in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation not yet recognized, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="lab_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:to="lab_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA_label_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:to="lab_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:to="lab_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5_label_en-US" xlink:label="lab_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:to="lab_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED_label_en-US" xlink:label="lab_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:to="lab_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities (Note 10)</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:type="arc" />
    <link:label id="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5_terseLabel_en-US" xlink:label="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant related expenses (Note 7)</link:label>
    <link:label id="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5_label_en-US" xlink:label="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Related Expense</link:label>
    <link:label id="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5_documentation_en-US" xlink:label="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Related Expense</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantRelatedExpense" xlink:label="loc_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:to="lab_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing expenses</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:to="lab_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:to="lab_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Series A cumulative preferred dividends</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividends, Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:to="lab_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:to="lab_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:to="lab_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:to="lab_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:to="lab_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:type="arc" />
    <link:label id="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5_terseLabel_en-US" xlink:label="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers</link:label>
    <link:label id="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5_label_en-US" xlink:label="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officers [Member]</link:label>
    <link:label id="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5_documentation_en-US" xlink:label="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ranking officers of the entity, appointed to the position by the board of directors.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ExecutiveOfficersMember" xlink:label="loc_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:to="lab_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:to="lab_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:type="arc" />
    <link:label id="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520_terseLabel_en-US" xlink:label="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success Fee Agreement Costs</link:label>
    <link:label id="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520_label_en-US" xlink:label="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Fee Agreement Costs [Member]</link:label>
    <link:label id="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520_documentation_en-US" xlink:label="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding the success fee agreement costs.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="loc_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:to="lab_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-related Costs</link:label>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16_label_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:to="lab_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C_label_en-US" xlink:label="lab_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:to="lab_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE_label_en-US" xlink:label="lab_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:to="lab_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:type="arc" />
    <link:label id="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302_terseLabel_en-US" xlink:label="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RestorGenex</link:label>
    <link:label id="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302_label_en-US" xlink:label="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RestorGenex [Member]</link:label>
    <link:label id="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302_documentation_en-US" xlink:label="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to RestorGenex Corporation (RestorGenex).</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorGenexMember" xlink:label="loc_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:to="lab_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:type="arc" />
    <link:label id="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36_terseLabel_en-US" xlink:label="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diffusion LLC</link:label>
    <link:label id="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36_label_en-US" xlink:label="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diffusion LLC [Member]</link:label>
    <link:label id="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36_documentation_en-US" xlink:label="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of a company with which the reporting entity has entered into a business combination.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:to="lab_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fees</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:to="lab_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, issued for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:to="lab_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options compensation cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C" xlink:to="lab_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933_label_en-US" xlink:label="lab_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:to="lab_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C_negatedTerseLabel_en-US" xlink:label="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C_label_en-US" xlink:label="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</link:label>
    <link:label id="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued liabilities assumed at the acquisition date.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:to="lab_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Liabilities, Quantitative Information</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:to="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:type="arc" />
    <link:label id="lab_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61_label_en-US" xlink:label="lab_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:label id="lab_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61_documentation_en-US" xlink:label="lab_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DocumentAndEntityInformation" xlink:label="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="lab_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D_label_en-US" xlink:label="lab_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:to="lab_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:to="lab_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131_label_en-US" xlink:label="lab_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:to="lab_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:to="lab_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD_label_en-US" xlink:label="lab_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:to="lab_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B_terseLabel_en-US" xlink:label="lab_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B_label_en-US" xlink:label="lab_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:to="lab_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:to="lab_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:to="lab_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F_label_en-US" xlink:label="lab_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:to="lab_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:to="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, liquidation value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:to="lab_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A" xlink:to="lab_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:type="arc" />
    <link:label id="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038_terseLabel_en-US" xlink:label="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038_label_en-US" xlink:label="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations</link:label>
    <link:label id="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038_documentation_en-US" xlink:label="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate expense recognized in the current period from continuing and discontinued operations that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations" xlink:label="loc_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:to="lab_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:to="lab_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:type="arc" />
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for advisory services</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:type="arc" />
    <link:label id="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E_terseLabel_en-US" xlink:label="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant related expense and change in fair value</link:label>
    <link:label id="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E_label_en-US" xlink:label="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expense and Fair Value Adjustment of Warrant Liability</link:label>
    <link:label id="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E_documentation_en-US" xlink:label="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expense and Fair Value Adjustment of Warrant Liability</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability" xlink:label="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:to="lab_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows (used in) provided by investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:type="arc" />
    <link:label id="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2_terseLabel_en-US" xlink:label="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received in reverse merger transaction</link:label>
    <link:label id="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2_label_en-US" xlink:label="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash received in reverse merger transaction</link:label>
    <link:label id="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2_documentation_en-US" xlink:label="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow associated with a reverse merger transaction.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="loc_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:to="lab_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of Series A convertible preferred stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:type="arc" />
    <link:label id="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F_terseLabel_en-US" xlink:label="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of deferred offering costs upon completion of private placement</link:label>
    <link:label id="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F_label_en-US" xlink:label="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Transaction, Reclassification of Deferred Offering Costs</link:label>
    <link:label id="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F_documentation_en-US" xlink:label="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Transaction, Reclassification of Deferred Offering Costs</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts" xlink:label="loc_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:to="lab_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:type="arc" />
    <link:label id="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3_terseLabel_en-US" xlink:label="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3_label_en-US" xlink:label="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3_documentation_en-US" xlink:label="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_OfferingCostsIncurredButNotYetPaid" xlink:label="loc_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:to="lab_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of subscription receivable upon sale of Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F_label_en-US" xlink:label="lab_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:to="lab_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible notes and related accrued interest into common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration in connection with RestorGenex Corporation merger transaction</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA" xlink:to="lab_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="lab_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription receivable</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Subscribed but Unissued, Subscriptions Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:to="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:type="arc" />
    <link:label id="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25_terseLabel_en-US" xlink:label="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other current assets</link:label>
    <link:label id="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25_label_en-US" xlink:label="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other current assets</link:label>
    <link:label id="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25_documentation_en-US" xlink:label="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="loc_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:to="lab_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:to="lab_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20_label_en-US" xlink:label="lab_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:to="lab_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:to="lab_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:to="lab_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2_label_en-US" xlink:label="lab_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:to="lab_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:to="lab_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, $0.001 par value: Series A - 13,750,000 shares authorized, 12,376,329 issued and outstanding at March 31, 2017; No shares authorized, issued or outstanding at December 31, 2016 (liquidation value of $25,000,000 at March 31, 2017)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity (Deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:to="lab_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 10,345,637 shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:to="lab_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:to="lab_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4_terseLabel_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of RestorGenex shares outstanding</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4_label_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of shares outstanding in the preliminary purchase price consideration.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:to="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A_terseLabel_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of RestorGenex stock options outstanding</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A_label_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated fair value of stock options assumed in the preliminary purchase price consideration.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:to="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243_terseLabel_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of RestorGenex warrants outstanding</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243_label_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated fair value of warrants assumed in the preliminary purchase price consideration.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:to="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E_terseLabel_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVRs &#8211; RES-440 product candidate</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E_label_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contingent value rights in the preliminary purchase price consideration.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:to="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986_totalLabel_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986_label_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPreliminaryPurchasePriceConsideration</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of preliminary purchase consideration consisting of the fair value of assets transferable by the acquirer, liabilities obtainable by the acquirer, and equity interest issuable by the acquirer.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:to="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296_label_en-US" xlink:label="lab_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:to="lab_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:to="lab_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:to="lab_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:type="arc" />
    <link:label id="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4_terseLabel_en-US" xlink:label="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charlottesville, Virginia</link:label>
    <link:label id="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4_label_en-US" xlink:label="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charlottesville, Virginia [Member]</link:label>
    <link:label id="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4_documentation_en-US" xlink:label="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the location Charlottesville, Virginia.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="loc_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:to="lab_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C_terseLabel_en-US" xlink:label="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share (in dollars per share)</link:label>
    <link:label id="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C_label_en-US" xlink:label="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</link:label>
    <link:label id="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C_documentation_en-US" xlink:label="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:to="lab_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:to="lab_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:type="arc" />
    <link:label id="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6_terseLabel_en-US" xlink:label="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering Costs</link:label>
    <link:label id="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6_label_en-US" xlink:label="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6_documentation_en-US" xlink:label="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Costs Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_OfferingCostsPolicyPolicyTextBlock" xlink:label="loc_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:to="lab_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654_label_en-US" xlink:label="lab_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:to="lab_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62_label_en-US" xlink:label="lab_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:to="lab_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4_label_en-US" xlink:label="lab_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:to="lab_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F_label_en-US" xlink:label="lab_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:to="lab_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:type="arc" />
    <link:label id="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3_terseLabel_en-US" xlink:label="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy RestorGenex Warrants</link:label>
    <link:label id="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3_label_en-US" xlink:label="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legacy RestorGenex Warrants [Member]</link:label>
    <link:label id="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3_documentation_en-US" xlink:label="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Legacy RestorGenex warrants.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_LegacyRestorGenexWarrantsMember" xlink:label="loc_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:to="lab_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:to="lab_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses and Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:to="lab_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:to="lab_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181_terseLabel_en-US" xlink:label="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Convertible Notes</link:label>
    <link:label id="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181_label_en-US" xlink:label="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Convertible Notes [Member]</link:label>
    <link:label id="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181_documentation_en-US" xlink:label="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the convertible notes issued in 2016, which were issued to an investor and certain other parties in connection with the settlement of a litigation matter.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertibleNotes2016Member" xlink:label="loc_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:to="lab_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB_verboseLabel_en-US" xlink:label="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Note Series B</link:label>
    <link:label id="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB_label_en-US" xlink:label="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note Series B [Member]</link:label>
    <link:label id="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB_documentation_en-US" xlink:label="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Convertible Note Series B.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="loc_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:to="lab_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="lab_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total principal amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:to="lab_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, net of current portion</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:type="arc" />
    <link:label id="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF_terseLabel_en-US" xlink:label="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price</link:label>
    <link:label id="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF_label_en-US" xlink:label="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Stock Price</link:label>
    <link:label id="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF_documentation_en-US" xlink:label="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Stock Price</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_FairValueAssumptionsStockPrice" xlink:label="loc_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:to="lab_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:to="lab_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:to="lab_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:type="arc" />
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4_terseLabel_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preliminary Purchase Price Consideration</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4_label_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Preliminary Purchase Price Consideration [Table Text Block]</link:label>
    <link:label id="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4_documentation_en-US" xlink:label="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of preliminary purchase price consideration in a business combination.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:to="lab_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7_label_en-US" xlink:label="lab_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:to="lab_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="lab_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:to="lab_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:to="lab_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:to="lab_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB_verboseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of Series A convertible preferred stock and common stock warrants (in shares)</link:label>
    <link:label id="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB_label_en-US" xlink:label="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB_documentation_en-US" xlink:label="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:to="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Series A convertible preferred stock and common stock warrants</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:to="lab_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:to="lab_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of change in accounting principle</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Series A convertible preferred stock and common stock warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Series A cumulative preferred dividend</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:to="lab_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature for accrued interest of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C" xlink:to="lab_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9" xlink:to="lab_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:to="lab_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:type="arc" />
    <link:label id="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55_terseLabel_en-US" xlink:label="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09</link:label>
    <link:label id="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55_label_en-US" xlink:label="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:label id="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55_documentation_en-US" xlink:label="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_AccountingStandardsUpdate201609Member" xlink:label="loc_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:to="lab_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:type="arc" />
    <link:label id="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB_terseLabel_en-US" xlink:label="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RES-529</link:label>
    <link:label id="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB_label_en-US" xlink:label="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RES-529 [Member]</link:label>
    <link:label id="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB_documentation_en-US" xlink:label="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The reporting entity's product of RES-529, a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and was in preclinical development in oncology.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RES529Member" xlink:label="loc_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:to="lab_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:type="arc" />
    <link:label id="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66_terseLabel_en-US" xlink:label="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RES-440</link:label>
    <link:label id="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66_label_en-US" xlink:label="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RES-440 [Member]</link:label>
    <link:label id="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66_documentation_en-US" xlink:label="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The reporting entity's product of RES-440, a &#8220;soft&#8221; anti-androgen.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RES440Member" xlink:label="loc_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:to="lab_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt, fair value disclosures</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:to="lab_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA_verboseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative-effect adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:to="lab_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:to="lab_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:to="lab_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4_terseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4_label_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Consideration Received</link:label>
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4_documentation_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Consideration Received</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceived" xlink:label="loc_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:to="lab_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of preferred stock shares per unit (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock warrants per unit (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D_terseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred units, outstanding (in shares)</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:to="lab_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2_terseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash proceeds</link:label>
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2_label_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Consideration Received, Net</link:label>
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2_documentation_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Consideration Received, Net</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceivedNet" xlink:label="loc_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:to="lab_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188_terseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts and commissions</link:label>
    <link:label id="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188_label_en-US" xlink:label="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:label id="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188_documentation_en-US" xlink:label="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityIssuanceCosts" xlink:label="loc_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:to="lab_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7_terseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7_label_en-US" xlink:label="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Offering Costs</link:label>
    <link:label id="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7_documentation_en-US" xlink:label="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Offering Costs</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityOfferingCosts" xlink:label="loc_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:to="lab_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares able to be purchased by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, options outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, options outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:to="lab_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:type="arc" />
    <link:label id="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3_terseLabel_en-US" xlink:label="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Preferred Stock</link:label>
    <link:label id="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3_label_en-US" xlink:label="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Preferred Stock [Member]</link:label>
    <link:label id="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3_documentation_en-US" xlink:label="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Preferred Stock [Member]</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConversionofPreferredStockMember" xlink:label="loc_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:to="lab_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:type="arc" />
    <link:label id="lab_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07_verboseLabel_en-US" xlink:label="lab_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceived" xlink:label="loc_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:to="lab_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock warrants per unit (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, dividend rate (percentage)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Series A dividends</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246_terseLabel_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per share of Series A preferred stock</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246_label_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number of Votes per Share</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246_documentation_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number of Votes per Share</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockNumberofVotesperShare" xlink:label="loc_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:to="lab_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87_terseLabel_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock conversion, measurement period</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87_label_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock,Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87_documentation_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock,Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays" xlink:label="loc_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:to="lab_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046_terseLabel_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum share price (in dollars per share)</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046_label_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Minimum Share Price</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046_documentation_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Minimum Share Price</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:to="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680_terseLabel_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680_label_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Proceeds from Issue of Common Stock</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680_documentation_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Proceeds from Issue of Common Stock</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:to="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:type="arc" />
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88_terseLabel_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88_label_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Conversion Price Percentage</link:label>
    <link:label id="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88_documentation_en-US" xlink:label="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Conversion Price Percentage</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:to="lab_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:type="arc" />
    <link:label id="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26_terseLabel_en-US" xlink:label="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26_label_en-US" xlink:label="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label id="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26_documentation_en-US" xlink:label="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="loc_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:to="lab_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:to="lab_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and payroll related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:to="lab_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:type="arc" />
    <link:label id="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89_terseLabel_en-US" xlink:label="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical studies expenses</link:label>
    <link:label id="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89_label_en-US" xlink:label="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued clinical studies expenses</link:label>
    <link:label id="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89_documentation_en-US" xlink:label="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</link:label>
    <link:loc xlink:href="dffn-20170331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="loc_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:to="lab_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>dffn-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/Acquisition" xlink:href="dffn-20170331.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual" xlink:href="dffn-20170331.xsd#AcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails" xlink:href="dffn-20170331.xsd#AcquisitionProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails" xlink:href="dffn-20170331.xsd#AcquisitionPurchasePriceConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="dffn-20170331.xsd#AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/AcquisitionTables" xlink:href="dffn-20170331.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="dffn-20170331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingencies" xlink:href="dffn-20170331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="dffn-20170331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:href="dffn-20170331.xsd#CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="dffn-20170331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebt" xlink:href="dffn-20170331.xsd#ConvertibleDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual" xlink:href="dffn-20170331.xsd#ConvertibleDebtDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:href="dffn-20170331.xsd#ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertibleDebtTables" xlink:href="dffn-20170331.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:href="dffn-20170331.xsd#ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/DocumentAndEntityInformation" xlink:href="dffn-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurements" xlink:href="dffn-20170331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:href="dffn-20170331.xsd#FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/FairValueMeasurementsTables" xlink:href="dffn-20170331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/Liquidity" xlink:href="dffn-20170331.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails" xlink:href="dffn-20170331.xsd#LiquidityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dffn-20170331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables" xlink:href="dffn-20170331.xsd#OtherAccruedExpensesAndLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensation" xlink:href="dffn-20170331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual" xlink:href="dffn-20170331.xsd#StockBasedCompensationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="dffn-20170331.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.diffusionpharma.com/role/StockBasedCompensationTables" xlink:href="dffn-20170331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_40C31596E277CE483D3DF8101F6F60DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_40C31596E277CE483D3DF8101F6F60DF" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_EDB25DE259310BA98381F8101F6F2BF1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_35384FDC8ECC16BD6CF1F8101F5AA9EE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_13CD74A8FF2849C59919F8101F5A92FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AE5778AAA43D35939C9DF8101F5A6232" xlink:to="loc_us-gaap_StockOptionMember_F8BA0CD3595746093CC2F8101F5AD327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_26FF394CF67B94A9F1BBF8101F5A1286" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ExecutiveOfficersMember" xlink:label="loc_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4DB868BD744C28CFE375F8101F5A2BC0" xlink:to="loc_dffn_ExecutiveOfficersMember_AE35699BFC85D746D604F8101F5BC5D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_245806C4B3C4CE7CDF21F8101F5B079E" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="loc_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_350DFBEDD9DF3E4E5DB6F8101F5B18B3" xlink:to="loc_dffn_SuccessFeeAgreementCostsMember_E69AE3107C86FF12CF66F8101F5B3520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_9E96F1FEEF854CAC8809F8101F5BA0F1" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_95C5F45EBF3535CAB30EF8101F5BB502" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_7694B9576C8A9DAC91AEF8101F5BFD16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_BD1EF4DFBB7CD86795A3F8101F5B717C" xlink:to="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorGenexMember" xlink:label="loc_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_805E260CF55C4A67E75EF8101F5B58EE" xlink:to="loc_dffn_RestorGenexMember_5BD8DDABA6B57240FD83F8101F5BB302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40E88D27A63885B42390F8101F5CA8B0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1F3DB004B2C1D8816691F8101F5CCACE" xlink:to="loc_dffn_DiffusionLLCMember_6BECC18ACF5E5FAAA289F8101F5CBF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3236EBEE9D25CC1F62A0F8101F5A4A9A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_78DF1ED93291B917095DF8101F5CFF6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_PaymentsForFees_22369801F7CA7EAAA2D1F8101F5CCF74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9B7FF206736398411665F8101F5C6BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2743D47F0DA2C83A7E4CF8101F5C3D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_SeveranceCosts1_3A3DB3A38BA96E151E89F8101F5C5CF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E668DAD196F8B30339A6F8101F5C9506" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF3B70C3BBA421A7347DF8101F5CA954" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_AE89E949B38F5AEF12A3F8101F618EFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_AE89E949B38F5AEF12A3F8101F618EFD" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7C36EDBA539ABB32DAFAF8101F6159F2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6EBF36A4E2EA4822DDC5F8101F61F232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1F8FC248C706109ADD9F8101F61FC92" xlink:to="loc_dffn_DiffusionLLCMember_6EBF36A4E2EA4822DDC5F8101F61F232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39ED962393E542C45C51F8101F611ED8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_DC8141C7DDE17FB25AE9F8101F61D183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7F4EEFE1E017A2FB655DF8101F61AD1C" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_92AA6A650F00DB3B7B0DF8101F616F72" xlink:to="loc_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_3D3CC32DDBC7CEEA3367F8101F61A24C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_39E15FF64C49DF6881EAF8101F6A58A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_39E15FF64C49DF6881EAF8101F6A58A9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:to="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_148027EFE7CE395535E8F8101F6A5E91" xlink:to="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_BAA705DB0E21FA1666FBF8101F6A053D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_F1DA661AFC7132ED7387F8101F6A3C45" xlink:to="loc_dffn_DiffusionLLCMember_BAA705DB0E21FA1666FBF8101F6A053D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8424A142830D8A67AEE8F8101F6A9713" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorGenexMember" xlink:label="loc_dffn_RestorGenexMember_EC7D19E0A615D735CE09F8101F6B745E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F05B6CD29B2EF7F477CCF8101F6A422B" xlink:to="loc_dffn_RestorGenexMember_EC7D19E0A615D735CE09F8101F6B745E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_134C5425D978E5335C69F8101F6A5415" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding_34CC586EE4B464419481F8101F6B04F4" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed_4B30C1CE28EF13D34D40F8101F6B9C9A" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed_1278E0D73737CF8C03E9F8101F6B4243" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights_F3989853D85405503548F8101F6B342E" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCCE67F79E2D3F0B1C7EF8101F6BF2FB" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration_06522F3BBF65CDADF97EF8101F6B6986" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7FFE45C9BB0FE67CB5C4F8101F65B3E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7FFE45C9BB0FE67CB5C4F8101F65B3E3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51C2CDBCD4954484391FF8101F6501E9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DiffusionLLCMember" xlink:label="loc_dffn_DiffusionLLCMember_6E17A02994CDAFE01DC3F8101F663EEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A988C25B3226CC04C53DF8101F6682F1" xlink:to="loc_dffn_DiffusionLLCMember_6E17A02994CDAFE01DC3F8101F663EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_898B66F9C252680A7D5EF8101F650E3B" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_82B679A747048E36BCE4F8101F66FFDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_E3198CB2BE203F867641F8101F668289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_B4EAF672385FF8A4F0D1F8101F667340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F1C7E3C05A359144A610F8101F660DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_Goodwill_BAFD5D0EB4FA44892108F8101F664933" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_42424EFA618C86AC1366F8101F66B13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_64EB440CF411AE339881F8101F66B320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1E6F8F74DB0B5EEA7CD9F8101F66BFE6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0085DAB8C645243BBDEAF8101F668947" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/AcquisitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1ACBD5CC3FD33DECE646F8101F6DA81E" xlink:type="locator" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:label="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1ACBD5CC3FD33DECE646F8101F6DA81E" xlink:to="loc_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock_315B7B004AD485773660F8101F6D2DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1ACBD5CC3FD33DECE646F8101F6DA81E" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_80CFB3212856CC28EE6CF8101F6E350B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1ACBD5CC3FD33DECE646F8101F6DA81E" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8C6995B0A6BA8531FA88F8101F6EB9AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EC0FF48D875EA7CA8850F8101F7E0B4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EC0FF48D875EA7CA8850F8101F7E0B4A" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_85ABD8640254CE0011DBF8101F7EF68C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7E88FC042E1A7D896E18F8101F77D310" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E88FC042E1A7D896E18F8101F77D310" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_534BBE27D172DDB1DC04F8101F773F94" xlink:to="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_AccountingStandardsUpdate201609Member" xlink:label="loc_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_AA0AADC35FA0C1051EC5F8101F771463" xlink:to="loc_dffn_AccountingStandardsUpdate201609Member_D4F093AA49BD1890E07BF8101F779E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0AFB248EA295AED17EC7F8101F7754E6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A6837406F8898AB90CBEF8101F77CE5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78A1D3C6C99EF9EDD351F8101F772683" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A6837406F8898AB90CBEF8101F77CE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_FC71FD917B8FBAC0BDBFF8101F77917D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RES529Member" xlink:label="loc_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:to="loc_dffn_RES529Member_35DE5D3956DABC09F8E9F8101F77BEBB" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RES440Member" xlink:label="loc_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_198A0EC796D25018EFB2F8101F77A38C" xlink:to="loc_dffn_RES440Member_C5D54724F027EBBDA90EF8101F777D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C107B445C6BA6222B90F8101F7704B8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BC328DA7C6F3A4406FE8F8101F7754A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_DeferredOfferingCosts_3FDA36721B63345FAA36F8101F78CEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5FD6F3286B3D320CE0ECF8101F780AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B82842EC2F0AA751834EF8101F780479" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_Goodwill_B82842EC2F0AA751834EF8101F780479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1A07C9708C1404F75BDCF8101F78FFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_D87719ADB65F8FCA38AAF8101F7852AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4158BCDE0A7F2F252155F8101F779ACE" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_937B227AF308E33C7B94F8101F783AEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F73CACD4EDA693884CB6F8101F72FA62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8333826F43FD2E0C6E47F8101F72DF2C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ADE606F79074F29261FF8101F72FD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_CB2921893B97EB3B0AD8F8101F72B730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_WarrantMember_6B4BCDE1D2B8A618177BF8101F7296D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0577AC3BAD1217D04AA7F8101F72798F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307700E2D6DFF49D8610F8101F72D784" xlink:to="loc_us-gaap_RestrictedStockMember_79ECCC1BB3AE283664E1F8101F726DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D507C27711D903AFFD16F8101F723520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3601D1BC4F0ABB67F4C5F8101F73D799" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D2D4ECD0D118801D6C0DF8101F736C66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03982FEAD04A1EE34AA7F8101F7C6078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_us-gaap_UseOfEstimates_DE0409EB0816AB614FD2F8101F7CAC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9757BD9CE42CA5D3D93BF8101F7CCEA7" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_OfferingCostsPolicyPolicyTextBlock" xlink:label="loc_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_dffn_OfferingCostsPolicyPolicyTextBlock_78926AF635DCD78D1A9CF8101F7C4CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_FCD444D4BD4B2C23DC62F8101F7CAB3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5DBC274002E6ADDF6DCDF8101F7C8506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B92B83A02C1D6B499EEAF8101F7C0A2B" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_67960EEE4CDE73340CF2F8101F7C93B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1F5FF9A04705B1933B13F8101F7AB685" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1F5FF9A04705B1933B13F8101F7AB685" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18B08D90BC1982F305D9F8101F7A8DC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_512E0DB8454B115A2A6AF8101F199466" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_512E0DB8454B115A2A6AF8101F199466" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_B95F02489F95B3EC3B1EF8101F1970DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_88B7F4855D4B75788909F8101F14E8FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_88B7F4855D4B75788909F8101F14E8FA" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4EF40566AD206F78ABDAF8101F143420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33C4191616A8A950A443F8101F149608" xlink:to="loc_us-gaap_BuildingMember_4486BBD1515752D7F59BF8101F14B296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:to="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_16699A1F5FE498CC8B16F8101F142F6B" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="loc_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3E7E2A7DC0FEA0B27246F8101F1491AA" xlink:to="loc_dffn_CharlottesvilleVirginiaMember_948F35B10CBF4BD36C4AF8101F15B8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_85AA77EBCED963EBAA59F8101F145596" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2F97250D2B5C047465F6F8101F15BD33" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_6AF7FE28566AC61F15D9F8101F15B552" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_307FD458C8A29AFB025AF8101F103619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_355052E5168D6D821BF8F8101F101B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3CA0CB42BC3B2F7702C9F8101F10E470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_DD1C68F08AB3668B500DF8101F11E53B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B42A4694B8CD866E9397F8101F11522F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_71B53158F8878C7810EDF8101F116BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14FE0DE8B2C97106D989F8101F105EC4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D51C5C2537901D3DF5DEF8101F11D8AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E597E81E3B487F9A91EEF8101F173165" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_107AB36EECD5FC4BD5A9F8101F17B339" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_303DA781DCC4EBC03C27F83A37637B60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_164CCB9EEE66B22D7621F8101F9F86FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_879CCD14C166792942CDF8101F9F2854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_60E6358547E3AC8A4470F8101F9F5A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_07B179E349BA3F7C4ACDF8101F9F7330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_B34CCCF04DDE2E6A1F59F8101F9F1A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_BDF8F9059715E3B38892F8101F9F7008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_CommonStockSharesIssued_2442BA3678DD75A59EF7F8101F9FAC35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DFCC7975CD7D13449EFCF8101F9F16B2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_BCBFBE1CAEE7F4602B31F8101F9FDF3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6D7ED973233ABE930464F93F84423222" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6D7ED973233ABE930464F93F84423222" xlink:to="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FBC3182E4C4510E39438F93F844262E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FBC3182E4C4510E39438F93F844262E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_A6371F326712ACDC03D8F93F8442BE63" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="loc_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:to="loc_dffn_PrepaidExpensesDepositsAndOtherAssets_23DCF8968EF83DB1DFC3F93F84428F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ADA38DE05AE3747FB6DF93F84428C1B" xlink:to="loc_us-gaap_AssetsCurrent_8F73704832EEF6140B24F93F8442CD82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_E6F5F37A62E146E3D70DF93F84421AB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C741C41C17A013177FA3F93F844229D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F8A8F9725E6CFBC981CCF93F8442CC45" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="loc_us-gaap_Goodwill_F8A8F9725E6CFBC981CCF93F8442CC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_221DEEDAC5A46B4A0D5FF93F844268E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3791002F9B09BD8D6051F93F8442E953" xlink:to="loc_us-gaap_Assets_BAF49AE27BFFD6B55498F93F84428C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6D7ED973233ABE930464F93F84423222" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_E14D7510C93A0939A947F93F8443F006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:to="loc_us-gaap_AccountsPayableCurrent_5AADACFC1242E6C4D696F93F84481911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8DFF8F105FB568463760F93F8448686B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_2D7C4AAB200A2D4FB175F93F844852D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_2D7C4AAB200A2D4FB175F93F844852D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3A5B1DD2CF796CAC4947F93F8443853A" xlink:to="loc_us-gaap_LiabilitiesCurrent_725D5F10CE3EF1E2C1CFF93F84485938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_80E622F55CBCE96F88A8F93F844856DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_38F33F8CFEAD70A48A71F93F8448A895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_16E8AF3D82EE08FCCD59F93F84487801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_Liabilities_853B3566554A50F6AAE1F93F8448F7A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_CommitmentsAndContingencies_C6076A284A0C1D479D9EF93F8448BABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_B1EF6806019AB1F13F70F93F8448384A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:to="loc_us-gaap_CommonStockValue_F8CA58265E8B501CC768F93F84499F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D94373CEC306420DB47F93F844956FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_752219A8108150734E1DF93F8449EF55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2B1619F0BCF8EDA48497F93F8448C765" xlink:to="loc_us-gaap_StockholdersEquity_B2D580BC9FD90B2EEEFEF93F84494CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B9171A816385437A4032F93F84426740" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_065844DECEA664039774F93F84490870" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0998C034923DD5FFAE19F8101F9565C5" xlink:to="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B15332A054B452715E03F8101F959DC8" xlink:to="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="loc_us-gaap_CommonStockMember_A919326B1E531364F763F8101F957EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7F626239B414C0F7FA37F8101F95ED08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3EA91DCBB57B28BF53BEF8101F953B5E" xlink:to="loc_us-gaap_RetainedEarningsMember_9C55D74BF69E72BB5D38F8101F953F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06CBE2329E6E75CFF93DF8101F9513E7" xlink:to="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_07446EEA08E93DBA13DEF8101F9607B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_E22A2A50010BCF0EE2CDF8101F96312F" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2137B77DDF3573F006FAF8101F9660BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_EFFC1188956BE585EC7AF8101F969C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_F65B41FBDF7A920E3C05F8101F960CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_FF98AE76A5CA76189709F8101F95F1AF" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9C6F15BBF64463245A7F8101F964D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1D8E351537761AC763A2F8101F95C2A4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_SharesOutstanding_47D52EE90FA60216A710F8101F96A677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_StockholdersEquity_CEB0AF19EBE9CB23ABE8F8101F96BD51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F5E25DB731DD171319C8F8101F9652BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C7D52D405EAF907AE0FF8101F966D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_DividendsPreferredStock_5B2831570B5285EBAA23F8101F96CE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1130C0F162780D19024EF8101F965F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_AE6630F3EEF775A82C20F8101F96C06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E0C05B02E4D46742AB55F8101F96363D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_NetIncomeLoss_E0C05B02E4D46742AB55F8101F96363D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_SharesOutstanding_915478463BE5616D45ABF8101F97592C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4CA746D470A0EF0E83CEF8101F964E61" xlink:to="loc_us-gaap_StockholdersEquity_6E9C5BD344472546C114F8101F971FB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:to="loc_us-gaap_NetIncomeLoss_625E48AB798614F53F3EFE6DE1FC872A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations" xlink:label="loc_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="loc_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations_905C3C5CD7E688BD2B93FE6DE1FC0038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="loc_us-gaap_ShareBasedCompensation_BA9B7AE4FFBCAD6D69D8FE6DE206B250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_43832823CA66AF9FD870FE6DE206A725" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability" xlink:label="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_8E45C6F78582114443EEFE6DE206BA3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_5264407E9CB186D777D5FE6DE20642B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94CBCB7E0F0C33258101FE6DE1FC2215" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E970B90A7672F02233BFE6DE2061D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35CE243AEEF8D81307A8FE6DE20615FF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7E707BD9E0EC00ECADC2FE6DE2064CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CC48D392A01AF82B863FFE6DE1FCE6AE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E1FE875389924DA0616FE6DE206CB95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D239C81195081E4DEBCAFE6DE20609C9" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="loc_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:to="loc_dffn_ProceedsFromReverseMergerTransaction_95EB7CB43C48A06A6AFCFE6DE20610B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7B7888E5C1F77315BABAFE6DE2066547" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2C96299567EA254D51BDFE6DE206F9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_F60DD3874382A30E77F7FE6DE2068635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_EB07079E4ACDBEFCB99BFE6DE2065CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_993700F820E538597AF5FE6DE2063AC7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_630AC581C7AAA4B6620EFE6DE2068403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CF6B77E4CB667BA4E006FE6DE206E9A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66A484A9E7456D73C0C5FE6DE20698E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8D60383743E00C07A55FE6DE2067BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1250A7DD57372DF3F0C5FE6DE1FC0EE0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts" xlink:label="loc_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="loc_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts_B89D4657CB8DAA63AD39FE6DE2069F4F" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_OfferingCostsIncurredButNotYetPaid" xlink:label="loc_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="loc_dffn_OfferingCostsIncurredButNotYetPaid_7DFC1D3922835FBA42BCFE6DE2062EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_62A1C8CAACCF6AF77C7DFE6DE2066A8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_62A1C8CAACCF6AF77C7DFE6DE2066A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="loc_us-gaap_StockIssued1_F4EB715D0B39E226F618FE6DE206057F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4927880DE24FD3E75C0DFE6DE2064B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_950371F80DC860337807FE6DE206AEB7" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_F1B8405C559EEA7EDDEEFE6DE206A7E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FB95189B6A5DCB612F1A08F65398AE6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3A5ABE12B16A84A4E0CA08F65398E917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ED95F64A30656529994008F653980D89" xlink:to="loc_us-gaap_DepreciationNonproduction_A79AB3604B440B8DD57908F65398C2CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_OperatingIncomeLoss_709AF75404F092153CA808F65398095B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:to="loc_us-gaap_InterestExpense_10B4A37F910BEA61569E08F65399D4ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_EE912CE55C14302E378108F653998D2F" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantRelatedExpense" xlink:label="loc_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:to="loc_dffn_WarrantRelatedExpense_AD64673FB254185671D108F65399D4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpensesAbstract_C45DB45BBC1B6DE8145708F65398C1F5" xlink:to="loc_us-gaap_OtherNonoperatingExpense_37D36C63D311CA6FF10608F65399EEA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_NetIncomeLoss_87E899736804BAD69D0808F65399591E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_6C0C34E7F1BE37411A7E08F65399D344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9C78165B4256FFB74ADB08F65399DD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ED10D9FC24B00C7E3EC008F65398EB2F" xlink:to="loc_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6B745C31D05ABBE70F2F08F65399E71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03D13B2423C79454689A08F65399A950" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_62856D54CF2737BEF97A08F65399BB44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D541688DC2EFA0C73389F8101F4B4CFA" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ED499F262892520D8941F8101F4B0B6D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6A596FAABE5810A2EAAEFD52BD5D945D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6A596FAABE5810A2EAAEFD52BD5D945D" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_03673FD4018E3DF52AF6FD52BD5DBF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6A596FAABE5810A2EAAEFD52BD5D945D" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_F2CADC820D8081628B46FE1E245B7839" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_68E7B6B05E89A9E8B510F8101F47F5F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_68E7B6B05E89A9E8B510F8101F47F5F7" xlink:to="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:to="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_79D256E083946AD48B01F8101F470197" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertibleNotes2016Member" xlink:label="loc_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:to="loc_dffn_ConvertibleNotes2016Member_BC6589B4BB99C02DE3C9F8101F477181" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="loc_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AEA21E08472CF4D899C1F8101F47857C" xlink:to="loc_dffn_ConvertibleNoteSeriesBMember_A284EC37E1B7DEB9DFBAF8101F47B5BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F5EAD8A871863FFA3D26F8101F47FA1F" xlink:to="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B75853610BEE7C8CE220F8101F47FFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_45733C5FF1DC5FA316A8F8101F472338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_ConvertibleNotesPayable_D1A94AB5C76FC4DE7E40F8101F47854D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_C33B323F196E89E851B4F8101F47CBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71C42CC7473E207F2331F8101F471BE8" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_7157AA4ED902D685930FF8101F47D7A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4EA046C7B12F0DA0DF96F8101F497234" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4EA046C7B12F0DA0DF96F8101F497234" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_4924ECF9FF8C24811591F8101F49D7A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_F5491E701CEF7C3254D50C423C7C2AA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_F5491E701CEF7C3254D50C423C7C2AA4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E74A191430AE4396FBB0C423C7D6127" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7CED85C7066935B959BE0C423C7D6BC8" xlink:to="loc_us-gaap_SubsequentEventMember_C457F2068797B1FFF5EE0C423C7D88E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8495CC8BC73C387F88D90C423C7D860D" xlink:to="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_800C993475265C8D00160C423C7D3F13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:to="loc_us-gaap_MinimumMember_800C993475265C8D00160C423C7D3F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_952EA01A2E69945085E00C423C7ED194" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6F844FC84377EAD533A80C423C7D84EC" xlink:to="loc_us-gaap_MaximumMember_952EA01A2E69945085E00C423C7ED194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6AA667AE908C166D9D630C423C7E1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_A8F61D83114E6D2A86C60C423C7EC9E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:to="loc_dffn_CommonStockWarrantsSeriesAMember_A8F61D83114E6D2A86C60C423C7EC9E7" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_LegacyRestorGenexWarrantsMember" xlink:label="loc_dffn_LegacyRestorGenexWarrantsMember_5B5A1E2D4716366262510C423C7E698D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4311DDACFF9C895694280C423C7E6F48" xlink:to="loc_dffn_LegacyRestorGenexWarrantsMember_5B5A1E2D4716366262510C423C7E698D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FB3341AC5E06814579780C423C7E18F1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_62D07BEBEE3BC3CD5C060C423C7E7215" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:to="loc_us-gaap_PrivatePlacementMember_62D07BEBEE3BC3CD5C060C423C7E7215" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConversionofPreferredStockMember" xlink:label="loc_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6EB53CFBBA3FBFCBD2F50C423C7E5846" xlink:to="loc_dffn_ConversionofPreferredStockMember_CA1C900B7C6EE650B6780C423C7FFFF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C27B3623BF677B5F92500C423C7FCF1E" xlink:to="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3F2FE278188EB6DC1F870C423C7FD7EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_23820AF673D03B47AFA00C423C7F2C2A" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3F2FE278188EB6DC1F870C423C7FD7EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87F791D3A5E5657C6AF20C423C7C36E3" xlink:to="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_DD51C328B81EF7030CDC0C423C7FC8CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_DD51C328B81EF7030CDC0C423C7FC8CC" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceived" xlink:label="loc_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityConsiderationReceived_93B0F25962A05B7AAA930C423C7FEE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6C2687510FA7C7302DA70C423C80EF3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6C2687510FA7C7302DA70C423C80EF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B05DA739794A64742F90C423C80DE4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_FC92A33B3B15646B79C50C423C80409D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_9F634823D59347B6B9630C423C80E7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF0CE5AAD518CCFD85F20C423C80E20A" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4A16B6A5AF54B8CD85290C423C8091B9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4A16B6A5AF54B8CD85290C423C8091B9" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceivedNet" xlink:label="loc_dffn_TemporaryEquityConsiderationReceivedNet_6E4F1602099FB60022530C423C805195" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityConsiderationReceivedNet_6E4F1602099FB60022530C423C805195" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityIssuanceCosts" xlink:label="loc_dffn_TemporaryEquityIssuanceCosts_4E2D34B1EE96ED573FC40C423C801883" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityIssuanceCosts_4E2D34B1EE96ED573FC40C423C801883" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityOfferingCosts" xlink:label="loc_dffn_TemporaryEquityOfferingCosts_5B1476B5C9679AC533E80C423C807366" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_TemporaryEquityOfferingCosts_5B1476B5C9679AC533E80C423C807366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_482F8276AA7C164EEDEB0C423C80571D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_482F8276AA7C164EEDEB0C423C80571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E0C5E7999A7714FF669D0C423C80BBBC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E0C5E7999A7714FF669D0C423C80BBBC" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantRelatedExpense" xlink:label="loc_dffn_WarrantRelatedExpense_EE806F865B0CECBA84FE0C423C81EC06" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_WarrantRelatedExpense_EE806F865B0CECBA84FE0C423C81EC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_32DA7E04CA6B9F40C2E00C423C81DBD1" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockNumberofVotesperShare" xlink:label="loc_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockNumberofVotesperShare_A39E3CFE2E440077937A0C423C81D246" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays" xlink:label="loc_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays_36F820E07D094A0C83980C423C819A87" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice_0AA8DCB7A0DC33F107CD0C423C815046" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock_4534AB7F24C823441D7C0C423C813680" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage" xlink:label="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage_64EC4CD246B9C44DDC290C423C812C88" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="loc_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_ClassOfWarrantOrRightExercisedDuringPeriod_6120B05D4057A5121AA70C423C815B26" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability" xlink:label="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_4FB8FB8F32868B57AFDA0C423C81F3B4" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BB3FC6A23161C71D66FC0C423C7FAD8A" xlink:to="loc_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability_4FB8FB8F32868B57AFDA0C423C81F3B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E5F9A1999A048ED96871F8101F425A1C" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2550EE18432510D12243F8101F426C44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6D3263695E6A18FC5A24FE0FBAE42B53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6D3263695E6A18FC5A24FE0FBAE42B53" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:to="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FB4A94EEE90FB84030D3FE0FBAE4F654" xlink:to="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:to="loc_us-gaap_MinimumMember_130B08E37B36619C8480FE0FBAE572A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_437EDFAB65E4055CF014FE0FBAE41B62" xlink:to="loc_us-gaap_MaximumMember_D2E6912C73D573A544CDFE0FBAE5144F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DE8BFA1C7A3A91813D1FFE0FBAE5BA10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_LegacyRestorGenexWarrantsMember" xlink:label="loc_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:to="loc_dffn_LegacyRestorGenexWarrantsMember_F4E48BFDA90FB1DA1A55FE0FBAEA6EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9EE6572FE91D06DC78A8FE0FBAEA7328" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_120B3051AAE99A26CD8DFE1ED56E185F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5CE7636D1DAA5A72614DFE0FBAE5E232" xlink:to="loc_dffn_CommonStockWarrantsSeriesAMember_120B3051AAE99A26CD8DFE1ED56E185F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A3010200009A3310C3B4FE0FBAE404E2" xlink:to="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0164008465CEB3CF3559FE0FBAEA19F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_CA2B8C66885ADD1D7326FE0FBAEA4AA8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D21CAA8D5B36B045809EFE0FBAEA16EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2C97BE27CFA826088390FD52BD59E905" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2C97BE27CFA826088390FD52BD59E905" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3412903EE28FCA3692EAFD52BD59BB6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="dffn-20170331.xsd#dffn_DocumentAndEntityInformation" xlink:label="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_EntityRegistrantName_DC1D55CA498B07154676F8101FADB74D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_EntityCentralIndexKey_FAEECE4E3785E091A5FAF8101FADC95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_TradingSymbol_18423EE1B4C81D611293F8101FADC131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_CurrentFiscalYearEndDate_B4B2315EFFC56AF3B162F8101FADE358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_EntityFilerCategory_21EC2C0FC26ED380AEC9F8101FADB7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_93B0E7341A14F1259F49F8101FAD1F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_DocumentType_A1B2D619E742B5345B5AF8101FAE192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_DocumentPeriodEndDate_8386C1CF836B3FD52F2DF8101FAE9EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_DocumentFiscalYearFocus_BF052C9276355BC6FC88F8101FAEB675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_DocumentFiscalPeriodFocus_23A3D81249F622A5F7AEF8101FAEFC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dffn_DocumentAndEntityInformation_B23D7DB252D47C442AB3F8101FADFF61" xlink:to="loc_dei_AmendmentFlag_DE5077ED9DF4EAEE1CA5F8101FAE7D2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_41C75E94DD1FEDEBCD55F8101F0B4682" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41C75E94DD1FEDEBCD55F8101F0B4682" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_E54BC5D42C2725C0C54CF8101F0B05CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DEFBE5195A1DE5BC99ABF958CC33E60C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DEFBE5195A1DE5BC99ABF958CC33E60C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7C312181543E0D6B605FF958CC33D94B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2DC92DEC38C02FF07D93F958CC33E9B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7D2CB1CBFD693F918577F958CC33E510" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2DC92DEC38C02FF07D93F958CC33E9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14079B391F27E91AB591F958CC33CE07" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_43BD1AC420001E9901DDF958CC34A7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B039A3736945FC285F09F958CC3408B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2352C62E58DCC1EDD3FCF958CC347819" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F7EEE67A57ED0E6F9452F958CC33DA72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2352C62E58DCC1EDD3FCF958CC347819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D19D9A445C655CF52C1DF958CC34941E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CD9484A75E661F956AD7F958CC33CE0A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D19D9A445C655CF52C1DF958CC34941E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D19D9A445C655CF52C1DF958CC34941E" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_40761C368EC2745446E7F958CC346D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_63652B6ACE89EB5F7FA0F958CC341899" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_17F92B3A8FC19CB2C5D2F96BBC6131C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07E20A5B65A10B991856FE0FBA632387" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9F81C6704B5EEBA97347FE23778292DF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_CommonStockWarrantsSeriesAMember" xlink:label="loc_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_36A9967941C4E16A3958FE237786D1EB" xlink:to="loc_dffn_CommonStockWarrantsSeriesAMember_4550B616727DB90CD196FE2377E0ED03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7B73D02CD9C794E0123AFE0FBA63938B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_B7152EA59BAEE6B179CEFE0FBA6305FE" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1FDF094E41573D70E89AFE0FBA636F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14E9C12B336DDBE0085EFE0FBA630D29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BC31833FFCC1F466C8BDFE0FBA64AA4D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7CCE6CECE72C1BB69E47FE0FBA64E72B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F8446D461BBEDB54FABBFE0FBA637DB0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BA4A81B78AF59D67C62AFE0FBA64F4AB" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_CFDCA27A83F8866963E6FE0FBA646C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9BB82DF1FDDE9E1EDE7EFE0FBA648581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_36A347857BE7CD2C6E4EFE0FBA64B01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_C7A08480930CE2BA22FDFE0FBA642776" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30B2ED8008D4CAD0973DFE0FBA64A20B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:type="locator" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_FairValueAssumptionsStockPrice" xlink:label="loc_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:to="loc_dffn_FairValueAssumptionsStockPrice_EF7A4EBE0238D9569FB4F8101EF659FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_6292CC90DED4C2C23C5AF8101EF6A975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_BC38CFB00C42E1F2BE51F8101EF68737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E26376DB3945F8F8A8B9F8101EF69146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6C58C08C479FD72A4F50F8101EF6CB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C0019B807C9ECC360FF2F8101EF68C23" xlink:to="loc_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_0F2927AC2B681FD62845F8101EF63736" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_58592FDB9370880CE96AFD528ACABFF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58592FDB9370880CE96AFD528ACABFF8" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_094F1191DD7D46FC1594FD528ACECC69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58592FDB9370880CE96AFD528ACABFF8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AE24C6E12E757036E384FDC213A3388D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58592FDB9370880CE96AFD528ACABFF8" xlink:to="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_73CF1259D83945211859FD528ACF4CF3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F9CF3F5D22A6BDB86AFAF8101F869E57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F9CF3F5D22A6BDB86AFAF8101F869E57" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5A3A5A5FA51D264C374DF8101F86177C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/LiquidityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37249F915FD6BA257E320C74756AA887" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37249F915FD6BA257E320C74756AA887" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D23F449FCB6386A0ED270C74756D5C51" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_503A734AEB0266F9F6090C74756DB579" xlink:to="loc_us-gaap_PrivatePlacementMember_59BB8EE8A3CEE4E32E1D0C74756DA965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ABB16E613954E8D93CF0C74756EE18E" xlink:to="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_DCAEFBA9B62E6D74A2E50C74756E25D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_C4A45D459C7340BB30C10C74756E3EFB" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_DCAEFBA9B62E6D74A2E50C74756E25D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A46EE2261791036624F00C74756CA170" xlink:to="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceived" xlink:label="loc_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityConsiderationReceived_FE96407835F0E880E1870C74756EA9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4F23A9DD3E54CA9E392C0C74756E7BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_E1C3ECEDC53A4E590BCA0C74756ED61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_C03A4ECF93D375E232E00C74756E2F62" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_D9245CE818FBBBB417C70C74756EC13D" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityConsiderationReceivedNet" xlink:label="loc_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityConsiderationReceivedNet_55FF5DFCD82DCFC439750C74756E55A2" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityIssuanceCosts" xlink:label="loc_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityIssuanceCosts_7F0A7744EBEC5A19FBE30C74756F2188" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_TemporaryEquityOfferingCosts" xlink:label="loc_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_dffn_TemporaryEquityOfferingCosts_5CB227C1BA7BC0C083AE0C74756F3CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_E9B14A2D05BDD8C208A90C74756F5328" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable_E9B14A2D05BDD8C208A90C74756F5328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_17DD72E1465646FBA6420C74756E44AF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B73E1DE8578C1E8262D90C74756F4955" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD62E731B23BCA3FA3BFF8101F88052D" xlink:to="loc_us-gaap_NatureOfOperations_B58DF1199B744B767660F8101F8891C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_BF9E5138F5F25AB5C8A1F8101F53CBBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BF9E5138F5F25AB5C8A1F8101F53CBBC" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1C0DECC4B828C1DD632EF8101F539892" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_us-gaap_InterestPayableCurrent_B5EA760E4866F1D86095F8101F4E05A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_FC40163EB6A7E59FC11DF8101F4E89B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_FC40163EB6A7E59FC11DF8101F4E89B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_us-gaap_AccruedSalariesCurrent_F80A83B2D967EFEA09AFF8101F4E7289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2C716281ED4DAE935108F8101F4E9590" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="loc_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_dffn_AccruedClinicalStudiesExpensesCurrent_0B490D588BB7B0FC09F4F8101F4E4A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_6A9ECA12A1F5A8671697F8101F4EA88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5603CA47116501710326F8101F4E3057" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2CB5C96D765155ABFCFFF8101F4E2162" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_FFF4859D10608EA5CE60F8101F509F06" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_E7647D1243ECFA4000C1F8101F50EF87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_E04B46DC3B97725391D1F8101F2F70A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_E04B46DC3B97725391D1F8101F2F70A0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D11D23462F04702D7FAF8101F30588B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8D9F00FE97395A7C4D7CF8101F299DBE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:to="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14E31A15EFA37DFAC739F8101F2A178E" xlink:to="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="loc_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BBD77C569A375056042BF8101F2AD4A6" xlink:to="loc_dffn_RestorgenexCorporation2015EquityIncentivePlanMember_4BB575219C5ED81B2FFFF8101F2AA720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:to="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_DBAE3AC5F16B1F78689CF8101F2ABB68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_NonemployeeOptionsMember" xlink:label="loc_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="loc_dffn_NonemployeeOptionsMember_1E73A5034A25F4D0BB24F8101F2A0167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28163DFF554F1DB9AD32F8101F2A515A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28163DFF554F1DB9AD32F8101F2A515A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_471D7C11C239ECEDE553F8101F2A92E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2EBF00D86F7BD1E73C35F8101F2A273B" xlink:to="loc_us-gaap_RestrictedStockMember_471D7C11C239ECEDE553F8101F2A92E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DD09AF20375195501F7F8101F2AF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:type="arc" />
    <link:loc xlink:href="dffn-20170331.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="loc_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis_C228FE4586B4E804653AF8101F2A4618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67D974DB0FA4896CBF0CF8101F2A8588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12FC71995758125A3A64F8101F2AAC90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5B1A53209FA860105FB3F8101F2AF427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41D1E1CD82745286C79DF8101F2A8568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8C7B8AC069BDF57B9E89F8101F2B950D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E0D968B65F43D9E724ACF8101F2B6D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_AAE5C22AF488F5239C1CF8101F2BFA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_16CA193551F32ADDFA48F8101F2BD8C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3F41453A103255CDA267F8101F2B2F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46231639EBC4E6E8E484F8101F2B110F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D9A1565AB8184AFA56B1F8101F2B3D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ACF517404660B22212FF8101F2B028D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_97C2308CD4B5CE87869BF8101F2BF015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_92918A3DF3B7ACA6ACEAF8101F2B0E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07BF204D6F254AE7E580F8101F2A1061" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_A85001A5C03FF40E15F6F8101F2BF8CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8E9A9561613B0EA31E3AF8101F1B5EF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8E9A9561613B0EA31E3AF8101F1B5EF1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4B6EDBB4A9D5C7DED5B9F8101F1B035F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CD954778D743B776E6F5F8101F1BD20A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8E9A9561613B0EA31E3AF8101F1B5EF1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CD954778D743B776E6F5F8101F1BD20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_98B68BA3D2B5FCAECD96F8101F1B5C4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8E9A9561613B0EA31E3AF8101F1B5EF1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_98B68BA3D2B5FCAECD96F8101F1B5C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_37D02809A980056430A2F8101F1B02A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_8E9A9561613B0EA31E3AF8101F1B5EF1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_37D02809A980056430A2F8101F1B02A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_09D1987F5121C325C9C20C423C103795" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_09D1987F5121C325C9C20C423C103795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2984BF32C200BAE032280C423C10820F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2CCC551997CAB05E719A0C423C1075A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2CCC551997CAB05E719A0C423C1075A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_BB44B389DE6E6B864DD50C423C100364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DA7C8B0B8D7E18B2FDC10C423C10AD4A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05322B22000523D140E20C423C100E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_09D1987F5121C325C9C20C423C103795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0842CF3F1C4FA0E0C4620C423C117929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D20F4BA0B2835067808D0C423C11B7E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56B5F1664389217A14DB0C423C11C0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CB431E0291D9792F4F7A0C423C115EF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AB3C11A0C194A97BA3750C423C113063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_09D1987F5121C325C9C20C423C103795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1590AC9E4ED7E74B98B40C423C113AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A8B80049F7C54E24364A0C423C121DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1F813786FB205194CB140C423C1137FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_CEA4E421E901AD6BF24E0C423C114610" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F328763822836147F0970C423C12E405" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_5DBA250640EC7A3F2396F8101F24FC63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_5DBA250640EC7A3F2396F8101F24FC63" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CBCEDEEAFBDA3666879FF8101F2472A8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_082ABFDDDBDAE53FF690F8101F2453CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F911D668E3C50C296665F8101F2449C2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_EC79815A384A91A4C7B2F8101F246B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38A2EFC0FF3213D5F516F8101F24885A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9620872DDE610F56FE50F8101F24228C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38A2EFC0FF3213D5F516F8101F24885A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC537C9C47D3590F85C1F8101F244A7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38A2EFC0FF3213D5F516F8101F24885A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC537C9C47D3590F85C1F8101F244A7E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2E1A45312828F0DB5C84F8101F2D2CE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2E1A45312828F0DB5C84F8101F2D2CE0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3AA3ECB3880BE31BAFB8F8101F2E9768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2E1A45312828F0DB5C84F8101F2D2CE0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BB252700211D7D9ED620F8101F2ED6C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2E1A45312828F0DB5C84F8101F2D2CE0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8D6BDB49F31DF1B88F4FF8101F2EA3D4" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>diffusion.jpg
<TEXT>
begin 644 diffusion.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $P I # 2(  A$! Q$!_\0
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M_B<7D?F>9%'\_4>7)_WZK[<_X.[_ /E,7K?_ &*>C_\ HN2OH/\ X)7PS_\
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M?[4WB?0=$TK5OAIXG^-]QH&NQ >5#-9W$=[]HN8__(<G^KKX[_X.0/@YX:^
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MG_!"_P#;ATZ'5H(/ /C:.#Q#_P A.#[;)Y>I_P#7Q_ST_P"VE;EA_P $>O\
M@H1:^%#X>30_BI%HD<?D?V>-<N_L7E_\\_+W^7BOZJO[2G_Y[T?VE/\ \]Z
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M]W)$]6O%G_! ;]M#QSK]WJFJ?"[Q1JVIW$GF75W=.\DMT_N9.M?UL_VE=?\
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M1>'3_L7]F_&*2R\CR/(_M^\\KR_^>?E^97G7_$.E^U__ -$@UO\ [XK^N?\
MM*?_ )[U)_:5U_SWE_[^4 ?R_P#[%'_!"/\ :F^&5_\ $1]8^%FK62ZSX/GT
MZS\Q/];<&]LI/+_[]QR5XI_Q#H_M>R_\TAUNOZ\]-O)YOM&]_P#51U3_ +2N
MO^>\O_?R@#^1C_B'+_; _P"B0ZU3_P#B'1_; A_YI#K=?UT?VE=?\]Y?^_E1
M_P!IW7_/?_R)0!_)EK__  08_;<\86-G::I\./&FI6^EQ^7:)=SR21VW_7.B
MU_X(-?MJQ^$I] 7X;>+(-$N9Q</8^?)]FEG'_+3R_P#GI^[K^LW^TY_^>_\
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M $1W6Z7_ (AR_P!L#_HD.M5_77_:5U_SWE_[^4G]KW7_ #VD_P"_E '\BO\
MQ#E_M@?]$AUJO=?^'%_[3[?\$W)?!A^%FK_\))_PL.WU5;3/[S[/'IU['))_
MW\DCK^G7^U[K_GM)_P!_*L_:Y_[&W[_WGF?ZR@#^0S_B'+_; _Z)#K5'_$.7
M^V!_T2'6J_KF_MFZ_P">TG_?RI/[7NO^>TG_ '\H _D5_P"(<O\ ; _Z)#K5
M6=+_ .#>?]L?0;V"[M?A1XC@N+=_,CD@?RY(GK^N'^U[K_GM)_W\IG]I3_\
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MS#Q70:C_ ,$H/^"C6HVKP75G\8KFWN(_+>"?Q)>21&/_ )YG]Y7]37]IS_\
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MP/H?@CQ);^"+#P!_9,<?C/PW;V5]%>6]Q9>7;6=Q';V_VR/RXY/WDOF22?\
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M>$OBU=7\'AGQ'INMW&E_\?D=I)_JJ^%_$G[*_CSP3XW\)WWA7P)))]F_9_\
M^$<O()+.2.VNM4^TZ;)]FN/+_P!9)Y<<G_33]W5_]@/X9?$*+]KWPOXJU[PM
MXMT70XO!?]DW'V[P_'I,5K<1^9^[\N.WCD\O_GG)<^9))^[HIFA]^T5)4= !
M1110 4444 )%-!9R1SN\<<<7[R21_P#515FZE\3?#<NH2;-;T?\ \"DKS?\
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M4_\ P,DH_P"$IU+_ *"FI_\ @9)1_P 1'_Z<!_Q)7B/^AC_Y(?TW?\+!T/\
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M>@SS/_8TG_72OYZ_V!O^"@?B;]A[XCBXM7^V^%+]X_[7TJ:..3[5_K/+\O\
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M08C,:EZ9_3WT?/&'*>!J>*AF?_+SL?BC_G_649_WZ_:W_B'U^"?_ #^^*O\
MP-H_XA_?@E_S^^*O_ VOD?\ 4#''].?\3B<)?\^YGXIX_P!ZC'^]7[6?\0_W
MP2_Y_/%7_@=1_P 0_P!\$O\ G\\5?^!U'^H./+_XG$X2_P"?<S\5?^_E'E?]
M=*_:G_B'W^"7_/UXF_\  W_ZU'_$/O\ !+_GZ\3?^!O_ -:G_J#CP_XG#X2_
MY]S/Q4Q_O48_WJ_:S_B'^^"7_/YXJ_\  ZC_ (A_O@E_S^>*O_ ZE_J#CP_X
MG$X2_P"?<S\4O.3V_P"_E&Y:_:W_ (A]?@I_S^^*O_ VC_B'U^"?_/[XJ_\
M VC_ %!QX?\ $X?"7_/N9^*7_?='_?=?M;_Q#^_!+_G]\5?^!M'_ !#^_!+_
M )_?%7_@;6?^H./#_B<3A+_GW,_%/'^]1C_>K]K/^(?[X)?\_GBK_P #J/\
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MK+]__KG)110 43T44 !_U<G_ #THE_UOR?ZNBB@ ^:I*CHH DJ.BB@ HHHH
MDL_^/^#_ *Z5)K'_ !_25'9_\?=O_P!=:LZS_P A22@"E1110 4444 %%%%
M!1110 4444 %%%% !114D% %C1O^7G_KG5.M#1O^7G_KG6?0 4444 %%%% !
M1110 4444 %%%% !1110 5H:]_K(_P#KG6?!6AKW^LC_ .N= &?1110 4444
M %%%% !1110 4444 %%%% !-YG\%>2_ []D/PS\#_B/XG\56L$5SKWBRX^TW
M%])_RRC\N./R_P#R'7K5%9U*5.I_$.G#8W$8>G.G3G\83?ZFKGD_\4Y_VTJG
M6A_S*\G_ %TK0YO4SZ*** "BBB@ HHHH **** "BBB@ HHHH **** )*IZS_
M ,>UI_U^1U<JGK/_ ![6G_7Y'0!T^NZ9]KN=_GQ1_P"_5#^Q_P#IZMZG\4_\
M?-9% &A_8_\ T]6]']C_ /3U;UGT4 :']C_]/5O1_8__ $]6]9]% &A_8_\
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M>]E_#&98W+9YG@Z?/"G\9]D058O/];5?SO/_ ._E6-3[5VG@E>BBB@ HHHH
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MW-!_[\&OB'SA_D4OG"E_K+F?_/PT_P"("<"_] ,#[=_X?X?&S^YH/_?@T?\
M#_#XV?W-!_[\&OB+SA1YPI_ZRYG_ ,_ _P"("<"_] ,#[=_X?X?&S^YH/_?@
MT?\ #_#XV?W-!_[\&OB+SA1YPH_UES/_ )^!_P 0$X%_Z 8'V[_P_P /C9_<
MT'_OP:/^'^'QL_N:#_WX-?$7G"CSA2_UES/_ )^!_P 0$X%_Z 8'V[_P_O\
MC9_<T'_OP:/^']_QL_N:#_WX-?$/G4>=1_K3F?\ S\#_ (@)P-_T P/M[_A_
M?\;/[F@_]^#2?\/\/CA_<T+_ +\5\1>=1YU'^M.9_P#/P/\ B G W_0# ^WH
M?^"]_P ;/[F@_P#?BC_A_A\</[FA?]^*^(?.'^12^<*/]9<S_P"?@?\ $!.!
M?^@&!]N_\/[_ (V?W-!_[\&C_A_?\;/[F@_]^#7Q#YU'G4?ZTYG_ ,_ _P"(
M"<#?] ,#[>_X?X?&S^YH/_?@T?\ #_#XV?W-!_[\&OB'SA_D4OG"C_67,_\
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MX<0_'O\ Z!VC?^!R4S_AQ!\>?^@=H_\ X')7[C45Y'^H66'Z;_Q-IQM_<_\
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M]-*/^);_ --*S\?[%&/]B@#0_P");_TTH_XEO_32L_'^Q1C_ &* -#_B6_\
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M\2?9?LUOL\S_ (_(ZCJOK'^IL_\ K\CH W_%/_'S616IXJ_X^JIPZ=/>?.E
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MP>_Z 'C/_OS:?_'ZC_XB&/@[_P! 'QG_ -^;3_X_1_;V6_\ /R ?\0;XX_Z
M*GW'WYILW_'Q_P!<ZI^=^ZKX6M/^#AWX/0[_ /B0^,OWL?/[FT_^/U!_Q$,?
M!W_H ^,_^_-I_P#'Z/[>RW_GX@_X@WQQ_P! %3[C[PHKX3_XB$_@]_T /&?_
M 'YM/_C]1_\ $0Q\'O\ H ^-_P#OS:?_ !^C^WLN_P"?D _X@WQQ_P! %3[C
M[PHKX/\ ^(ACX._] 'QG_P!^;3_X_1_Q$)_![_H ^,_^_-I_\?H_M[+O^?D!
M_P#$&^./^@"I]Q]X45\'_P#$0Q\'O^@#XW_[\VG_ ,?J3_B(3^#W_0 \9_\
M?FT_^/T?V]EW_/R O^(-\<?] %3[C[LHKX3_ .(A/X/?] #QG_WYM/\ X_1_
MQ$)_![_H >,_^_-I_P#'Z/[>R[_GY /^(-\<?] %3[C[LHKX3_XB$_@]_P!
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MB@ HHHH **** "BBB@ K0_YE>3_KI6?6A_S*\G_72@#/HHHH **** "BBB@
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M=#N],BWW5C<VT?\ ?DC\NG/"UX4^=PT,,-GN5U:GLZ5>$ZG^,IX\\;*^^?\
M@CS_ ,%*=5^#7Q!\._"WQ"+S5?#.L7D>GZ0\<<DDNF222?NP?^F?F2?]^Z^%
M]#\.7?BG7[#2M*M;F]U#5)_LUO;QQ^9)+)_P"OV;_P""6W_!*;3_ -FCP]8>
M./&-K]M\=7R1W$<$GF8TC(_U?E_\]/+_ .>E?4\'8/'SQ?M,/L?SW]);/^&,
M-P[/!YM:=>?\.'VS[G_UL4<Z?\M:*CFED@-2?ZVOW+U/\LX5*=1_NPHHHH+"
MBBB@ HHHH **** "BBB@ HHHH *T/^97D_ZZ5GUH?\RO)_UTH SZ*** "BBB
M@ HHHH **** "BBB@ HHHH **** )*IZS_Q[6G_7Y'5RJ>L_\>UI_P!?D= &
MYXJV?;_G^YY?[RO@G]J34K.S^/'Q.@\47WC"V\9WYL_^%81Z=)Y=MY_V:V\O
MR_\ MYQYGF_]-:^]?%/-Z/DCD2LSSGAB\O?)L_S_ *N@#\YOB%^V-\7OA7-X
M?M?$WC>R\+_\)%>:I91_\4_<7LD7]GVVFR1_\OD?F>9)>2>9)_TSKK=8^/'Q
ME^#-KX@\8WT'_(QWEY;2>'I+.23^P9/^?F.X^T?^0_+_ .6E?;>H^%-*UCQ3
MIFLW5C;W&J:/'<16=W)''YMA')Y?F1QR?]-/+CK9^V/_ 'XJ /SK^ _[5WQ[
M^.7@.W_XGFDZ3)H/VRYDO_['DN9=9CCDD\N/_C\C\O\ =^7^\KT+]L/QOX,M
M/CY\/[[XHW&JV/A34_!@D\NQDDC_ .)A)]HSY?E_\M<5]G?;)_)\O?1#>3P_
M<H ^!_A9^T5\7O@SX<TN^\=ZC)_PC?ARXTNRU2">SDDOOL]Q'>R7%S)<>9^\
MD\RWM_\ EG_RTK/F_;\^(7_"6^$Y]5US3= DUG6([;3]"DT.X_XGUG<?\M/,
M^T?NY(_^N<E?H1]L>&7[\DD?F?\ +23][7':]\"_"/BKXG:9XSU70-*U+Q/I
MD?V:WOYX(Y/*C\O_ *YT ?&_[7&L>%9_VS/BAI>J7WBBR\?W6EZ?'X'CTRXD
MCD^V?8H_L_[O_5_\?-<1_P -[?M&:#K/Q$T.^T?1-)N/#FGQ^7/?^9)_9?EQ
M_N[G_61_ZS]Y_P!^Z_33[9Y/W'D\OS/,CCCJ.&:3S?GGDCC_ .F$E 'YUZQ^
MV]\38?A5H_B"3[-X;L[[2[..\\0R:?)<R^9]F\SS/+^T1^9YDD=7_ G[8WQI
MO/!&A^/DOK+6M#BM[./^S8]#DC_MGS-.C_TCS/MG[O\ TF3S/+_>5]P?%3X2
M>'/CEX;CTKQ5HVFZW;Q7'VV.WN[>.2+S/WG_ #T_ZZ5K^'=$M/"/ANQTG3+2
M+3K+3;?[%:6]K'Y<5M''_J_+\N@#\N=!_:N^,OQ@NH]5U_Q5<Z;I?AS7-0MK
M>.PT^3RM9\R.R^SVUQ_I'_+.2.3_ +^25[99_M:?%N\\7:QH^G3V4?B#[/);
M7FA2:7))%X7C^TVT<=[YGVC]YYGF2?N_W=?='VQ_)V/YL?[O]WY<E'G>=]]Y
M/+_Z9T >5?LJ^*O%6O>&]?TKQ7=6VM:KX3UB\TY-6C@DM_[3CCN)/+D\OS)/
M+_=^7_RTKU'_ %O\=233)-]__EE_J_+_ /:E1_/-]_\ UE !1110 &S@U(?9
M;I/,@NOW<D#_ .JECKF=4^ ?@M+]_P#BE-"_#3XZZJS_ ./NW_ZZU9UC_D)R
M5G4I4ZG\0ZL-B:M!6P]3D.(_X45X*_Z%+0?_   CH_X45X*_Z%+P[_X )754
M4OJM/^0V_M3&?\_Y_P#@9RO_  HKP5_T*7AW_P  $H_X45X*_P"A2\._^ "5
MU5%'U:G_ "!_:>,_Y_S_ / SE?\ A17@K_H4O#O_ ( )1_PHKP5_T*7AW_P
M2NJHH^K4_P"0/[3QG_/^?_@9RO\ PHKP5_T*7AW_ , $H_X45X*_Z%+P[_X
M)7544?5J?\@?VGC/^?\ /_P,Y7_A17@K_H4O#O\ X )1_P **\%?]"EX=_\
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MHOP=NS_PB^@_^"^.OB3_ (+F?!72H/V7;%= T'3[?5[_ %**VMUL;2.-Y/\
M5U^@E4M:\/V/B )]KM;>]^S?O(]Z>9Y4E<6,RFG7POLSW.%N,<;D^:T<S]I/
M]V?#/_!*O_@D];_LY6D7C?Q]:Q7GBV^C\N"QD@CECTS]Y_K/,_YZ5]_ZQ!Y,
ML?\ USJG##Y5:&O?ZR/_ *YUK@<MIX&G[.F<_$_%^9<18^>9X^ISSF9]%%%=
MI\V%%%% !1110 4444 %%%% !1110 4444 %:'_,KR?]=*SZT/\ F5Y/^NE
M&?1110 4444 %%%% !1110 4444 %%%% !1110!)5/6?^/:T_P"OR.KE4]9_
MX]K3_K\CH W_ !3_ ,?-9%:_BB%YK@;$DK,^Q3?W): (Z*?]EG_N2_\ ?RC[
M+/\ W)?^_E #**?]EG_N2_\ ?RC[+/\ W)?^_E #**?]EG_N2_\ ?RC[+/\
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M6?\ N2_]_* &44_[+/\ W)?^_E'V6?\ N2_]_* &44_[+/\ W)?^_E'V6?\
MN2_]_* %JGK/_'M:?]?D=7(;-_[DG_72J6L13?9K-_)N/^/R/Y_+H Y?XH_L
MIZ?\:/B%>ZI>^*/&^D/%'!$EOI6J_9[< ?[&RL3_ (=YZ!_T/?Q1_P#"@_\
MM=>W6/\ R'=2_P"V=:5 'S__ ,.\] _Z'OXH_P#A0?\ VNC_ (=YZ!_T/?Q1
M_P#"@_\ M=?0%% 'S_\ \.\] _Z'OXH_^%!_]KH_X=YZ!_T/?Q1_\*#_ .UU
M] 44 ?/_ /P[ST#_ *'OXH_^%!_]KH_X=YZ!_P!#W\4?_"@_^UU] 44 ?/\
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MK^Z_=_\ (P?_ &NN0^ '_!1;6/CI\99-&M/ GV?0/[0DTHW<^KVT5_921_\
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M_+"@#Z9HKYF_X9C_ &C_ /HY+1__  W$?_RPH_X9C_:/_P"CDM'_ /#<1_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lease1317exa.jpg
<TEXT>
begin 644 lease1317exa.jpg
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MXH$/?.#BL8]][.*1CWSDXJ$/?>@D#WG(0Q;WN]_]%@][V,,6CWK4HZ:C@<5
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MSSOY5ZA[W>M>TXM2/*H(*Z0>YI#\U!MH1WM4/_>YSUU,'WFE?[CFV*8[B.G
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M;?R;WO2FBUO?^M:3M]-;]9_ZU*>F.E$_ZFL.J1]U!?J&OS?U+U*@?2'UFWY
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MAOO"1:_D'Y%.E80;&#A,&,1T?630,G"TGC% 8GB^#.2(")*"Y!C(V!\$!Y%
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MUJYL*V+74W?VTG$8#&P&]5C'*XX:SZ7QD\<28=(738RJ9QK$T8<12$0(L41
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MY3,49C6,N<Z!='I(5+KEFW0X'@H/O0=+'&$<DX<\,QC4V;*TD49&@Q'0X3S
M]$NGBV?4@RB,!]A?I3*&'C(ZT-4^,(.'M!@$AI !=?10T8$^;8<8&#BL6$9,
M$9[# ,^S0=!SCIA:-O,M91-4-LFSCS 9:$EL0+4#?K-+!NNZ= BV%_'<&%1X
MK.QA_#?_YM\L_MV_^W?3?D?>+OL;>;0L4=I"\.W?_NV+RUSF,I.]0FJ_\SN_
M<_* ^?VO__6_GCQF]AU>X0I7F/9.VC.JK9!@^_/_U;_Z5]->0.F[+TV$P3G2
M_;W?^[V+RUWN<M.^5D?Y"6^";G^J/97V6]JW*;_O_N[OGN+0U5Y"NOH_=66@
M"P^4>W1PS&_AD!YBSZ*TY6._)D_?J:>>.M6)E2_[%Z65O:C*9/^G\,+<]:YW
MG>*K/UO$D!.DPSY0Y9*F^J.7,M.7_NK:.1WH](__\3^>]GA:<5.VJUWM:A/)
MY3GTYR[VBU[VLI>=Y"I7N<IT7SSITD'^O.+R33M*V\J?.D.8D"?UK8SRYC67
MAO((\T_^R3^9ZLA^3-=3+NTG'??L@U4GTG;/[]PW^;$E 3$S^3&6&M/T66.@
M:R8;R"3RB+3Y5R<D6?W27?U(6STJHS;^E__R7T[E^;9O^[;%/_VG_W1QU:M>
M=:I7^JD/]_P6]SN^XSNF^O'>B'*:<"&$B*\)D_'7F(V$&8^-W<9BOTD/QM@Z
MO@?(MDF3\=F8;:+#.^KY].Q)&^?PK ;2083%R622+B8<R#2$_/4P=[U%#2?]
MEI@BE-H@?"1<*5Q*G$C.(9Y[=LGV#"1;&KDO?LW;;_?JM4-/3!561;255Y%[
M*A0)9#3,MK+I-Y(&TCD\(,BJV:6.9^9E*<(#A:2"O"-TT- ZIS?5/(CRU%'-
MKJ3)8Y!X]6B %0]!1E[I:2^,!QP9->M%<G5VW@^Z^RU/'2VZIX,GW8'] <^X
MF3NB8-*@;S!  T</!LW#3DP]WP8H7C(V*$A?XZDTF'G^P7//YK )/3L(T@1A
M#?PO?.$+)V\8@L'F&,#9*3:.=RP>3V)"'H^H>P9@WDP#/X\>+Y85'42/[:(W
MF^D^#Z15*7;1A)NM\T:PY4NVS(0?B> MDK>]^I9]><OD:0F45Y'MDY;?A,Z(
M#;*%!+F&R'D)!PFA$WN<="T?L^GTHS^Q6A4/I3V>TB,\@/3@B12/%U%XZ8C#
M9K/7RF5<\/(//;050BLN1X(Z(LI-'W&DQWLM'K+&*>&:_;RNR]/$01TAUPBK
MNE!?R!RQ7&XI&;G@A<PU=1[Q/*@/XPC=K,(AD<HGK.L(*P>(HWH3AUU#)*4K
M#^12':I?NJEK;:GL\N4YDYYR**=^HVWT&>VESSCFFOZCS8EZ5)_B:&OUJW]H
M$^'58=)SY)EV=%V_U,[2=RX,T>=,'$Q\W.=A-KDPEN89V VDX5GC1#(FAZQ5
M>';=KQ#.6(ZHFG0Z-ZGTO/+,:G^8&\-=W\GX+GUYT3E0)_I\O0;*AD^$%XE7
MXR9_7F)] ]&N>HF_2L=#3TQ5 @GY[!GD5)K[/(T>6 ^SAA$WL/00KX*9D(=#
M)P(/I%D8#T/BU0:5OH9BO,S^D)8,(#6/'@PD##L#XH$#>X$8(@;.@VJY'U$V
M8_7 &4 "\3T$Z3RK.L7 SF&FJYVTKP'%0)'?M3\,["^6$=.YMT,/&M@/SS:;
MY&4.=L= 9P+,4^J^I<9,J&/G8A-[D)Y^ZLC#B!A('S&U3+E;("4(%= /63"1
M Q/TNLT"F5"6 ('P?('R(2N\N<IBB1J!!G;.4K[E5C"P6PIV! X'!#*P-&W0
M!X.H9[4E#'L!8P1"! 9LQ&,W0."00=YNY&TW0# 0/6,*HNME*G6X5U@UYJ1?
M&I_U/?KH'[WQND*;KAH_>WGK<R8VQGD3!>.IL3O]+6E&KYW F*L_*8NV9H]L
M\]!O34209GP#"8V.(8CZG^T%ZH!X)J6A'\-<?=)U[MXRB*/>:WU[+DR,Z-/6
M@;"Q%>*0A,G1Q%@_3_FBE_MM>D'"#&+Z3:B,D :S<S,N'8@A!"\0Z$!F?AY6
M#X/*UF!!WH8T"[8G*8W,D,I?^L(3!L5L4Z=%7"SW/.E)3YK>(J1+VV@ZIJ4:
M'HP,JHBQS>!F4 RM>(Q)]B?9*A#011KRID<:?V#G,"!F[TV%OH.(Z@^!V;]K
M]LT-'!UL S'U'*</&@21% ,7FV+YS'WV)P-+[$IL3,\.L%FQ73QHR!3[%[+B
MNH$6Q)>VO"/5SK1Y.#>99^M .W@VV"KI(L!T#X%$'GF;0#EY14..$0EV3GZ
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MRR</I=FI#?EF(!X<UQR14]X,AI=A\9M70&>2A@<S#1XX3WG)P,!AQ""F%Q]
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M0PCO@="H'B+>40]/KO.TFLW8"L"H>$@9%<LB]&/@TNCB],H],'!8,8AI'^P
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MXAOT8]L@US,(R<<UL@R)QS;%/D6WF@;)N6.5A)V[7O-I[9_KP,9:[4+,V-;
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M]3,&WI+7<<S"S YT' U3.ZI&E(=.C]#ZL*_E?+!W*'M=/&@:6)R 46*0&(Y
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M377>+4+P#+AL),)C)8P=SV?VD$8ZL<MTKSK2.743*"=R6+UKPB=>KXSRX$A
M+NEDC&&G+9FK7TX* [M[J3_IT%T<1_D*6QT7\B&IWS;?0%AYBI<PCCRAR)LZ
M0=;L#50OB+N50L3"N,=SYM\1D1*$Q(H?LB&<N,Z1C*P@(E3&1"1%&.3#"\;&
M+HX6<1!-R^V<-,@8PHE<(I^\F\(C;+:R&>,X91!1Z?(N2I>^\90BNLJ D"*W
MPB--\N;EDS;BC9@:P[6],5L?Y_0!]:RNH-:EWZY7<2VR4^39X5UV-"&DF_[
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M.JWII R6SRUC>S'(OD&$1-M;\J<O0N>Z"0K/(@^EZ_E# &0P6\R0#1Y5Y4)
MD7![:O4AQ-AO_5>[(*72Y9U%A"T+(\[2$-?R.UV05MO@[&>D"\+I92CAW/=]
M<)^-RG_A2Q]Y%L]V!'E*%\%&K)%:^OCC'$O_TI 7$JM,4-M4_]@MI*7]TZ;.
M(VE?XES>B'1]L<CU$';HZ93X26L.PM0^ 7[G^4M<;:K^<E[O.<;CZ;?XF9PE
MC'ZNK<23MO)#CMK!Q"/(<PA;_?+3'%1L&BZ5#&G0&-\T)'$>@YT.6)$P[FG
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MS]'QBEAB]<41]E < Q"[6$E*\DS^$>>NRT/\EJCDO(:GA_#Q' H+CLZ),,N
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M\F0EU$;&A_R+DZMMC!_\>'83E*<9WRFGG-/UO/!K//GS;*OLWDVYLPRL[E@
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M>%>X-2S,?#' R4?/)[0?B[\ZYU<[!7[E5]U'3*6E++T'Q-3$H'J9V(GI":C
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MD_V?^C:B9W)N:TW[O5D_$0&6*M\Q+;\3XF)EM<1*YSOT1(\@\>E/I';J4O$
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M7M>$OO0XKK#Z:WFE%Y6%OK6D'Y'K/6+*0AE)**[Z.QT0K(;0);8'V/9 =[.
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MBNIGAB4GW+%TSB&9$H=Z-TYH![+'20\\PQGF@6:ZS.H%:V\6\VMB)Z9W ,)
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M@"5\I^2=XJ:PS68MU=A72JE1!F;#"!!B2DF!=(+.( ZS-H>=D$W+__9!VG;
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M\&LX?NA0$Q77P75AYO/'@?"<M&\;%R@3E$=D]#N^XSL.6]C\1S-\P#=DG>$
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MGF;7R*<T4N#>\VOF4UP)/&$$RV0.25%&2"WA0VR=A)4'>:&@Y,L @4PAI.)
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MM0L_ZED']6M@+2X*TZ!K\-CQ=/"\$U.Z)KTVKU=$5H!N:F!&NDQ^R3\BH ^
M]W-P;2(>R9S0YT+IZV,L/^<&UR9Y)N)(HGO]CHY^W(%9?YQAZ4,6UPDDZ=PA
M4'5 C^CS]*^ZV2(<3QKJL#(@TE;(TN,3Z1UDDUZOS,++.QC3Z"DD%IF/')(!
M[5;;*5=A@G%..QBSZ$EMGWQ(HTF(-J-GU:?Q%+&T%Y=,,8080Q%<;2P?]*UQ
M3)Y97-6Q]&>^E0TYFT3<LU8OC:W\"N,=W4P/V%9@+)87VPYL5[ ?&0$4UGC=
M%@5Q"#_A7K_@E*U\70I^A=L*(\[Z7C !TCZ%,_E!W"O;M7$),6RKQS&<>W\*
M#YZ8ZAP4"$*)/%*VGFTU+H7)DJC#ZZR$8.VD!,:W+=_YSG<>A!KXU]','LV\
M"/I'/O*10V>P&1[Q#!2"!I.^Y:JWO>UM!PL"0BE^2RA.4MJ+)7[+7>+RW)*3
MV9YG'_C !P[+9\+IF Y>F1%*7\<3?P-.Q-JL7X?DUX$&G=M,$F&SM&\6^A"1
MDF3YC)@B_CH^A0#JWF2!DJ2<:O-076Z!G(@WA:8]M''UON/N\3P04S*;CB)K
M^G.#IV?>D7V_.>\:( O?(.]7.._I,Y-B?<&$WJ0,A!&'\-(T\)OXFGS3G=,/
ME!;TJR^R2@K'KW0-O/2F7_VHY_J1Y7T6-'T3$?9<7Y4W^9]P7]E+#^156&D'
M9"HK;T#0Y,T$E%]I*8O\B-<U1V_0(R:WRC'3.@7^<C>!](51-])3%X@><L@*
MJ"ZJ\_0.(X:ZD^\U/7'D'Y33LU5&*FOAU;N50.V!Y/F%TA .R 4CBZ_+,+XP
MWB"IGK$\&V\87&S38%F59X07664H,4[+3V4Y!N_Y2^?*G[*H+]"6QC7.N*A.
M;#6P7<'V$.,?HBM?QF/QD,'"!_?JHKIQ7YNL=;N%ZF;+;W4\99EL&5."OF&E
M3_[N D^:&-X4#YZ8 D$CC Z_L'01CH0*7"?8R%O+3"DW@JX#)!24 V70/6'7
MD>RS,>LC:):/I-G,1USBT(&%!\];OJ TI461. 7JVW[-]G0NRD">^/%,O/9D
M21MT:J?[=2[D59[%F=#K%)9^Y$F'1)8]LURM<TJCN!X::D.*D2*EI)09M$G*
MC[\44,_5G?N@SGK.B==[X;3Q?*ZM^=]Q]WBHQ)2,YL@=.3,P1UC<3T<&<]U'
M/KC>@>?)MT_K( ETD$$<24NN)^C = N+DWY0_]B"?(O3JI/\]HQ_X5P'^;)2
MH;]&*,7/R0?__+@73C[<5\X5^5%.8+VS$E5XH#NM3-'OTD0(0%TA?\82<2-
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MT=UQ73Q48HIP&J -V 9F RN2@0#2;09P9-5S S$]YV 2DF&@0\P0!&2,O!L
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MN.][3!$<EAUU'!&-0!BLW+.H<-X;K!K(&DB/P7N.7V$B0EG!#,CO?.<[#\3
MOD%[$*7'V=/'D@7R8^ NW KOA3&P;KV7;M8^5C'6V;GD.5&YBL?2IL%:'_!.
M'40..-?5EW(X;(4X!GFJWO(;P2@-O[US73K >F6/(HL;"Y_^J#SB$\\IB*OT
MM9]P[M755GU:INZ$.<*"D%<6\F&/KWY8/K61/;:6QFV#"/(O+;]AK2^6;99-
MUG)IB:^V%W;6!Y %^5''R+/P]A;;5PH18Y 7^SBML#A,9CE?.4QV^&$-%4Y<
MWJD?3CV[=\C)"H+P=*!W\J&?VV=L D(F^ 5YX4?>9SD1/'M-[9,&;6>"@8C+
M'UE4Y]K5OFGYJMS(L79@B5;>RG8.TI87<01YKQXG3 KLH^57.'!?O]L*\Z2Q
M$],=.W;<:SC48(!\EG"?B2FL@T\#:_"^@8MKD,N=0_YFO)$65B0'45A&+7<Z
MG"(M@[##1$Z!@_"><<?2G /Q"N&D">1'W%MR5/F@7WFS%"Q^SUKV1/"XPG ^
MG.YD>FD!LB*,7_XKG^O2 /&4!N<]F(@Y[>T@CV5AU_;)GBIO*![Y*0_">8:\
M('.>(U81.U8]G]!"4'U5 -$&Q,E_/;+TC4@B^D[+6_96/TB7.$'\Y7_6:>W'
M1>(01@2N?.4/O$?*U(&E=_\B5/HLD,BC0U-('S_B@]("\M->T=DF6Q >P2:3
MP$IMHJ0]39I8A2US.^E.=L2-V$)$4/YG^DBW@U\(+RNO_<2^V^N@E#I&;-4_
M"ZZR6#% >*5%[A!5;8/ 5C?G(!_:<O4_\Q5,>I2O=^I;^GTUX"ZP$],=.W8\
M,_CM__#;!Q?.W?^[_^W?/?KYO_?S7[D[[_^N<-^)Z=- 9(4UR."O_@S>3I][
M!PB(P?L2 G8)I(=\6 E@,37@!\]9$)&$%8@-"]=*;(3QK/PB P@CJQYXSB%9
M7->3(+B.S.1"Q,)2/LN9>O(% M8UQ$CZXBS,##M1NOS/M-0K0H5@*KN]AHB9
MKPT@2+[IB;BP.-K&@#SZHH%/7UD"EB^GZ/EC3;8= X&J7L4O7@[4K3J27FTJ
M;YXCOZRGPN;?.[#WT_*W$^^^26KIVS*WO;\F,_*[9?T6GN6/A1?$.]M\"X@@
M9\D?>?3]7612?;.<^D(""RA+HWSX L!<35*_7$15/<DWJ[*]KBRMODB ]"+R
M)AKR16Y8:%E1.>GZ0H!PR*]Z.]:^*_BK[B9FNU?_TLKB#,HB7]/Z?6WLQ'3'
MCAW/#'[]-W_]T8=^X4,O$TK7Q^Y_\[=_\]'K?^;UC][YOW_G2?_BO&OLQ/3Q
M82D?X3+P^R23@3I8NF910J@:5%=L/0L&7\0Q/P9K R]"@9A. H0L(3=;EB;6
M(T1A):WBYC_"ZII5#)$29X34>V6('$8*0-XBC!&&2$7Q(F#VW]IN 3.\ZTDX
MM^ Y?_Q,PN)^EA4A82U#D%@(6>P00-911$O^60L=1 1MA[C:SZFM'.HQF>"<
MAK>GTW,67@0.L6/I%+_Z1!I90MW;SF'/ITF#^I:&YTBAN/H ?]9KEDL$4ELB
MM$T>Y-7GR"Q'JS?65),=I-LR/G]D"@$G PBB4^FLQ.+TZ2B$4'BD31ZD)_\L
MQNXML?-K#[Z#>_(J/!D2-TNJLDO/),5GO>QU-:G@K__8Q3+K$VGJ5CF0?VV)
MO"+]B*SZ4\^LRK/='P?D@$L.01U.8JH/D%]YF[)R3>S$=,>.'<\4(J>1RF/W
M;_K?O>G1?_$O_XNS_I\&=F+Z^##@^\ ^$N"_YDQB:C"./"(L2.46^<KJYQW_
M!EV#K\$> 9AA(HD&_&,#O3@F8?-)(02,?T[<Q>G7 -Z]:T1IPKMC:<V\A9DV
M(&?K_U8'896'6\.L*)_EU:\PRL(!:^>ZO2$",[&6!;FQ#&W_*6*&W")N2!<"
MBKCU3PZ0-8>&D&!61Y8YA!19<Q#)$G;E14(1))]XLJ5 NVA35DCD#6'+PNH>
M<><BK61+OOR7)VV(!%M:ERZRR_)<7J5IZX*#9:[5#T0:Y5MZM1>2W6?.O).>
MO) 3^596^61M_M9O_=:7K<HLH[9DB%/=RCO954ZR"MI#VW#2J[V.H3R=0K++
MK]_BDU<$&$I'W<Q#D-?&3DQW[-CQS"&"&6Y[?]?8B>G-T6"*2%C:9*6QS\X)
M?40$J6&!LZ^0)0RY0<"0 P,X(L!ZA<RP>+&21:H,KI:=D1_@GS5*&,3'+RN6
ML,+83L!"A31H1^DA6/Q91D5@D"<6OLB;.)%I!(5_D#_6,N2:90Y90KQ8^I0)
M49(&("U(#R(3*4%F$ 56-<0,@1)6.2SEM[P:J? ;,3U&?%<(,PFIZ\*Z1I;X
M81V.S$1<M9D\<^ =_\B>0XDMI\\X"@OBGW#/RBP<?^)7EA4F* @@ B?NXI&&
MO(AC"\*I;X1QUD]IK4 <32JJURT_\NH=F=&&Y$$XD"]AH?3(B.T'/E5%;L@O
MF98WX$\X=55]B8-SK;S\;.4E>+>^G_?B$@^W^M/O]+4)DPG]YZZP$],=.W;L
M>,+8B>G-88 T8"("/L^C_NP5M#2*3/CO.RRI#KBP=K%L(0"L6<@!,H<TLH*Q
M[B"6R*!!W[(M?^)A#;(G$GF,2#A@Y;\4(9'\>2ZL7X0#$?5.O.)"D"WY(JI(
MHL]K(:[\6^:U;"M=^RW]^TN'71!N@S[BB7"*DV4.N55><?@D$/**O/@_^0[V
M*0]2('[A+1_[+T_V._(+D1]UB&S<A)@*PV].7"M9\8PEK_?2Z+GKTD><(E3J
M7]VXWD+I3;B/Y&ZA?/F5GQ7%67XF/)_Y+FUQ23.2NY8=BG.K7M2UO"@[(+V1
M:?Z5WSU'7LD5JZFVU<XF'?:<1F9GWH47;ZYGB.M6/L'S+5?^N>IBJ[S:S02O
MN@+;(5A-[PH[,=VQ8\>.)XR=F-X<#9#(I7_9Z.",Y4Z';@"Q0^A8PU@/#:X(
MP3$R ?;\^5>?]O*U/"L^_WJR;Y :L W&')**Y(J3!2N"$9 #SZ?U"#ET$,?>
M08=JD%6P#&Q[ *NH>"'2$0D!9->>6O_:TCY&I-M^1\1S?B<UHB!]_V>>]70M
MMWMYY'<2G'/8BN<4^3D%! \0?Z3Z)BC_-\G[I1#W,5F)^*WOY&-:/2?XG?[G
M-?_NI4>&7)-7<9%!UG9;$4RNR(R)T;IEXG%1OCCYR$VX/U;FB&GMZ+VV;+7A
M+K 3TQT[=CSSH-#O$K=-;R>F-T>#)P+)(LCR9"^@_SL.2)N]>^JU/7 &>P.G
M 1:AS-K&PF-IW@EM_]+4LC+":_G?@2I$T)*X\(B#\-K<;U@'[,"?</RR8B*?
M/ICN?Z$CF0X'2</_]V?=+$_*@Y B*YY9JF<1KHRV'B"E+,8L:?+O8!!("U%(
M+EG9LAQ7_L /=RS_X=1[[XIG)37G@& )Q\)L6T/I1(;4G>MCZ0NKK.J(_YNF
M/[&F4=SR$/C)HID\^>57'DR$./>ALI2_TNE7>&&S'L_T3*H04P?$M"%Y][DH
M2_JG(.[B/P5^Y&EU*RKCBI;R2TL9D6=;3^X*.S'=L6/',P-+K10@RYAK@QPR
M@5@\21B$6 !R]O'!DTIO)Z8W1P.A]GC;V]YV6$+WN:A7O.(5AV5NIZ-9.\D%
MBR(BVF#-(7P-M-K3H$^.G!I'D!!!%CS+[0@E8FK09<U$)B-4!FQI(!:>LXXZ
M68]8!FD)1TXLS?J5)\237P.[__#CUSUY$QXIBB38V\IJQE+JD-"TPLH' L-Z
M%3&*J 'B*ISR>2[^$&&J/D/U%"%1AM6?:_GCAW.]QA.*;X5R(F/(,Y*3'W%)
M]U2<0=YJ3_E8(8Z5\&VA/$ZGKH2'\E1ZE5N]N)=&)+DP(![ARE]QN_?KF3 Y
MSX3G3)KLH;;5P_="6<5]]Y7,E0;_$\5=_,?@W4QKNA65=84V,PF<L.W$I/"N
ML!/3'3MVW"DB@5M #A")+$(&?*=5+X$]ADYJ7P(*GO\<$FG/UTS/$NVIM$^]
MWXGIS=& :RG\K6]]ZZ%N[>-\XQO?>!@H[=UT. GY0]CLQT0RD @#;P.RMIU
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M2C\0-^D+4\.1+VY32'-*[LPQ#=29N;X^: X+@Y@.# SL'8.8#JP+P^+F)U+
M+)?V%P7*%P$RY*YN*<R<\Z_*V1Q!I-'0.M(898Z$(%Z9CRD-?A2T\Q!0?@@!
M F/NI6M$!<D(23$<'/(F/G]Y.=9AV4"8A)TB!!65<%2'!)&=K(BQ^8X(E?('
MPO5(ON"^.E >9;,(S)2 F@:$J($XXO,+P5-&<=1%)5X)ZS@E2T7J@GQQD7,*
M\@?EMNA(_@G?QZUYDX_5DZQD#Y%/W7$AH_J3>:NU3.">-C?74AKR2QFU"S(L
M+M+/FJ[O2+/*))X/+]9:>^:J?U9KTT 23E\S?U=>TM&GQ),/?_TV]0ZUG)M
M?E4VY\K,&FU^K#+%G[4Y%NK#P""F P,#>\<@I@/K C$UI$[AON4M;VG#R^ :
MZ3./T/ ZY>F(H" =E&K(A'E[AG$-U9H?QZ(&AB01 L.IYI&Z9W@[H(Q9SRC^
M"B0D! R9B4(/00AA% [<#W$)Q$L:E1!4))ZP*4]<XB,IZD&XA WD%__D[4@^
M?H%TS,E4U^986NSD&BF"Q)5VXI%-/&0+*0T!#XE/F1SEQXF?M/@GO913&(1/
M&M)5GXDC3,H>R!]8';6]>/RD)9SXY$J=2*.OAT!8Y%'?2)\RC]@0N_F?M;[
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M]%%BFHDV]V]DR&KF$H-PRH- 5_\*9?,AD+#*94<*UFM36Y!T=<G:.HCIP,#
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MZYIKKFGR2M,\WLLOOWQQV667M0\!9$\=DW'?0 RUJ3FCYN6>=MII;9B>3*9
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MU6Z77W[YXOKKKV]#^3;8=_SPAS_<9$^;B[NN?.18QTTA]VK]:@<N'PS:QY\
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M *RB5U]]=3L/Q-4O?^_W?J_U9>CS 'YDD:Z\N(P 5,>_0CQQ:CF$0]8-Y?N
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M-)S;14$ZRH5@(4O(/7*$=(FC+K45&:6C?2TN,A1NGUH+V\SI=%0>Y ^DI7^
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M!B%^/E98T"WX,N>T0GKB<+N071I].GD.0'[JV;.F7\4"GSCZ+"L_>581Q%W
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MTC"T&"7D>DI9]]=S$&[=L-M".4*^0DJ0C/P=)1B^M] $840B__JO_[KY S*
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M!E$X43X]JD**0@ZY<3T79\I_'8@G#_F1/7DCIBRF8#XH2RG+&6)6%\N12?C
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MWT ,]9$LP )MN0KJ.>U.UO0+:52G#/I^7,T'!C$=&!@8&&B@,,X[[[Q&5%@
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MBJJ'N%5!)X[A9021!3.84F+)FZ/L<YYK3IB<)PX@<H@A4F;W!*N-60S-H[6
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M--QCRZ<IW%'_\>ENE)7YP5W6TV(Y71.L,V>??78C?H@9 D69(Y?F4%*.4:9
M"8MCB%0<PXY0E11%YKZ_[T0 LO54E!$EAQ@A2H;66;20J"AY8>4I#>18/N8(
M4HCUON%Y"AQ!14[EDS2$Y6=+*GM"*H]YH?Z!"=&T*A_)9+%EU63E1%(14D N
M$6=#WW8/0&RLUD=([6E*_OS'O_*:NXE@(*+*S6+ZZ$<_^AY#^?Y''R)C7.JM
M@E_<ME#?R(0T$ I#V=5BJAZ2OK!IYYIW[E>06=CJ5I5G5Y!V\J_YS,G*^NV#
M@G7>XK6WO_WM[:-(&U74\@?):PK)KY:[=[T\\0?]'7QT>>X@^9M6XD.+3%/I
M[ -3Q%3>GB-]2!_7A\@=N;:%<J;\P2"F P,# R<)[D%,OW_[XLN?O^=647?<
M\M&R(A]FYI#>=JRMR-_$6@K(G/_*-Y2-A%DM#Q11$ 4\!_<I,,JF5^Y3H-B$
M11C-N[1 !<1UCXO5LT(<2M)Q2EDCE^0 :;%D(F+20V[?^][WMC\0,#<4\41<
MP?T<D55D&GG.XB9'Y2<GDOK!#WZP37E 1/FS<"&B%=+VMZ2VJP($.7\DD/KD
MILH1U'O.XRJ6Q5<'J4=U]LI7OO+X8BP$_5G/>E:K+^46-NF[KNT=_\CK*#R7
M<L0E[#98)U[-OX;O\\VYJ1<^"'S\6'RFS2Q^JO_Z!:F#=9'\N+X.XJH\$'](
MN^@WK.R0OJNOVHH,A-]$KFTQ1TQ=DS7/'1G[NM\4XDNK8A#3@8&!@9,&?W[W
M<0KW_"O2?8#"L4J=I<\>CRQ*E YE5)7/G"+B'P46DM,CRC@0#G'[V9_]V3;\
M;3BS)Z+)3USA.<J,DT=-,S(X5CE-#V"-0E@I>Z23A=8<4_/Z6$&ARH^XQ&J*
M<"*H@. @-BR?EUYZ:5LD9EB8DF7-15ZKLD5\;; ?JZKI Z9( !GEQU5Y*VJ9
M'*><O)>1%O>TK[ ^-$Q?0-  26?15<;L/ ".RB%.X)RLR2_Y3SGRSI5I%=:-
M5_,*4D^!M@13*NS=:O&3G1%LKF\_V7P,)8V4S?4Z<B1<7&2JKD\G_CD'?3 [
M)41F5EY38*I,^T:(:<TOU_J#YY-\R_KLNI!F_[P/8CHP,#!PDN!_?.FZN\^F
M<,?BEJ6K\@\.I,U&\#:\-P?3:FV*"&&A0((HTL"U^R$LCN)Q?;P0G3AA_56G
MO.SA:+@^J\,K7"-6<11CE&.<O.* T@R9=)0^RZGI!RRTR)E%0'8",#2?>([F
MH;(@FR*@_$!>8-DR%2!D57CY(SS^"4H>R&_28RG]R9_\R>-S&4U;,!\6R)BR
MS"GY6E_23'[5)8W(V$.<2DP-Y2/,P&+*<IRXR2,DI*8IKTI,A'.?(W_OML$F
M<6O>0?P"Y0!SI\VK-2_Z=:][79NJ8O&:N"DSB.L\=;N.+)%YF:NH^04^7'PP
M061&3,FLOH7OT]D'IH@IJ!=RD"UM?U!YI#&(Z<# P,!)B+__WW_?W#Q83&]>
MS"S*WPF0J4<^\I&-''[ZTY]N"T-8 %G1>@45\(\"C[)R#*EQ'HC'7QP.49*V
M.7^L=S:\1^YLQU2G#P"%&%(:8A1RE/,HS,C'S_9 5OV3RUP]?@@G H"8QGK)
MRIDR2C]_*XJL(ZWDC$PL;]*MD#>RBYBRSIJ/F_00"Q9)UF#UZ3_:D5ME(1=Y
M$W8=I/XX<5/GW%PZ"0N.MLC*U *+P,A4(;PR1<;XJ3]^[CF/_"E#[[;!)G%K
MWD'\ K("8FHZAP50R+B%:\KN0TCXE--Y[5<UK66(W+WKY0%Y)3\0SDX/4Q93
M'Q!)QW'?F".FSE,O:?>#0CIIGV 0TX&!@8&3 -_ZG]]:/.&#/WKWU0RLRM^C
MU91UT+9&5M>S+B**2!8B4E$5*E!0_.(H+^2.FU+(_) \UD961W\+:CCY'>]X
M1]MV"3'M\Z 4*41I4F0A8KV3MG#.I6^X%AFA\&-Y0GY9/,VA1=#<0U9!?$1%
MW,BN7@P!AZ1_^]O?;L/_R"SK*Y*)6!OB=]TK6O<0?A8Q]_U//K*+O/;ULVO,
M$1G3$,PQ51_^GM0\6:BRNZ>='$%:[O/3)_BG/=V;<MM@D_C")/_ -;F21LID
MD9/=(4P9T?9VF["A?2SB":?O.$]?6[>-DE_OQ._3(%_?QVT7I?]#[NE[V<U!
M6GV<?2#$5#TX!O&K[7Y02"/]*QC$=&!@8. DP;?^ZI-WGYT8L)B:"VD%O/F5
M2!WTBF-*.5(P_#G*:XZ8NN:0 23/.8+$8F>[*(20E;(GPR L6:3?NRA*RC-Y
M(X[GG7=>&Z[U+TZ&ST,L$5.+D)!$1$78Y&$E=/)W;3$8PB!-0_PL;^;@FA.(
M]#JRHEKM+_T>Y@@^YC&/:18Q9-2_#F7AT3X1(J$,/5B+R:5,%CZI(U#_@;BN
M0]BD(SR_DY68YCIR<>3G[X.'I=ON#?9M-9Q_PPTW'/\(45Y0+N541D=IK0-Y
M3+G(4^&Z][-7;N8>BP.>1?Y09=PG5A%3+O5[4"3-BD%,!P8&!@8:6 2MRK=*
MV>I@J\ZA5Z!3"BO*EW.?0N>J\JI**.%9WZZYYIJF?%FP#.LC?ADVKZAYU+RX
M*7^63_NQ(KVLI,@C./>//X9Q;?=D7U(64_$ >416I)$\4Q9^Z@F)EA[B8$LM
M"VB0[9[$ P+HGY_,;50N&_)G(_5 VB%#\JOUV\.]6N=DZL.[EAZ+=XAEA<4_
MF6-J?F_^Y:O*GW*G7N1'/O7C*-W44<T_\O4RK8M-XO=A'<G+D2LR RLUXN=#
MPAZ]MLG2]WQ0) PHEW;B:OG7094GC@Q]&[GNT[4?L ]"2)NQF)J"4M/9-Q##
M*9F=DSFR"[,+]/4PB.G P,"1@1=:=0.; 9'SUY2(J?EWK(Q3F%)8E!0%$\5%
ML8;,!<Y[DB2\+7L0!%LO60C%*IFX4_E4E_RJBZ(3'L$TA"Y-Q)=EE 74*GKE
M,XT 66'I3%[R1E22%K+FFI,G?T/ 2 -$%O'=<PY)#S&U^,F0O_*_Z$4O:O4+
M*0,2Q%),OI!)_G$I&UE2MY').?_($#FDH]R.%>)8@)5MB)#TRRZ[K-45R$\:
MTI-.RN%:7,24O.2HY0TB0^)MBDWB]V$=4U^I6S*#?LUB:F&?72#L8:H=U5$M
M@_#J8AMB"E4FKJ]'<-VG:P]=4T: #,+K8Z:@"*^--Y5E&WAW3LD,J5O'OMVW
M19_.KM_=0Q,,# R<,%12NNN7V[T!B"E+&HLBI6T!U!1ZY1CERS^*"VGAJM)Q
MSJ]"7$.LAL2ST3GB@RA.*4;7<37/Y.N(5" ;8,-]NPP(:\A>NBRRAO594FVN
MC[A6\A;YDWX(0<B@HWU>,_Q?(4YD=@X6&3W^\8]O%E;W+KGDDN/[50*_R*WL
MTJ_I.%;G7LK*U;"!:V507NE5*(,5Z1DB-K_7OUH)+[VD)5UEK]<A;8ZIES[O
M8,Y_%<2+6P<UG',RJ1_R1F:P*X+MO\R?9DDWS];\XA#R0'VEC*F3@X!,?5].
M^U7X*,MN#7E.6.,]&V2J;;%/>'=.R0QDYJ;ZW+:05L6NW]U#$PP,#)PP5%*Z
MZY?;O0$L1(BI.9B&JEF3IM K)-<A 1R%1HE2KC6L<_X5E!PK%BNB#?8SK"JN
M=)8A^4991F$B8U8S@WF$IB<@(_FO>L3;E %66GN9(HGUWW_D.Z64^2&PANQ9
MWPSI]Z2O@BQ@%;A5^>J5G_FMSGT(*&MD5^:473W)KY:+XR<, LL_("M9DEZ0
M.(B6>I&V,K",^U]_;7[^^><WRS&X#J0CS:0GCRJC=*7?U]-!(;UMTQ2/7%S2
M2!OY(/&18)%1MHMB+5<W">NH?+&6IAU2_]M FDD_4*>UG8!<II7()_<L1-17
M^W;=)_+NG"+"J8?>_R#HZW77[^ZA"08&!DX8*BG=]<OMW@#*^-G/?G;;\-ZV
M1ZR)L(Y"CL+B*%!*K5=LSOE54/I(FOE^%A@9SD84D()5^4JOYAL78J(\_I/>
M7X;:M],644@996]X'2EE-3-\:L%39"6_="I<(V/('4))/A93\O9A@_A;"1YB
MBF @X%9:VY**//RD1UYEYS)<SI^3=T@A8BQ?_H'R2BOD4]ZI'W7.WSQ:\1RM
MQ/<7K*Y-,[ UF#3D&Z@'^?$/G$M?FE/UM"O4?K,)Q"-C+S.8PN$C@>7T:4][
M6MLRRD=1M@93'O%3UTFGNFWEZB$OKH+E'C&MSXV='O0?;=V'WQ?R[NR?7W"]
M31TDWE3<O@_M^MT]-,' P, )0R6EZ[W<_L?B2]==L;CN2__#[O:+ZZZX;N%T
M"C_\=Z!'#U;EGW[ZZ6WXT#\;_>JO_FKS7T<A4BYQPE-JO6)S3KE7&'(WQY3%
MU+_PV'.4U;22KF609LV;BP)$0"UN8A%%1/T=)2)FP9(]1_W_O>%\Y+4N?DH:
M@7/WR*Y,R!K2B @ZUK!3\!_Y=CNP^$G9$&*$8QEZ&99A$\)$=K!=DCFOD WV
M0XP#91:^MC^YY,?/^<D&,FFCOI\!8JI/VX'@J4]]:ALBM[L"ZSHBFCKLRZL.
M.'U2VKLHMSQJ/E"'\@.6?!]L9(O;-[P[E757>579I])4#]5_O7?W^AC$=&!@
MX(2ADM+U7FZ%F*[ ][YY\^*C1YR9(F<L292A.:8<K$-$W(L35IR>,#GO"0.K
M(VLI4HJXL6:Q2/9*>PY1=KT#P^V()P*:[9'<RYQ6^5HA[Z]*J\6TII/R("21
M"8E15Y7$+0/KZ#GGG--6A9M.8$6X/)V3@Y4,.49*6,?\CSYKM7F0SLV#-.3L
MW#0 YQ;$(#+FS[)\.EJ];66WU?8(OOU3I8D$(QH^.)!D<<USM9, 2^J%%UZX
M>/6K7_U#;:.\XM5V3YUPJ:^3">2:(Z:&\M6=#Z$KKKBB?9SX</&QH"U3MI!W
MT-8LU-6"O6[?7 9I].EHORQ^2MTBTUFI'_GV#>].S\,N0.:XN3[3U\-Z[^[U
M,8CIP,# "4,EI>N]W-8GIOO>W/YD  5\]MEG-X+(8FK#>XBB7Z84W:M.>*XJ
M(N?QJVF:6X>8(4W^=8I5T[UU(;TI9S-[TQ*4"_E )@%A15 04QO+(V^Y!^*2
M*\>^+)&Y)Z;N4[()EZ-YC6>==5:3A[76/J8O?.$+FY78U(D++KA@\;SG/:\-
MKU]TT45M(9)5\N:!.OH_?ONQVF^4>\8SGM'B^/M8UC\$2_TA,*9@(+V&K)$<
M"]A8BI%/A-@?*-C#4Q[FR"(@_,@3**MR.&JG'LJ5LIUL(%?:*\BY?]ZR39>^
MX(/%1T$6L?4$7/E9Q$-$D57$5%J[*+MT>D+F@T([0F3Q,9.1"WY5QGW!NW.7
MQ#1RQ]7^D_:J6._=O3X&,1T8&#AAJ*1TO9?;^D/YA_&7H"<:%+3YABQPK'.&
M>(%2[I5'CZIT'(7OX[B'Z+B?H5&P.MP"'%8[I,&</Y:J;2%]I#&D2KY(F$WM
MG;/*(G#^CI0UU4IM9#BH9>$0B)Y$J!]QA"-KRE.'A%,&\QBMRL]. >+5N9S+
M(/W4$R@7@FN%_QEGG-%D7P9M8$/Y1SSB$8VL:F/DG[4T8#5$5@,6:Y94]=>7
M&U(W)RO(1^[(F/HS=<''%J+WH <]J"WTLVU7VD(\YRS,YB/[J FF^O-!D ^S
MBDI,([MV]J$!_,BX;WAWKML_5R$R5\<OY0/U4*_7>W>OCT,GIBE@7 J>%TE?
M$5-AJQ-')3EW3#HUO1Q[ES3[M&N><?7^,A=9<IZXRV28RJ?WGZH[KJ:5>%-^
M4_YQJ^[/.7&"N?A).VX3),T>FZ89.59!.&WF!927T#KQ*K2SN)1JYK--U4/O
M3D8<5+ZY^.HH?I64YN6FWL&+5CU2N#](8Q-B>O3GF9ICRGK&2L/*9D$,Z'?J
M>1EJ^W#"]W'T703.?>>Y;_6_E?-U%P!AMH5TD2O$4'L#BZAMD5A/K<JWCRE2
M:O$3$J)O),]>=K)R@7O77W]](W?B>#9#YI @?IQZ ZNJG_C$)[;MJEB%$45#
MM"QX'/*ASA$GUFJ$R+"N(7?#\8;G66A],%A)+XRA>GN19IYHD'JM]4<VEE?[
M=YI/:9$-.7P0F YP]=57WV,H'WEE,5-_M=P@W=1'S>-D0^I!F4),35$QM_0I
M3WG*XN*++UY<>>65S6J>=A+'- ]3*Q!U?SI@,_Z#EE/\FH9S=>O=7J'-\U_Y
M":]O9&LQ?GU[[ />G9Z';9"RQJ4=JJOE<-[KQKR[=X5#)Z8*%,6O\W%>?%F=
MZ%P'$"Z5DCC"ZI 4EK"<EY8'TH/,.?=UZPO5PRJ^,+Y\W4^>TI%7\JNR.,JO
MRE#S]P5,!N?DEG[2\1)QSS49Q"6337?)FWB..:].VIR\:OZ<CI$.PJ5>(G]D
M=I2_]%R['_D2/G["U'BY7^LBYPE//L=T5" 7OY0]\3AI1GYP+K_:L2-#((RX
M*4.%>.XG3DVGYN/H.FWD?!F$TT^TH>$[UWW><R!#RJ[_V7C<R](7-3E2/^HV
M<G'2KS(?)L@DWSD7&2.?\+6NIY PPFN?]!MI ']E1JC,XZNDE$.NKKWVVD8(
M#'GZ^T$O^:S"W928WLE,C_0\4WW5D#/BIKY8D_+<I*W2'CW25G%IZPIMZ+W5
M^R-X_I>?4LY[I0^S"<B7=XK^ M[7/__S/]_R1_!8,?TE*4)FN)N5+,^G_#GQ
M4YX*LHD3,NM9]4[P+JO/N/C*PT+GGY],D[C/?>ZS>/"#']RLG8]ZU*,6IYUV
M6EL8A;CZ/WW7#WO8PQ8/?. #%_>[W_T6/_9C/[;X9__LGS4_*_L-W__3?_I/
M%P]XP ,:>4*V5M65N:4_\1,_T=)#REA/[WO?^R[N?__[+Q[[V,<VA[BJL[QG
MI<FIAUI^9>(_5S<G"\BG+<COW4M._9J5%-EWSU"^*0WTJ?OB</H,@LIZZ4\9
MU,M!(&UUEKI*'NH9XN\#I">F/F!\..7Z,.#=Z3E9!O(H1Y!K]5K[AV/Z4AR_
MQ!5&G%H^^>\2)XR8AAC%>4GHC#J4^[6RG OO7DA&2&@FM.N4[O'W4!OZL<(3
M^/N*R8M,Y^+'A4Q(FPOI$J96//!/WI'7BRXR2!NA<2Y^AH$\1+Z8$1:=1UF$
MD4:<M!Q#LN65_%/^7AZHG:C>3UE ^3*$54%&>0JGSBM<NR_?ZOA)S[%V6"[W
MTW[.4Q?\DK]PZKTB]0+*X7[-8PK)K]X7/D>+"U@UR!#_99"G>M*FK!ID3ATN
M WG)(*QS<K%JL)08TDFYTJ["DH=33]Q<&?>)R##G(AOGFHQ3?; B=2&\?J)?
M:]NTI7-'BQHHD$I*.18X^Q5:4,)"Q$J&4%!0=]71AL1T<<?BEH_><N?OT81W
M"^+B76<8W_Q+[:4OID\YYKQ"6Z4]:[O5-M9WM5F-KTU9,JT\MD+:^U;?[M\A
MFZ#*HJ^ _L,"20;_66]>IK]<M?CIUW[MU]J'?\+*6[B^G^9(9A^*-;PZFI+9
M,^I#R/ YZRC+)P)B6@%BY-S1/%0?5ZRI+&>.K*(L=IY_'Z4LG/ZM27\VA.\^
M6>1+UKB4W[ERR-_"+TY\>3EGF243V>3A_5W+(+YZXY=Z2!ZY3IV<;" ?N;F\
M=^E3\W-]=('%9Q:!Q>BCKH1W'?"+7DAY-RVSN.E/X*A?<)#T6-;S5[7Q,Q\:
M68T,AP'O3OF3<ZJLY" /':=<>:^KN]1AZLM1.ES"\4M9A.%7\Y'_+G'"B:F*
M"BESY/BYQ^D(">/EASBPA'IP$3]?[NXC$H@ "P(_#ZZY3RH7(>7$=T\G1CY"
M I.W%S"7O/G%@B8_81-&7%8?_F3R('%>4%[4_+VHI",^8AJ972<N.>*D$Z>,
M"*]CY.-/?NDK@WOB2<>Y^\ZYE$NYR:H>Y>U!%S\RJCMAQ:?D*#CW4D^.<:ZE
M0:ZDI9XY\7+?D9,^F>1/%K(B&/(CCW3$0U+D[>,!F71T+T-E600AGO"Y5M_Z
M$WA(E$4Y* 1DQH;CKWG-:QJY<4Y)D$N;)$Z%?JF>I<%"DWZX#'F0N<@"XMD#
MT="J>B([>?/B<*PO@%Z6PT#RCBQ5GJE[Z\@H3,J79T@]NN:O+V@#<^<,3U92
MRB'RR XBHMT0$-?J]JZ_8]R4F![M>:;>)1;C."*FAKG!\Z7-(.U1P2]M&I=V
MKE#O^BW_] 5IO_.=[VP?$2Q#\O9\U_Y_$- -Y-%_O$/EZ?WI0\7<RA>_^,7M
M+SD]5WD^Q:%X/</I:Y#RZ'>>Q_J^Z,MZ&%"7G@<@L[HD-YFYO(_YKP-Q*Z3!
M3]IIK[C4R<D*\FD?;:@,KND+0_FVRO+>8&VVP(P_J$_AU1F]0-^ \J9.MRF[
M\.HP<:6CKZ6^^8./E1!388!L_#P3F^:[+;P[Y:7^IO(DK[K"791!G7&I;\>4
MU5%9^,7Q2YFG\I'_+G%"B&D*"AH;V?! AJP@-R&*.AR"@Q@A<SDB,B%0.J.P
MPH40Z:3NR\<Y4J2C^9IA315//L*X[UP:&H0<.I4P2)._R-/9I$TN#2M/)GO7
MXCC*0SID=NUE*$TO;@11V9RS[B(_[LE#NAP_\=2%L @?6<FHS.*%@#LJ"S]I
M>TD+$Z(H+?E3_OQU2@^ULB!\G#K4*1%!5@'WI*M<PBHSEW/Y1!9QY>/KG=*0
M7L(DCG85-F12&!80?NI/.'%]=2HGYUK_4!YUKUZ4EY5".JP.AG6DI8S:%*2)
MS C#LN+%('WA'6-UL H6025_'L \8([J21F50[WD9>.>NM+V]:%TE$Z.@7:5
M-ZL2F;1GTH*DD71.!")WE2'7!Y5+VNI*?ZY*5AWR\^%@F+:24HZ_+7>LO&5Y
M<D1^I,'"NCDQO6O;J)N/*#/UOK$Z7']F+34- J) @]KW0/ORJWW >>W#P%^;
M":L-DJ[WX]O?_O:V.M[[UG/3Q]T$D2%P[CW*,@D^%.7EGY]L&V3*AV?>.Q2\
M!\@669-6CNY[/[N_"E/Q';G4$2=<W!02Q_W(E_0"]^K[1+IDY,>)0T>F;N,G
MO'!T1>Y!XDLW^<<=)K;)E^P<V?4GY:2/3-W0KS_[V<\V_6G' SH!A D8->@N
MJ/EO(D/0QR>7ND]=)TUZQ:(\B"ZB._('$(<%[\Y\I$V![.ZG#'$5RJ3NXX2-
MZ\/S2QV _'>)0R>F"JR CCJ5QD.NO&!T1ATOA 8I";%!+H1#<'+-(3 AA#HE
M4H$4".=E+4TO5)T%T9%^TN"'W/&7CI=M"*8T\L+5H(A49,I7K8<#.=) [DM;
MF+C(3S;$Q+GPXBJ[,I-#WF25I[S==Q3?/21/V9176O)R3%E=DUT\U^*)KRP>
M%GDHI[QU*"^ND'C7" "R)D[D(J_[G//(+1]MQJ6^',45CI.VHS*16?UFT0"9
M*1DO'&70-DBF<] VB*5P^@@HGR$S^9,5850F_2$/F[01T\0!Y3#T@T!KL[2M
M-%A?$B8O?DY]J4.R&W;+RT8;I]W)+!]^4P^L>^I$?&D))YV$=S_Q3R3(LD\9
MU(4ZFWIAZF^&)BLIY8PXV,S<QX<V9C%E-4-$],%MB.E1GF?JV3#'U/O!<*?%
M0= 3L+ZMG:>OYEY<C_A+T_M!>R(!]C&EE,G@F:C/P1R2EK#5D8,\%9X=P^_@
M'6&NL>V:7O*2E[05]IY1^4J/7!P9I<.O0A[N.:Z",-)(61W)-X649Q7$EW\?
MUK7\IN2E>[QOY!]XCWB/>6_EV:IEFDMOWY!?\IYRN1_7@U_Z@'KR_N3G76\G
M!B->]+7I"^;ITJ60=A%6'Z%KTA=V@<BE#!4I UV5A4[IB_2UK<VT4=[[^X9W
MI_XR!W4:+N1Y==V#G.J?4^:T!Y=V#%+O@?QWB4,GI@'RPJ)$$8&7# *ATA \
M1$2C4V (AP[G?BR>"(]KECY?TI0<$N4%;1Z.-) C+S9I( GRTGGEY2BL!T C
MZ>@ZE+DA2!-B) _R4(@AEQX.:6MD<C'EBTL6_LKEA>J</-()N:-HI<FQWK$&
MN(]\<M)@X42F')4345/V6#K)*&P(JA>7EQ/"A2B33U[R)[>RL4)RPB*4[I%=
M^3W PHFC')&G$F;A^7.Q:AH6(Z_[*6_*D;!D%R;$-.3:T*SR>,FH+VTJ'74J
MO/E8CB'^RB1?X;6M,H@C+0\:$A-2ZN$)$7+O;6][V_&OZT"9U2,9A=$'."]Z
M:3B2CP)P= _(1UXO'/6:_#S0<;EV7QVQ$.?#0'CE(;\PZZ*FOTF\'F2+S(XI
MPT'2K.CE<ZY^>R6A#NRY^6__[6\LGG#Q%8N+G_"/CA-35C_/JWKW_'M.6"5L
M7NX%N14Q/<+S3+U;S#'U?*D[*Y;5=]^F4]=5";F.6P9]QW.C/5BQ6+&3SEWM
M\\.H:7/2J'D[ZHM]?,]\K%$^9I%1\PO]7[K_B?=.%Q^4F9.&]'L@"-X+GF7'
M=<I995P5?A627H_420]^9/;.43>!<WZ<\N[R^=T6\E<^CCQ3+O>Y*7GY*UN<
M=RSH U;BLY8R1-#S]G;U#I&.M,'1>T*?$'_J&=@64S+S PORLC44?2%?,N,=
MRI VVC>\.^7?@]SZG6,M [F\FU,.2-CT>2[G?1W4>'!DB*E&\S7DA8K8>,$B
M1L@3DD(A(4 (A# <1>_H)16'D+"H(*C(C,[+(H:,($8ZJFN$QMQ#I ^)0Y*<
MRR-IRDMX1V0($90> D0F+S7AI.W%0%XRD=]]+VQ^KN/X(VV.T@FIE <9R.B\
M$FYYNH?0I7SN<REW2*JT8[TT;$P>U\G+ RPMJQ7)G+RXY&68/!\ RI;A?/((
MS_$CA_I17XBSL&D3][4GN<@M/K^T&Z+A'-GP D&JU;VR2(L%)I9;Z9!/FRF#
MCQ0?#!23CPORQ*(F/0LQ$$9]!\%&+,'#YVO6?$9?L+9>L64,>;2'X1;$,58'
MB@"<JT]I(K9D 0^R?IHO80]M'E@/KQ=B'EYI:@__]\WJYP/&?6V?E^HJ",/)
M(R^*O"0VA73(S)$CQY2AQSKR]4A=5&@#>;F7#P;]@G*QR.G_^$=/6)Q3B"D_
M_UYDRH5YC%[ZVEY=2F?@GO"^L7K;N\R\RQ>\X 6MCZZ"]NC[P#IM+IQGP[/@
MW>,9#-F3EOXIG>K$X=)_Y2=L\G8DBWN!<^_SSWSF,RVN=T+FC-L2R+\I>0^D
M3^EGRTB /+)1NS#2/&S4^JUU4_U[Y'X-ORK.03"75UR/&BYM.^7<JT[X"G[Z
M0/HD707:2WL;#:"K&+/\H0$=+@UA \\ G9&TIN3=%-+1UQTK(C^]:BZ\:_J'
M\WXC)SV4]]^^X=VISLA1R^V<OHH?74:'TI/1>X'SM)5S+NW5UV6-!T>&F*:P
M*@C9T=%4(*6-X/%SKO)TR! <#J%!BAQ5- *!: B##-IJ!AGPXM)1Q$>,D%=6
M-\0-Z4*"^"%&R)0T$"8O6]<<HB4/?N+)5QK"92A%&<@LOF-U\4.P/&0<0AA+
MK$Y,-D2.O,(C+XZN0[;)0!Y'+VERDU^9*2)?2X@6<D=.^8GOGC@>(/4K#?[R
M%B866O'(0C9Y)C].79%'NNI:O)1'6+)SPH80AXQS2'[NY47%7[C4;\BHLHLK
M?.2-#/J(NM8&B*8CBXVO5G!?VA7ZP\_^[,^V?V%A:3$_S0<*D(?ESHO'"TY;
M\I,'Z)_JF/-RX2AA1^'EE0?8.?_Z *MCV_>P^JA?Y?$1H*[Z![V'^WDQ2%M^
M7,V;RTLDX9-NO4XZCM7U<5T?!,F[0IIQ^JA\M"6"86'8__&0<Q;G/.0'0_GJ
MB^5/GV050TJU]2"FT]!G[2?JV5=7SCU#,-4>@?80EU.OZ4_I#ZM X>K/VI2C
M%&LZZ9MQ\:M]V+$Z]T'^GDG/+C*J/!P+K6%=S[$/OHRV);RRD!\<<QZ8YN #
M&/I[AP6R*F?JP/DZ=>[^JC '!3EJF\6E+J=D<.U>VG:J7>,O3)QTDY9C'T][
M AW!2OZ*5[RB&4X8(OPC%GV<>$ &^D"?<%[[PKH07GJ.Y",G.7 (_;W"?:!_
M3#,2AWZD@T),Q>7ZN/N =R>9U%W?1F1(F;Q;[7N,-P1IPY39D1_G/-<5PE<<
M&6+J188T(5W(C2]_UYP7DHY'L2-PB(IP')*"R,4RAT@@2.XA7.+%6N>>:_>0
M(_GP\Y)S+CX2$D(L3 @6Y1ERYEP\9$J^K'S.I4,^]^3GFNS"(UKR\& AILK@
MOC19'CU$PB0<&<7CCW226UJ(H XO/^64CJ/\8KU4!FFS1'HPA15'??!7)FFK
M8_F(3VYE,YU >"0["D9ZPJ0...7FE)5,PL<Z+(\,MRNK=#S@PJA7]Z4I'Q\6
M9!>6+,*[[X'FIVWY(R/*X*'RL'BXY:U\ZH?UTZ(81$8]Y$&17JS*ZD9]>J$A
ME^*JUSQHRBJ^-B*KO P5B5M?)A9G"9.7(,BO.C+FI98''<A,/F57Y\JJ?J8>
M]A[N)ZT<Q<L+D\S*P _([)ZP7LSQ=[[JY>B^YZ"7*6FFC(YQ4Y"GEV,/Z9+9
M?6W,@NSE_9!SSED\Y&Y2RB$BK&$61K%P(5O":>L?PFT3?B<A;CMV[>*F6^\B
MB_N ?\917T8&[&^I?T':;@IY/M/O]1&N5VS.T^Z!N.E?G'SXY=IYG+B<<VDG
M#]?BR=N1GZ/\$I=L+.?>4^ZS"!O!,+1KVR@+XX!LPDH[<I)#G/15U]X9/GB@
MEB>0MW"U_+N&M,F5.G>>^ETW7^%JN5+'4V5:!^*)GS9(>_*3/I?\>ADC0]HW
M\3GEXYRGG#7-7'.)GS34#] %/K9,5V&9I"L9&;S/0=S >Q9))*-\Y0%D3'D<
MDW_*E&OYTF?RY*)'^?>0CGSH<L^>=!!8X<7U(>U]FG?>OK&,F"HW/:$<1A?5
M'^-:(%YM!V61!I<ZZB%.S>>4)Z8IK$8+X:3T$89*X+QH6*<H<Z0EA%5X! ;I
M<BY>G'00*L><\T^:(7G.D2KW$$/$!6&*U2[IQWD8<HYH</S$EYYX.B@2IC,C
M1-)$Y"(/?_DKBSC*KWRNE4LX:89P4RXZBK0,6^MP.H,\A ^)5Q9'>2!\%O60
M3P<C+W^DD",O.93=@RLO+VNDTD-%OI"G$&!IA*!S9)0&&1 XI%<[L+QZ6?!+
M/9,'\44(A=&FTD\;\!/>0Y(YQ8BDLBIWTB(',D-N5G+;U%!2'_G(1YJE*(I8
MG1H*]E>"-K[V0I.N]K%)LZD K"U(4<"O7JM?>1H2DBXYR:3,_0,/>7 Y[94P
MRN"EQ%+**DL&=9RP_<LJ_N)7)US"QWG!Z#MD59^NA5%^]\5S+R]A^:K[92"K
MLHI;H:W$S?.8<R^ZI%^AW&2*'$G/,?>F]B_M'4)BGI8/!<^F?BK/4Q'[)*;:
MS;0(\[)-2[$P1/\%_<%S/@5MX3ZG7J63=M67 N?N2<<Y)XQGPU$Z-3RXKHI.
M&$X_E98C_WK-R4,<?OJ+=+S/O,- GS#Z@9CF?]-!6+*+G_Z6=,BH#Y/7.\H[
M;PYD4A]DZ2'=R)0\5F$JG/CJ@FP<F>5'7L^,^\ORX"]<K<^D0WYQUT7*(^^:
M%N=:>ER5K9>+7^0APY235M(3EI.FZ]P7WW7DR#N=OKG@@@O:GPG0 ?2.[:,8
M"Z#*XZ/#Z!0_::0NI)F^KI^D?,F3'WGD22?1!YER1G?13_J@\('X0#[SK5,6
M[UHZG1S>P5-UM@]X9Y*!Z_-S37;E-TIU[KGGWD/G)5Y<Z@W$K=? 3WU5R'^7
M.'1BFDY,R2%4%#Z''"$@R >'7+FO<3GGE#MRI/.$).H8CN(B7NXY(KG..?&1
M)"\I'3L$S1&Q0H+<CV4Q:8KK&%+*/VG&XD<)L.!Y4$)VY:?S(X/BDQFYT[F%
M]P!XR,B<?*4O/>1 QS;DI,Q>JNZ379VYUOGEY;[RJ#N.'[DH?QV,G[A)7YUP
MY!#.D2QD0D35B:/\Y<?IS,KC7LBI,HDK#S))6UG(+_VT&3_D,F5-O4B7C,)*
M3UF]"(1UCPR(H?:6OS(KJ[K5!LB>%P:":HH".?0I#XNA<HOA3)9G:?,0B6,(
MT%>LH?S\C:(X\O7BR0O$"T>=:"_RDE.YY.W%4Y&'-G&Y0#\GE[AD40<IOWL)
MG[@@O##BJ!?MIF]ZX6:QG)>ENM%^ZD1_46_\G8LCKCISK7\H)\>B0-&K5T?7
MTD3N36](&R/SZH356A_6K](6Y-/FZLBY-M0?R$,N?4$]Q4+.7UVZ%E];V ZJ
MDM IQT)JD9SV^8N_^,/%!][S@<6W[NQ#IR(0TV.WW7VQ8WA>;$"N'?5W6SBI
M:_U*7].G>NAO4=;BAQP([[SV8^D(Q[FG'TE3/$Z\7DD%TG%/F/1!UX[QJ]?.
MQ7$=&91)GP(6,]9A'Y<^*/7?0'QRB9=\R>LY4!^>X_3!*8BC/,(C*LD?^O-Z
M/05UYAD'89US\2=;_%+VU(<R).Q4/OS%%U[YM%G:C;_[ZR!RB</)5_Z]/%SD
MG9(I95H6/TZ8I)4XY!;6.>=<.WC'2-M[UU^1VHG!^XY[^M.?WMY9(!WPKO,!
MZ[TF'>V<O*1'9THS'U\<F2!EH#?T-^\S:0CC72PO<]WIO-0O.<%]1I*4AR[U
M7F3-G^MK^X!W9NIPJHTXSX!1*$1:O8*PM;T<4Z?@?I^>^ZF[0/Z[Q*$34P7R
M(%%L*BJD*.3*B\$U:PF%ID-1KA0@ZPE+I [B9:4#488ZI# Z"7_IA"A1C/Q\
M*2-<K%_N:1A*/&$37M@04/?D$9<\<YYK\E#>9$02R*)3.THK)(-R%U[']1"$
ME+I/3O>479WPH]C)@(@)QQ_!052$508R2%?YY*=NU:$\/!CD<L^#"^I='N*2
M-V147/5-#GGRRXM N/@I*UF4BSQI/R]]Y_*-XR=]=2EM3EID()LP\I6'N%X:
M9$?&TJ;*0W8.2;'JV";;K"><K87TB?HP@9>2?,1A24)*.98E]>%!S9<M^?,
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M>FE[1U#^PBJ7^WD&\JZ9@K!]/?S_[-T[K.W;4>_YX 9.6\2 A!_XQ0&#W]N
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M3<860*5'66_WR)Q=L1]C<,)TIE_W.!I'O*C/B9N'-NK@PSF>^H84.'5?86>
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M!I@2H$ GF',6=L8"+B$$N!B:(">P*<X)S+, D&#+R<Q"H)X+FH(\XW:?40O
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MUH!/P"F%J ,TZML]_5#,-#1@H'[C0P!VKKTZ"GX8I/'TX;EVYA2?# 1O=O5
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MMM@ 3O+5G_D!18%3_2"\JT-6 5BV2[9(W^JX9B- I;[I%O#2GSDB8QO+T7@
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ML<;;"0D9"2 QQ?HH:3'E$+WPP)3@"(KS!)P*_H")P"<8<YB<42"IH*8=4$-
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M+]:(Q^(R/UT?9&DN2L \>N&!*64#=H*Z@,ZY *8"),=**, $D%J6A(.B;$6
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MI1Y01_[DYKY@2E=^S0X,VP0 <>:%ST">0 V XIFL %7R P3QQU:T<^TU39\
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M*$:]CL92)P#E&F POB.0".QY!O!Q_L8V;G/R;((,]SE7@!)H8[#: 6T"K8#
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MD6$!9&<VG@ZG_B?1K6+G:+'B%> BZUY3Y_P<R81^+7+GY+KE%+(3=F'.> <
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M#^QB 1+') RL>?%"73Y;'# W/EC<G;0E]Y<&F )*@C^! : %98$8 5'N VG
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M4>'?_"RR%K!Y&,-N4M#3'WGBVVY=]D8=?7AF;N3!+LT1#Y[E5!TK%K0QS0/
M)6O@#D!S3B<RB^[I@XS=!PSI!S@3J-DIV9@7'@$2_7'<,@D<CNRBM01< /D
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MI,:C+Z 2WV1"ANQ1>[;.1K,W.C%W=HC,0\8(>-2>//TXQ#50R3F2%Y!/EF1
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MVYS%6K3U3/_^-S/0A>C>6&Q#?_@@0T3&Y.O:O/1CC)7(Q#/Z]1I>-A%/;"/
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M7,NZY" Y6(".40(<C"[C(VS/E<"7P.?(2!D,QZ8OP5B_M2?\'+#Z B<%3>+
M]$TIE*TO[9&C(%Q&29_&81@6A< BJ&N/#]? !^<J4#L"0.;&N3IF4,;3'_Z
M#J4Y9^3&,BX>S0UE@/IU3WUSUK?V[@ON^@4H&*FYZ\,]UTA=?6N/=Z #C^8;
M$#8O<_>,[/1C+#K%@WO-U3UMDXUBKEX?^[&+S*3O&0%2.V)Z!E3MWCRC%[P
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MLJ@$='RXKU]\*.Y-YZ9/<U5'X$8]TQ;O@(=Q]:EOH 88 AH!$>2Y?A1SQ5\
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M;G%)++1^_$UJZRP9\1>>B2G%$WZ97_?F4<PS#_U;.UOT4F1,"8PP" )X!$"
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MC(Z0U<GX!%#"% R="];(<_53%F(\&;6%X%P=1)'X K9:+/JC0->>"\9X!;"
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MB;(7"])<!5X E6P 3_HF"S*C3X5N 6Q\F6?Z0_IJX38FF9 !W@$^/"CF#1
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MM4?ZGS8RB['<]UR;^' O7K;:J+<E1V.)E7RZ->=3-/7TA_@J_LMS<\H&STF
M*7[Q'<\=\8K$*IEGWWKS^4@<]79*,D:,*5;[;K:_?,.GDXFY)$?CG),N#DP)
MBP %2:!"L!7T!##72J\Q"60Z6 )QCV$(@H(A(1)NAJT^@!$ (T#/$WC $1G#
M#DQ]?6NKG>L64O<"6<9UU)?GBOX%7LIVKBW"CW;&-BXP"S@(/.KJQWT&3"[F
M)M#+ N++_#Q'ZAA;\#:F.>#3_.)/'_APWBY''=?X4D]QKB[@X%K?.>KZ,I9Z
M#)(,\*J^8PL0'^H9DSP:QYCX,WZR<M]S_W7"CR$ ,,[%JWK@$>#RFL'\'8$3
MWYFI)X/FAS  *C!J80&+GAL'CWC"IX7G!QJ^;P-.VVE'V9^2GA YIB,+5&&3
MBBPMNS07/'"6^K1!"9"18=08D_!'+L > $J_Y('P[9H3:,/E&1O!#YF0#Q[(
M(W!J;!L::XB,\<&^W,O6C*=>A:[4U[="IQRIHAU0ZNC:^M!&/\[5UUX=MFW.
MGAE+:2SG^F6# 5/7B.[ITG>$,J+F09X<HW5!O_YTB6*SXH<Y]&W\-^CE J;/
M2_R6+*D,DO7D;Q2R:[;&#JO3NF2'"OWE0]A?_E.9P5FI36MF%F-4MFC?_7VD
MOK$:&Q]XY)?PR^;<,Z=U#:_DN;[TJ0V[Y9/T01[Z,\86C^[-\B+10^(;#W1$
M%W0V=>N>Y\5>MA?/V1<?"YCR"VR<#Y0QE3RH[^K7?_9;:;QLQG'E96VCJ+,E
M0WWPM^Q(\D1B ND'\74VU,56]<]- =-XGK*Q?O#FC>0O_N(O[O[JA3=241M:
M<1B)/9)/_*]8)1;65]2Z.A==!9B:E.#%N&3 ^K94%D6 %J $-<<,R+G J[VV
MTL^$31D<#$>3\^I:81A EX I<#*H *_[@K#ZKM7WW#5%",3:U0>#\]P]B\C8
MP(Q^*5,?&;7G^G%?X1 =W=.?H[9X83C(^,!/<YY!(N?<N/H $LC$?<^UJ<Y<
ML,8ROOZ=*^H[NJ>-^2GJN=:_.GC&IV<Y#_SI-]F0": 6;]KKQ]S,I_;Z\FJ<
M_BQ<X)/N.1]94,^ 28N=/<B>";86"7 H6^MUKZR;Q63^@!PB(_W[=M&O=2T^
M.UG] &(KX3\9(7:E/]E ?&<KOA4"C!W-#P]L%$!5%TC4+D=@_O6WDN?Z!?KH
M37_(D1S,"5 C.X7-!S(#?8Z!0<^R9;S2EVM@$)!3E\WV600Y&%L_^E8\-P_C
ML@7CTI?VGCEJ8SSK09^ ICZ,U[KAO !,1[KVC%Z-[1Y>V:<,Z1>^\(5=%MNK
M(IL(MD/G],4N!!\;&/[!!D0&G,S?H'^]^<XW7@>FW_C.ZV>/9"T"INR<3?I[
MCVQPVI]K^FA]*M:+M:NXGY^9I:!-;XIVK9N*<;9L/3KT;!_59\4X*P^SWA:Y
MKVZ^2EO^@;VZU[SJ:XOJ?]\8#Y$>$L]X(-]L+GVD2^?N.<_>XCN]\&5>/?,9
MWK#87/BFFH] [!HUEC[WV6_CK7Q4;RWJ;,G1.'R>?@ W/@NIC_A+&4?VIO]#
M-G8J DR-/WE.]G@U'[+REVW\!0Z?5$4RHWY<*G.*=^WY$C^*]":&?W:O@LX]
MIZL!4T&2,  -.PZ!2:9, !+H'<N2$*K=DN"*!&$&FN #6$KG!5@ 0*!DX+)-
MSO4KN** FCX%:@&70>D7(,('9Z:=/CGRE((O05< =A]E",;6I[X4]\P[(@>\
MF:OQ$1 'Z*Q*-TX 4!W@P\++$ ,'.=V,1SOWD@G V'PK[BOQB6_WS4/ <@T(
M 27F3P[F80R@ W@QIC:>-^?DCU_S-"=M@4^+PZ]] 1. S"9#ALP]K]^]LA%H
M@4 _BFG3TBZ.O%VS!Q]Q)U=R\;T=<.I?DGH%#%#.C&F$GU7.[,)"+(";AP7<
M*T#S)0MV8BQ@BUUJ8VYT1.;[B*[-ARV2%T=!=L8S5XY7'7V1F;'(E^S5I_-T
MC3<\T:DQV:GZVN%+/VVL.!O] )?:!'#-(9V1H7YL"!5U Z3Z<V[>VI.[:WQJ
M:RVZ9XSL0."@)^O,N3'=]Z_N9+7MSMF!302]XYN>_$);7S8?]&WSH@#/;]"_
M ].7X9=/)R#VXU]X6B-D+?/!1E:BWVGOVM%W =SS2M?J.%H+SO,KR'GE(1*^
M\&W.'>]*#WE^*\7K+->F9+]5LBVV-NTMOOE$Q(?XL1.LP+>P\0]_^,.[1(7^
MW4/-6=_U-_M5]O$P^:AT?]I-8RCQQU=*GB#W$7\H9O#O^K@$K1G32>[QU7PY
MC.53B)(UYNKO#DN^ --\?)C!4<)(C*ZN,5!R.!==')A2%(4)4D"=X&/7P>"\
MRA0P"420<HXX3W4  \18!&9"TE\9/P&;0 O<QA"<*<2U<PHQOL!-88B C4$I
M J3^C*&]^A2"%^,+TH"%NO@%!I Z^L$3_H$41_=3*%[Q 1"8.SX4_ KX^&/4
MP!R>Z]=]8VNG#WQ;&/5M',4]SQ0+&F_FJ3_CFIMS8(*\C&W>YJI89/&D+WV2
M@7$#,4H F<&:1P8Z^U=<*\:F%T<?7?M>"!#[RE>^LMN8"*H I]>\OC4$)LE9
MQLPKWGX !<@ KN31=XAV>?K&O[EX[>N_50 _0(_%1A8K->>YP,S7Q@#H!:K9
M 0=HGNS1V/1(][U>[Y4Z':I/;OI="6\ &H %1)JC>;A/7_KGX-H8D3-9TB';
M2(_I 0]L$Y_:VW0!ANJP';K$F_;D@R]]*Y[36WH%,AN#G0=PS2==>V8L[=FB
MO@/ ^'6-)WV;HS[4#]RV'NC2:R3?&9,G!RXSSF'2K[Y]HN'O9-(E &L#8[,2
M?>^;C\ THGOK2(:##7F5SR>@[!K-<\1&^9+\R5K8>:6U\J+17-OX9W_FV_4J
MDQ>9FNLLUR8R9C_94W8T[T\;G#R[1OS8YS[WN=UK:.WX@==>>VWG0_D4_A,U
M9^W8_[3K['CRT'5UXF,6_:@S*1X[BM<PC#[9%^*'95&+K9>@@"F^IQP1'LP1
M^/1C)G_7V)M)Q&_S'_ZV,9\+VQ23Q&J) C$ N==\DN&YZ.+ E+(%<>0HB'D=
MZS6@X"CH,D8!3-!$A!WH 6 %+]<$57^"8X#*N< H( J> GC!5=OJ,>Q(&X&4
MP0OD2+_X<JTO8 H8\1I2?P(Q8YQ&B5SCJX)/_6M;!@GXP8<YZL<S1HY7<W,.
M$!D3B'3M6/_F%=# -V,RAJ-K.QWS!7[*CL6SYXP-;XR+3*J'5WP%3#)&LE*'
M?MRW^/!L#'/7QOWDJ*B;;O"I#7D"DUXG>"5#S\"'U[AD[^\= J<R9@"+9XX
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M G!XA@^OFV4ZU5. 0?TKKO$O^V?!N#:^^3CJ3Z!@N/IG('@5S-4!'O!O?HX
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MMI")M>>^=@^-]LF_^\>6:U'C9U];>D'NBQUTX9S?%EMMM&V878L/? 4@):8
M4_T+WDGNTVN :99#M-:-7_T$=%U'SOEHFW/^F ^UH89%Q"3^2N)!S%*7'Q<C
MSDWS5;YQ\5W"R;S(3E94\892K"0O=<0#,I=,$/,BL8!?%@.1-52\2E[GHJMD
M3 F0(@FG5^Z"LF#O*'"[[V@715B<"H" .%P.!G!BU)XY4HHZKF64&#DP)\,F
M2R<#!)@!D3)# "&@"'  %P*A("@ "](R-< !IV^1: O0 KOO>M>[=GV_Y2UO
MV0%1_UY17X  D&@LUX"B>NH G *']@(T'H!.@07PQ9?V_^$__(>;][WO?3>?
M^M2G=MD0?RK#4; &!  &?]=-P&=0LF& KCF;I]VE.OJRP.TZ 1-S UADNL@N
M8K3DGCQS%HPV:H/@&1E;G/3GW,)3'_":H):. 2N SWU "M#T/0O@ ^#(E@$M
M'!" !=C(;) ]?2AV<A83F=.-<2U^0(;>+$(%F"0C(!X80Q9BW].PO9S-%IF3
M\01X]J4_#M"YN7NM04X &0"E/S;*(9G?7*CK.5F2\_R\A(P*C,"$OHPE2^N9
ML<B/S#D_65'RH5]9?#M:]DCG9 FTLE$.!M"D;W9+5NH ]^P:,.10V9XYR5#*
M3@"W[(0^.%U9"[;#QLC=O&UXM ,FV22;_8,_^(,='W1I+':M'VW5]3VQ38(C
MNS57^C6N-4_F[)J>@5IUS,%&Q=']:8N/](P$%QM>\F2K]%_PL"[+BFP1NRQP
M[2O/0UO]'5/N0OA7K*/.)[EF.V3![L05,N&W'.\ZWJEIG?LIRSEI:[RM,FGK
MFE[2A4VRMS=\DU@IIBGBM]A CV**N,I'3[(.5EO?XN%88C>!O/H(R(EODBH2
M/Q)+-OO\-IYLX-WO._ML[]P$F.*5#.(]G^D>N<$+Y A46P?F!4OQ&][6B<MB
M%!)/X ?Q%#Y25Q]T=0FZ.#!M)T*Y@KG Z_6Q8 U "+B"51DJ DP@@1_ 4[ 6
MO#D;?;C'<#AE1X&5PQ:@&9%@9]<ER GH,CIV"I2E7^!7WW[X KRY)P/EE0%^
M*4[ !OCJ3Q_Z JK\TEC&B")EAM1Q[KEQ!7WW  7!5M"W$[0(98W*\ 7$9!3U
MPU  %?-C0+W.!M[,'V $H!09,8 )P"(W8QJ?(?I!$2"G7B"T!2,;)6-)=G1A
MS!8@N0-R/K< SMRS"($H )%AJRM3ZEI;_=*S_MRC#_H%.O .A  N0 M>9.\
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M^M36W( & <:8=B_X]!F!N@(V\&%<P$W =P\H N8\LXL#!O NNP4P ($R9N:
M)S**+&I ":B476.4@7M @,P9-/G0 =D#I15U\>W(L'ME[YG[BK[3M2P9$ )D
M ML $;W0#][IROR!%C: 7[L\"UXV3E:-C.B6_MD($(?PJI"%5\ME88$U=D2W
M[(7MF=,D]Q"0*<-JH7(N@"[YFA=YX]<&!B!CE^1";NJ8WZ1L4S$>!T%.=*XO
MCCC2/WF[QW[-B=S8M#6A;_T AW0.C+(I>F8/@*@YLD5R]8R= Z?DQ>;P3AX^
M.>%,R5)=SP!)ZX&=L&G%&P>Z\'F MFQ7OS8#^LA&V9WZKJT7:X%-LSV.F[[Q
MK="A]6#CJ8[Q\0]\XD?_KO%G7$"5+/3+1SS2FXG-RR"1(;GYMKUU=PPPS4ZC
M;':K'$-K&_T?6\QE7L]^]M&^<?('BN=DP4?-S9YUZ?Q:%._G*N>B.<:4N7)H
M[-DN2OY\L,^"?#_*?XM+_!&?\)[WO&>7O0-2)0]D_/C0VB%Z7?WZ(5YN(^WT
MQWY6 CKQQE_S2_R3F"2)4QRU@1=?M6=KYR; 5'Q)!Y/R \"\N"!>B&_\!#E+
M>-@4\+GZ,"\^&M;Q!AM&(]])]Y7KL71Q8)K"@17!&&HG,*" 4H$0(!$0%+@$
MZG9'E,P0 Z89(B D>#,8AD(1Z@!T?6\)A J2@*,@+%LG6^0:R- ?QV5,P-$X
M'#WE "(%3$!'(/;?)WS[*3#W_]^-X9E%)(LA<+OG51NP)5C+&@*VOD5Q!,I\
M8PH$^ Y0,%8'4",3H-4N3) '(( 1_0+0LEOXUD8]0 ZO0(#7(N8-H $H "I
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M %#J".0,ATSL4@0;Q@Z :"-0 V_ZQY/,%6"@+Z!6'T"H "^X P?X , !98#
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MO-OHR-H" $ E^; #_9LS"N"N9!$;EYR!,)L,&RLRS1F0E3G2/5FXCR^RY.
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MM!>P+3)_/4!PD54"/(!)F2/!VAC 1J]B@5CM!&T9)H!!_Q8NG@$ \@(\  /
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M(V)M&S=^6AR0Q* 'Q*?0T27H:L 4N!2HI<4%>2" XW /8.G5*(!":(B "(Z
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M<CP*OO ..-&+__M/#^I84( 0<./3">W9BVO/(M?Z !H!67RH-[-M[$]9R5P
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M\2MA84Y(S )B80)KQES4,;=STM6 *4<:X 0@@2G?DCDG1*!4'4(F%&"GC!Q
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M9^:=8R G&QLR(3_@V^('FFTL/&L#QHY=DZ&^VSQP*$ W8,=^S<F\R89ML@5
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M1@S8Z[6Y[!F0"O18. "1P/[^][]_]SH?J/0Z'K $*KVR!TP!TD"I(F,ZP2E
M*HNHN*Z]7_0KZ@O\@*;Q@%%@0]8*"'4MH^7H%2D9 B^> 5, EJ-@9L='=F1)
MKD 08-HSAIQ1<^9T17>.Y,RY.S)0,B<_=1FN.OHC;X ;"+50[2)E'&78@!D
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MKT"?YX 04.IO.)8=#926,5U!J0Q8O]8'0H%9X%0!5 %6]=SW^D)_ K5 #QP
MGH*[N;@/) OF%K.,%W B@X5/@(EQ"61DSRC-20%T@$WW%9E0<E!_&B*9NN^Y
M^OH@,]> 9X;+D($[_  G0 H@(S,*?  N@ Y01F<RT.KW&E\6S4ZT30!= "L
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M10X &YL$FGR" ("3(T#%G@!N1_-GC^;'IO%O7MK2IWF9@R-YFY/^TPNG9QT
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MP[EZZ@-1^@*J #+\R) ":/BV01 \O<8%0 15F51SX'3($5@#3F7,U -:."-
MU\Z4(U"?'F6&C8U:)'-QL@.!6E8I4L]S?*X+"V@$X-D9>\.?U\ALBK[)P::%
M'9@K@(UO]@%D U+D &33CUV^N; 1&QMMS9L>.5H@DQWZRP7LCRS9*_DI=(5W
MX[(_FRMK(5+?M8(?V4Y\M$G3?WIRS[6U9EWI4_',?7,$1-5#YF4^]*$.F>&G
M#2,9*&RB;T39&Z=L?0&T-G=T[ID-AC]5I0YYL5T!AGT"HD"I9VR7;.A"'39
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M!="8!R!*OEX3VRCX"P2>F2?@)P-'?^:!!SQ.P@== H]E&1'>U75<%Q8;8(/
M<AL@3H?N\0$D^NZQN>./G0)4VLD&DC&0:3-@4\-)F8]L,!EH1R;X!\#8N/NR
ML/2@;P#0>< 4K_A@D^:*Z) NV+YC #,YF+MGD7//U5/THU_K!D_&<32F^^K0
M-R(G8]"QM4#/J#H //FP2[IB=_1D39@7'=.Y>X GL$[G "E[L*;8 IF0H4T)
M'2@RWH"I\:-'8/J,;"@ ?NO4IS%\&=H"IC- .F<3^<Y9M-M7'@)M\37+)-?F
M+["2"7^AY /,=Q_MZ_.4-,>X9KD+U29[R8[(4^DZVUK'6,=S33?Y++J*O#43
M_\1L\8$_;]WKVWB=Q\/T[[-,ZMXZAUG6-L@]_?.?^/2Y$9^/]&,>WNC9_&^U
M/Q<!IN*5N+"N]4EPEOB4;T=XGO7#!H[\"KVX-M_D1C[GI(L#4T(KR F$'*O
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M]2![@!$P('1] BB D',*<:U_@$N0ZT=.7AW*U%$"(,&1 T."J9T.H0,;0 !
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M@XP-, !N!%_!3\ 6I+33#P"@+@<MN*]*H"SU9>=D)+U"[UM.K\=E)AF^U[<
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M.1MC"_I*MK-P9#DSU_H!AF3Q@%ER!_Z\?C=OX^+!!@'/ +/QZ1*0 JS,W_T
MIITIAVK7CV=97GHS)QE20-6U#") (:-,7^1J/&0N9(U'A$_\F%_\MZ%Q=*]Z
MVI -W56TK3V;)".D'S9@3M;AM'<\Z4??Y-M1_\E97^9L/H[NDQ>[TX\L.; M
M4RRC;%-"/NR"SEV3([N0/><\_5K4N5?Y>'ZD-U.O\NG'#QK($M%- 26=L8G(
M,SI7W'=]6WF(="Q_Y&$=L4MS)B_WIDQNHSG65KD/;?5SS7(LK>W(L=*]NU)M
M9EN)#'\JT<8=B2^](3$67:)\8:2/:?>'^/%L7]DB_8I%2'Q8-\VPRZ4WTA.8
M(CR*'>FD>^*3V".VBL>20%[G2RJ)J6+_H;E'^E+.15<%IL 40*)PL(0F0]5K
M4<$)L  0RI8J@*D N )3@5>0%-@G.$, A#X8*L*']H'?P*=[^%+?.7#HV0R,
M@05UC <4%,3UH3U@4288K^XC_>C3/4&; >/!W*<Q QFR= Q%ALV8YF>NZ@%K
MB'-5S!E/G@72&*1^ ([ ,#[=TQ_>\>B(/Z#4.: 4OXVK/P!E!::*\<D5L),9
M!$R!+B /6%/7 G"M;V##XI4U=03:S+7Z-@OF3.X*@.L>N;$/K\)]FPCDXM?8
MYHP_\L&/N> -D-<.N6\^R4S=G)LYZIM]X5>_^+1XC0]4 5KZD]UEHV2"V E
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M"UE[8VIGGOA5\./H67/0OX('UV2JGGDEWV24[(SC'F &%/>C%GRETS)?-AO
MG'X $(O#JUS #8"E%_/ *U '>,J663ST#O!Y[0#\ ;Y>!9OS\Y+YT@-Y^KR
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MV6@3\, [8E@3J (3=*$??09RR)_,]:.]A9>,U<6#<V!+MM%"!3@!5.!9A@R
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MV&('OI(OXC=Z$SCOH^:IF%-RG#XD^S@771R8-ED!3: "-'I5+W *Q IE*T
M0"HX 6WJ"_;J"-P$JR_!4B!T%#"=,["")J,&( O&@J=V@J9@J@X%.1K'.5X#
M=^JB0"G%%G"! " $:6,,/)J7,8U5=LJK;/.,]&,\?"JN/2</19LHX\"#/B/U
M\&B^&4YRUL:""TCHSQSQ8X[) L_N!VH4]Q3SU#<9)%.%W(S3+E$&S"_L9;P
M,XO6ZWE@1M]^?2YKVH]]9%$M8D!5?9E%SP!11V!7H 5*C0<P*L;PBW??90;&
MT]=MU((BE\X5<Z S<B0K<J$7O)DS, 4PNV_>[(YL^J&63"Y= WSF(=L'<).Y
M^;CG7\.Q8Z_\94Z]UF?'Y.6YUU2ND2QI=LC.>TO SL@23_K&-[V00WJ<.JPN
M^6G+?MP#!NF5+7FN_=1M?9DKF4P[U*^ZQJT.V2F>::N^8@S]J6\^OJ/U>81O
MQ0!T]VQ<W),M+?"0-_T[TC<;1P'2:+U^U<C:D$%BS_Z+ELT.8M.1=;$"T];
MN@Z48]91I&YM[M)NB^IC+7<AO)B3^5H[S=M]:\7:=D^YZUS/27A1CJ7[RF<?
MU5?R(SO%^:G&0/JOWTGT03?KG+S"]^^];6#Y7/&C?R(Q25O]3DJFQ_*O#_Y,
M_.7+^%=\;5&Z\I:'_T/N\7?> HG]*%L\-VT!4V.S^?POXLM]2N8_0/E[TO[C
MI:2(>:BSZ@6Y1[8 KO/LY)1VL=+%@6E$Z90G@PBX<+",(N=!F(Q#%LDS&4GU
M!6E!BI$&2I"Z,EKZ180H0"H,1]%.EDTP9'P440!5C,VP/&-,!)]BC0UT ,H
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M83K7EJRG[LS/_4O1U8%IQ'"DO E+4#1IBQLXI4C!#:AA# 0FHR+X 0P"NWJ
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M3TPC0W&"S^#'Q62R4'<E<C57<NNY>UMUST57!Z:498(9(:4"2$":P"YSYEC
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M-5/I67;T4#IG7ROQ_S:%?!G>7=MT[ZT1A!=U U-\+9DZUVZ/U]H=(\_UH>]
MU6UM7E5*K\TY^4U*#IU'8HHXP'^(SWR$C78R2P=;LCM%#P\AL50,@",:1\SF
MH\71:Q)@B@=C^PV"-W(2/_RGPG<K/@D3;R0-_$<M"0F@WQLML5D[;[4\=PY+
M1/I7R#[,="EZ-&!J@IRF@",P"K:!26!4\):=<N1,!&#7 C@ )P ""8(I( F
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MG7/:C@PH Z8\3AL H C@P>O3=]]]]Q H!6!!M5?TP(- #' P.)\- ,@"LB
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M HJ,P2Z-ZS4S!T2&?5Z )]E]=@6,VAB1G6OR(#,+V&Y:>SJ2A68_^B!/&Q!
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MY,99L4_/R8.>S-M]8)0>?"["!F4( 4GRD26WX0'BZ,"\@4;VQXF0$R#G]3W
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MO9R8(H/KC8.-B.PZG7%Z[$6_V0/@:3/(GF5RV8R^;4!L"@5^]@'<LR5S\(8
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M &4>=J# !0"A;P8)I'H=+//) 1C/JU7 #R_X!HR!" !>M@QX 1HX"F#2*V;
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M9"&@>5V?7N@)F 4DR5@[<G6?GNBKP.4:* 0>V010RIZ 1<[ N<U6]Q7C 6M
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MB!]S[YH4,-V28?K#'[S [\(Z$@3BJ1C/#RN1^4S9Z?<^:_J^]-(!TX"6H S
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M 0.(I0^OR,W+]ZGJZ4,!KC@*B^XV(I\<5<XE<HW('T@#YH!._=(?$$K/;$\
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MN:/^O'T2VQ#YJ$M7RCK6'FE3T>98F75O*Y<@_<;'I/A#\YG/HF1,Q02 CV\
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M;CQU.#3?C=*Y/_O%5FQPZ-3K?/S[Q((>.4!O'&13?:]-KNR+/0&@/M^PUL@
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M0_<J$G 38($E =9.S7,D0#- P$!;@1Q(DA$#Q+RJY&!RM/HVGET+A0-3LHP
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MSR\AU^BE :;K)%T3@(#;[D.6$O@D7,$L<":@$K[@#C P8L\1 5K\[20X$8Z
M<A@4!7DUX-6]S(/ J!^OL]T#!!@_0,&!6BR4#&P([.H:/R!:G9RM>W@Q)L *
MU')V7M'B%4AP9,P<('Z &?PI0(+Y"]+F9?Z> R;NZQ-  IX48 7H$/2!#.=D
M!)@P6N,X!QQDK@!#BUT@ 3B!">> B?^%_K.?_>Q@L.8() *TV@*I  \Y %R
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MHSZL _=LLO!J#$!7G_A2R,H1+XIGUA#G2@<*1VH=D:=K?>C;^C(^P&K.9 !
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M@'K)"'R5$.!SQ5WKL/6*=\5\5QFFHTO2HP'3N>#G.8%-8R,4PA)D^T6R0,4
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M)05T@0N.D= Y DZ#\U&/X+U.%"31'C!5#__3X!RO:8#'"!]W68@"A%]7RU@
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M5AM^!?#9FF?SOZU<FLXQ7G:W$M_ #_WD)S\Y^)8VM:LNM4UOD3K*?7G2CHX
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MT"_ "I2"KW[)F^SQ[K69?O2+3^"9;GWS*[OL.ROZPB\^!%WCF1L@H@ZPSDX
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M$.P $9-7.%!U.#@.2H#BW#A[&39']RU@NW3 2A_:<>X $'#1JS'C)%B.47_
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M-YO5#Z#GFDR .@X7R&,C AW@9MP"LC[)CEZ=>\:1D 4YLWL!GEP%/OHC9VN
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MXO?Y'O9JP\9OL4W$3\C:></!=A'9BQVR3Y]\\LDA^+_UUEN'#-1KK[UV> :
MTY6U09=\M?[9AW-\3K(VQ#^$MTKZF/=>%<(K6=-'\YBT-1=^Y;WWWCOX2O&>
M_R=_I'[]T$L;%^0^VU",>1_2AZ)]?-.3L=@/?MAOV6YUK3'Z#G-,'B])@*DU
M@D_CQ2L_@5?WV!DL8AW!&>2UDGKF9TZK39I+\IWGEZ"K U.",G$+DI H4A O
M RH0*X3,05 P$,>A V-(\)0I (8X-8&+ ].'?CDR!@/@>:8=(0*'[;Z!/.-3
M$(<)? $^!0W] 'Z<" -T+P>'S(/S*LM!Z>J8B_E1<$;! "C:7"/CXDO?YJEO
M];05.  DS_ AT 1N]0M@Y\S445_P<0YP"$9(&\$!'\9SU!:X >PX/T"@<5P+
M(((7\"0S)D"Z#X **!R$M@*=-HQ<':#)V$ (X,*AJ,OY!C X<J][?4?&Z0(M
MY.YHYVE! U0*G>,3H/),YE# QAL@2[=LHP!*?O==*"U [?$/N-&%0$*&0"D]
MFZ^-"YFZ9WRZ$T3)$0]X!$+8HOGBGRSQ2[8RDL"IS9GYF:>@!?31(SO6KZ/L
M+=UG3ZT'_<JVD;F^; ($=?8(')(CF?<:WVM]&T"@4E:3S-D>@*@-6Z,KF2%
M2?_ H7X%9/-Q;3QV ,1J9VQZ9E<R6X H>1E'\/#<AI-^\8478$VVW3U@Q+6U
M;#X*V5NSUCM[ IS-9762+RO1H;5!UV1*'NS*FO&'K060W_JMWSIDT( PFP>;
M6L'7-;*F '_^S<;"NF-/9$)&_"0;1'R6K ?R]D(FSYI#?!4]LP>ZEL&V00@
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M6^?JD0&;U1[IV_SPL!7PK!=RDF'TK9N-JW%0(%P[Y^P6D.97"L23K ?CL9D
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M+JLKQHNS='R?<>]+>\#4_%LG9,36K2DX2+&VDMV6?>%_SOE:]&@94T"/\^:
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M+PL:H-&W+(1G,JR FW$4(!D?>#07FQ3UZ1P()\OD<E_2/MWB&X@B?_)0V)S
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MH  QR@-(!7A*)5B!U7W*=<X !4;*!U($2HY/5H$SL[ !5XZ0<3(41?#U^@4
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M,:;VQM-?@%K1'@^R6A'  >P F0 P.0IX"H *>  + JW PL&J1V><N1\W^6&
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MG0<BV]%;D P8**U?P$!="T\]]8UE_NXS=F/6KS;UZWGC!(CQ@1_\D1_^ J:
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MN/[JIP"OKL*@ 1P!O?I*X]67>_IPSQCF@(!4_>LG.;HV9R T$*N^HVM@!?_
M$I[4]7&^U^L"'O D@P XRF+A$^@"%@150$)& (B01: ?0!/8H@? RS,@U6MK
MKZPYF<"=C"QP)Y.@/K!'-YRY0$;7>%  9[MG3DG@ %@Y=;I!9"\ 3>),<N:S
M3')-YMHJY@9<(G/G&/%*-O@0K/#(KKQN4X!6,L<+.S1'>F"';))>V3C>V;2
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M$IRT=S0?O' J,ASDS8[(ABW8Y  3^*(?^J8'X-J<V20^V1I0#FQI W@K=OW
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MC\@UOL0@9+WZ#T-]AF33R _P6;XQM0E&;)XOPY\-%M^I_XBLS,.F5O;:IV6
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MJ9(C$ H@>&4OR)"Q# 8'S$G++ "5,@XV#0*D:TZ%4Y9Y]6K?*RW9,?_36UW
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M/24'I>106G".]4%.P#C[1 "J>9(;_> 9F*1/S_1-=[Z'DT4):+(=<J$'H%J
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M&?<<%3)5W&.;JTVE VO<6K6&W6//[-KZ )3(DM\RI]IU[%R<\=D2N=BPBVL
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M#IPPYWX- DQA#_X5+E&<5ZQ9I1BJB+^=B[>>54\;ZXY?MDDE<_.Z%CT:,!7
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M/_(?.M.?#[@?&;5.OEL?R98=@".0U*_UU[=^$4O [9./NU;'_":PNA]IG'4
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M)2X3E]PD.L\E)L'I.\!5$!LGBP %(4# $!E] F%MD#^$5+)' )TX27;&,J8
MX$R>NR?Q(D^<3'\(+" $'MH;UV+EP)( DB%I.IDT/L*GO80JD0H$.IH77?2)
M;#J=1- D W4!G'D0WQ%%G\BI($)6D'9_K$!7A!#)0Z012V107U[#LZ,B$!%2
MOZU! I!%P8VP G8@*;CO[NXVTN33O(T!2,U;>[9T#RD&#(@M4DHO((M06Q_
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M<$B( //9<Z00$4!V! Z2 J X@N)4#K!P6$YJYR.YV04I"*]VDKZ@1\H$(2*
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M_#7_747=/7L2<2H7D;6.G(-\>L6,*!-Z\&$Q[% !;CAQM<D/Y_B]#3KL(NS
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M)$A"<4\=Q$T]K]P1PE[C SG *+B=?#HU]>H=Z7,?>)H[.]#-N BN[XB!3\D
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M'Y4@) ":'1 \I-%XDI]$2&^^S/;LR,[6!=%C1Z<W^N,S0!=!]>G4,E(0F9"
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MQ'<D )G4GX"EFS$05R=C$H_QG%[U.M6UI",H!;%^/'.2"F"-*?$@H^S=3R@
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M4U#7;:3,AY^I:S[TXL/:\2OUV,HIL7FSJ_O6B3^5!,2"DQM -_U+'-@ 1#H
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MOGDGZ>%S3YJ'N1X5[2\I>V.XSY[TFW:_KZ3C.@9[A$OZ]YR_V.C8B,!9XNT
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MI,<9).AV_NI[+F$B#25\ $P @=].28+: FO@JSUPE%#=!Q+TX63TZ=7J=&#
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MT1>LE$NFF!^1@^@&#YW<DFQ)&L]<Q3P_A@%P%4;JFX@'<X*9_HU3V(BP$O.
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MK?K&ER39BAV(:WYA/=@C6UHKWPO:/B=H\06^(R'P#>,#0(D3Z-(/,8YD\4%
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M=ZE$:/0A4">P[HGQC8L<"$QV<4WLR"25=*$G?=A"@C!G_\]GP6Q7+[ET.H4
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M 'I%\I<PO#[MMT^2!UOZ*8!$@5A*5D 9B4!X]><?WXXP1G(!JZ3DY%6R 6Y
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M]^9XB6BW9Z/Y79YU^)!=/(.=\H4YTN=YQ[^OG"*F7T6Y.3&UV !(HI+@%4$
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M;=[Z\MTUS!=;QJ S?>@(']7?T^M:TJO\QKV&W&HNY.;$U.)Q8 FW5Z,"Q:<
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MX#2.0*:?/B5U@0GTTT'@T1&IT+\^?3>/BGN=?G%TR5J0"D) )- []31>NT*
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MFU-E> &ECXBN $P'I,[8 @Q!U@_R11<)5-^^2_P(@WH"V3US$;1("3! :("
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MUT'6T%PD&'V:I[5 SMD- :,/<D('-O(J"=E!%*TM.QA/W_R!' 5,(+,^][T
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M%BA(EQV[Q*@?H"E@_2ZI.L:Q@W.RX+1/$M27'?Z::.D':)T^ EH$65V)U*F
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M8W>^1S_C>V;]DX+=/22 \$FV59Q666]$ER^KR]==]YM3WQ$TWXF^U'LL,7:
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M'X"K(X@\%VR2H& 47$ "000 ^A"$@ YX2GJ"SI@28J]'"4>RN!S:>'XZH*T
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M'UJCUUY[;5O'[)H-+A%]F%ND'#[N$:*$SOFRW+G:HN_P4$YP^$#?A*\ATO
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M=>,#"CKIAZ[TEE!] A  K8VQD17!A*CI0\!ICYR:CVO@HCYR8TSS81=C(S]
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M)=:23[;^)'\7Y_[(! 'UQR(1T];8!EH=8KUL..$.#&L3(;[AK>_P!IX@2<:
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M/+,[1V(17<G';U"=<ND3@" 13@W\' !YT(_^D%LZ("B(B36POH#):WT[8&M
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M+.(S'F+.['$+04RMR=3;-7WII+C>FQ=ISJ?JW%)N3DPYK83+22T:LHB82%[
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MU\;!B$T]W\RO6Q]B+'YJ#?@V?.+#<$[,TH?.?%_[O5@TA_Z 2CMD%B;"4W:
MW>9*-_."-9[[#;#-G3S4/.J_L<01O(?M;&S>B>?B$!81<Z(O,1_Z6P]^$WXE
MZL(<_9E;X](C#%AQ0!WW;+ZM3?>.1-W$Z;F-!_PDWLBQ"YF8X'J-&SJX?VJL
M^\KL"W;",3[-9L93Y"W^D2UN(8CI7 _BFDTJY^S@>>6QY>;$E/-*OD#&JUY@
MY/0)6;+0@AM@ 0_!T>L93DTD*:<JP$I@67B$-;(J6/4-F 0W,@0@ 9R^$5:
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MK&"FGWGJ6UV@F5.S1R!GOD[,]&-\[20>@6TNYN]^8"9Y W&[R5YU2^J]HD>
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M\I:OITH&">'B 2(C^2DA90P9D%?;P>3L!S>9!/'2+M#^EF>,$B1?P3U&!D%
MY++,P2@B LB,O5C:QE(9(FD)AT= /$0A3^".2"T/(8*HG1A_RW&.6>I!=A$F
MGA $P@3&V/!8,R*(K7R4JY\8IF<]ZUDC\;"'D+%F !%,<J8O[>UB0!D>RXN,
MF7SIA\F6,8I!1G[5U:2C'9"UW@"DO86V/>=!&R*BXGOH0.21,#KAH4A[:C?$
M/=!_)J:^;_4+ ^_A"HDS0?-H60KE@=7.,;#T73SMJCS]3;?IEGP9/AYDNB]?
M]_5]C+$X=% [&"?B:Q>ZR'@R6-HG[>!<'LHU$9D I1'D*Q_7Q)/>N;KXK:YD
MTR_2*E<:\07QY*ULDXD)-F"TZ1G=H7OJI \%DZ_K)CHZ9.P)QJ\'LUT!&=?Z
MR3&(+NOOW#/Q UTT!K4[_4)$0-\E31XLTO^0//MQXYPN>EN?K0-CE,XJ0W\:
M?_09C-/LDP2_]6& U(:8TF\/J_*AM\:W_E4?NF$YGKT #ZOVB(H+="3>8'53
M3V_>TS%UI'O1\=3)?&%[4,9 "V62(3#?T#?UM/HC#[:.C0/Q73/^TK:@/:1A
M[\P163TRMY%=D$YHRPOD:TR!.9!-E)<QECHC] ';R4;I P_20>03V GMP]ZR
M:<ZU4=H9C%OG^HI3@2?2 XZ^4D=CCNS:D_ZDOCW(9OYI(0V;(- '^B-/GG8V
M/O.N/%N=!.<MR?.PXDLOEL?-W[9_F,<@]84I79:7.JX'R*=^^H=^J9]KZD;O
M7%-^7[_UPCR/Z6HA;1MV)'8(,55I P!AHOP&)@/CFF!Y 7E$4@SV/+F;M)TC
M"N*8 #VY^VV0>MI&4@T6URDV<BH=();.D4Z3L,$*;4<@8>)3=/(9P&0*<9"O
M?!@QA-5U3X(4U" T:#RINX; NH]@('OR0;RE0[;(*0XCKZXF:H17W:6WY\E3
M/%*'**J;W^T6!X3)@$>2&6%D2AD&!Z/*,#'^EOL00.7:DZ6>)@$3FW(C-Z/*
M* DF/ 2*;(B:\LDD?WEY(O<$SU#R,IC,Y$T^;8@ ,[+:)7L+U95G5_F,K#95
M7W&04V1)7;6-R8FA-X'Q-#HBK9:JE*%>(4?]0*)G^C#&;S4#+<MOVI4WSSXM
MNL*PJKMK^D-=DA]CR$"UDXYK#!3]8J#T!;+N(4>]Z8,\D+1X/GDK,XF9"$RT
M,> ,#M)&?^BTMC61BF_<:#-CP3DR88)SWU&^)@YIM+-)U%AQ#XP]Y$*;F@P%
M,LM+').!(YGEI3W:"4#=E44N[9SV('^,L\E;_GZG?^F>_C>VM2D]XTTC(_)/
MYUQ7[WC5=G;$#O7Z2K?H $+D7JZ!_D0LM+%/)GGPW%X8>_:7ZG,PWO47F>@D
M/38>P%A)F>XC5O3=;SK@8<X8!P]H'B[):LP:VXBK,4I_?*;)N 8V%E$5#WAE
MZ0/035M"R,B^SH+R[:\EH_9JQZC?ZI)V%M=X9 ?) <@?N]."?AO7L2M^&[^(
M$UUEV])N(%Z\A[,@#I!'6VL#Q)*M()>^#]@GXT1@EP*R2*]>QK=/9^4_@6EO
M@1QD)8L^D3>=4J;YB<W7WMI7'M*DW:)WVLOOM(.Q+M_<$]S3G^J%%',B^!?7
MYB(RFL/B<8<V_R"V$S&U;]H#O3W$^D:=TF_@M_CR:2'/-M[6('69!??4D0-,
M>RD[<IBGM!WT]5HOQ&.ZK?6%U#EA1V+AQ#251B(1OSQIF-PHG$G2),HPB:.#
M#7J3,@+FMWLF28I!"2BY)S&&SX SP PV]WD.&2:=9H)#2 T.$W*4R4!*1R!N
MC*XT9#'H3*:,+^*" 'B297Q-MA33($9:#!Z>(!.O29<7B*$V()$R2\\,,<*#
M##+," M"R-CS!B)XEBZ0-'$88T;#4R/#J5[*WF^__4;C;, K RGD:4).O4#B
MFK@,*V.9%PP,;GDBT@R;^^+S#B##SI6G'1C:O/B$,(N/ )/9D=S:Q7WGCMI>
M?<FHKMI?.UJ^ETX_(;]D0YP1;'VO;.VBC3U\* _Q)3,#+>\04_VAOY2/V*?O
M6KC&, IM_TXA>H"$>>"0)SU2?WI ;]+/[K5+8_*F3ZT!DE\F$\0+&2>_HXD!
M>=26Y.>--+F:<!!Q:>D\@B9O\9%O\M![==?&\A77->UB/" 4^L_#AC%A+Y9M
M$"9G+W3H>_JBK^@#><3S8.'E @\59%!?NFT<&E/J*^0A3SOI4V/!;V35A&:L
M,-+I6_JN_>F"<J6G$XB4!Q'U1SB43;?I'%G(0??))CY]W!5 !X5V0G74AMJ6
M3N6ZO@>VR+BA,_HX#TVYWR)I@W9\M# F+:/3=;+HQY @\>D7_03]3_\ 26'S
M]+\QX:&)C:*[;#$[A)B20YEL@W$%Y/4-TI0C+9N9AQL$!5GS6Z ?B#A]A-0M
MXQ%! +H3+S+=3%W5@[SR O,#>XR8LCGR8\?8\Q[2*D.=](L\^S:4GWOBB3\+
MJ4^0-'F ;4$F#W#&M?%K/ 7*5V=']L78\G"GS8U59= ?ML2#IJ.X'EK-L\:P
M^BB#33+7BH^\1C[WU$4\\Z<ZMI!?XOJM?=EU<PM"Z:4ZNF'>]UO[(JED4><>
MKM$/CBBV2Y^S)7B"O-/GH.YD:Z]M#^2C+O/R,^:,#6VDOD!F8\"<!FLESTI
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MR&:)EBZ1B=>';MD20B?)IYWHI/X5Z)O):U= JZ^]CO;G(0O&$"^?R9'GDBX
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M@;,%RH?;Z1X;@ZP"_6=K OFT8WX*XJ3-TUX)SG.MS2=Q03\A/&DCI,]X-3^
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M,!D79%6&^^I/UN@074#:3;+R\UM<;61"I=.ND5L_[.J@IW2,GH>8F@21-^,
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M\,XA!LX1**0!N>0Q0W!#3J4S(;H>\HH$\="1QP.'EQ-<X\ES%)],R&R\/"9
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M17G%U$E]I.'Q1"H%;2>="96'5%ED1-9YIRS;V6=(7IXA1$0[V7NJC%T=QIA
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MJ[CR07#(RM- +G% 7:4G,WEX71EYY(57+?5:)NAW<JNO/M9OKB$_'AJ0,O=
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M?,V"^HFC#D"'R*;MM"%H3S*FS?6%=FKAOCKSVO,:RA=L%> 9S7Y6\OI<D[9
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MSAUSS5%(?KDND+</R3LAZ=MK*6<64E8?-CK(F/HF;(OLXB,''B8L3WNP\"4
M1!6AD.\4MK6-I--O??K^7+GZ;Q[$X85#5J;RLV?6%Q*4U\*]6?6:!^FB4QZX
MK P@\-IL2H:M 7FBU_(* 5.>8^1U[,M)G 3]&0*;<=+FL=Y 3)45O;*_-[;
M5P,LW>>;Q5[4LX6$!]5>8E]3L(7!ER"\P(>\\GQ[68]7-75:23?6$D5,"X5"
MH5!8$$SRR%U+6GQBRHM"2$ \7E.$:%L@GQ"+-K_VMSC*1&K(T$(ZH947X6F)
M2O)"?.R;5EX+YY:&>W(C7=+F=\X#\M@2( _DRDMCY$0D^_RV%M(CE"&F9-3^
M?L\#&;6!>-I-2!XM095_7Y_U &*JG.B/AU3DW2>W+-W;/@0^O^439GDQC_?9
MI[!\'<(6#6V+M'I@LHW!?_?RF2[UV-ZVWAH4,2T4"H5EQ_V;A\WSO\M>V"!
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M#SG@ 47H$#AI>25]+Q401?>E#6G-_YCWUK7E;T TD%F?+<M+,/*TE&L?HO^
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J*!0*A<*&0!'30J%0*!0*A<(&P##\/R*IRNE$G7RI     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>lease1317img2.jpg
<TEXT>
begin 644 lease1317img2.jpg
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M@,Q>D;&:_P!;J NDU8:2$*B*&"2<#RH1]NESRUTG4Q4CQ^VO!R9%83M5QE\
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M4YIM@)JT,'^1P"^MG:0Y;QK/ES(@R%V74]NE/#$DUIIV"#/'.0">V[?L@U<
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M1G%V_S\Z>>CJS7=9X6,HD.03NO4CU^[/__4Z8#OBBU8#BJ/"&[Y95*XV@*L
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M"]:RANLH[,CN;TZM>K)V^<&/;;_HRB]WWU#J 19&GB?\-&"H;Z(MLF=?O^Y
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M(CJ0H=: NRU%\R&#:&J@:>_C6L)C-V!Y4N*4"DLC,5D;4BS%Q:3UH=M.QK.
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M=\>IK?_Z'5?V2Z% 3>&->KV.')>I?!QO^^<;-_W-9\X_O.7E@PIJC1'S2-)
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M49V3&H(<R=D\*.?=3,>_,<^ANEJ;<TC6K%HS2&-"' 9 =&;O>QHI]J5Q+N7
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M_5+P2[$OC;,/?<WU"EL"+%)]Q7%P @-T^*F_+&OO5!_9P[=15T+?X;4W[?O
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M%TCPM3AA6#3FS/\6Q!PJV5*& :&;"G%&[]Z2O>T7KKM1PY;5NO6DC9SHL,'
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M8E]JIR .)J@*BG5 J00UJFEJZKAH5T"A,@?U+@Y1B_PUU?A&3\UJ1JE$"IU
M A&W;#1\[(A+8=OJ^_C>73N#_LL7@:\AX;H>1T T7<.2.@8!Z#,^[QCA@<12
M9M"Q1[:O')A;7-5O>T<V/!R&NHI4X_PHY\[\T-*K@5ZO/VQE>$W5@%[%XYK9
M$K83+;POVB!YG\#$8C[M1 %M4Q83C>),/UDI]J5V,A._UDG90JAX6Y>'B#^S
MRC&!.T 4NU):!#B<NQNF:E%"?5X$ZCD<1]N:UKS'F#>#%HDH&,?K R7K<WHE
MF:*:+Y8NW;-L6-C2MZU,$X-D1-CBH:E>7@Z,NROR%5T00W-]S'!F]X$_.WM)
MI3HU R9$6M.JQ;A&/FNU@QHI;7K5C^0>T0#S-CYN8A/*<(F[5@OT\23;322)
M7%UHIL/\%56#IQB78E]JIQ#':V]A:X;2DF(]#!-6TB<-Q%RL$@H\"+E='.?#
M3:I5*JZ' >8C'SAF]DM?.IA[Y\HS!R1:(LXD]6N4^D6$BZM1E "[-]YW%P_<
M";N0$P9558%EL8B&+,OWJGW9V3P7IN&[CF^B+_]P^V/OUX!53.[1EH!C*%X:
M7A[6\=+SB,1;1A:ZVQB%55VS8)HA/-)*])H52>O%@#XBND<KBQT;D33#FV)?
M:J<0]"7B7LT#:6,= -TLY3: C8 J&3^&L9Z .L7)Z@E>7R!-!]2N)<(I:U9?
M=^&F+S[V-V\J4"J1$T4>-*IG9"5N2FCR*;_J$'O\\6]HN%0,<%<W :%O7CV^
MY_ T&+F,5]Q2I7-!@#$7I>RZ"[NV?';B\L4N6MQ5A@!Y'E/7JX<>;S2F+9K:
MP8J^Z'JPDFGTT[6K[E$:@4(4W__T/K1BRQ]JH10T0[A.]!KO5.,."S_ID#=B
M% LZP74MZK2Y(L6^U$YZFS^OK+DG%M,<@6R/J[(=6NCC)3XZB B&( B,D/!4
M7:+KJ)U/S?VJ[YI7+A6/_%EYX["7I_6JOE *(:9]+, 0N)EBYC/FBV?*-+NH
MISR^;Q_-9M =/[7RQO+^PO[]'<MV57,6<P/)&[/ZR.<.%]$[I[ZPQRC 0:IG
MYJ8K0;:SVZC[IW'.U0N<Z4<*]T\K5_HH1%?YS+PX\;WNLRY]8H<SDC$A[%>+
M>5]R@#E6[##\2>[.%3F89<LF1(O5HYO21RD.IMB7VDF->VVV1#VY5N]D=N*3
MO\-H:5;KS(39 B[]7H90P"GE\I.D14,[P"*$M#\+-E2<,+=V5[ESR0/7(<G9
MPCFWH;I[#?JDC\U\8?%__-10^= R8WC%Z:L65:?+$D\S=/A@55NU;&KLXHZ[
M;I_,!(XA,=8+NCO^:Z?6YWP.G^,]_<&.'<%E5]L.$::9]&Q#[ L8Y(^,/;5Y
M2?ML3?)^A>.S\V:M8,T*JR.BC'&U3[/>C+H%KGQTD^E%3V JX5\+9Y"(NM97
M:BGVI79*^\:9@7LV5#[Q4IJ9J."YK&T*W_<9\P,U1=*T.7<-MPHT9X*CRCTT
M)7G*)0BP0/XC\0R95HQ$GMYYB.:W?.V-I5"P)=)\;]0!JM*\0*#@!<9-TUVO
MRWS^T,-S94FM<A0ADLN49@.@FD#9WG/7G+&IR[(QKXQ.7WS&Z.&U]WPV"\&G
M"ON]_FMS\HA4HZPA>A\.6*\BZ!LI5MQ[EO?! A&_&DXZCFY?_/6?_731:4NO
M@X!"W&LBQ#SP8T()H.)27UE)$>KJN!22=4(-WIM2OQ3[4CO):5_STU%.M# T
M.;ML[./W']Z_8?];KO[O+T!?UJH4 W\",D-!T#VT9"B36;%TRC,M8&ZU5$::
MIC%A9PW*/,]C_O2T[Q4G#XPXN,-\>/8]F?O>MLHUI&];UQ>MGY (S/9.K-^^
M[=ZNBQ\P;NR=G5RWSIL8.S(\@0L;5DT<Z>V;F-NH)NN6B"E?;:^"LZ%@;]MV
M_>"O;OO)BTO!"W/45I' 9,>:&ANI&O(Z'QI]W^=O^-B5AL(HUF:JB"*B6,UA
MZNC(^FO/W+:M6\4O-5'70HUGDS=B?IBH"FO-[I#8ZB[>;]:<W#3<EV)?:J<R
MW:MUA:'\HMG)#2L?K@ZM?/=WX>M'-AM=JX8F#I;%X"!4YV:=TDT'EBX;/S +
MT'W.:<[(OF&:RUJB.C+6T\\KI:(+9GY< %[4AY%AS6Z?-#MWK5+J\QSAJ("P
M3OLPQ;Y8L79J]YIM -F.C7O6%*!(=4DQN:%[OJTQUP8HE@PM"U#U35V"TTS^
MS/&J,7G&>8M>&T8CS:KTQ7'CPRV4TCTF&AKXV<A?/?VS#5.]2FV%28;7U*\K
MZK-!5*[VAG/NWC7<G9=8+N&_5GHHYKF]\@8"0<V.@?$YX@[MA:B"YM?F[XKG
MX94I]J660I^(*D\X1J1S<N+\?_K5TN_^@KS.]@ ZS4>>?.%9M#PQR;3N+E39
M=6#-FD-[?&SZ=_]\CO:M-XA! [&H8^?NGI4#O2;,S5$KF]6)XSGY"U^]=^BO
MQG:MJPUY;,R35)A!01,$%6S%H,RUG1+Z("=1,DPKJX&Z1&4J,A%EL\*!P9J%
MD9U7L<2+O+$5:C>3XD87<#BB4OW4"B_\]^KGGLPM\H2KJ_Q,\SRYA*B#*7_Y
M]%]F>KH?U\Z7_K'$9XQJ9*XIAQ$Q0(FD:YYXL <T3^D8,&T^#*4<,,6^U$Y%
M8ZI8CP23\.Z#AW*W]670\##)9DS/I91SC5:K'EVUY%\/]B_-DZGQ*B\8$T]J
MEN"4^H&>0?[CW.I_T37%L8[.TA1SW,-W'+[U@NF7J<]>J&\O&M,U1#W=:U"G
M"#33"[F*I[IC*2$X\(- H8TJJ:%Z708K8(0Q76)C=6SE4X]IN0(@74]<O>J'
M$^$/_6RQ]>G=XZ/+-=^S5%_R0MQ(>M/>TI>,EE=?, CAE#>,&CYO,RU6>Q,$
M*_H.+ F,64<ZTRP>Q-N<,4K!+\6^U$ZA4&"H7*!6<4 ?M*W/WWS&#4Y)7Z3Q
MR2F>/6/MOH>/E#LZIR>4S!1F(FL8C)&N[L[9F96%B2..=%\9W;1J_TZL3S[Y
MKZ7"BH.3M$<X?2.K[YG=\(NWOW]3W#*R /QDK$"%WK"MHW@O2@53"BV<0X+6
M <72IU55-58/9%=FC7:^GWQ6Y20"T;OUKNT]FLJ"J.'#\]O::ENJW@NW7XJS
M%TOLLW%-%6%A$6?-]4I48.XI[&.TWM'W?*%?"K4I]J7V+-$/6"!T"CZ^CQKE
MT:_PCI)JF2T[FE8LGWZ)7.@5W0 NL4<1L*H;&)E:A0MS$-'1V(299;R3WOX+
MR ;>7,6R+G[PJG]8_H;R/=*7=3%-*,>'TVX3YZY53R<K"=M^8#'$_709WM$=
M*6.)><T=H#1DJN;^M>6W=0+H:LPOFC=.J(Y73,,[]H_\>%VOO'/51=>F124!
M,O*_ZH0*'@JE<QWPZ*(2X"N>^[];:BGVI?:L*(((O$"N?G/?Y& 7]O,^9$.0
MR8B@NR^D9SF FHX]M33>*.XCH8)Q7T%5/G/^PA>&1U/3<2_CFW?>,;FR1[JJ
M1.,L406<3* >GX6HI'SEZ*S8C-%&-"O%JX1*(.EIU^+=2^Y;!"&7DQ]^U%SI
MEY!X9AK=T/^ZL4(O:$$5$XR::6%+*D,=;&=OQ4"AA@OCS4+0QX-\OP&QO52_
M+\6^U)X=- 8!DVO^2-!7L 4K=<:;BY6\71LCI.)IC*GZ9$*#JO)*:7U>&2@7
ME-;$GCU?:"S8O>7!NX*+S)(M%&-+C"*JGS/6_62J=CK4J*\_49OI%BHJ,\94
M)W&8HX@C<H#FYV+C+*V\!JTCLY[[E4HG@:/5=(N 8>C$-SYDY'JRK&AD<.,X
MJ.GK(KIV^;2^9Z"B<:S59M>AX\>]U%+L2^UD='J)KHI%^%"V2J:U'U]1 X=\
M'B*!JQIH1.T/$O;F*=>K&48\^J3I2$-4G/ZS"PZOF0,6 @?F28H6X58-#I6>
M'\+)T>1U:HCJ)XY40A7T!96*I]N&WD3G8J<:@>'YL^-[-HF^ ]M+^.BT%U')
M$7_QL[OO[-ST#RM)8-)F=!2UOK9:%9_B?433@K*%S(#&?1T)Z$L!,,6^U$XY
MPQH6&D!U6?]#D@#]Y)IH*W.T.AS%(!1VN:E^"A:$\BX"U<9+"LX#H6I4?,\+
M-,TJ>G]_8U?NOFK<(XN:9!0@.<E#J<,D<#1"OJ:V"D@JR'BEF8K-L9%T3J.:
M/75$S0BF#Q]VH6\8]#8>:1,$4L3<73OLUWG!ND-9K"T0)$A FH_R3 ^\3 <X
M64-K[)2B7HI]J9W$7NW18FQ*:UGNH<.Z.TOF9*371X'FOI^[F)%0M$_YN%CI
MN"B<DQR1 %D@>ZMI=B"A*COZ\/*!A[@K,,'0,B--U%(#$?.+,[PB,6:\R9>5
M;*]1G<Q)5@^H3@,<ISX$B.2<2F0-.!<NGSFP"CK:O0O)(P=^5KOD)Z2\:0,P
MTD.;G>?H/6N 6WCL:;/G4*#-7E#60V05Q_7FII9B7VHGMW&BB55>R2XN]?2J
M%^1,@"]DME<[')U '-C'DNH%3'V@>)$:)!S#&Z%%7,&GAEH$C '/NWM&Z- ^
M\ G,G\.!:M7.HBG\Q^-M")(2J9"<#L(9)_D0M^0O) E],4X% K++KRA,'UJF
M'M!6YH>2,!4$H&5NN_Z-9QK,3"K6)(EG7;HO+)B9MOL.^.;XYK$50!+//K]5
MS2GNIMB7V@D2/S%_W5"L%8US,610,%N97O5'61,A"QR&-$V$(\R9? J8"T8W
M<#^::2Y"C0),Y1X\H(0%@; UZ'C1:P[=>N\ZP=J-2$5B_ORD>H(#!&J^6-%V
MG:.V**!\XUSO]]\,CYWN:_.@K_FXF# R^-GRN0"DM_DP:-Z<CUCGI; W-\.%
MT5:W%(DV,S"?BS]LBHXI]J7V+-<0ETS)FBALE9S&<EGI8Q.SP?9KNJWN;'DN
MKR'A^X@0<7 \*-VV8]UID_LK7E1\$HZIQ/F,5_&88?IN (6"X6[[5>G@V'(B
MH&W?:S0S"#6IJ4:1P'D[)VM9E)A>$,YHJP]3JI=YA(^Q4HVF-[U)WQF,+*9P
MU)Y;0A'<5?[!N7I'3M6L$#53#H>:5<T3F@2*@Y-<M^_97!+$UQLE?_$>\=VD
MEF)?:B<_\6M5(5%%:W+AFYVS?<!=;K!5^VZ]\IXOSE2 GK%I9H3',3_/92B?
M^>5-/;T0-"IZ*>R9'1B"\LX1'R$^6]VX-W_EF^CGIG35E\L MU88BU:L$+4!
M:K4(&VH/?C5YYII7BD23,K-0JJM^#Q_82'.T=I<U=*RE;>.#$0U#:??7;G[3
MVR7V(0V80[2P@!HGU)Y1?(#P45#.59@> B.C+7+8T8XI *;8E]JIZ 8+)D@V
M/]I-BTP@XU76Q+?\+Q=Z>.G H:4O($@%V 36C$RNKYMR1$P#A8K&(67$83FT
MJPJ,]>#A^W_GSLO7GYF_\\$L"N<="=(ZP5L@T>*-M:!8 A03UXG#QMW:F,P&
M7ZRWU@H@4Y65O/=,Z*K#84OLKG8\1'WQX@O%AS_RU;>^K5>YL0$/\\FUT7.Q
MT+Y ]>F:0;FCI$0/% ?DN-7=3E,>*?:E=JHXN2U1(:[/,=UD73[%*,"^?F!:
MUU]M&:7R9=F64CY>=3&EBN4050!3+W(V0J AZX;@_"4]&>ATE'O(1=OH6(@5
MJ!GZ$G2O,7:RN8(9"XZ:YH2$77)(U*? L4Z/><*#0&LED+4=:YM49YSW__=\
M2/>C\<1$>M2\KK":&.(9B[]@9 YG,583A%L2UZAV[2GZI=B7VLE.\^8);ZK5
M.\LMQ^]U+$T 9G!0[M,!8(E@"I%:)@(1W4 D:S#!@]@'C2N361#5LP#&>(^9
MR7#/J#AZ=)IVTVQ;HVI0)W[SU =:>M=0<V$U:K0(R\V>%3A!:19<;3[""R02
M&W"X./9E_VIEJ)*%=7EH%KOGHOE2>4@"-6NRVT%4DS07S^LE1N)Y@+ZTM##%
MOM2>B8_;M F!!E71=:"'<, <FP62<R'T[(@63B7C/$K%2DZ( Q;5),<9AD!-
MHI3/,0:2#7+3<(.\^>';J)WQPC'G-3QIP=IY+J]H%AM(($L"!\6\A&IRXJZ*
MV%%S1)6[Q.$],0_Q8W\5L<"P'MQ[P:6=<4,*5X4VM:$=R7B>",NX_3SW)/93
M*GRM&2#G7_3S]/=,+<6^U(Y)&-I1!@=G2XMY*-(.%G3@6>7.>M('EC2',X5N
MP"3(">GWX2@I&G(RIMJ!I<LHY'-<8]P :W*L=.9+;_UYF>BBSH=:U^J\AP+-
MWVU^&*V-% )*@*'$/F*7#"'B_I'Y*1X!,?BYI3[XP2._6ZMPD9!>DS85H@W!
M"BQ'H2S1$".D%?F>!TNA+\6^U)XQ44AL4,/(YXRYCBI'JMT+1#"309IT\"31
M(2$RA&U<7(&?J@]!#<DGHK(/2@=%(4-8EVS#6*%WRR,=E"D5%HS:KM4%>$NK
MDA0Z+ABH(R+3F,#063%"CL=:!?82A^2F5<$OO7C%7!Z@HB:E*\Y7NZT$^$DR
MB%2RADS,91CSD:&E>8T4^U([1<$OI'U)+0!!565<,3.5J[(HAU%Q)I<0,YPZ
MF009Q7BXP,W<3".1'RI!AX1B5[8]JU5&#_3:144B,6H?J9K'Z!+YA1/!%A2'
M"R/L Y_C3%>E&QA& 1>H-7978XY^8 $=(\'?W?'N5\%,5E,^.89&_CB<>BZB
M?F6B+I6.SN29*NS6<"A&C5+\2[$OM5/3[:T;#[A$+#'B]/M'^DD0;C, O5*$
M?6'S.,[\O@:<J(93^_MB,',QW+<VZK7 :($3MQ8$(W$\3*\EJ2!J+F_4?!%(
MSSUO2O>42>QC;($&$+6G8T'EPS\>0_]X&8"&A @P0J1>-QCGET4X8#B\ S8W
MML(-/$-777X(GPQ_PU2_+\6^U$Z(^(D6=U)YLG(MCZ$<'UM6%X^W+O&YC[%@
MY-@$IS;J0E$E1H%4W6]<S'=NBG(/N.EL(GD!HEZ75]M% #HJ_(EF^)NW^#EX
MQ#:%!+, $RX6Y): >+78,;)YP[X;E9-.E"]/&HA6+X@6BN5&"C9!*5,5#&D4
M'VT.2(I4)X_A]"U(K8X<;9<?#A5:0!_8C_IKLLIST/FK2M7$)^;:2:3P S79
MX[7GWX7_[ 9@'+4PI,B+3%R.2,Q.JSFDZ"C7'^\N(DM,7@M_2 ^] Z9P-0!-
MG1LU)OBVBJ?J'4&@?^TCPV/7_;X'NJF"FM&EB@8ZQ_,[%0 *,/.+.$$652/A
M5-([]7E3[$OM%$._><,E5,U:($3GT%[<CZ*<!9N!P>\6W1->WJ'2B[1-<Q>]
MMH)'Y^%#77BE#F$+L<AVE][(PXK$\1*PCJ2OGM6<PD%?/84))DFQK6BZ4*T_
ME^0R7K"F^B:\XTB1JBQ-'29CZ>A(&0L3266E >E94=&,#&6,A]B76HI]J9TB
MH"<6<!,!$0WY3GEQAR#C><S5+%KIN*X_XF86>,$\0!)U!S'R[*;WGO]'5R#;
M"[PVT-=\2<VTKRWTB09:MH6_QD\%=-5'OT.^8X0I&*K K[9+@U'6AA5A3F#C
MZ6_Y'3.\YIIN?O*&5 );8E_@,@2SW0.C9% CJI*'BX5YGQ I+J;8E]I)!'W0
MW//?LG018])7S<"DK8KX),NQ87TP9R;]Y+941S1C1:@L[[M0?&#=!WZ[&'!@
M_'B<\ 9:H(6&1,8XF40[,>^>5(\=C&Y[ZZO_TU-RU,J9;Q59K0M428)*Z-SD
M8[=N_.TN6Y7N8-1\38D+$DP(M]C9-8;[D&KR.%9#10I^*?:E=O(!8(/X-%71
M:=FA\H[>XIJ9W:9:ZGH'+.O? =4&2(IV_FE+"UI,K4B@;S4?_,FC))>W<2OR
MM()NTY6AHU\YBKW6H_G&[M2EFPCE\V!1-)]"/L0Z[<MZNY<;%+6&'.,W2(EF
M*6_7+M# 6 Q&-7 K'"E'&F-(Z5V*?:F=.J@G%D(-I 'L>Z107C%ZKQ'K!QB+
MGA958+7DAYCOG#8A4OR+Q M*RSG_%WNO.I,KN0 1\ 1S0_%.=5N(*B5\Z<:U
MHUI97?-K&[<D@&MBU^U?6)Z-$RF0\/1% J!#'Y?*FR2[0Z=8-. O/')T$HP0
M9X&@"-1D(RB#5ZKXTI.F&L%H >P3*?%+L2^UDX_P0=*W;.FGA8$E8_;3XX<8
M& 8!!D\4KQ9ZD_Q4F.],)%G;1 YQ*/!2GK7S8L=LGR5AC[N^2+B2(3JV\VQ%
MRZ-:?"_Q? ,XFYAFXE J5IG=OV2EZ]>3R/-N.UX6D3#^Y/G&5! =N$$,47)"
MG(@ZX 1\[W,W [=IV=144R]Z!@"7)H93[$OMY '!QA.E[@V'[-U%[JN'P0@\
M.GLYV*B%A\4%'O/!3]2<1,GUA%?J6';K^5\TC0H#X4>9WV:O<A[OFP=^(A)/
M:&[+@"3M:X.@ @*<?[)GE1?4$'3^",E:L4N8X)B\8/&A&8 F91B4Q-2H?TTZ
MR-4O?/3!#D%(Q5#];:AU1N7QOL^I/8>6UC:G@'<<)$1IUM/ ,_C9CI)TPATP
M9 (+>W@;8LHB#O )KGL8U<3U&J)XD="H'Q2L]Y3U&Z0SF562H"RLCE9*\] R
MKPV:"GX3=<@U8$5-/6GHJ.RIUH>!.9VQ-"4\,^]]:*X=#!W[[/90E$$58>,F
MZ*U=CQH@#(QFYDY?RK4']I0TWMBGC4A#"GHI]J5V,B,?:NL@<.3D]//+\G?7
MR$^MRU:BL;4BFL/;%#0,IZI%G5^H(<$BH0<+X3.ML_MEZ^ '%3O:DW.B_H=$
M.^FI!9S'</9:?1C&PJ"'FJ%/>>7$.])IQ)6,J 7Y6J /<I7S-7,!!TF$W1M8
MD4GENU^3$<,//)E9%+1 M4"MTH@+^K:_[LZ.%&A3[$OM^)=+^[X)H;1(#0E_
M:TT)!:ZG84O7/*/F.*)$.8D$)0WO7"]\-;2RN5LB"@BJB8][W_._1W]Q>0@I
MD1PHGQ\=7!@)8H<Z:GE#]4%&QT83>0$(NW/E7CJO;+K]R7*:R8PV&C.B+EN/
M"#!%(?& [J'3'^MI31N)UK$GT7N<*KV<!);&^U([#DB4O QTR7 VR0?,ET3'
M(CA(+.AZYZT(AU7L!\1YN_$:G''U;7O-M@L>NR=DC9A$\E9B/OR@H[?MBJ1$
M'CJN%K*PY+@ZQ2@Y3MZD2?!#P-I>@ AKM;'*Z(I*A>2HW[$YL)6&82NL)A,R
M*1=+L2^UD];:>KS4%JCBN.?+M1M .(&C*<N X_RLA (UKF<9B#A3VE3>I]2<
MPY=E[D:78#5$'+"F$12JN:#Y8E91MVS]LE!B<^M^[<$OD7 )YR)A300]6[:#
M:BI&M; A6A!H17M**)+O4OR3ZIE,Y_1@B=6U&>K%/\EH@#CA=SYU>%.?-[7G
M%P_-2>YYP3+7#(0JW?6A/HLL3'IBT1AYQO@Z+]*L;QJ<$<W24&OR2&9X9.0
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MH*L_1* Z63QRZ:=/7WMDYLSWNK,YBY<%M="N&UXO7[1O-WB^]%&-Z??^V^J
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MN^/V2OZ<K<'(A\3+5>6(*VIP(/^S EPRGZ@@BS:FCS=4^@1*Q/*.T?R 1!M
M:<KF-J4U! GVC/4O46Q.U'@?!H1_J_\'.WSY>]DRHG+&+_U5M?><2_KK0/J[
M]VZ8ON-:7R/9>V[]Z%3'7\NCAXV_J@0[,9G#'E\<EO;@,!7>"/BAHU.L%*-2
M[$OM)'.#1:T'/Z0V1C4W^\"U%;,<0+<.@\O5;DNWQPOZ[<R$N2.+-SWYK<+%
ML!JJ5URAE%UZ^YU]%^2!>P[1)-?B8>N;ZJ%PW,</%"QZU(5_#*EC5!>[0O,C
M:_&8D5;P"WR[UV:2?Z(H/QL^8S[TRPO/J;)0F<N(8G5GO<->\D8(BI%(%Q]!
MA<'2S;Q2D/"VZ.JU.[^]?GOM;$U!/'-\6?T:Q'$[E^*X_QXG])V&TEQ'BGVI
M'7.5M'>#1?2/0-$##LB=!E?#!0N%<3]P792+G#T?2U\OGP?HL94B2C38UI1P
M>/$O2@JBPE)GKMI^0ZZ%#,.3/F] %BSDBZ W%#M&Q_35VZCUH413;\,<;PG
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MZ/5O&M(+=0?S:*N^J3^O%HZ39AK=H11T.$4DFA8>Z'FX\J?W#W_WZNF\3_6
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MI@8;L0\#"G**'_;NG4\?6XDEO"^QY^STAN"4*K7Y,Y7XAV4 ZO5Y 91URB2
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MC+K3_W-C&NRM4,CF1F8@4>DE:Z<7 0TXF7OI51P$@YT'-Q"L-%"ZZNPW%C'
MUG?L7?2UW<KV*]P!<9[ -^?LX/JJ!EO[DV+VG'@A^(MP^&2;\XH%6L#BE=/5
MN&D"5@GV)?92@;X:4E 9[5^PDL%I4\4@X#!@3WJ])9%6$'5NHOI#8!^JEGS$
MPF8L-N8R(GZ&%PPN=?QP)&2($TQJUL?1B2)5]==Z!=K'9E0-RS1)%4\)4Q'U
MZ/26OD,;@79@ZL/OS2'@=0>/G%@YW*])/QR"F%2!I'VGJSAQ.T^</]0O?
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M >;OF94-7C&^)?.PHEL$8 9:P26K#<JH/BU,),>PE;]Q)X[V Z#;[M\MSYG
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M95^Y:XTM@&SOX;9VL8<&O:<[%[SI"?%S!Y[^WI?0TZ]Y_27+FUXR\0I!1B@
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M"?8E]IR63JTQ0G2RH3B,U-85];G_UQZ*E6;!;4=^1C:MD46 2H"J_# VV(?
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MQU3_([>D*&KLDXO/J21$U&9S!HG$SX"*_1!X85HPPBGLHME7#%=J[L0#[(4
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M0%'7>1P4K'$^W& /OY'B6L:_%BUZ/K=N#7[R#UJ309*]GGUT^@^4C51APZ&
M: @;ZU:^ZY%HDG8:LVN;,Z:,"W6V]GO"3$6'%?N4G3G\HM;'L+U^$'&FLS)D
M("<0\7A86RCA1'JCXV#+7\XMZMY@@JU"LW8+A5Y:0(%$4(8K@8KB!LP"4G=8
M1]?<=/$EPI)=4U%+)>:.(1ZC3R3KA&% 4@G/C.8QHC&I7L]*]:534CYMJ;&2
M83E,Q3D/=)SM/ZA"W^JF^O<I2ULYHJ>K"R5TO !A-*(R!F2XO1?.I A&8R2<
M4Q%"*[)P!@B,QP?!Z-C5RKWDN ^B$2+G:B2*9#DK$?/I7YX)ZN)$U()/CAVR
M:I!'EQ_-!HY?1.!C!V?0,ED30^':#A7K4'3K5%BR&6&]6G0,*+C8(,Q1Z%.Z
M3]D9"[^V=H$1;31P4L]8XPU3)^V]-!BF) >M][IZYD4]46"4^IM8BI%[*V=]
MB&0R2&JOY<#1A2(Q <,_ !,?Q*@^'BB^>+</^1]E_W8<7;YTE$5G[WD1=M6C
M'N=4EO=J@G3N"<+UT21]!"4 CJ<CQ(10S%'L4_83PT+JNXA+R-2!:VJD57LK
MW5F8-IX\&FP;]U.!<>5#PKN%<:/F=11Z)7T3J?(T(1QR>GQS(Q>R+T[A W*0
M<.L*PEE*B2[,@?,L.TI[5 [/E'WWX!E7MJU"2*ACZ!A(*,&EV*?L)\9\;C1W
MW#,W" PY)[?EUX84%*W=NZ0*2@[^@!UQUY:3*V(5F-)-)9B!!/LQ&2+^C5_6
M>=DT9&4&C[)E0.QN\L1PW>[*,D@ Q,$P<11D!8I.VL*S=R)'ICQTY%+N$U5L
MA BO4*&.-4SM]RE+7=FP\U/BKFQM+.:!%8_[CM0>BO[K&?&!@RV^Y$TM:V,H
M_CUP?GG"6^R_:1:V< ;DV$VO$WK-"40E#]4>EP'DUM W*3:E\4B$!F"3O".&
ME<ED3$/7TK[WA5C5:16I! QNLJ<VN\T#$JE0<(4=I?N47;A:+[FX.<H<)<6:
MJP<CAF!;N\'U'+[*(R+YUU7:P5F4_D?E7F)4?];^FN9 ,S*/7*QEK0!6C 5G
MH+(^ET<.+XQ&9H9^KXC&B,N;P],PCO#J7P.P+_=Z8N+R!D^;')B;/19\47"H
M<ON4[E/V$V):\0%]:(6"> /O7, UH1E%;"TG._)>F[5F./V"<R:B #/W;\F-
M?=\%!2V8QL$%"^I]@SA(2^)%Y_5OY_&I$VD?6%LKN;E;_XE5'NE#ND;,O%:3
M8^+0AL@N@8J_BGW*SL;I[<*;3Y)9PAB+M_K%N5F>L(T^SBEN!4FQIH<9T#IQ
MPC3D('&:MS.A/<?3 I]:IK)PVJ0 F\( ;B&"4>1+\R#7A0>)B&%@.71'7;ZN
M=Z1-9"'6>-7^?</EHIL"S0VQA:%,L4_9>AW>9.J)=#N7(97LBQ:6 *TLO\>E
M3>(_15#_)A*>)>.N T#]> . IL,X;$-%,L^IZ2$>&1<(>[8/'7V%  =X( R4
MH&AT;H"N%HY\$E*/TF;%%LQE_6"7JNQ6QXFL9LE6AJ289*+GG I_BGW*+ACT
M=7Y*"/#LRD#5$ZT%G<P=7@<]5GTR**%$S ,ZD>ZL_^N1FPYI&F#->E,,"UNZ
MO>T81GAYE/+PP\LY-#-\ #%:+RX6A!P++$+=%P8[?-@1VA9N@CLV(S^T3(%U
M83=LNX=P9XZK((O1OY8E+:L#)B4JA)T >D+HI]"WAJE8QT\[YMI+I']J!L3
MH\Y(DW6M*]BKCT04OX#M,\*U+T%P_Y-X=$]<2K=U*Z!03O2H?>PK+_QYBVIQ
MC5;L\U(63>7@@1\L@-GD3K$R'K1HB;*J6]1A[0P;Z1\S$]R_P\Y(F>D_G=F'
M%0*FLD2 ] P6R;YY$V> AX5(V6I[G&DO9\XQ"%11FV*?LO7"+VVIB6 *HVSY
M5'CL69I851ZV/&*8#(FFKWK1F0"# ,-;.A_KXY"4;MPW56*L%0N.+]8&'!K
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MMW_Q-1[R""#0=665AI!C*GUI!K$F*-,,!*@CM_ODV%]YG$X%R.1O:]1*I_+
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M[?<I]BD[;ZMM/4LI4>(;3KX%&J#]AT9RQN,6T-I \->FQL>__=$!F0SC::3
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M4W8^55_'8FWUR(LKQ>0#XOP(&#B47;(&QF%?%&T31O!;QW*'G6DM,!RY(<*
MB6CU$]"+?'):=SU(,(QKWDCVD 0/1]('#I-;$A&/H+.S?\O#,R,_>V?9 Q9>
MQ3M</Y9\'1J^?$Z/;5[.8@-T5SWW[G>*,VITHTRQ3]D3OSW">;"WAH.M$IE>
M)Z5<&WUR.F12VJT6[W0<2UM]^\EW;C79#8\A$6I& 6-'F1@#\_Y=FB9#O9
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MTQ4%$37[<_@K7E$]G2GFZ=6?S//A6]\8:&#!DZ.!(>SV@&G-4NQ3[%.V(?<
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M5R7U,X;"^D 'Y7GTP)MVZ*"6Q9T"?=.9Y(FX"XS=9J\.?I<TD.8M;1;#3Z>
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M7&*?(]EGT5JY]VZ03AE(J,"BX*)5NC>&PYCWQ79"T;YIPU-!<4IV$'@Z)YA
MI5D__0[V)NS6$0\V E!X2;<S[Y]O*NJA0!S5 #V% S<-FR-=FJWAN>^_^?VE
M)R[1TSIG.L40!XS.$]2J(I*]NW1EQ8$NP3[MC#B1P<].@1I;SY5N;:.X,X5M
M0PO:$PFE3H@#)B!//K:-;=V[T&]8DX[NPEMG?[_S9(F#1O;[H++QDY#6>DB
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M?54 %EU=O.F1MZST9V'B&IC5OM8:)! 0?0\\M;BO!?0%]$MXXR?G9Z;F3G7
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MZAC[8COF_1+LNII3&>P?+?("./7U(5.R&7,*AJ7KHB0)64U^N$$QU'88T;'
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M_@U+R87H\_N>>'QV%TZM.^/ -B-#--=Z^L'T2]LH*!/,51X9 M@,U&)II\3
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M-_?((:YA7Y!D2&H05.PK+@-NL9UR($@4_*"&M: :+YN0SBA@6+K;"%L,S4J
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MYSU"#__@09*_H-B;H9,/[ ,[&VM!:6@\;[;<IQ&M+0V AY60WX6I7S./A[(
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MH;P_8><Q?P!S-6B!<@*,-)V6KQARD #& ']1;$@2/\8#,V-MP38#+.0C-;'
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MUP'8HZ/D$@)Y:4755)3$;!@D;EA$^P![<<5Z\"6"/UDJN+C)/*^TV*YCS6X
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MY5)^G=Z#)!=<)B+*5(?$/FEG)2C$1U<X5 @=#Z@EVU8628G$F%FWW1VZH02
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MGQR O\$:('I=0/QBXD\PD2<>[!V:_L+3-W?05^47A;74[!:S5AK;"@AC\1)
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M0A=.C:[_^/!1_.1%[[?+)V;6KCZZ#_;VHVW3LQ4-/O+#YRY[^!(C!>K&4KC
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MT @?ZT&7"OKG'M0/FEVN)'(=#OC&X,CDNV[G'+&>P8AY;K#G@M:9;@"060%
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M[INL<9&VI,\+FF,=.SN9;'&V$>1&&2.BK$5=;12+XZHK?O%22CM)G$(50\R
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M'3)J6JGOZL!<JTX)_6F*NOKX/&.!^2SVCT!OW=3?(A1"U F^(/7C?$S)S&M
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M-&6!\($7B"#J[MD#2E!3$GL9+L$^$!)]'0+[<&K!R-=Y1P=*]$9 (7$5S/0
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M$3AUE$JH+L 6N IF"R.]D5_0Q2 0M@3MDR:Q3]KY81KW.Y%&O+]4%1+?I^Q
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M5,^NC_RGAL'/Z(%T<O2N?^9J91 T_FW7M5/SR%4";$KXO+ ;B,-F(6(X^PW
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M0O_(ZO]"'J+UGU>59"3R$2-AZ3W;ICI !7;<09)H >W]BLO; J[%B1#:,L'
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M>&!BW$'*'*:A&HVJ"M.C!N1;0 ::2XU 1;BZUEOW_<./4I!+!]B'\?%O!VI
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MGGAZ1BNG%P@^AN;F9J?W478] U]5"<&.X&%J<=;M<C:/.JKP8*W%18TI)GC
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M7V0OD_LUK\'DIM/9,XFVM!&XHWR>+).LW"N7.^#(Q[N[MC_PV=.[E86?*L8
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M?)B59Z#V'3UTX_H[MU:6L#/GI5;F 9>7=+N$BA/24G9LT4N+4@KXI:&563,
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M&S_F4F4^#=H42)A9K8;OPHENB"/A/4I9]U\]NK7(AT'7*J.Y&RD/"7,;QLA
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M>5@SL%V989=O,<I'#WCT^,S$D1?VK;@I#>P*Y^YSNTZ\_G^7]SYQ_U?24[-
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MEEK?%O21OF=1=I%3K17E)38I.&0^T?1B$=@6_@B:0!.FA>UJ'[[[W2? >PV
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M*CA$RJ\L\)#($P%FB#[.,6;,6!2_DK%:RW,=>Q !#CJ##+9>5^(+.%<D'UP
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M(R8^8V:DD8!CK0%7W[ K#_>M"5]1H4CCO @>?.#J6T'--V!!F&BSUL=;]&&
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M/^(M<+Q0U.OV=S"N^H!GCCXN'>3ALG_\LP-7%%Y]2PY0K=4A.CX$H0!<S<>
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MLVZA5U99))_@3.NSL]/80++ @TG#%R;26%B5^$3XK@)JVXR$E7D(56U&.22
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MXIW7H3CN@A"-^%S 3C<M7; /TL;\OAA]=?.L>3DDSB:.\?#'=SGF=0=/]NN
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M4^-B^WT/18%6F*[RC?_76O.OG_W=WP)A#Q]4WQO0"[)'$!=K?AR^Y2VL5,D
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M;EFXGNNJS_=N/5]^QM<[NYX5!*YX]-C9,"M6X@L41\.F&U.41?VH&@>1 VN
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M:B>2DW7X+>?/OQZA&DOH,W%8VDH]O+&BUP\G)GQ1T??M^&=I/?9PV;""D/E
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M %= I]J,W*2ZB[\23&[&?0!7+II$?+@/KDS.QS7-75:9SM\!W <%@_X^P'W
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M%L8ZH%]^7 + ?0  N \(_ !P'P  [@,"/P#<!P" ^P  <!^0] +@/@  W <
M@/L  ' ?  #N P# ?0  N \  /<! . ^F 3*>0+N P# ?0  N ](>0%P'P
M[@/"/@#<!P" ^X"P#P#W >H#P'V ^@!P'Z ^ -P'J ]@=CA< L!\@/L \P'@
M/D!\ +@/T![ VL!8!P#@/@  W < @/L  ' ?  #N P# ?0  N \  /<! . ^
M  #<!P" ^P  <!\  .X# ,!]  "X#P  ]P$ X#X  -P' +@/  #W 0#@/@
MW < @/L  ' ?  #N P# ?0  N \  /<! "R6_P^UHF&8D=:H!0    !)14Y$
$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>lease1317sig2.jpg
<TEXT>
begin 644 lease1317sig2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( 1H# 2(  A$! Q$!_\0
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M^Z\3AE;Z$=:=<0^>FW(VGAE(R".XKG)?AUX<DN8Y$T2UCV,S?N<Q %OO':N
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M* I.&_[Y-<S=>&]7FM'5?$U[#-YWF+(UO;R*HP $V^4,KU/7.3UZ 9MYX/\
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/U44KWHHH D"TM%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>lease1317sig3.jpg
<TEXT>
begin 644 lease1317sig3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "* 3X# 2(  A$! Q$!_\0
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M/T%+H!V@4#H*8T>[.:<3@X'WC2+N&=U,"/9@^U/R%& ,YI^?7%1RJ<#;Z\T
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M@2D%CT'&>?;- %VS^#?Q#\::G9:7XNU?4X?"Z8:_MI=6CN%O@K ^5B*&)BC
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MC(W<YQ7K/P!^._PN^!?P/T2"&Z?6_&^K#?>:)I4)GU":[P5",@^XJ@*@9L#
M!KGOVI?A;\2?C%X\^''B33?A]<M97&F645[I[RQ%K*5IS)<0W'[P *%VC<N<
M\_2@#9NOVM/B-X5U73/%WC*QTOP]X.U".5M)\)1Q%]5U(&/Y)GD+8AB#$')
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MJE\-]0@?_@H_XM&HS^;<_9KF"T$V%\O9#;^6B?2,R?@34G[7'BKX-ZG\1Y=
M\<^#_%]IK^G6Z+#XNT2R5%D1X]RH)"=LRC<>&!P<]* /I?X+>!O%O@;P]-:^
M-/&,OC/49I_/2ZDMEB^SKM \D, #(,@G<P!YKTH[, D#\17Y^?LI>+OBK>_$
M>RTOPM=^(?$GPWBN MS=^+[95$%L<_-&^XD/P<*CE3WK] )$=PV %.1@YZT
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M@A>2V@?48'B<AL+G#*S':=Q4$>@)/%>M)&D8)50N?2FAF+],*.,4 ?(.G?\
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M_B+6+B"&0>'X[0>79Q0%%5IRRN!))N'W3N;'05V-CXQETGQ_X3UB#PSKT_\
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.. '1^5*8U/50?PH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>lease1317sig4.jpg
<TEXT>
begin 644 lease1317sig4.jpg
MB5!.1PT*&@H    -24A$4@   9L    [ 0,   "7/;7A    !E!,5$7___\
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HE;_3R3KOXHL/53JY7?]?2TL^_P'?1%!T.7@]0@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>lease1317signature.jpg
<TEXT>
begin 644 lease1317signature.jpg
MB5!.1PT*&@H    -24A$4@   5X   !  0,   !H3HT&    !E!,5$7___\
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A4#J_LK*P'K3@;!Q_ ;7R#-J1'AQ>     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753541952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>May 05, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DocumentAndEntityInformation', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Diffusion Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">dffn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DocumentAndEntityInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DocumentAndEntityInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753995632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,212,025<span></span>
</td>
<td class="nump">$ 1,552,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">8,280,935<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PrepaidExpensesDepositsAndOtherAssets', window );">Prepaid expenses, deposits and other current assets</a></td>
<td class="nump">138,986<span></span>
</td>
<td class="nump">50,844<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,631,946<span></span>
</td>
<td class="nump">1,603,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">79,524<span></span>
</td>
<td class="nump">79,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset</a></td>
<td class="nump">8,639,000<span></span>
</td>
<td class="nump">8,639,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,929,258<span></span>
</td>
<td class="nump">6,929,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">63,815<span></span>
</td>
<td class="nump">232,675<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,343,543<span></span>
</td>
<td class="nump">17,484,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current portion of convertible debt</a></td>
<td class="nump">1,880,000<span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">557,629<span></span>
</td>
<td class="nump">1,684,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,016,263<span></span>
</td>
<td class="nump">874,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">48,145,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">51,599,412<span></span>
</td>
<td class="nump">4,438,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt, net of current portion</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="nump">3,279,363<span></span>
</td>
<td class="nump">3,279,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">33,307<span></span>
</td>
<td class="nump">31,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">55,462,082<span></span>
</td>
<td class="nump">8,299,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.001 par value: Series A - 13,750,000 shares authorized, 12,376,329 issued and outstanding at March 31, 2017; No shares authorized, issued or outstanding at December 31, 2016 (liquidation value of $25,000,000 at March 31, 2017)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 10,345,637 shares issued and outstanding</a></td>
<td class="nump">10,346<span></span>
</td>
<td class="nump">10,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">69,700,264<span></span>
</td>
<td class="nump">69,363,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(88,829,149)<span></span>
</td>
<td class="num">(60,189,237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(19,118,539)<span></span>
</td>
<td class="nump">9,184,684<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 36,343,543<span></span>
</td>
<td class="nump">$ 17,484,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PrepaidExpensesDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PrepaidExpensesDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate monetary value of a new issue of securities which have been allocated to investors to buy. When security is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the security to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753620368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">13,750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">12,376,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">12,376,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation value</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">10,345,637<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">10,345,637<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753839520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,007,571<span></span>
</td>
<td class="nump">$ 2,352,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,553,139<span></span>
</td>
<td class="nump">3,862,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">6,603<span></span>
</td>
<td class="nump">7,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">2,567,313<span></span>
</td>
<td class="nump">6,223,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">55,719<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities (Note 10)</a></td>
<td class="nump">12,919,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantRelatedExpense', window );">Warrant related expenses (Note 7)</a></td>
<td class="nump">10,225,846<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other financing expenses</a></td>
<td class="nump">2,870,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,638,778)<span></span>
</td>
<td class="num">(6,223,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Series A cumulative preferred dividends</a></td>
<td class="num">(58,845)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (28,697,623)<span></span>
</td>
<td class="num">$ (6,223,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.78)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">10,337,726<span></span>
</td>
<td class="nump">9,996,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Related Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760430512">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity (Deficit)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of change in accounting principle</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,134<span></span>
</td>
<td class="num">$ (1,134)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Sale of Series A convertible preferred stock and common stock warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,376,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Sale of Series A convertible preferred stock and common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,376,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, total stockholders' equity at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,184,684<span></span>
</td>
<td class="nump">$ 10,346<span></span>
</td>
<td class="nump">69,363,575<span></span>
</td>
<td class="num">(60,189,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity (Deficit)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Sale of Series A convertible preferred stock and common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Series A cumulative preferred dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature for accrued interest of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">366,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28,638,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,638,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, total stockholders' equity at Mar. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (19,118,539)<span></span>
</td>
<td class="nump">$ 10,346<span></span>
</td>
<td class="nump">$ 69,700,264<span></span>
</td>
<td class="num">$ (88,829,149)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of this standard.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=75116239&amp;loc=d3e34017-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Beneficial Conversion Feature<br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760401936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,638,778)<span></span>
</td>
<td class="num">$ (6,223,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations', window );">Depreciation</a></td>
<td class="nump">6,603<span></span>
</td>
<td class="nump">7,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">366,383<span></span>
</td>
<td class="nump">393,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued for advisory services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability', window );">Warrant related expense and change in fair value</a></td>
<td class="nump">26,015,746<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense</a></td>
<td class="nump">57,185<span></span>
</td>
<td class="nump">3,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="num">(99,737)<span></span>
</td>
<td class="num">(97,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(1,123,303)<span></span>
</td>
<td class="nump">797,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,415,901)<span></span>
</td>
<td class="num">(4,630,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows (used in) provided by investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,372)<span></span>
</td>
<td class="num">(1,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromReverseMergerTransaction', window );">Cash received in reverse merger transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,500,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(6,372)<span></span>
</td>
<td class="nump">8,498,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the sale of Series A convertible preferred stock, net</a></td>
<td class="nump">14,269,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(187,649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,081,446<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">10,659,173<span></span>
</td>
<td class="nump">3,868,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,552,852<span></span>
</td>
<td class="nump">1,997,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">12,212,025<span></span>
</td>
<td class="nump">5,865,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts', window );">Reclassification of deferred offering costs upon completion of private placement</a></td>
<td class="nump">180,456<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_OfferingCostsIncurredButNotYetPaid', window );">Offering costs in accounts payable and accrued expenses</a></td>
<td class="nump">178,258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Series A cumulative preferred dividends</a></td>
<td class="num">(58,845)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of subscription receivable upon sale of Series A convertible preferred stock</a></td>
<td class="num">(8,280,935)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes and related accrued interest into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">711,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Consideration in connection with RestorGenex Corporation merger transaction</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,261,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period from continuing and discontinued operations that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Transaction, Reclassification of Deferred Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_OfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_OfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ProceedsFromReverseMergerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with a reverse merger transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ProceedsFromReverseMergerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Expense and Fair Value Adjustment of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900891104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:621px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Organization and Description of Business</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diffusion Pharmaceuticals Inc. (&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), a Delaware Corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company&#8217;s lead product candidate, trans sodium crocetinate (&#8220;TSC&#8221;), uses a novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby enhancing tumor cells&#8217; response to conventional treatment without additional side effects. TSC has received orphan drug designations for the treatment of glioblastoma multiforme (&#8220;GBM&#8221;) and metastatic brain cancer. The Company expects to enter a Phase III study in newly diagnosed GBM patients in the next twelve months.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the Company completed a reverse merger (the Merger") with RestorGenex Corporation (&#8220;RestorGenex&#8221;) whereby the Company was considered the acquirer for accounting purposes.  The operational activity of RestorGenex is included in the Company&#8217;s consolidated financial statements from the date of acquisition. Accordingly, all comparative period information presented in these unaudited condensed consolidated financial statements from January 1, 2016 through January 7, 2016 exclude any activity related to RestorGenex.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900880336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:621px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Summary of Significant Accounting Policies</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Summary of Significant Accounting Policies included in our Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 31, 2017, as amended to this date, have not materially changed, except as set forth below.</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim&#160;condensed consolidated&#160;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#8220;SEC&#8221;). In the opinion of management, the accompanying&#160;unaudited interim condensed consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, its results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The unaudited interim&#160;condensed consolidated&#160;financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying&#160;unaudited interim condensed consolidated&#160;financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> filed with the SEC on Form 10-K on March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period.  Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may materially vary from these estimates.  Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined necessary.  </font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Company&#8217;s outstanding convertible notes was approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Offering Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company&#8217;s private placement financing and are recognized in other assets on the consolidated balance sheet.  At December 31, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred offering costs. These costs were expensed upon completing the private placement of Series A Preferred Stock and common stock warrants in March 2017.  </font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company acquired RES-529 and RES-440, respectively, an </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> indefinite-lived In-Process Research and Development Asset (&#8220;IPR&amp;D&#8221;) and recognized </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> in goodwill. In the third quarter of 2016, the IPR&amp;D asset associated with RES-440 was abandoned and written down to </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">. RES-529 and goodwill are assessed for impairment on October 1 of the Company&#8217;s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment indicators or impairments to RES-529 or goodwill during the three months ended March&#160;31, 2017.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">766,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">428,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,376,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,016,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,796,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,665</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,471,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,715,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts in the table reflect the common stock equivalents of the noted instruments.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2016 and interim periods within those years. The Company adopted this standard in 2017 by electing to account for forfeitures in the period that they occur. Under ASU 2016-09, accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> cumulative-effect adjustment on January 1, 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&#160;15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604037264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:621px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liquidity</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its membership units (prior to the Merger), convertible notes and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. In March 2017, the Company completed a </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> private placement of its securities by offering units consisting of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of the Company's Series A convertible preferred stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share (&#8220;Series A Preferred Stock&#8221;) and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of common stock for each share of Series A Preferred Stock purchased in the offering. The Company sold </font><font style="font-family:inherit;font-size:10pt;">12,376,329</font><font style="font-family:inherit;font-size:10pt;"> units and received approximately </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate net cash proceeds from the private placement, after deducting commissions of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;"> of net proceeds on April 3, 2017. In addition, the Company granted to its placement agent in the offering warrants to purchase an aggregate </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,179,558</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock as compensation for its services. </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be. The regulatory approval and market acceptance of the Company&#8217;s proposed future products (if any), length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The Company believes its cash and cash equivalents at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, together with the subscription receivables related to the Series A private placement received in April 2017, are sufficient to fund operations and meet its research and development goals through March 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=64819266&amp;loc=SL51888449-203568<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64819266&amp;loc=SL51888443-203568<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900942176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Acquisition</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse Merger with RestorGenex</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the Company completed a reverse merger transaction with RestorGenex. The Company entered into the Merger transaction in an effort to provide improved access to the capital markets in order to obtain the resources necessary to accelerate development of TSC in multiple clinical programs and continue to build an oncology-focused company.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchase price was calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of RestorGenex shares outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,546,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of RestorGenex stock options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,321,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of RestorGenex warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CVRs &#8211; RES-440 product candidate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;The reverse merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&amp;D was the cost approach.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,500,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,929,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(377,432</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,644,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Qualitative factors supporting the recognition of goodwill due to the reverse merger transaction include the Company&#8217;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the reverse merger transaction to the Company&#8217;s later state product portfolio. The goodwill is not deductible for income tax purposes. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro Forma Financial Information (Unaudited)</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pro forma financial information reflects the condensed consolidated results of operations of the Company as if the acquisition of RestorGenex had taken place on January 1, 2016. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2016</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,655,944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-recurring pro forma transaction costs directly attributable to the Merger were </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> March&#160;31, 2016 and have been deducted from the net loss presented above. The costs deducted from the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> March&#160;31, 2016 period includes a success fee of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and approximately </font><font style="font-family:inherit;font-size:10pt;">46,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock with a fair market value of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> paid to a financial adviser upon the closing of the Merger on January 8, 2016. Additionally, RestorGenex  incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> in severance costs as a result of resignations of executive officers immediately prior to the Merger and approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> in share based compensation expense as a result of the acceleration of vesting of stock options at the time of the Merger. These costs are excluded from the pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> March&#160;31, 2016. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> such costs were recorded in the three months ended March 31, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1524-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4922-128472<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4934-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4926-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=SL65897772-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748496496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Expenses and Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Accrued Expenses and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other Accrued Expenses and Liabilities</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses and liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Series A dividends</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll and payroll related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical studies expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,016,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">874,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900942176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Convertible Debt</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the details of the convertible debt outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2016:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issue</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/27/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/27/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,880,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/15/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total principal amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,880,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The current and noncurrent portions of accrued interest related to the Company&#8217;s Convertible Notes and 2016 Convertible Notes are included within other accrued expenses and liabilities and other liabilities, respectively, within the unaudited condensed consolidated balance sheets. As of March 31, 2017, the Company had accrued interest of approximately </font><font style="font-family:inherit;font-size:10pt;">$90,000</font><font style="font-family:inherit;font-size:10pt;">.  During the three months ended March 31, 2017, the Company recorded noncash interest expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$28,000</font><font style="font-family:inherit;font-size:10pt;"> in connection with a beneficial conversion feature associated with accrued interest that may be converted into shares of common stock</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900868464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Common Stock Warrants (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Common Stock Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">7.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Convertible Preferred Stock and Common Stock Warrants</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contemplation of completing a private placement, the Company amended and restated its articles of incorporation and authorized </font><font style="font-family:inherit;font-size:10pt;">13,750,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock. The Company has classified its Series A Preferred Stock outside of stockholders&#8217; equity (deficit) because the shares contain deemed liquidation rights that are contingent redemption features not solely within the control of the Company. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series&#160;A Convertible Preferred Stock Transaction </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company completed a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> private placement of its securities by offering units consisting of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of the Company&#8217;s Series A Preferred Stock and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share common stock for each share of Series A Preferred Stock purchased in the offering.  Each share of Series A Preferred Stock entitles the holder to an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> cumulative dividend payable in shares of our common stock on a semi-annual basis.  The holders may, at their option, convert each share of Series A Preferred Stock into </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of the Company&#8217;s common stock based on the initial conversion price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.02</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment. Each warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of common stock at an initial exercise price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment and expires on the fifth anniversary of their original issuance date. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon completing the private placement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">12,376,329</font><font style="font-family:inherit;font-size:10pt;"> units and received approximately </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate net cash proceeds from the private placement, after deducting commissions of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> payable by the Company. The final closing of the private placement occurred on March 31, 2017, and the Company received </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;"> of net proceeds on April 3, 2017. In addition, as compensation for its services, the Company granted to its placement agent in the offering warrants to purchase an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,179,558</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.22</font><font style="font-family:inherit;font-size:10pt;"> per share, which expire on the fifth anniversary of their original issuance date. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 815-40&#8221;).  The conditions within ASC 815-40 are not subject to a probability assessment. As the Company is obligated to issue a variable number of shares to settle the cumulative Series A preferred dividends, the Company cannot assert there will be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants are classified as liabilities. The Company will continue to classify such warrants as liabilities until they are exercised, expire, or are no longer require to be classified as liabilities. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are no proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the Series A offering and the fair value of the warrants granted to its placement agent was </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate and was recorded as warrant related expenses in the statement of operations for the three months ended March 31, 2017. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company shall pay a cumulative preferential dividend on each share of the Series A Preferred Stock outstanding at a rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable only in shares of common stock, semi-annually in arrears on April 1 and October 1 of each year commencing on October 1, 2017.  This cumulative preferential dividend is not subject to declaration. The Company accrued approximately </font><font style="font-family:inherit;font-size:10pt;">$59,000</font><font style="font-family:inherit;font-size:10pt;"> in dividends for the three months ended March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) or as required by law, the holders of the Series A Preferred Stock and common stock vote together on an as-converted basis.  In accordance with NASDAQ listing rules, in any matter voted on by the holders of our common stock, each share of Series A Preferred Stock entitles the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance.  Accordingly, shares of Series A Preferred Stock issued in the initial closing of the private placement on March 14, 2017 are entitled to </font><font style="font-family:inherit;font-size:10pt;">0.84874</font><font style="font-family:inherit;font-size:10pt;"> votes per share and shares of Series A Preferred Stock issued in the final closing of the private placement on March 31, 2017 are entitled to </font><font style="font-family:inherit;font-size:10pt;">0.50627</font><font style="font-family:inherit;font-size:10pt;"> votes per share.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidation Preference</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Preferred Stock is senior to the common stock.  In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A Preferred Stock shall be entitled to receive their original investment amount.  If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution shall be distributed ratably among the holders of the Series A Preferred Stock in proportion to the full amounts to which they would otherwise be entitled.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Preferred Stock is convertible, at the holder&#8217;s option, into common stock.  At the Company&#8217;s option, the Series A convertible preferred stock can be converted into common stock upon (a) the </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;">-day moving average of the closing price of the Company&#8217;s common stock exceeding </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;"> per share, (b) a financing of at least </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> or (c) upon the majority vote of the voting power of the then outstanding shares of Series A convertible preferred stock.  The conversion price of the Series A Preferred Stock is subject to adjustment as described in the Certificate of Designation.  </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon any conversion, any unpaid dividends shall be payable to the holders of Series A preferred stock.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Make-Whole Provision</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until March 2020 and subject to certain exceptions, if the Company issues at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of its common stock or securities convertible into or exercisable for common stock at a per share price less than </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.02</font><font style="font-family:inherit;font-size:10pt;"> (such lower price, the &#8220;Make-Whole Price&#8221;) while any shares of Series A Preferred Stock remain outstanding, the Company will be required to issue to these holders of Series A Preferred Stock a number of shares of common stock equal to the additional number of shares of common stock that such shares of Series A Preferred Stock would be convertible into if the conversion price of such shares was equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">105%</font><font style="font-family:inherit;font-size:10pt;"> of the Make-Whole Price (the &#8220;Make-Whole Adjustment&#8221;). The Make-Whole Adjustment was evaluated and was not required to be bifurcated from the Series A Preferred Stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2017, the Company had the following warrants outstanding to acquire shares of its common stock:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of exercise price per share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants issued prior to Merger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$20.00 - $750.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants issued in Series A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,555,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.22</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,016,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> warrants were exercised or expired. The common stock warrants issued prior to the Merger expire periodically through 2019. The common stock warrants issued in connection with the March 2017 Series A private placement expire in March 2022.  During the three months ended March 31, 2017, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;"> in warrant related expenses associated with the private placement, which consisted primarily of the change in fair value of the common stock warrants from issuance and the excess fair value of the common stock warrants over the gross cash proceeds of the Series A offering. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900891104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-based Arrangements with Employees and Nonemployees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">8.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Stock-Based Compensation</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2015 Equity Plan</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Diffusion Pharmaceuticals Inc. 2015 Equity Plan, as amended (the "2015 Equity Plan"), provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the board of directors. Accordingly, </font><font style="font-family:inherit;font-size:10pt;">413,825</font><font style="font-family:inherit;font-size:10pt;"> shares were added to the reserve as of January 1, 2017, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">356,148</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock available for future issuance under the 2015 Equity Plan. </font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,194</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to all stock option grants to employees and non-employees for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercise price</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contractual life</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,207,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,184</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.84</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,548,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-employee Stock Options</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. During the three months ended March 31, 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">9,394</font><font style="font-family:inherit;font-size:10pt;"> stock options to non-employees. Key assumptions used to estimate the fair value of the non-employee stock options granted during the three months ended March 31, 2017 included a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">2.4%</font><font style="font-family:inherit;font-size:10pt;">, an expected volatility of </font><font style="font-family:inherit;font-size:10pt;">136.4%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> expected dividend yield and an expected term equal to the remaining contractual option term. The total fair value of non-employee stock options vested during the three months ended March 31, 2017 and 2016 was approximately </font><font style="font-family:inherit;font-size:10pt;">$53,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. At March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">27,561</font><font style="font-family:inherit;font-size:10pt;"> unvested options subject to remeasurement and approximately </font><font style="font-family:inherit;font-size:10pt;">$65,000</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense that will be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.0 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Employee Stock Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value of stock option awards granted to employees was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.08</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended March 31, 2017. The total fair value of options vested during the three months ended March 31, 2017 and 2016 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. No options were exercised during any of the periods presented.  At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense that will be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">5.8 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:90%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Awards</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">7,665</font><font style="font-family:inherit;font-size:10pt;"> unvested shares of restricted stock. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">1,533</font><font style="font-family:inherit;font-size:10pt;"> shares that vested and the Company recognized stock-based compensation expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense that will be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900882416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">9.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commitments and Contingencies</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Office Space Rental</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases office and laboratory facilities in Charlottesville, Virginia under a month-to-month cancelable operating lease. Rent expense related to the operating lease was </font><font style="font-family:inherit;font-size:10pt;">$17,000</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. On March 31, 2017, the Company entered into a lease for its office and laboratory facilities at a new location in Charlottesville, Virginia. Lease payments commence on May 1, 2017 and expire on April 30, 2022. The company will recognize rent expense on a straight-line basis over the lease period and will accrue for rent expense incurred but not yet paid. Future minimum rental payments under the Company's new noncancelable operating lease at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rental Commitments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,464</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company&#8217;s former Chief Executive Officer under the caption </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH </font><font style="font-family:inherit;font-size:10pt;">(Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on April 14, 2015, the Court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. No arbitration hearing has yet been scheduled. The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#8217;s financial position.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643744272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:622px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">10.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:58px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:37px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;The asset&#8217;s or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,212,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,552,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock Warrant Liability</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued in connection with the Series A convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,225,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common stock warrants issued in connection with the Series A convertible preferred stock are classified as liabilities on the accompanying balance sheet at March 31, 2017. The liability is marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the liability to be reclassified to stockholders&#8217; equity (deficit). The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrants granted during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:90%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753768944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim&#160;condensed consolidated&#160;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#8220;SEC&#8221;). In the opinion of management, the accompanying&#160;unaudited interim condensed consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, its results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The unaudited interim&#160;condensed consolidated&#160;financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying&#160;unaudited interim condensed consolidated&#160;financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> filed with the SEC on Form 10-K on March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period.  Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may materially vary from these estimates.  Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined necessary.  </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_OfferingCostsPolicyPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Offering Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company&#8217;s private placement financing and are recognized in other assets on the consolidated balance sheet.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company acquired RES-529 and RES-440, respectively, an </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> indefinite-lived In-Process Research and Development Asset (&#8220;IPR&amp;D&#8221;) and recognized </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> in goodwill. In the third quarter of 2016, the IPR&amp;D asset associated with RES-440 was abandoned and written down to </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">. RES-529 and goodwill are assessed for impairment on October 1 of the Company&#8217;s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2016 and interim periods within those years. The Company adopted this standard in 2017 by electing to account for forfeitures in the period that they occur. Under ASU 2016-09, accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> cumulative-effect adjustment on January 1, 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&#160;15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_OfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_OfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750327072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">766,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">428,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,376,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,016,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,796,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,665</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,471,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,715,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643866480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock', window );">Preliminary Purchase Price Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchase price was calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of RestorGenex shares outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,546,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of RestorGenex stock options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,321,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated fair value of RestorGenex warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CVRs &#8211; RES-440 product candidate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,500,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,929,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(377,432</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,644,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,261,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2016</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,655,944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of preliminary purchase price consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750368176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Expenses and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Accrued Expenses and Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses and liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Series A dividends</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll and payroll related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical studies expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,016,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">874,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750284464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the details of the convertible debt outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2016:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issue</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/27/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/27/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,880,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/15/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total principal amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,880,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900942176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2017, the Company had the following warrants outstanding to acquire shares of its common stock:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of exercise price per share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants issued prior to Merger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$20.00 - $750.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants issued in Series A </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,555,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.22</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,016,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647989808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-based Arrangements with Employees and Nonemployees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,194</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to all stock option grants to employees and non-employees for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercise price</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contractual life</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,207,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,184</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.84</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,548,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:90%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900901616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum rental payments under the Company's new noncancelable operating lease at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rental Commitments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,464</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750235680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,212,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,552,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock Warrant Liability</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued in connection with the Series A convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,225,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,145,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock', window );">Fair Value Inputs, Liabilities, Quantitative Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrants granted during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:90%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760238832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock warrants per unit (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Preferred units, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,376,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityIssuanceCosts', window );">Discounts and commissions</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityOfferingCosts', window );">Offering costs</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">$ 8,280,935<span></span>
</td>
<td class="nump">$ 8,280,935<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of preferred stock shares per unit (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityConsiderationReceivedNet', window );">Net cash proceeds</a></td>
<td class="nump">22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityConsiderationReceived', window );">Consideration received</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityConsiderationReceivedNet', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityConsiderationReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Consideration Received, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityConsiderationReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate monetary value of a new issue of securities which have been allocated to investors to buy. When security is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the security to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759897584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jan. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,929,258<span></span>
</td>
<td class="nump">6,929,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative-effect adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member', window );">RES-529</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member', window );">RES-440</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debt, fair value disclosures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=dffn_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative-effect adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of this standard.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Convertible Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=dffn_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=dffn_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760338064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">29,471,085<span></span>
</td>
<td class="nump">2,715,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">766,351<span></span>
</td>
<td class="nump">428,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">12,376,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">14,016,608<span></span>
</td>
<td class="nump">477,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,304,132<span></span>
</td>
<td class="nump">1,796,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">7,665<span></span>
</td>
<td class="nump">13,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749005728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Purchase Price Consideration (Details) - Diffusion LLC - RestorGenex<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jan. 08, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding', window );">Fair value of RestorGenex shares outstanding</a></td>
<td class="nump">$ 19,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed', window );">Estimated fair value of RestorGenex stock options outstanding</a></td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed', window );">Estimated fair value of RestorGenex warrants outstanding</a></td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights', window );">CVRs &#8211; RES-440 product candidate</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration', window );">Total purchase price</a></td>
<td class="nump">$ 21,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preliminary purchase consideration consisting of the fair value of assets transferable by the acquirer, liabilities obtainable by the acquirer, and equity interest issuable by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent value rights in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of stock options assumed in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of warrants assumed in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares outstanding in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_RestorGenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_RestorGenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748985344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Summary of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,929,258<span></span>
</td>
<td class="nump">$ 6,929,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,929,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(377,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,644,159)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,261,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748793072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Pro Forma Financial Information (Details) - Diffusion LLC<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,655,944)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759835296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details Textual) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock options compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,383<span></span>
</td>
<td class="nump">$ 393,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember', window );">Acquisition-related Costs | Diffusion LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=dffn_SuccessFeeAgreementCostsMember', window );">Success Fee Agreement Costs | Diffusion LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Success fees</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares, issued for services (in shares)</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dffn_ExecutiveOfficersMember', window );">Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock options compensation cost</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=73531572&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=dffn_SuccessFeeAgreementCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=dffn_SuccessFeeAgreementCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dffn_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dffn_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748937824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued Expenses and Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">$ 57,173<span></span>
</td>
<td class="nump">$ 29,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Accrued Series A dividends</a></td>
<td class="nump">58,845<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and payroll related expenses</a></td>
<td class="nump">135,072<span></span>
</td>
<td class="nump">399,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">185,163<span></span>
</td>
<td class="nump">72,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AccruedClinicalStudiesExpensesCurrent', window );">Accrued clinical studies expenses</a></td>
<td class="nump">346,861<span></span>
</td>
<td class="nump">220,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">233,149<span></span>
</td>
<td class="nump">151,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,016,263<span></span>
</td>
<td class="nump">$ 874,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=28361426&amp;loc=d3e1243-112600<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760317296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Outstanding Convertible Notes (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total principal amount</a></td>
<td class="nump">$ 2,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Current portion of convertible notes</a></td>
<td class="num">(1,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, net of current portion</a></td>
<td class="nump">$ 550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotes2016Member', window );">2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percentage)</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total principal amount</a></td>
<td class="nump">$ 1,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNoteSeriesBMember', window );">Convertible Note Series B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percentage)</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total principal amount</a></td>
<td class="nump">$ 550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotes2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotes2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNoteSeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_ConvertibleNoteSeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904412368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest</a></td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Noncash interest expense</a></td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Beneficial Conversion Feature<br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762421008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Common Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 03, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>vote_per_share </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>vote_per_share </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2017 </div>
<div>vote_per_share</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,750,000<span></span>
</td>
<td class="nump">13,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock warrants per unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Preferred units, outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,376,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityIssuanceCosts', window );">Discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the sale of Series A convertible preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,269,095<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantRelatedExpense', window );">Warrant related expenses (Note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">10,225,846<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Accrued Series A dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,845<span></span>
</td>
<td class="nump">$ 58,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockNumberofVotesperShare', window );">Number of votes per share of Series A preferred stock | vote_per_share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50627<span></span>
</td>
<td class="nump">0.50627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.84874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability', window );">Warrant related expense and change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,015,746<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of preferred stock shares per unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays', window );">Stock conversion, measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice', window );">Minimum share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityConsiderationReceivedNet', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityConsiderationReceived', window );">Proceeds from issuance of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityConsiderationReceivedNet', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_ConversionofPreferredStockMember', window );">Conversion of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Redemption price per share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember', window );">Common Stock Warrants, Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares able to be purchased by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,558<span></span>
</td>
<td class="nump">1,179,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_LegacyRestorGenexWarrantsMember', window );">Legacy RestorGenex Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Conversion of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Legacy RestorGenex Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Conversion of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Redemption price per share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.02<span></span>
</td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Legacy RestorGenex Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750.00<span></span>
</td>
<td class="nump">$ 750.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the sale of Series A convertible preferred stock, net</a></td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Make-Whole Provision, Conversion Price Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockMakeWholeProvisionConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Make-Whole Provision, Minimum Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockMakeWholeProvisionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Make-Whole Provision, Proceeds from Issue of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockMakeWholeProvisionProceedsfromIssueofCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockNumberofVotesperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Number of Votes per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockNumberofVotesperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock,Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityConsiderationReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Consideration Received, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityConsiderationReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Expense and Fair Value Adjustment of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantExpenseandFairValueAdjustmentofWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Related Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_ConversionofPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_ConversionofPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_LegacyRestorGenexWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_LegacyRestorGenexWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749305792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Common Stock Warrants Schedule of Warrants Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="nump">14,016,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_LegacyRestorGenexWarrantsMember', window );">Legacy RestorGenex Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="nump">460,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember', window );">Common Stock Warrants, Series A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="nump">13,555,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Legacy RestorGenex Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Legacy RestorGenex Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 750.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_LegacyRestorGenexWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_LegacyRestorGenexWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761404208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">98,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">5 years 310 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 366,383<span></span>
</td>
<td class="nump">$ 393,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dffn_NonemployeeOptionsMember', window );">Non-employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">9,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">136.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested in period</a></td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of unvested options (in shares)</a></td>
<td class="nump">27,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested in period</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares of restricted stock (in shares)</a></td>
<td class="nump">7,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested in period (in shares)</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Compensation not yet recognized, restricted stock</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember', window );">Restorgenex Corporation 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis', window );">Percentage of total shares eligible for plan reserve on an annual basis</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">356,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dffn_NonemployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dffn_NonemployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901050928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 366,383<span></span>
</td>
<td class="nump">$ 393,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">43,322<span></span>
</td>
<td class="nump">242,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 323,061<span></span>
</td>
<td class="nump">$ 151,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749492400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, options outstanding (in shares) | shares</a></td>
<td class="nump">2,207,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">98,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(1,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, options outstanding (in shares) | shares</a></td>
<td class="nump">2,304,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, options outstanding, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">2.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, options outstanding, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,548,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900897680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Share-based Payment Award, Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-based Arrangements with Employees and Nonemployees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 281 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905262288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Charlottesville, Virginia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=dffn_CharlottesvilleVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=dffn_CharlottesvilleVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749157072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2017</a></td>
<td class="nump">$ 73,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">112,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">114,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">116,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">118,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">39,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 575,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749338816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value On a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,212,025<span></span>
</td>
<td class="nump">$ 1,552,852<span></span>
</td>
<td class="nump">$ 5,865,611<span></span>
</td>
<td class="nump">$ 1,997,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">48,145,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,212,025<span></span>
</td>
<td class="nump">1,552,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">$ 48,145,520<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749417200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Common Stock Warrant Liability Rollforward (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance, liability at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">12,919,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance, liability at fair value</a></td>
<td class="nump">48,145,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember', window );">Common Stock Warrants, Series A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issued in connection with the Series A convertible preferred stock</a></td>
<td class="nump">$ 35,225,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_CommonStockWarrantsSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906405264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Inputs (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_FairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">127.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_FairValueAssumptionsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_FairValueAssumptionsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MP^\J['OK]NX?&U\$=0.__H7^ E!+ P04    "  WAZ]*F5R<(Q &  "<)P
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M%+G@?2"&K]41DQ3P&>M@EF;3QLZ>:6^EWGT440X>QLR(. P(-$/ "0&T[4D
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M]+NNO\W"?7/Y''$I=/5I_-227K_WK/\#4$L#!!0    ( #>'KTI7@\N.4P(
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M$ZZ;ZRG*]::K3^,)478[IEK\!U!+ P04    "  WAZ]*?I.9.Z\!  #2 P
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MGD#AD-,M?7,\R:;UT<&*K!,-? 7_K3O;8+&9I9(:C)-HB(4ZIP_;XVD?XU/
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M]K]%=."E)#=^A'K_P59#0NO"\9T_FWG,9L/AL/P@MG[CZC=02P,$%     @
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M/,!4SR=*IN*_P16D#P]*?(X"I8TK*7KK4$TL7HH2;^/>ZK@/XPW?3[!U )\
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M_0=;#0FM"\=W_FSF,9L-A\/R@]CZC:L_4$L#!!0    ( #>'KTH;6834M0$
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MNW"\]V<S#=ED..SG_\.63US\ 5!+ P04    "  WAZ]*38GJ*+8!  #2 P
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MW^'93F,V&=[T\P]BRS<N_P!02P,$%     @ -X>O2JBWUOD% @  - 8  !D
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M@RV&A,:'XSV>[31FD^%-/_\@MGSC\B]02P,$%     @ -X>O2OVQ:KBW 0
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M@L:%XSM_-O.8S8;#8?E!;/W&Y1]02P,$%     @ -X>O2N41(QS/ 0  G 0
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M970R-"YX;6QM4]M.W# 0_17+'X"SWEV*5DDDE@I1J4@K4-MG;S*Y"%]2V]G
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M,FY[;_=J&I@I,+*?WP*R/$CY'U!+ P04    "  WAZ]*)Z45P-$"   M"P
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M^+-G3% 9OWLG6^8HA_1FD=&]4*^1?.?UI%HO!"O-%.XT/P66_P%02P,$%
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M%VE;2H^<*Z99_0=MOM#/\3BHV%&9;JS[HG^3^H'B[?#>>N.CG_\#4$L#!!0
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MM#FH[CB=A-!@>EFOC.W.O!=S0.&D[;0P<^EOC0^T&*8' <VO4OT74$L#!!0
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M?^PI<>)<42WGO^@2Y?I+HY\P>E)FF.BQ:(_;=J)XW7U*>/WW3/8/4$L#!!0
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M:&5E=#,U+GAM;'54VX[;(!#]%<0'+ Z)-Q?9EC9;5:W42M%6;9^)/;YHN;A
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M>*F*9OB<O;PW;55J+QV5,O\Y?F]WP_=A_"=AV@P;D#:@HP%-&W!MP(\&<MI
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MZ_']PGC15GO][B0\OL!9_@]02P,$%     @ -X>O2GDK>-9" @  XP<  !D
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MI.TT-7/9/3O=0HNF?U+1\*YO_@-02P,$%     @ -X>O2AU^0*>O P  ]!
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M+4;GH_L#'XZ.QOB6W3].!_ _;J;O ?\6[;%L.N]%]NI@.AX?#U+V0H49WJD
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MF>BUZ"=DOU&\':8_&C]!^3]02P,$%     @ -X>O2JG?].Z/ @  Y@@  !D
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M,U ^Y5[@W1W/7=,JX\!%-I &OH/Z,5R$MO#*4G4,>MGQ'@FH<^\Q.)U3@[>
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M8VT/WYES!=HR>-(U5_IVG0(&9V6FJ9Z+X8X9 L6[\?I$TQU>_@-02P,$%
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MNNT;/'.N0!L*'O3)-[K+S@L*9V6FF9Z+L=6,"\7[J8VBN9>7?P%02P,$%
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MH^X0O7GS!JABOT8)#D+R 31Q./O;HD1BA$\9*LN(&N"93Z#Q/Z0YF );@E?
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MT4[;16-=1LR<-VEUA5&<SR3#]W"T3581QMTZKG+#N\)JMU5QX;7#:2QY.AN
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MK.$A7Y@*NZJ^ +680XZ]O@?& 02,4E0*V"@FI#]EQF6ZIYJ(&+BV$ER7:?.
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ML3'67[FG)#,J?X(O;,/1Z7,@:BOQVOPQJ+R&FDN&H]#BR0I48'Y&?$_K>]S
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M[BEB.-B?<$8:=F4+#LU_\AU02P,$%     @ -X>O2IV0BXJQ P  =QX   \
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MGL"Y:W=9Z^YO:MO'ZD?PT5]02P,$%     @ -X>O2B4:.3S$ 0  3QP  !H
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\79/6["0!"&X:L@'R#+S"Q_
M44B5AC;)!2Q8, )LR[M1X/9Q:&(D\)<"?31&%FCFK1ZMEI?WL,_3MBICL:WC
MX'C8EW&>%2G5S\[%91$.>7RJZE"VWZRKYI"G]K79N#I?[O)-<#H<CEW3G9&]
MOG1G#A:K>=8L5I(-/O-F$](\<\>]^ZZ:72Q"2-&=/^2I7=#^Y%2'_ZROUNOM
M,KQ5RZ]#*-.5BK\%F;L>I/U!2@^R_B"C!_G^($\/&O4'C>A!X_Z@,3UHTA\T
MH0=-^X.F]*!9?]",'B1#(..0GX2PYFLM@&OA>RT ;.&++8!LX9LM &WAJRV
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  WAZ]*?O.K/NX    K @  $0
M        @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  WAZ]*
MF5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( #>'KTH#"X^D80(  !4(   8              "
M ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  WAZ]*
M+&LB>?D#  #[$0  &               @ &."P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ -X>O2E>#RXY3 @  *@@  !@
M     ( !O0\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M #>'KTI9T7(;%@,  *D+   8              "  482  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  WAZ]*-GHK=&D#  !##@  &
M            @ &2%0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ -X>O2LL2C7TT!   LA(  !@              ( !,1D  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #>'KTI^DYD[KP$  -(#
M   8              "  9L=  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  WAZ]*4/>[G;4!  #2 P  &               @ & 'P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ -X>O2CZ9PQ2P
M 0  T@,  !@              ( !:R$  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( #>'KTJU,+:^L@$  -(#   9              "
M 5$C  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ -X>O
M2D7F:&NT 0  T@,  !D              ( !.B4  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  WAZ]*(K.1JK0!  #2 P  &0
M        @ $E)P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( #>'KTJ^:25CM0$  -(#   9              "  1 I  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ -X>O2AM9A-2U 0  T@,
M !D              ( !_"H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  WAZ]*&=VR"+8!  #0 P  &0              @ 'H+
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( #>'KTI-B>HH
MM@$  -(#   9              "  =4N  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ -X>O2JBWUOD% @  - 8  !D
M ( !PC   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  W
MAZ]*S"3Y4[,!  #2 P  &0              @ '^,@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #>'KTJO4D"[T@$  )P$   9
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M970R,RYX;6Q02P$"% ,4    "  WAZ]*2)BSWK8!  #2 P  &0
M    @ &_/@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M #>'KTIT1XNESP$  )P$   9              "  :Q   !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ -X>O2B>E%<#1 @  +0L  !D
M             ( !LD(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  WAZ]*>_!)-OL"   6#   &0              @ &Z10  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( #>'KTK<S'Q2J0(
M -L)   9              "  >Q(  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ -X>O2K1O_T/? 0  \@0  !D              ( !
MS$L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  WAZ]*
M%T;VPF,"    "   &0              @ 'B30  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( #>'KTI8@B:+Y0$  *$$   9
M      "  7Q0  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ -X>O2H'FRDML @  VP@  !D              ( !F%(  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  WAZ]*<F2C.4T"   G!P
M&0              @ $[50  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( #>'KTI'(Z)I-P(  )P'   9              "  ;]7  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ -X>O2JD=P_?-
M 0  -P0  !D              ( !+5H  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  WAZ]*RAJP\;$$  #,&0  &0
M@ $Q7   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( #>'
MKTIY*WC60@(  .,'   9              "  1EA  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ -X>O2AU^0*>O P  ]!   !D
M         ( !DF,  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    "  WAZ]*T-(8<S0"  ".!@  &0              @ %X9P  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #>'KTJIW_3NCP(  .8(
M   9              "  >-I  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ -X>O2ERE?>3@ 0   04  !D              ( !J6P
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  WAZ]**WN)
MZ>(!  "A!   &0              @ ' ;@  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( #>'KTJ+UK]@# (  ,\%   9
M  "  =EP  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M-X>O2L1%*7&4 @  )0H  !D              ( !'',  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    "  WAZ]*Z/J$]!<"  #7!0  &0
M            @ 'G=0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( #>'KTKX-#WQ# (  ,T%   9              "  35X  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ -X>O2N_FN>3$0
M1Q ! !0              ( !>'H  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ -X>O2O*ET>!0 @  "0P   T              ( !;KL  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  WAZ]*G9"+BK$#  !W'@  #P
M        @ 'IO0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -X>O2B4:
M.3S$ 0  3QP  !H              ( !Q\$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ -X>O2K1F&&*[ 0  9!P  !,
M     ( !P\,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #< -P#S#@
&K\4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>85</ContextCount>
  <ElementCount>217</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CondensedConsolidatedStatementOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Other Accrued Expenses and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities</Role>
      <ShortName>Other Accrued Expenses and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Convertible Preferred Stock and Common Stock Warrants (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes</Role>
      <ShortName>Convertible Preferred Stock and Common Stock Warrants (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/Acquisition</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Other Accrued Expenses and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesTables</Role>
      <ShortName>Other Accrued Expenses and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/ConvertibleDebt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Convertible Preferred Stock and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables</Role>
      <ShortName>Convertible Preferred Stock and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsNotes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Liquidity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/LiquidityNarrativeDetails</Role>
      <ShortName>Liquidity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOutstandingDilutiveSecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Acquisition - Purchase Price Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/AcquisitionPurchasePriceConsiderationDetails</Role>
      <ShortName>Acquisition - Purchase Price Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Acquisition - Summary of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/AcquisitionSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition - Summary of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Acquisition - Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/AcquisitionProFormaFinancialInformationDetails</Role>
      <ShortName>Acquisition - Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/AcquisitionDetailsTextual</Role>
      <ShortName>Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/AcquisitionTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Other Accrued Expenses and Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/OtherAccruedExpensesAndLiabilitiesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Other Accrued Expenses and Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Convertible Debt - Outstanding Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertibleDebtOutstandingConvertibleNotesDetails</Role>
      <ShortName>Convertible Debt - Outstanding Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Convertible Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertibleDebtDetailsTextual</Role>
      <ShortName>Convertible Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/ConvertibleDebtTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Convertible Preferred Stock and Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsDetails</Role>
      <ShortName>Convertible Preferred Stock and Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Convertible Preferred Stock and Common Stock Warrants Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/ConvertiblePreferredStockAndCommonStockWarrantsScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Convertible Preferred Stock and Common Stock Warrants Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/StockBasedCompensationDetailsTextual</Role>
      <ShortName>Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Stock-based Compensation - Share-based Payment Award, Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/StockBasedCompensationShareBasedPaymentAwardFairValueAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Share-based Payment Award, Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Fair Value Measurements - Fair Value On a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/FairValueMeasurementsFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value On a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Fair Value Measurements - Schedule of Common Stock Warrant Liability Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfCommonStockWarrantLiabilityRollforwardDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Common Stock Warrant Liability Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dffn-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Fair Value Measurements - Schedule of Fair Value Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/role/FairValueMeasurementsScheduleOfFairValueInputsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dffn-20170331.xml</File>
    <File>dffn-20170331.xsd</File>
    <File>dffn-20170331_cal.xml</File>
    <File>dffn-20170331_def.xml</File>
    <File>dffn-20170331_lab.xml</File>
    <File>dffn-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001053691-17-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001053691-17-000015-xbrl.zip
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M;_#2YZLR._#['2F,.EN9IV5E'AJ3'*@T9ROS4%;F,2C,:L@[Z,-#1M\0IHU
M0HC>2OGX;Y78QH\[(*/>Y6KVVTS\?RKZEX/FS56GM5CU)%PU!]W^:%0,OW2Z
MW>(OG<$ES-OFTU*T'<1TJW#+<CI2#L-:*<\R>C>)^?OUHF?]/NOWL['?I^OF
M7/?(7XKF<#PHQR0/R@-"K6_USUNX<OAA5C7L:4V >VH3?1A%ZT:BAIP-0_$T
MUU].H//TK/-'TWEZUODGH?/LK/-'TWEVUOG3Z/QB"_,SMGE4.G_&-O?3E_VL
M]F>U?PQJ_^C6=?8[UQWZU]?]7IFL,#M1-#VA^K1T>-OYJ6U\?B<*<@+P< X2
MST'BHP8/)]#Y<Y!X#A(?F\Z/>YV)PG_ICXK_@NO_:X@=W!95Z7K"YL0C+E\V
M>^SLDML7X7-KWM(;KRKJ[-8IP>,#'CH>MNN>V!GV!:/ZS6\?X]Z/++D;KJ=S
M\OTAE,YZY"T^N^SXL.3-\8Y?Q]<P)T;]16W>D;O_M43(\H,6WA"+7O^ZTUO[
MCLV\+K]DY5FSK^:LK4H&.WXYT/]V.=.ZS<O&5#<_%!=+F/3%Q!XW6Z-7U--D
MK?*):">%"BZ)[).T7$KN8J8O?KIH=H>@0)6'S]X88)+B1YUAJ]G]6]$<I DX
MVN'E(=)LF#""9RISEE8'+6*,F@OBI8&7OYK-QTUOFE$2^ZVRO/;D@O?E1,WP
MV7 '4IS)UGFA+3%<4J(\Y\%I2E((BIH<7_STYRD5:]]23P;2N2L1+"DJ6"8J
M@/@MHRZJH$-.-G";@V$O2BA:1\;\+:M$3.C;?4A,8E1J&9(D1'J=3 ""<E8A
M>Y5=Y"^6T/#:-ZV2@5NR.[S="FL2E5'A*#CX0Y),6B8?I0M>AA<_4?+JS\OO
MQ4?/7I=*8Q_@TT&S^[;7+K[^9_%M%\$+Q7G4,MH(;S?)4&U<L'!I9%D1N^R_
MU[YIA8S;2*<T3\-WX&G!G>!&]!)-D\5S]J+1+EJ=:YAN\-&O>5$LD61)9*(F
M2NE],LR8K(S(200%X_2B@2:@?-;,RE+"A51<+U&[@:!ETG.G6PP"C.-E?["+
M_+@ VDBVU@0I$P%5)5&9Z)A4F@BF7_ST$?B"9S8^%#?]P0@E@.U.F[UOBP0N
MO7:9H@_%99DYUQMA6O<.))%@@21ME#="1AA,JKB*/EJ2+/4$%'G>O:7Q'J1Q
MW6P5XQ%NX0\;;WNMUXMT+;]\1MBG01,E]_';]>=^=R=3:UFR"C2*&"DR]]%9
MPCVC/NJDDID$R)/W+CV[?"$B!==J#<9%.W0[/23TXVC<+GO(EGEAPZEY7*9D
MBKD7=8LLT)1@DFGM6=8,S1YU(#3'(AAE%:*R?$&S2DC &+': (T[DW-7XD&,
MZX@WPG$6E=961@E^PUEFDJ;@MY+U4:15XKE01M&#B*_I _1^T,]]4)M*I][F
ML-/"S#WLU5NTJXIQQP:U"\)@2_J>+ G$*IV#M(3:Q)U,61 '3DUHL2R,6\A$
M7@L]%<GA3%;D!)/[,R*7\A%%MX,P9O#M_1C"D>:P>#_HM(K0AXBA74R.82Q)
MZ5Z[N"Z(\Q5?D"= $\LM)SP8+YV$62%EYCD1+PC3*51F!F6*@I=8D>6^@KBS
M).$7-*^@O&5 52Z_#1^?>,$D,QL(E<)(J<!SB!P=#UQ$KZG19%6\*-J[RK96
M-'<6>!J.@$&8!/,@=EKI;WI$U0V'@%/:CV\(F  ;D4@$B7N9N'=!)4DSN,SD
M,PVY,@2<'4'!=Q37289EMN#\:(>$&^N%(2&S -&0TX#Z2182HA(B.-.RXM&,
M.,V(K$CJSJ.Q.-@;L?"C& 85$L"TH**58/4!#A$N25#@2&F.UL3*S+ 0.M]]
M(#8):=,(?"A:_<M>YW^*]MOIFF+S<[> H2M&$TD,BC;XZI_AXTX7A%+,AG6*
M@1:^J,0E=^M<O0:X$<U]3I2$X*@$%^MII)SH["'Z\A#T5M1<:U#_]=(]H@#F
M<J[=QTI?BT&K,RS:<8P+DY.0=QWT/U9%Y[5A8<Y$$YN-L1"Q UYWCD&L"A&.
M%]PYXVO"PIF*[L[=K4!N.Y6MU,QM_J/XZU4?/^Y_Z0PGCG9:J[M4<G@0'JUM
M7A:U\/Y(W5;6BDEX95U*,3%OK?-!!B("Y1 -.,9%L MBFJVETM=$SB1U!+8/
MD>&TT&AI",K';56S$XG/$#"#21CK<M91F@3H(%"BG4_:L,S7!1;F]=P@WH7M
M0V0'/[2*HCV\&/2OW\),+_H7"VL?6P6YK8;NHMN0BY)2 )]HHL:;)*2RD4<9
M*$M$&Z&CL;68EAPBI<T,/CZ1':V9P3K1!V&53!K<20 @&[UDEH/H70+GDH+T
MCT?TOY8FIG_Q%^SV>#.=+5N7/9:G)#4N)*I"@$ I49Z4,B8G&0)74JFP&#RM
M[D&1UY(HIK?Q74OE,9A;*?J]ED5@RW+J#379:P<QBI-QPJ+T(NJTD44CC!8G
M8O'3%3A2T(@V0K=I"_'I:EUL?EN[RG\L*WWK_.')D8#)R>#/E*8)%#]0T.LD
M*(^1O?CI/2=QFQ"V<#,71RQN!C!2)=J"G[M%"?UZ;7>-J[G_4W[^MM?JCLL[
M.\-6&6H#M'IW,P6W-9)1TQ72>I H<K+<9:9B%#)$]-U!9 41$KAOKBHK!-I(
M/F7W"-2>EG.]D7.OC,I2&9=8DB9+'RP$'AYWZ0S1H<*Y4N04G,_#D1(L3Z+S
M4FDVPI%UZY,Q\\R54C99)@2'_ZS.A@@CA0 \X=?!"/::S]:;-Q,TI_O7?J_5
M!*4>O&\.1M-?0*=[0R!C$BS@S(,@87+TNG\1IS/BW07\"W(I&ZKOJZXQ1TXR
M$XHZ"L&C\2+Y0""ZL5IE8'1UT&:NYSC4GISYS1J;I*,A$\((AQB$TA@" >99
M  .502(5]PL#+]5I)+#T*>@ZKN2W_1B>//I;,7K?[-0OR6_@CMM$)8 %#7Z6
M$T)QG\0$CCNR*6MCU@WM=DKN1/26(1'.IFBM(8%ISB*U(B#1AG@>HJ@B(@#S
MTNQ/^6V4\^[B4W_4[$Z6+E*W<XGN)L.P=IL]K&@P^%*\ UOD>KUQLXL;"-N=
MY7%J5BU(:&FQS4GP*,J .0HZ!@&1(8D0U\"XIJ!]JHD+R6LB9J-[%\9OI3<H
M;D":LVTG,-G]86<T!(O];G15#"9+&'OMZ"F8B=P+#7@@2BJ2X_ ?2TH0+ZCC
ME;4K28R88:6=J+DK[9LV]%S4W'KP]4%+ @X?/(2GDG)%A6>\9D7:6*,.)'X"
MXS/ ^ \%!AW%+P7HU6#!\NR-6**C(D3"0/"22.DI>#EC''S.I? 5\@T8%478
MG/[M%-V1_,T6@WB2HLB>Z6RE5<PG"/N!<D,M?"#H.C.W%^&?BFN<M(-OD^FZ
MM/X)EKZ F5M=ES]V9]Z[M\%:%X<J'I2&8%\1#;&*EUEE$P@'6*"-)[2ZGRZ7
MXM!=I+.7*'\M1CM)\]AR8.!XK .P'EA,1B5-A0: X$+(&H"2KN85T'WE *S=
M212/L+G:VH4E'01).B4 F:!:'N!3"BD[XS!U+M1D:1Q3FKC*T>SA7L4J,ES6
MIK7D.P&!:6+$Y^2SI00\E U$,^V2$,F("OEB _5+U*PC>3V8W9%D(2CE0:1,
MDY=2*&8#AWG,C7(*$'UE]U]NH+@>IJY<5.I(N9ZTM/H^P12_%K^77^V$RY?7
M460"%Z.)#-D["6[)@2$W@3*N@X]T:2MKGCH&7RK.;#TWNQ$Z9W.ZPS#URLW>
M[2:C:_]]/!RA]O=G^Q"S?9B:E+,MGE<1B#\L+DP+PFB0@0.7')!#2,JJBN>=
MC=1AU!V=N<U^F0&$-]%EHD526D> $\GXK!"WID2JTP>$(;50CYW'I0E'/<LD
MDQA#$@B^J><I&^V")X;7)",PM>0XC\/DAZ*+^^#3IQQB-]"D@7'3.:FH*3,P
MD4RV8$UT<$;*ZLXQA,Q5-I;IV(/*':8*8P!1F/ V2J%%P)U#C=HD$LR5["MQ
MX5%)VZSH1EOODG6!9J4R#P#Y94[@)QB+ELB:G" &(>NJHE<IG!>*;K7ZX]YH
M^+[Y#?>'#\F7%"K#Y)/>4 (@7WMC&//<*? 2/IE823FDR@B*8?5F&@ZA<D,<
MY0!Y*4<<N"LB%06?99.B6E/ 8S'9BB"EU KM_5Y$XL8Y0/^+8HC;(LUN+@Y+
M0<V6BVPM0.24)9AQBZD 05/-.(#GJD@U@XFT1.L&2NY"\Z9 -4-H1\%6,=!
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MH_.&@2! *DI%R9+11GJ>:@TTLT)3L@39GI0HG@*8T2QFE0,@:9<DM\[D0(0
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MG"29L5X=S#M)!3@SZ26O"!CD+K@4_,ZD'W2*-+AD@PS@U 3VO_,PTHS")\"
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M91;"*,#9 3O1QI!(M>8@I2M9,"MLUTEDNID\VUNNJ:&\?3YGS[3-V+W-QDQ
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M%H8+8E6>J(PB)#WE,#C/3LWA2C+,4B;1@BLHNXY@+:5.=SQ:10@[5+))47'
M8(9$;"@G+35E=X&(I7:BK4,T6!F6FP5.#Z/T%+QNGI Y #9V"4)WHV090YH<
M&/$*/@3;7@>7*8&H7R]6MCV<60Q8WLRVIT+_^G.G-XNCNYUK^&7P[?UXT+IJ
M3I,](;:!T*>8I-U^*A=K@%G?W5B5[M91I\30*4N3A=34PV@Z(6QP-@<JE'WQ
MT[]V1S^V.U\:P]&W;O''%Q?PR%<7S>M.]]N;3YUKL'=@6AH?^M?-WH_E=T/
MU6\HN1G]^.)?+T<_KMS>!;9>797">0.0YU]^1/I>-;N=R]X;7.KH7'R;?(2U
M_GNC-\+<?%W[7/R\CJY.[PHLWZCVOD]71>-F*K_&39D._'L3C':SVYJ4N&K
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MO=VZZ-FWRLS2O,H#A\L+AE8H-8GN^RVKMMM7)Y0[G4^B-$J5Y:^]\0.@!&^
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M[YG/ H>C LTP.XQ#H3K*.'*JO"&KSAG2OLYA=*D*!RAT96Y2-WZ,XQ1,=R^
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MUSJWWKJV/:4!2;2SII*P&I"D0FE@-U&_KP%)M M<(5-""S0MT#0@2:7$F2I
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M6175>;>Y.1M-LUL_65'JU>_.PU3LV:S14DEX&;5<E=F!5L]L=1IFO5N2CMQ
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ML@/7%9)GE=.S6H)I"?;. X&695H=93;O9?/-L2),GW3_]#,/>,1$@U'F3KW
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MR]U4'!?C9@9^I0-Z;$']OO=_U^9MJ>]>E%N@>6/6D[Y3774GS\S@D T>\A#
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M6VGMF9WQ*AG[>( R&B8(U= K=VA?>1%)2F0Y(9:4;!VV$;-M+6Q*21X4.LV
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M-V@U?WFKD@7@PSC]'(OYE>L];3?:E$@P5Y7#^E5%C_V5(*0EO8%=#,78C[[
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M6]4[J+TDS<+<9C[F^0/X6VL&"2^X3MAU,E"-^0PS^G>\=^"""(M37]V-G3/
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M3\FK$ZAL[<KJXR^O?K\AIS=GEY>O_OZWO_SU/PCYUZ_7;T_.:SL=0S4Y.6M
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MIHYG^7[HTTT2+#&SSK+0JP])EBZFO\WC]30-CWR(\Q_>)*LPQJNHKLVO](U
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M6V?<5#J70C_&"O*?1.Y[,MD<5KNZODXG2;8\:*4<>SRLT)@R*;4W@H8N,\L
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M& F%!AFKC262$B((EM"7H$!7_^CZV"+WE;5?,1!Q'G OP[FLI! !/XT18L8
M8H)Y50Q5@3R\S$!$94V>[66NA]?/P96+"D0,1Y$QY",P![D"2$H2;&/O +0&
M%WW$8<6^"#]R7=Q/'B,Y!YN^A_:CC=#'9++X.D__E4S?3H.9DEZG^;)883MA
MXN5-^(4+C]S%L[P(4(5YH9L/1P)IQJ7BA ,B'&;:.%*@[;V]C*!8<]-W5"A?
M)*?769;?.[!Y\D.6?(O3:7&7T7QZM;I)LNWO^J)ZU?Y$#D,IC$;:(1 F&L89
M@0_SEJAOKP\3/!G%".@(_$L<&!^R1=B$K>[SVZI7NVGAVW9;V\M ./C]2!.G
M/.,("QI,+T4\L"7V')/Z!9V'B<V,@?AM@7V)1'\[7\7SKVGY\&:8?[Z)YW]?
M+*9_I _>K(X)?[(?D<]=W]@ JC"5D!#%8!'*9< V\- ,$QH: _';!KVO 5"!
MFZ4$6GE++7":>!6VK!)!4,2_&)'XTHK)U:5-33S:C ?6IJF:3+)U\O@79T0-
M6_QJ1%#XG_-A$ @CF#(0%]<R!O AKG^^=Y@:=.=R:7P07^**:Y/K)!C:T\_Q
M]^.,[N_C$2-A/B# > *A<AA+42;R,8T;7,W*+X+8HT5ZY/PN%I6] +Q/.M@L
MG?IB!("@5FEA&*&(8*VM4^765!)>F\GB9V!RR_ .D""R"7(>ROG8]:6-3^:U
M*Y97UQ^R9!G W%X%,)^6Z2F?T@#U=3K)-Y23R6*]R<SZL)BEDW3LO=NES7P.
M_5K'LP-][7Y**M,G=PQ]PLA?DWBY#GR]REF]NS=S/GU\C>8&@7(<'9F(6OU.
M1" 5VE@'%/?((XH@W573XEQ6O!5GO'B>2MQI[1L1,!#PL%#F%? 50PCIXD(>
MS@'1HRD,.Q![%N/ ?=2Y00\7Z>:W=;Q/_G@TU66+>?CC9-.KY8F,H;/>$U%,
MM':(6\CS0D;0&D * +&7?9XU.BN/:  */:]LWB'.?=G1G\/7KJ[5=+$YA7+R
M'NM]CT=* :6LP=2K'$H*G2DG 4@8'G=R44=:7'0&W$NBQBASB4;,B)9\G0\"
M?<I/1L;9=/G;MVF\2G(J 'D\SZA2X\@2#R16BDAMH9# A2FVM P<[;5@3;5M
M;3.%+#I&J*]17RZK^K[\X_]-DRQ\_^;^77*7S$Y8']5>$ 'E-2+"*22I<F'P
M.,,+Z2FI=BY@B#HJPYL=G0#<.[UV4&UGV1_$.)G&>M9[(BX4M-@P(Z7STEF+
MBYL(.$=,C-Q":5OAA_C4(90_-[U&:>5<%*L&9M/;^;?U:KD!!9\TA(^TBE20
MA1/ O!!2J##A&^T*.8VC(TS([DB/A]C2&+.^N/%VOM-#\BZ]^S$Q1=__&O_/
M(C.S>'G*77/FFZ*\0I^W$G(MO%8&:*M]:3="7K_(X/GY=!=F.76+]$B8]R##
M^_CV]'F@&F^+8!B'(*P#DEE$ 10N+!$%+@H+,VYSJC,6G,>V%I']DWD%/J.T
MM"Z9<"TYG#ZZ3Q2=\"L]?B;"U#IJL:3,*FWR*G%%P1G.M=.]5D.L9BAUBOZB
M'9R:Z(\0<%)_Y3.1H982CHC/BSYK;94$I='&+>O3O3-"_=7%J:^)WBSF=TFV
MRJ6WR9=5:;G9=)E'38.A=LR@K= ZT@8C814WS&-%<NN^*!":;RM5G]4+SMT(
M#1HX;Q_;OCA5I!=>78?_!D V=X0?8='>YR/LK<*,(Z@9QH1Z%?ZVDTT8YT=X
MJ]4X>-,&FOV9F4^GWO?)RGV?S-9Y!<\*!RFJ-(^HMV%T(,$TMA@!X\(T7D@.
ME*Z?]=#9H;1Q\*@#<$=Y!D<@09 SR .E.(4"$U=*0/@(CVZ-@QXU >QM9KG]
M%F#*79A7U\^9?-84<\Y[(J@ -Y(#82 !Q'.J;3D<?/BG-IDZ.] U#C)UB7+?
MD\Z#+"<N^-S?(+*"<RB5U8SFM^B&S852A704J?K[X<X.<HV#0ZW V=NV:WV[
MGL6KL/UTP4R;!-H_2SY*YY/TVRQY._\0C+C%]"%;Y=ANK/9+(XFY1H@KCX%P
M&!NN99':)+!J4#ZHLT-6XR!=;Y#W=5RER>F,1^7W-]>F!E0^Y7AO5#)TQ=/B
M5M=D:A:W>>&0K6QY\>NOFU"GOG]XY$-\G_](_1%GTW<5#FHT?WF$&8 6:D."
M&:4UXYZ4Z6?8<EG)#NT(N;*,XTDQEX?DK%Y6M>$W(DN#<8#"G ^M!%AY;V&Q
MT468-C@NVO+IC#XI<[ J:[]@C_M(1IC*IC_,6EOC,YGZH+\<HO5V2KRZ_N&^
MZ/O]+SAU@*.[KT8"8RP0\P1[BQPPS)$BGP=9C_J,H-4L&]L;/9\?]QB-5OJR
M1_=WN%)P]U33" /. 7#(,NL]D5:4=5J"Q%R0<><0C((+E?C9&/*?@6RC3!MX
MD1P;13SSH><GDSE/M(RDLHX!YKD$G'@D$2OJ"W/D+1UA'+,]%1X/33:$:@!J
MA.WM-DBVN9?K'&KL:QD9'62$0F(MN=-8 V6+,"S2'-??<W06JNR#&BU U1<U
M=I=@G23"D^<BIDGN,X(6:9$7A8*\/-:%)+/UZ[ET%EGL3.U-@.E+R>[VVVQQ
MGR2/[N([J?"#;2) .5<&:V4A@MP"HE2YKG(IZH=Z.HL;=J;\MD#JBPCY;;59
M.EE5G?[W/A]QZ8PQ4&NL'!*8,>** Q"(65/?'N@LUM<9 =H :-C-1V5;6]WF
M3N_N/#K;]T<66>*,!19"(0"TS !;N/:8:9!4V9FQ.: _<PC(+R$><QDUO?JJ
MBA8X<)MN:SV$OI474O8#T)&/CZ2FV=6WS46+\Z_ODGR$;J.J56)?QQM&R$N.
M* BF(#6 <,*HW_E@(=6V6HWCKN-:>T6H'K(ZW#P2-%@\8:-CG)4,.ZT4W27M
M0T*I[',>/QJ-:DN)!R--K6$TZB#2P6K]^CZO.7(B&%2A=42<)X RIBS*'2Q"
M::L*L##I-;Q9,ZC3!A,670/7ES5ZL.=YOT]ZPRNTCC V!$K((%-"20H4(;B0
M6S(@QAU]:56S55G3&+V?ASVC#*>,G33#D$6OTUF>FG72W?'TP8@0P;2VD$+*
M*;+<4ZD+:33JU82IN!5M54<_%*]N $Y?JOX4MF ;Z^?OR>)K%G^["5NO4\6\
M#K:)(&-2*NBI=T0*8X0NLB@@09[53TCNN'Y7IR9'6W#U1HFM%?RXMR<7B(-M
M(NRX0XI; [Q30"..2"FCA$J-VZAH07?/V= R4B^3%:,T%L9$AG-)<. (O[F)
ML]EBM4J6=^ELEOPCS;X&3./C9_J/-HHD$1Y3#8'1GH0=/S-$E0X 87M-JZGH
MCVZNA45'\/0UNI\N>\N/ 8[=G9G'[S\YVBYBRG/OD,B-9\-R"8MK/X*LE*+Q
M4:$CYU:;,/453CCBAWXPE_QZM<Z27\-W;M>WN5CQ;!>P.7&*HQ^'>7\!@_#&
M^2:@-5\N9FE>UG>JX["IF"2?;I+ H=VMM-NC/;_-X_4T7>7!K?R'-\DJGW-&
MT<^R:P-UIEQCKZ[#/!KTN'P[/Y@HE >.\O_>+&9A6ECFF[?5O0V]FJ2K4X+T
MN+6J$AKY\>$(6N%PV"UBSAE4AC.L=G5D)#5(55I(.Y;L9.#CR8,18$8[A)%T
MS'%JO)?8%A+!L-:.)<311!F'-G]U$!AU *.4;#OL\KCY8E[A(I*C[2(=(,9(
M 4HTH8A#Z@ N )+6].E%/,^#4%//A^C2 CB])<L][>K)7>'>YX.IK22T1FO*
M-1+:4UP4=)7AC]1=B)^@F=Z>9\NUB-3+8L.X_0,C(,$PRL]-\<6\:J;\LV>C
M()'$B&GH*(:8$1]6V4(F[OP(MXL-=?-#0GPS1'K+BYQ.-PCG>[UT&NSS^%L:
M-GXG-7ZT7<0]0PQAJ0DD!H0=L<*\D-79!O'#SDY&M*O]-M'I+STZ[/'GR;3(
MDZR0'[VO020-I983[9ET' 7H+!8E9I[4#QQV=CRB7=VW DM_E?@F6>[&LLGV
MOV_GGY, 0Q9G]UM4/BYF,[_(\HS=(U0XYS51,*"%<IPI:E38@ G)@2R0\%#5
M/T+1G5.YO3UDATCUQ9EG'=XD4S\N G.$)Z>:1H 3PIQ30+BPR](*8EL,.@:X
M[O6BE:I5A;M0Z/.KY-K%;2"FF#C+[O.:3)O,>[5:9>F7]2K?8W]>;+VGU:ES
M^EV10T@A10& 0!L/G$.FV+<S#%']>:;#"M7]<ZEU(&O'+Y^3/+>=WRZ7ZV1J
MUWGMKJV_?<O]]\D?FU_M<T[5?UF$(.::<VL]IAQ[ )A7A:0,-"A*WYGMTBEE
M>D-RJ*5KORR;^G+'&-;D=9'SWN1GC21EVE%!G>$E,M(T*%71V0G209:X#K <
MSJC^,;)5UZX^^J:(!,P)LX0#!5R8J04VI1E '(/C6_(Z-:W;!*NWW*PSS.D?
M[4#"+47.2> 5 P@RQ8NCO)(IQON,RM6>7%K2VO-H3$.L^DOB?2[]T?C;\X<C
MXS10'DJGG30:8:6+NR$DTY:.< KHC0%-P>K-\SZR*L&>.D2MYAA:"SG$,"RM
M!4H4Z?H!G!ZMXFXHU1NH_84#_F>]W.9??5X<\&+OBKYLC;.C(8(SWQ5)DT_)
ME@#JE)> *P=\N6FPH'[IRAY-XVZ(UC66??'+IG?I-)E/ET^3OXZPZ$"+B&HD
M,*0<:(J"X:^50D4XC1E'ZY^([:P.2U]<:0>Q,<TXSPK/_9ZN;K8_RD/Y/HGS
MO-6&$U&53T008F" APQQ 2R4 )%2(]3+^O-39W<TC&E^Z@#B,9%TL\'X\KP2
MSL<D8+Q,5\FG)+M+)\G6#OB83!9?MRS8>#0:DK?)IR/E&,/ 8^?RV^.40 :5
MVR #6'WKKK,[(,9$ZAZA[XOL[Y-50'AQFYRXR.;)<Y$+PY9J@!RQA'&"E"ZN
MTI ,,US_TG)QZ31J@E-_!T2.Y>\OKZY-O+SQL\4?XSE4L"P/^(;?]MNKQ\M8
M[Q^L5#BJN\\_\J ]^LW[Q6KXNU[R[KV=+U?9NNI)C0,M(@X-0<9PPK%#@'N$
M\:Z&(>%0NTKY:WW(>.K,QIZG<\>#LD()#@7#WBML$2MD\PKVF7YS].!&8]W\
M<$%J4RQ&?83CJ7@GSFW\^'#$I464.2"P)$Q9(C0H8050]ADY..NP1B.U'J5(
M#5AZ<Z,\Z6BE*Q0.-0E&J$(P"$@X,IY8(:4I)124FW$?UFBBLJ/:;XS02^3"
M,!PX<51C#!1H*07JN465J_Q$_8:#+2)M&!52$ZU#;P&R#AM9]#G,C/4C@9W%
M@IO#O^@"FK;4^2G)TF2ISU+HDS:10H(X@[F#FENGI?5:%?W6M$%^6F?!W4Y5
MV@2<8:;G1P(\^#X_9.DD@97GZR/OB#2G@F(&@7:.&V$<*CQ*P?+Q>H2Y]=V:
M^>UA-0Q?WH8-198L5Q_CP/;<\S']$$SCO#;'U^K[OF,OB0CE&!OJ/;3AWPKG
ME?$*% +F(SRJU2UC6@2KOY.:3Q>Z#_']";_ @1:1A4H2I:GAS!MB'7<$/$S*
MI+X3M[-,C[;)T XR VM^5Z#F? +L&D8&8XT1]E R)Z03%&I22&NTK1\3ZBP1
MHR<>U -H #J\6\R_?DZRV_,GA'TM XR4*T6<E<%:9H)*7&23$&ZY&F&V18>$
M: &A'N,ZCYWW/=;0.ECEZ=')^%W&TN"! S.+E\NKZTV?JH0-]CX?:8V]80H%
MJP :#BT+*P4(9,.&^]P=.5S0X-'5RGF7]?U&@#,N9W_>*A+<<PDM5M11%G9K
M3'FTD]5@YOH\IWDTB-!04X=O4&^(R*A#"9_67Y;)_Z[SXB=WN_+9I^I [6^1
MU]PD"DI(,%".8,F\UCM0+(-HM$&%5A3]G#RM8-3;,80?>WNZ1/"A-A$WSHI@
M.P/&)*9:4JE=*:,V([^-HK'F3C.A$4XODQ.CC#6,APJCH,#)&C%[GX\,H<'P
M!DQPR37TWE-7RB:$&V%DH@4]'==\+61Z*PV4%V\]80*4ST2"2)J733<<&QQ6
M2R'"GJB0@8'Z3J3>+HYH;]&OBTJOFCU=Z>GAJ8AY08@W@F#.G;(48R5*.8@;
M>;I #7WLTV@C+"Y7MZ-<DOM5Z3"JW!5E/ZG,)\]% @ C)2:<(D:-L""\O) %
M>SC"8DJU-+%H#X/>]!E_KZ;/Q\]%DB*G %3(,2D)!8(ZL)/%62CK5P[I+%37
MBCX;8-";XWWK9MKY,Z^RC^G7FU,YF ?;1$PIQKAR$@@#&;/2,ES("(FL/V[/
MC\(-;D"UA=*@3#BY2S[2*B(80FM57G?<Y(5N)$'%N'',DY'[3EK07Q5&-,+J
MY7)CE ;;N"C16JK?#U&M;7::.I7N=[Q=I(1GT(H@!7',(B68*0P89V2O]VQ4
M7/1;T<:B.XQJZ_A=\C6>W'],E@'AOR?SY'O1F^,J/M$LHIHJZ) E'#+,\M+0
M%):82-&GOV0H#;<+49_.T'2:QMG]I[BT>BI$RO:VB;S&F$!E@D'+!"242UX"
M!X6O[Q0]/^=F<*NO+91Z8\)#+_,4YZOKSX&]RWB2:^)TB.1DXX@Y3;'Q6BOL
MM3?:(D\+J:D@;-PV8 O:?,Z/KB#[60@S2L-PE#P9AA\?LO0N7B4?9O%DDP!R
MTE.TOT'$D 5<.^T<U@8;2PTH+2..(!V?]=BFRA8=8-3P,% ^$!;73Y/BJAP(
M.MPN,@H:"8 .RZMSC +-RL'APS_UW47=%7UM7\==0-7;8E"4M'B<K5;UYKWG
M;2*#N,8,8>T9YYIZB6CA(?7&P_JYV^>GZ@YO1[:$4L\>HDTWJSJ&'CT<(2P0
M4$$D; '6A"NO2JF000>NG1^-G=A<6_L=0\TA>BD$&*?=-P:]#S3U;_U8%>V!
M"JTB[)%WB LHA-/,YH=J>2&GY?W&\,_R)M52UO/YOC5@^B+ WIM]U'IUL\C2
M?QTMKWNB960MA08CH05T/MBBP-@RR=T(,W(BO&N<K-\N/K7-_N?7[2S"G#C=
ME2W[F$R2]&ZOEBNWC236P",J67X?J>9**5D$3;QSH'Z H&OW<4,]=X70 (?U
MGLY76Z9NRSC_]FTQ?]C5'+,%SG];Q QB@E,(O.*&8X"LVLV( CC?H&1C9Z=]
MVYTANL=LT,CR^W4.9D KF:RSH*)D:>+9+)GJ>Q=/;IX^>V[\^9QW1T #&F#"
MDDNB&.$$>5E@9AVI;Y1V=IJX99[UC&!_3LK'@Z8H.YX73JA4I*)*\\@;B51^
MV%I#R@C37!I:2$Z K#]'=7;PN%WN= #20*;MQV0:?K JZJ^$[F^FV>H6[H$7
M1-(S3 3"EN9YGIII662-A"F9V_HU;SJKRMZIH=L.3(.N7.Y[X':Z3#8"E+]<
M[GZ[/%8JJ=;[(NN!<52IL"4(EK^W@A;^Q8!-V(G6IE!G-=![6*%:1JVM'=2!
MFP$[O1>4*,@T4U1Y2K0P05)4KK\2:EF;'YT5-^]NC]4)9)UNK]\G^^S;<YI'
MS!$/&4! 2J\9  C1<O*D4-:/H\K+(T!+(+6E\IQO\7R2F,5R5778/VD3$8<L
M)AHZ)YFS^76UAA3]AD(T."<#+D^[3:!I2Z57U\'FW128KZ[2)VTBJB'A3%,C
M&9?*4(R=*/K-,6N0_S)R[V?;T/2WEUQ,DF2Z] &7@H)7UP<]-$>WE6>]*0HV
ML1>(,Z6X@8PX9YTN9ZV >'VJC-R!V@]@(W6!/;=FVW. /7]S?N,+=5Q*J3B'
MQ'O&I"WPTEHW",1<BI^U5P!K+T*[[WY,9GG53_<]O\UIGWOB\,.1"U,I\X+1
M,""<T4H0ORO?(* SH,&R,W)79VN8]#5=/%R2^*2PHYI/WR_FDY/U,ZLTCW >
M''" &,6T],%N0L5950&MM@W*G%R(\[(#E!JF7^Y9S[83T>+Z'WDUQV^'O9(U
MWA(I+!TVWB%'" "<2\Q5*1MJDH8]<M]D]V"U3X3/H=DRO_TMW^"&52F_UOES
M%N<W7=GX_N ^I.[[(AQF100<X!9($B056!:&.)1*-#C9-W*O8Y^PM4^37^-_
M)K^'_H4?+^[2/"B\JSBQ8?'&67HV52J\,P)*"6MT&!/68.PAX*:P@B %3>:2
M2W!"]@A='Y0I]ES7NSU7LKA^=,JU!?X<_T!$*"9*<X^($0@3 BTW!2*8B?KU
MG.$E.#2'PK$/9CV[YN)H)+ZU=T>,.$-,ODIK:0BQUI3>?HB,:'"+Q"6X4 >
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M^Z@3 $I0]/VC"<]GFZN4)_<G/-T56D?<8(B@@)1@!RS3#%!?@!5PU&--&AB
M+H<(VQJZ?9G(^Q;1LM\G_:(56D?<(J.AT=XRB;T,&T1>8NHH!./VG;>JV4.L
M:1V]GX<]H_2NCYTTXR'+LIR43_IEJS2/D#4266>P, !Y#[C- =A)+AMD6'?F
MJ&E5GQ6XTA"RWLFB[\L__M\TR<+W;^[?)7?)K+K!<^0%$22 2XTE](@["96F
M$CY:\?NL(7VY-D][  \Z%_TH1JTE[.![(L^=<XPKRIT%CGE)*"KG?,5'GD;0
MML*K3%8M0_ESTVOLMM+X634PF][.OZU7RPTHL+J]]&.KB&!MH3(D3P:#3DH
M;>F84;Q!5<]>S:06]'B(+8TQ&Y(;J!8W=JTB#;!4F&,60/,&">J!+.0$0M>O
MW=-9N&HX;M3#;$ANX%K<P,5> 5-D&')46&.@LQ9[4\C)!:P_;W26'3$<-^IA
MUA<WMMN&LM\V7>8.[P"0^K)<9?'D6 FPDVTCAAE%FBGCA'2:>NX5*&2&0HYY
M?1DT\-$VLKTE6L3+FSP"'OZ3%UZ]BV?Y,%,K$V?9?8!G(\VQQ(HJ[:-@ C)H
M,!/.($XH(<P5.U7"+!WAO5XMZO-Y4D4'B/7%%IMLKB-.[Y)'8\R<KCQXI%D$
M@UQ(8R6\@=)H9*@-,S?3VC"(H1GA76#=<:-%H/K*J]F[3#^<9?DQM::L#_%Q
M,9M=+[(_XFSZ9XI'G;5**Z($U%PH3Z5E/-@J:IMHQ8@GJE+4=[QX]I?BX468
M7BUA4&MG-25>:;W#$7.K^XQ4]9CB49D]G:5XG(?[J%,\VCW"*+V AG% -'5.
M*\G#?L,[A#D72*(&MT-=3#I'96I4/O!X'J:7>Z@-,R7S6Q((-,1!IG P.W9R
M,@N='G>DH@7]G7&ZK1Y6+Y<;HPPSC(L2YU*A[U-0A%*@&60<A6E2 F.A9-O^
M.^ LN+ CCY6U<=8IJ/,P&B!OHJLL49W?38^,E29 Z@!$N+#XL,2B_O"_F(R)
MNF9%^^B^G#P_S2%%3E&IE7-,0RZ-*^0&U+MQ&QRM:K9&PE\]]'X>]HS2)!D[
M:<9#EK:S1*&W'@0X":0!7@Z<D"6JS,,^=\8M9HE6UF>=+-'S('MY6:).&H@T
MQLQ:[0 0] %:B_J,>U^NS=,>P"\[C4\;# 7&WAL#/6',"&T+EZI2Q%Z,*=2*
MPAOE\]6#\N>FU]AMI?&SZJ5D>W%C'#/..(Y,F/>9=+EG;"MG^%FOCKXNLKTJ
MZ_&,;*_S,.N=&\>7_\UZ_]M\\6699'?YLK\1,/QZ,9^$5IMR$B:>3=:S[0WH
MB]G,;T/O51C6U;<CPQ7(:\I*#(Q#6B'D2STBSAO<#W89V6:-8[ CT<R0Z^[O
MZ>KF!QF73X5<?GRF@%T*RJGLMDZ^%QEOC4)<">R%8$PR[%B!+3-@S+/S\'RK
ML/[WK:&QL_^ J)NKX2IML=O\7B2U%LAZZ*UU,J\]YWAAZ1%!Q9A/*;P8]K>I
MH0ME__82L[?S219>E]AD^]_^1L/^[^<1S_QP >7:<6.188Z4V&L ZY<;ZOZ<
MQDL?':UH;"1IN<\V0L?S;[NN_-97K;UWZ?^NT^FCRP%[^-3[/ ,A3^@>.L6Y
MG4O9(+>6(P<)H\$2VHY 8#CA--">J$KQEV[DZ^!2-L*<0XA!+B' C"'BP4Y6
MHR ?35IP0TV=<RG;68B,.F'WT_K+,@S0.+O_%)?"G@@Y'6P3680](=(;S;!@
M"CB+^ X82PVM;],.>6E;564_)U!+*/5E5S[JY?OX-OSQ<Q;/E_$DU\1)!_[I
MQA$%6'%,E-, ,>:E9T 64FO*Y;B#0BUH\SD_NH+L9R',*,,\H^3),/SXL#G#
MEWR8Q9/-PG8RDK._043S?;AS0F'CPIX"A\7<%M(IR498NKY-E2TZP*BW&6(5
MNIKW\K%I=LJX.-0F$DIKR!R#6%+BA)78^,*2<U#43Y$;\D*SNL9%2RCU?(9C
MT\VJ1S<>/1P9H@BUA$H3!@W0&@,#"ZFP\R,_S=."MO8?W6@.T4LAP#B-@3'H
M?:"IO_6;JZQ101HE-4..64X4<K20$U$[PHHL391UQH55YP%3^ZC6Y^3VVR(+
MAFU>K6-U;Q9A# 3\"D]QDMXE^Y(H*K>-O)., "XP]< ) <(X* QDIT99^;8=
MCU-7"/4VM1^Z4>;339PERTTP;?K;M\5\^^!C8VG?W'_^VR+B$5;26NPH,4HZ
M+)$I<.'Z<NXGJNNK[!ZSOKCT;!A\B+.K;+.*3C?1D@])MA'I"'\JOB%RT&!G
MG#44*^*H!-JH0G[+8/TDTJZOR6N),]W@-.B9\/?K'," 4!ZWW)8,BF>S9*KO
M73RY>?KL:>NS_KLC W*LC)?88KZYIM"!<D7VCRXI/Y=;Y#*XU3>";=DT&_&W
MLZ5=YX'O;:A[.XN^3_XXF"E4_V61E8A0XP047H=_".2F7-,-Q/7G(3INKO0&
M6:<&[_MDWTQR3O.(4N^I]<8*9(TW!$M>FN^4JOJ3!;L\ K0$4ELJS_D6SR>)
M62Q758?]DS81]T!Q3H@+%A7-[Q'5#N_Z[1$4]:];YI>GW";(M*71J^M@'8>)
MY1R-/FD34:,1X@9JQ74PF(' RA7]QD;7+],H+D^C39 9:$>Q74OR*-TD2[\$
MZV.]^FV>;I:<W0^_%6G18?(YD373^-V1DQH2A2R@VEIA$!"J" -YVN0Z=CEN
M-@V%X$CW)\\O#VYO=_+\S9'FV$'K!.7"0"<00[;$BTC:()H*+H-R_0+85Y[K
M5?8UGJ?_VAA.:CZU23E8KJYU:#%/ECUDEEZM;I),3299&+#N^[=DODR>'0T;
M0Q\^K6]OPY1S=?WLJ=ZR?T]WL:]4X&U$.EXF^=W?>4=ZNG![_W=W"O@<OKB.
M9P=ZT4/L*E^%?NB<RN>!KYMPGKY_>.1#?+^YMSS/T']7(9^X^<LCP+5'@-A@
M*%.B''=4 "\@@!XI"%BE+,O.DX]/B;D\).<9J<K-OA&%!01(%:#$G,(P<P<
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MN/ _&EG?4SO<0C]^@C?4PNAYOMMD;61;OIUOSS#\/5LL.TD+.?RUB&JH*$9
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M75)L;,?1H6NXGDEF9(&.L!&X39NA'F+=8M$H.2VI5JD:GU8#[ 8865LU&#7
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M&!$2,;;6(1N"V',9_85/$L*GYWW^DB2U^-P^TUQ7VY[N>!Y %@38, T/ZS8
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M8[3)-NKTZ*\*SEC')FGI*:WO1"A!1MK-:#%)DFW3I,1IN=WGY:%(OB3?*DA
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M)7EZSHNX>*'/:U4O]?FQ\-MV?Z!;#V"WJS$0-'&Z>Y^A^#FMXOW&TBT,/-_
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M#P([U/6^"#<,@,ZCF5(;GD$UT^[<4)HU"EK?/$:_2([P.9]JE<H]FVXN1KM
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M1PJ[ZQ A.::\O5I>%C_,=;!IEE;)!_J$Y'NR;,D>:-U(HXVT4>39!B+_:WA
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M!A+Y=.CTJ.M"F^[G>1E1GXE$KD-YIAIQ^JJ%#$Z84S_M=:0?F]M(N\8< #!
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MVY^@5MCLG<I1$MOK"_21FGZW!H 3"RZ K-.:VU>!S!72\_E187-_@?X<5@3
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M N9$,;(Q'S)"-HE01&(/JAVZ&C^><9FKMP]:J*IGJ#00*B=T4W.IIG(M.M#
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M,RC=$(Y_^GC/[^_I_35/6#&&&$?403&&U(+(8A2U0UFNYRBUQ!TR@.G)-?_
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M%/F9_"89 9;O,L7P<)+>/YD&G-@D]N=>F : RK"+ULW\BY/C+M^%>:"Q;^K
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M#".5%2$M QJ>N5T]#<L78-/ !%SF4_#;0X=4L0!2#]MR2TF3$ZTVJSN;9ER
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MM(#:.GR>5=>8IBW(?YF7GA+\D40NH^A^K!&YUH=+36::M^UKLDU$A7@[6!Q
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M4T0@9*VA91]'=\:]09V=VCP["]>WO'DFD5),,0H\ ,$UU%R#HC(29)[78=
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M(OTS@*IJW:UU=BB]BXM<6V5:\X#W0+0SS/HCK1(=AH^7@$H.J<,:"R%1.:!
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M?!N<.5?'QUES$:I=,>;39/'MU,I4/I,((JDQ0AN.#0[3L1#!W2UD8*!.:'.
M,?(VUJ)+L>R4#R?GC4=/)<$!(\0;03#G3EF*L1*E',&O&M=L<8'^7F/ 1=AU
MQ8'?LT5VL[DYR8(GSR4" ",E)IPB1HVP(+R\D 5[.#+'YB(MYLWAUQD7)C^J
M<>'Q<XFDR"D %7),2D*!H/'*O:TLSD(YLK.IC7"A!GZ=;4W$Y:^LI7:U_!1/
MT)ZP'0ZV29A2C''E)! &,F:E9;B0$1+9[0W3;]*6: K;7OESTK<]TBHA&$)K
ME?%>&B$IDP05H\TQ3T;FW3:@[RH,N@C;&HFL+\+8N^Q)=2J9]7B[1 G/H!5!
M"N*814HP4ZRGSD@WLKA9(YK,V\/W8GZ\3[]-IO>?TE703JQN_Z/HS7%ZG&B6
M4$T5=,@2#AEF##%$88F)%"/S9!MG1[/P=AD>RV;99'G_>5(NQ17"\J^V2;S&
MF$!E@FW&MH4F)2^!@\+7"9,-L-YF6X'Y)K#MC#\/O8P'!JZN']V^>SI&?[)Q
MPIRFV'BM%?;:&VV1+[;''!6$C6O):D#[S_G4-,1=$>OC,KN;K-./\\ET6Z+M
MI+O]>H.$(0NX=MHYK TVEAI0KLD<P9$EB32I[KP%?&L>[EIM[_!^FO=1Y8#7
MX7:)4=!( '28HIUC%&A6#BP?_C.V:[.;YT<;,'>V>A4%(/?68"7KYU";Q""N
M,4-8>\:YIEXB6H2HO/&U:A\.,)NT%>NG(6P[#M]LNUDU:O/HX01A@8 *(F$+
ML"9<>55*A0RJ<R_7$!>G^MI]/5AS.:2=332[.$'%E:M"JP1[Y!WB @KA-+/Q
M0"XOY+1\;'N,=13]?(YI#-0^9IGW%0XEO_I\HC7V82)&&#)H.+2,>5/(%D_J
MUB#,$*^N;F]SH1:N77'F647];0W7E=JLO^?+[%]':^^>:)E82Z'!2&@!G0]6
M.C"VE-<(,^*)YP*='[_GH":V%SM3S[H1;S+/9OM;RS^ETS2[>Y4AE=LF$FO@
M$94,*4 U5TK)8O/%.P<ZO;.VBX/JS;"D+7Q[.*?W='7=\?S=:K5)9W_<YHL'
M;_'8*G;^VQ)F$!,\%D-3W' ,D%7[]5L YW&WYXS?V-S4/MZ];JJ7U<S3Z6:9
MK8,):";S>3K3]VXR_?[TV7.WWL]Y=P(TH $F++DDBA%.D)<%9M:1.G;8V7LD
M;V=N[ O_[L+=CX=<<0%2+!91J:A'E>:)-Q*I>,);0\H(TUP:6DA.@*PS.PXP
M/M4L[UH N"=7X%,Z"S]8%[5NBMLCJGL$!UZ02,\P$0A;&E,V-=.RR+@)BP&W
M=:H3#=#!;-4Q: ;B7M=;]R.,BVR5;@5XN&UV_]O5L8)8%[TOL1X81Y4*+E3P
ME+P5M/#J S8(U%E7S[[ :B3K:L.8-^6O;D7>V:,VK/>+;V%\9/EL9Z=^2/_<
M_NJU -GE+TN(@DPS196G1 L3)$6EU2"AKE-27HQU<NL,[E8#(1_2U_R!<YHG
MS!$/&4! 2J\9  C1<MJF4-;)09 _$WD: K@IND2N3A;3U.2K5R^V/]DF(0Y9
M3#1T3C)G*0\0D:+?4(A:!X3 S\2,.K V18>KZP#V]E:)ZG1XTB:A&A+.-#62
M<:D,Q=B)HM\<LUK);J.-K3<-:W<>?SY-T]G*!UP*^EY='XS"'77^SWI3$CP(
M+Q!G2G$#&7'..EW.E@'Q.C0;8,Y3TX& -L$>:(CTN>7?7(#T^9L3!PQU7$JI
M.(?$>Q;OD=_CI;6NM;TX_AA^I^!?O'#NO_LIG<<JFN[';;I8O1: .OQPXL(4
MSKQ@- PF9[02Q.]+1PCH#*BU5 [PJ$&#2V43>'8U315QUM5EUQ16:9[@N&GE
M #&*:>F#G8B*@\4"6FUKE789?5B\!81KIHB_L@;O)L#\^C]B<=+;P_'N"]Z2
M*"P=-MXA1P@ G$O,52D;JG<^9;11[_:!;IY$7T*SU?=\/HM!B+"2KK.[],MR
M$J\1M)/[@_[>I>]+<)B-$7" 6R!)D%1@63@M4"I1ZZSNV?'L<1"K6<B;I]CO
MDW^D?P_]"S_.[[*88+$OA[(= =L@_-DTJ_#.!"@EK-%A/%F#L8> F\+J@Q34
MF\/&'=SN$/8NZ%;XMM=[WS;-KQ^=>6^ >\<_D!"*B=+<(V($PH1 RTV!"&:B
MUI71XPZ4]Z6#+ECY['*>H_DPC;T[8<098J)EH:4AQ%I3[D!!9$2MNV_&'9KO
M ?[+:7ALV_O)#N5!LE5^0\(@VB:?$4"YHA!!569+0JI1G746C3N\WQK(=4-8
M^_#)9#'SDVSY'Y/Y)E6S_]JLUO&86UYT^'TV^9K-L_7]B1C7F6]+B-<B_A<C
MP80.\GI;^D0>ZUHUY48;R.\.\ =R#>Y:A.T]+4][^P8N17#42P5C>!H0X:QD
M@A>W4B"J8*6]@9;.=T9PHVL9!L&NTQ'AA^LZJEQV4OD=":(4. <%P;&&D(4(
M$5S@P,)J6<=.'MZPOY0$+\Z6MP/O@$?YPR'(<J=GLUZMPW070QYO]&849C%B
MF$GJF(+"&ZI0W*OP6CF"-*V4,]/2)-#XS2@* PC"D % JF!^ !/6F$)60!P:
M]4"OK.@S;D8Y#]"NMKG.JSCO-5&2..=DZ+<@  .+"QD\HR.;_1O1YL&*\^=A
MV2D?SJHX3S!WUBO-:)"<4N,!+)& FHULHKA ?T<JSI^'75<<N*SB/,3!^14.
MQW(J#$HCB ![62A'U:X->V,\.%>+1RO.GX=?9URXJ.*\C:72(3(<QQ1810DQ
MMI %$E+G/-8 @P.-<*$&?KUF[EU<<=XZH7UPFKC"2D(!L86^D%$K6&?'98 <
M:<.6: K;7OE3J^(\-8X'.]U"JQ15'#%(RG'B$!Z9[=& OL^H.'\>MA='LUNJ
M*.Z)(P$3JZ)U%D2 BM)][Q5SM6IKOA5FG*O'<RJ*GP=O5Q-,\Z7N9*P8RI%W
M$EK K.%"B4).CE&MK=AQTZAY=&ML^+=TJ47<[\. 0J6<E HQ8T7 !#I+F8."
MUC%SAWM>H+E)IF%\.S9C:M9$- II81@3@BH;< M\9P7WB5)U9I8!<J=%\[<6
MKKV:OH]V1,ZU?Q\U3<(7"0""L# (-38>4RH+B:'T(RLS7U/K50S@R\']R<J>
M(&AB(BG5F&E J #2E=BP6G6 AVL<M4F\AA$?\/;P=N9_>QO R$BN'>+&*X$8
M$ ('_\=2I"V53H)*4VTG&\ OD@V><ZE25LBE[TPP@4@"[!P2WBC,)'*JP$EK
M5N<Z@@$N29>2Y/CF<6MP=SDMV'RZN=F=RG.+=:R6L;C.PQ/K1P58SQC]!QR\
M*E]Y[MP=:Y-HA"VW&M%X9YHA!"F]3\-1UGM6Z6#FL7&^2J=__9;?_39+LSC$
M2?Q+E(L\&MGA1\FN9Y_2;UGDUF(=+TYY3: #CR;60$NI440*#3BDA'%6R*$Y
MJ55N83CCL$%]YHT">IXY>!XI3)!U.9F_"V/FQ_^;OIK>>^C9Q"OGC",.\WB5
ML82*>E5(8235XS#<VJ1%/43;X<7^/.'G^YNO^?P 'YX\DT!!4%@UH";Q)"N#
M814IY3<0USE_/J 81#L\J(-D._K?'X#WV6HZF?]G.EFZQ<Q.UH<6C$./)YH$
M/"!UWAO*E,<:,E3(XC"M$YD:4'F+=EC1$*AM+AP^FZ=+$_KT+5\>7S:>/)D@
MZ PRP!O$G,4"*&?DP]+G1U+"N<U%HPZ>K9H2#_[YKACF\<!DM8;;BR(<CS>'
M0N(AHM*34C[HY4AJ,K=J9#0';SOT*>3^$KYQ@"B/'TD4U"@LCM+Q;18UB?=2
M[_OLH$1U[,X!U95HAQ(U@&Q7^;O#C\=MC5>?3006S$#C!69!?DN11[:00CI;
MAPX#JOW0+AWJ(-HN+QYL(!]^\FJ5FL-/)]H#BHQ$G&%*M6'>"%%(HAD?2=WB
M=KE1#],NV+%C;W5^/'H^05AA*R *RQY#*#C<7+E"&F]@G=EC2 6,NZ#(Y;"V
M0Q(5NC;;=F\^.62!/GDFL8X"SIV5UA.G@B-N0L_WO>86U3$VAU2^N!TRU(&R
MR\V$\J#\[^DD'IN-7>YO#['LS<,YWE6%'<5CS1("#:=.$AM,^%BMUUBZQQYH
MPD2E?.;NI*VRAWBT7>(HT89:@@SBB!I@*#&%O(":D>T3-J/ZO#V >Q_,Y0^O
MXAT+FV4LKJ(GJVS5]XGQ-@:[=5Z[>$6$@F'.U49*I;VDPAB,'0,]EI1XJ$BR
M6J7K55AHBCHD6;K:ZVOV2$6[FJO+)QH[=?:\L6\DQDHBB JCAS$8 &3*\@)'
MXVK=OO36)I'*E#HTB72LC*[RY4KY]/VCZ<8OTW]NTL7T_L09M@JM$VXP1%!
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M,S,Q+GAM;%!+ 0(4 Q0    ( #>'KTJ)XA 4,0X  +Z2   1
M  "  ?JR  !D9F9N+3(P,3<P,S,Q+GAS9%!+ 0(4 Q0    ( #>'KTIP/JX8
M+1<  -CS   5              "  5K!  !D9F9N+3(P,3<P,S,Q7V-A;"YX
M;6Q02P$"% ,4    "  WAZ]*:S((:]HX   7RP( %0              @ &Z
MV   9&9F;BTR,#$W,#,S,5]D968N>&UL4$L! A0#%     @ -X>O2AGU+"ZA
MD0  -(D' !4              ( !QQ$! &1F9FXM,C Q-S S,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( #>'KTI5,E>ZNUP  $&N!  5              "  9NC
M 0!D9F9N+3(P,3<P,S,Q7W!R92YX;6Q02P4&      8 !@"* 0  B0 "

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
